Spirocycle compounds and methods of making and using same

ABSTRACT

Provided herein are spirocycle compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

CROSS-REFERENCE

This application is a U.S. National Entry of International ApplicationNo. PCT/US2017/032276, filed May 11, 2017, which claims benefit of U.S.Provisional Application No. 62/335,597, filed on May 12, 2016, both ofwhich are herein incorporated by reference in their entirety.

BACKGROUND

Monoacylglycerol lipase (MAGL) is an enzyme responsible for hydrolyzingendocannabinoids such as 2-AG (2-arachidonoylglycerol), an arachidonatebased lipid, in the nervous system. The serine hydrolase ca-3-hydrolasedomain 6 (ABHD6) is another lipid mediator.

BRIEF SUMMARY OF THE INVENTION

This disclosure provides, for example, compounds and compositions whichare modulators of MAGL and/or ABHD6, and their use as medicinal agents,processes for their preparation, and pharmaceutical compositions thatinclude disclosed compounds as at least one active ingredient. Thedisclosure also provides for the use of disclosed compounds asmedicaments and/or in the manufacture of medicaments for the inhibitionof MAGL and/or ABHD6 activity in warm-blooded animals such as humans.

In one aspect is a compound having the structure of Formula (I):

-   -   wherein:    -   R¹ is H or optionally substituted C₁₋₆alkyl;    -   R² is H or optionally substituted C₁₋₆alkyl;    -   each R³ is independently selected from C₁₋₆alkyl, halogen, —CN,        C₁₋₆haloalkyl, aminoalkyl, —C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶,        —OR⁷, —CO₂R⁸, —C(O)R⁸, and —C(O)NR⁸R⁹; or two adjacent R³ form a        heterocycloalkyl ring optionally substituted with one, two, or        three R⁴;    -   each R⁴ is selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,        halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸,        —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   each R⁵ and R⁶ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, aminoalkyl, cycloalkyl, —C₁₋₆        alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        optionally substituted heterocycloalkyl, optionally substituted        aryl, and optionally substituted heteroaryl; or R⁵ and R⁶,        together with the nitrogen to which they are attached, form a        heterocycloalkyl ring optionally substituted with one, two, or        three R¹⁰;    -   each R⁷ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, aminoalkyl, cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        optionally substituted heterocycloalkyl, optionally substituted        aryl, and optionally substituted heteroaryl;    -   each R⁸ and R⁹ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, cycloalkyl, aryl, and heteroaryl;    -   each R¹⁰ is selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,        halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸,        —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   p is 0, 1, 2, 3, 4, or 5;    -   n is 0 or 1; and    -   m is 1 or 2; provided that when n is 0, then m is 2; and when n        is 1, then m is 1;    -   or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or        pharmaceutically acceptable salt thereof.

In some embodiments is a compound having the structure of Formula (Ia):

-   -   wherein:    -   R¹ is H or C₁₋₆alkyl;    -   R² is H or C₁₋₆alkyl;    -   each R³ is independently selected from C₁₋₆alkyl, C₁₋₆alkenyl,        C₁₋₆alkynyl, halogen, —CN, C₁₋₆ haloalkyl, C₁₋₆aminoalkyl,        heterocycloalkyl, —C₁₋₆alkyl(heterocycloalkyl), heteroaryl,        —SF₅, —NR⁵R⁶, —OR⁷, —CO₂R⁸, —C(O)R⁸, and —C(O)NR⁸R⁹, wherein        heterocycloalkyl and —C₁₋₆ alkyl(heterocycloalkyl) are        optionally substituted with one or two R⁴; or two adjacent R³        form a heterocycloalkyl ring, wherein the heterocycloalkyl ring        and the heteroaryl ring are optionally substituted with one,        two, or three R⁴;    -   each R⁴ is independently selected from C₁₋₆alkyl, C₁₋₆haloalkyl,        C₃₋₈cycloalkyl, halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹,        —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   each R⁵ and R⁶ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, C₁₋₆aminoalkyl, C₃. 8cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        heterocycloalkyl, aryl, and heteroaryl; or R⁵ and R⁶, together        with the nitrogen to which they are attached, form a        heterocycloalkyl ring optionally substituted with one, two, or        three R¹⁰;    -   each R⁷ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, C₁₋₆aminoalkyl, C₃₋₈cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        heterocycloalkyl, aryl, and heteroaryl, wherein        heterocycloalkyl, aryl, and heteroaryl are optionally        substituted with one or two groups selected from oxo, C₁₋₆alkyl,        C₁₋₆haloalkyl, CO₂H, and C(O)NH₂;    -   each R⁸ and R⁹ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, C₃₋₈cycloalkyl, aryl, and heteroaryl; or R⁸ and        R⁹, together with the nitrogen to which they are attached, form        a heterocycloalkyl ring optionally substituted with one or two        groups selected from C₁₋₆alkyl, C₁₋₆ haloalkyl, CO₂H, and        C(O)NH₂;    -   each R¹⁰ is independently selected from C₁₋₆alkyl,        C₃₋₈cycloalkyl, C₁₋₆haloalkyl, halogen, oxo, —CN, —CO₂R⁸,        —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   p is 0, 1, 2, 3, 4, or 5;    -   n is 0 or 1; and    -   m is 1 or 2; provided that when n is 0, then m is 2; and when n        is 1, then m is 1;    -   or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or        pharmaceutically acceptable salt thereof.

In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein each R³ is independently selected fromC₁₋₆alkyl, C₂₋₆alkynyl, halogen, —CN, C₁₋₆haloalkyl, heterocycloalkyl,—C₁₋₆alkyl(heterocycloalkyl), heteroaryl, —SF₅, —NR⁵R⁶, —OR⁷, —CO₂R⁸,and —C(O)NR⁸R⁹. In another embodiment is a compound of Formula (Ia), ora solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein each R³ isindependently selected from C₁₋₆alkyl, C₂₋₆alkynyl, halogen,C₁₋₆haloalkyl, —C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶, —OR⁷, —CO₂R⁸, and—C(O)NR⁸R⁹. In another embodiment is a compound of Formula (I) or (Ia),or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein R¹ is H. In anotherembodiment is a compound of Formula (I) or (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein R² is H. In another embodiment is a compound of Formula(I) or (Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein R¹ and R² are bothH. In another embodiment is a compound of Formula (I) or (Ia), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein R¹ is C₁₋₆alkyl. In another embodimentis a compound of Formula (I) or (Ia), or a solvate, hydrate, tautomer,N-oxide, stereoisomer, or a pharmaceutically acceptable salt thereof,wherein R¹ is —CH₃. In another embodiment is a compound of Formula (I)or (Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein R¹ and R² are both—CH₃. In another embodiment is a compound of Formula (I) or (Ia), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein each R³ is independently selected fromC₁₋₆alkyl, C₂₋₆alkynyl, halogen, C₁₋₆haloalkyl,—C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶, —OR⁷, —CO₂R⁸, and —C(O)NR⁸R⁹. Inanother embodiment is a compound of Formula (I) or (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein each R³ is independently selected fromhalogen, C₁₋₆haloalkyl, —NR⁵R⁶, and —OR⁷. In another embodiment is acompound of Formula (I) or (Ia), or a solvate, hydrate, tautomer,N-oxide, stereoisomer, or a pharmaceutically acceptable salt thereof,wherein R⁵ and R⁶, together with the nitrogen to which they areattached, form a heterocycloalkyl ring optionally substituted with one,two, or three R¹⁰. In another embodiment is a compound of Formula (I) or(Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein R⁵ and R⁶, togetherwith the nitrogen to which they are attached, form a heterocycloalkylring substituted with one or two R¹⁰ independently selected fromC₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸,—C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸. In another embodiment isa compound of Formula (I) or (Ia), or a solvate, hydrate, tautomer,N-oxide, stereoisomer, or a pharmaceutically acceptable salt thereof,wherein R⁵ and R⁶, together with the nitrogen to which they areattached, form a heterocycloalkyl ring substituted with one or two R¹⁰independently selected from C₁₋₆alkyl and —CO₂H. In another embodimentis a compound of Formula (I) or (Ia), or a solvate, hydrate, tautomer,N-oxide, stereoisomer, or a pharmaceutically acceptable salt thereof,wherein R⁵ and R⁶, together with the nitrogen to which they areattached, form an unsubstituted heterocycloalkyl ring. In anotherembodiment is a compound of Formula (I) or (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein R⁵ and R⁶, together with the nitrogen to which they areattached, form a heterocycloalkyl ring selected from:

In another embodiment is a compound of Formula (I) or (Ia), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein R⁵ and R⁶, together with the nitrogento which they are attached, form a heterocycloalkyl ring selected from:

In another embodiment is a compound of Formula (I) or (Ia), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein R⁷ is independently selected fromC₁₋₆alkyl, C₁₋₆haloalkyl, C₁₋₆aminoalkyl, —C₁₋₆alkyl(heterocycloalkyl),—C₁₋₆alkyl-C(O)(heterocycloalkyl), heterocycloalkyl, and heteroaryl. Inanother embodiment is a compound of Formula (I) or (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein two adjacent R³ form a heterocycloalkylring optionally substituted with one, two, or three R⁴. In anotherembodiment is a compound of Formula (I) or (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein two adjacent R³ form a heterocycloalkyl ringsubstituted with one or two R⁴. In another embodiment is a compound ofFormula (I) or (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, whereineach R⁴ is selected from C₁₋₆alkyl, C₃₋₈cycloalkyl, —C(O)R⁸, and —SO₂R⁸.In another embodiment is a compound of Formula (I) or (Ia), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein two adjacent R³ form an unsubstitutedheterocycloalkyl ring. In another embodiment is a compound of Formula(I) or (Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein two adjacent R³ forma heterocycloalkyl ring selected from:

In another embodiment is a compound of Formula (I) or (Ia), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2. In another embodiment is acompound of Formula (I) or (Ia), or a solvate, hydrate, tautomer,N-oxide, stereoisomer, or a pharmaceutically acceptable salt thereof,wherein p is 1. In another embodiment is a compound of Formula (I) or(Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 0. In anotherembodiment is a compound of (I) or (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein n is 0 and m is 2. In another embodiment is a compoundof Formula (I) or (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein nis 1 and m is 1.

In another aspect is a pharmaceutical composition comprising a compoundof Formula (I) or (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, and atleast one pharmaceutically acceptable excipient.

In another aspect is a method of treating pain in a patient, comprisingadministering a therapeutically effective amount of a compound ofFormula (I) or (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, to apatient in need thereof to treat said pain. In some embodiments is amethod of treating pain in a patient, comprising administering atherapeutically effective amount of a compound of Formula (I) or (Ia),or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, to a patient in need thereofto treat said pain, wherein the pain is neuropathic pain. In someembodiments is a method of treating pain in a patient, comprisingadministering a therapeutically effective amount of a compound ofFormula (I) or (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, to apatient in need thereof to treat said pain, wherein the pain isinflammatory pain.

In another embodiment is a method of treating a disease or disorder in apatient in need thereof comprising administering to the patient atherapeutically effective amount of a compound of Formula (I) or (Ia)described herein, or a pharmaceutically acceptable salt or solvatethereof, wherein the disease or disorder is selected from the groupconsisting of epilepsy/seizure disorder, multiple sclerosis,neuromyelitis optica (NMO), Tourette syndrome, Alzheimer's disease, andabdominal pain associated with irritable bowel syndrome. In someembodiments, the disease or disorder is epilepsy/seizure disorder. Insome embodiments, the disease or disorder is multiple sclerosis. In someembodiments, the disease or disorder is neuromyelitis optica (NMO). Insome embodiments, the disease or disorder is Tourette syndrome. In someembodiments, the disease or disorder is Alzheimer's disease. In someembodiments, the disease or disorder is abdominal pain associated withirritable bowel syndrome.

In another embodiment is a compound having the structure:

-   -   wherein:    -   R¹ is H or C₁₋₆alkyl;    -   R² is H or C₁₋₆alkyl;    -   each R³ is independently selected from C₁₋₆alkyl, C₁₋₆alkenyl,        C₁₋₆alkynyl, halogen, —CN, C₁₋₆haloalkyl, C₁₋₆aminoalkyl,        heterocycloalkyl, —C₁₋₆alkyl(heterocycloalkyl), heteroaryl,        —SF₅, —NR⁵R⁶, —OR⁷, —CO₂R⁸, —C(O)R⁸, and —C(O)NR⁸R⁹, wherein        heterocycloalkyl and —C₁₋₆ alkyl(heterocycloalkyl) are        optionally substituted with one or two R⁴; or two adjacent R³        form a heterocycloalkyl ring, wherein the heterocycloalkyl ring        and the heteroaryl ring are optionally substituted with one,        two, or three R⁴;    -   each R⁴ is independently selected from C₁₋₆alkyl, C₁₋₆haloalkyl,        C₃₋₈cycloalkyl, halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹,        —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   each R⁵ and R⁶ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, C₁₋₆aminoalkyl, C₃₋₈cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        heterocycloalkyl, aryl, and heteroaryl; or R⁵ and R⁶, together        with the nitrogen to which they are attached, form a        heterocycloalkyl ring optionally substituted with one, two, or        three R¹⁰;    -   each R⁷ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, C₁₋₆aminoalkyl, C₃₋₈cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        heterocycloalkyl, aryl, and heteroaryl, wherein        heterocycloalkyl, aryl, and heteroaryl are optionally        substituted with one or two groups selected from oxo, C₁₋₆alkyl,        C₁₋₆haloalkyl, CO₂H, and C(O)NH₂;    -   each R⁸ and R⁹ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, C₃₋₈cycloalkyl, aryl, and heteroaryl; or R⁸ and        R⁹, together with the nitrogen to which they are attached, form        a heterocycloalkyl ring optionally substituted with one or two        groups selected from C₁₋₆alkyl, C₁₋₆ haloalkyl, CO₂H, and        C(O)NH₂;    -   each R¹⁰ is independently selected from C₁₋₆alkyl,        C₃₋₈cycloalkyl, C₁₋₆haloalkyl, halogen, oxo, —CN, —CO₂R⁸,        —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   p is 0, 1, 2, 3, 4, or 5;    -   n is 0 or 1;    -   m is 1 or 2; provided that when n is 0, then m is 2; and when n        is 1, then m is 1; and    -   x and y are each at least one amino acid (aa).

In another embodiment is a compound having the structure:

-   -   wherein:    -   R¹ is H or C₁₋₆alkyl;    -   R² is H or C₁₋₆alkyl;    -   each R³ is independently selected from C₁₋₆alkyl, C₁₋₆alkenyl,        C₁₋₆alkynyl, halogen, —CN, C₁₋₆haloalkyl, C₁₋₆aminoalkyl,        heterocycloalkyl, —C₁₋₆alkyl(heterocycloalkyl), heteroaryl,        —SF₅, —NR⁵R⁶, —OR⁷, —CO₂R⁸, —C(O)R⁸, and —C(O)NR⁸R⁹, wherein        heterocycloalkyl and —C₁₋₆alkyl(heterocycloalkyl) are optionally        substituted with one or two R⁴; or two adjacent R³ form a        heterocycloalkyl ring, wherein the heterocycloalkyl ring and the        heteroaryl ring are optionally substituted with one, two, or        three R⁴;    -   each R⁴ is independently selected from C₁₋₆alkyl, C₁₋₆haloalkyl,        C₃₋₈cycloalkyl, halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹,        —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   each R⁵ and R⁶ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, C₁₋₆aminoalkyl, C₃₋₈cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        heterocycloalkyl, aryl, and heteroaryl; or R⁵ and R⁶, together        with the nitrogen to which they are attached, form a        heterocycloalkyl ring optionally substituted with one, two, or        three R¹⁰;    -   each R⁷ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, C₁₋₆aminoalkyl, C₃₋₈cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        heterocycloalkyl, aryl, and heteroaryl, wherein        heterocycloalkyl, aryl, and heteroaryl are optionally        substituted with one or two groups selected from oxo, C₁₋₆alkyl,        C₁₋₆haloalkyl, CO₂H, and C(O)NH₂;    -   each R⁸ and R⁹ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, C₃₋₈cycloalkyl, aryl, and heteroaryl; or R⁸ and        R⁹, together with the nitrogen to which they are attached, form        a heterocycloalkyl ring optionally substituted with one or two        groups selected from C₁₋₆alkyl, C₁₋₆ haloalkyl, CO₂H, and        C(O)NH₂;    -   each R¹⁰ is independently selected from C₁₋₆alkyl,        C₃₋₈cycloalkyl, C₁₋₆haloalkyl, halogen, oxo, —CN, —CO₂R⁸,        —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   p is 0, 1, 2, 3, 4, or 5;    -   n is 0 or 1;    -   m is 1 or 2; provided that when n is 0, then m is 2; and when n        is 1, then m is 1; and    -   x and y are each at least one amino acid (aa).

In another embodiment is a compound having the structure:

-   -   wherein:    -   R¹ is H or optionally substituted C₁₋₆alkyl;    -   R² is H or optionally substituted C₁₋₆alkyl;    -   each R³ is independently selected from C₁₋₆alkyl, halogen, —CN,        C₁₋₆haloalkyl, aminoalkyl, —C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶,        —OR⁷, —CO₂R⁸, —C(O)R⁸, and —C(O)NR⁸R⁹; or two adjacent R³ form a        heterocycloalkyl ring optionally substituted with one, two, or        three R⁴;    -   each R⁴ is selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,        halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸,        —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   each R⁵ and R⁶ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, aminoalkyl, cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        optionally substituted heterocycloalkyl, optionally substituted        aryl, and optionally substituted heteroaryl; or R⁵ and R⁶,        together with the nitrogen to which they are attached, form a        heterocycloalkyl ring optionally substituted with one, two, or        three R¹⁰;    -   each R⁷ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, aminoalkyl, cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        optionally substituted heterocycloalkyl, optionally substituted        aryl, and optionally substituted heteroaryl;    -   each R⁸ and R⁹ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, cycloalkyl, aryl, and heteroaryl;    -   each R¹⁰ is selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,        halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸,        —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   p is 0, 1, 2, 3, 4, or 5;    -   n is 0 or 1;    -   m is 1 or 2; provided that when n is 0, then m is 2; and when n        is 1, then m is 1; and    -   x and y are each at least one amino acid (aa).

In another embodiment is a compound having the structure:

-   -   wherein:    -   R¹ is H or optionally substituted C₁₋₆alkyl;    -   R² is H or optionally substituted C₁₋₆alkyl;    -   each R³ is independently selected from C₁₋₆alkyl, halogen, —CN,        C₁₋₆haloalkyl, aminoalkyl, —C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶,        —OR⁷, —CO₂R⁸, —C(O)R⁸, and —C(O)NR⁸R⁹; or two adjacent R³ form a        heterocycloalkyl ring optionally substituted with one, two, or        three R⁴;    -   each R⁴ is selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,        halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸,        —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   each R⁵ and R⁶ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, aminoalkyl, cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        optionally substituted heterocycloalkyl, optionally substituted        aryl, and optionally substituted heteroaryl; or R⁵ and R⁶,        together with the nitrogen to which they are attached, form a        heterocycloalkyl ring optionally substituted with one, two, or        three R¹⁰;    -   each R⁷ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, aminoalkyl, cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        optionally substituted heterocycloalkyl, optionally substituted        aryl, and optionally substituted heteroaryl;    -   each R⁸ and R⁹ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, cycloalkyl, aryl, and heteroaryl;    -   each R¹⁰ is selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,        halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸,        —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   p is 0, 1, 2, 3, 4, or 5;    -   n is 0 or 1;    -   m is 1 or 2; provided that when n is 0, then m is 2; and when n        is 1, then m is 1; and    -   x and y are each at least one amino acid (aa).

DETAILED DESCRIPTION OF THE INVENTION

This disclosure is directed, at least in part, to MAGL and/or ABHD6modulators or inhibitors. For example, provided herein are compoundscapable of inhibiting MAGL and/or ABHD6.

As used herein and in the appended claims, the singular forms “a,”“and,” and “the” include plural referents unless the context clearlydictates otherwise. Thus, for example, reference to “an agent” includesa plurality of such agents, and reference to “the cell” includesreference to one or more cells (or to a plurality of cells) andequivalents thereof. When ranges are used herein for physicalproperties, such as molecular weight, or chemical properties, such aschemical formulae, all combinations and subcombinations of ranges andspecific embodiments therein are intended to be included. The term“about” when referring to a number or a numerical range means that thenumber or numerical range referred to is an approximation withinexperimental variability (or within statistical experimental error), andthus the number or numerical range varies between 1% and 15% of thestated number or numerical range. The term “comprising” (and relatedterms such as “comprise” or “comprises” or “having” or “including”) isnot intended to exclude that which in other certain embodiments, forexample, an embodiment of any composition of matter, composition,method, or process, or the like, described herein, “consist of” or“consist essentially of” the described features.

Definitions

As used in the specification and appended claims, unless specified tothe contrary, the following terms have the meaning indicated below.

“Amino” refers to the —NH₂ radical.

“Cyano” refers to the —CN radical.

“Nitro” refers to the —NO₂ radical.

“Oxa” refers to the —O— radical.

“Oxo” refers to the =O radical.

“Thioxo” refers to the =S radical.

“Imino” refers to the =N—H radical.

“Oximo” refers to the =N—OH radical.

“Alkyl” refers to a straight or branched hydrocarbon chain radicalconsisting solely of carbon and hydrogen atoms, containing nounsaturation, having from one to fifteen carbon atoms (e.g., C₁-C₁₅alkyl). In certain embodiments, an alkyl comprises one to thirteencarbon atoms (e.g., C₁-C₁₃ alkyl). In certain embodiments, an alkylcomprises one to eight carbon atoms (e.g., C₁-C₈ alkyl). In otherembodiments, an alkyl comprises one to five carbon atoms (e.g., C₁-C₅alkyl). In other embodiments, an alkyl comprises one to four carbonatoms (e.g., C₁-C₄ alkyl). In other embodiments, an alkyl comprises oneto three carbon atoms (e.g., C₁-C₃ alkyl). In other embodiments, analkyl comprises one to two carbon atoms (e.g., C₁-C₂ alkyl). In otherembodiments, an alkyl comprises one carbon atom (e.g., C₁ alkyl). Inother embodiments, an alkyl comprises five to fifteen carbon atoms(e.g., C₅-C₁₅ alkyl). In other embodiments, an alkyl comprises five toeight carbon atoms (e.g., C₅-C₈ alkyl). In other embodiments, an alkylcomprises two to five carbon atoms (e.g., C₂-C₅ alkyl). In otherembodiments, an alkyl comprises three to five carbon atoms (e.g., C₃-C₅alkyl). In other embodiments, the alkyl group is selected from methyl,ethyl, 1-propyl (n-propyl), 1-methylethyl (iso-propyl), 1-butyl(n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (iso-butyl),1,1-dimethylethyl (tert-butyl), 1-pentyl (n-pentyl). The alkyl isattached to the rest of the molecule by a single bond. Unless statedotherwise specifically in the specification, an alkyl group isoptionally substituted by one or more of the following substituents:halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl,—OR^(a), —SR^(a), —OC(O)R^(a), —N(R^(a))₂, —C(O)R^(a), —C(O)OR^(a),—C(O)N(R^(a))₂, —N(R^(a))C(O)OR^(f), —OC(O)—NR^(a)R^(f),—N(R^(a))C(O)R^(f), —N(R^(a))S(O)_(t)R^(f) (where t is 1 or 2),—S(O)_(t)OR^(a) (where t is 1 or 2), —S(O)_(t)R^(f) (where t is 1 or 2)and —S(O)_(t)N(R^(a))₂ (where t is 1 or 2) where each R^(a) isindependently hydrogen, alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl,heterocycloalkyl, or heteroaryl, and each R^(f) is independently alkyl,fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, or heteroaryl.

“Alkoxy” refers to a radical bonded through an oxygen atom of theformula —O-alkyl, where alkyl is an alkyl chain as defined above.

“Alkenyl” refers to a straight or branched hydrocarbon chain radicalgroup consisting solely of carbon and hydrogen atoms, containing atleast one carbon-carbon double bond, and having from two to twelvecarbon atoms. In certain embodiments, an alkenyl comprises two to eightcarbon atoms. In certain embodiments, an alkenyl comprises two to sixcarbon atoms. In other embodiments, an alkenyl comprises two to fourcarbon atoms. The alkenyl is attached to the rest of the molecule by asingle bond, for example, ethenyl (i.e., vinyl), prop-1-enyl (i.e.,allyl), but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like. Unlessstated otherwise specifically in the specification, an alkenyl group isoptionally substituted by one or more of the following substituents:halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl,—OR^(a), —SR^(a), —OC(O)R^(a), —N(R^(a))₂, —C(O)R^(a), —C(O)OR^(a),—C(O)N(R^(a))₂, —N(R^(a))C(O)OR^(f), —OC(O)—NR^(a)R^(f),—N(R^(a))C(O)R^(f), —N(R^(a))S(O)_(t)R^(f) (where t is 1 or 2),—S(O)_(t)OR^(a) (where t is 1 or 2), —S(O)_(t)R^(f) (where t is 1 or 2)and —S(O)_(t)N(R^(a))₂ (where t is 1 or 2) where each R^(a) isindependently hydrogen, alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl,heterocycloalkyl, or heteroaryl, and each R^(f) is independently alkyl,fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, or heteroaryl.

“Alkynyl” refers to a straight or branched hydrocarbon chain radicalgroup consisting solely of carbon and hydrogen atoms, containing atleast one carbon-carbon triple bond, having from two to twelve carbonatoms. In certain embodiments, an alkynyl comprises two to eight carbonatoms. In certain embodiments, an alkynyl comprises two to six carbonatoms. In other embodiments, an alkynyl has two to four carbon atoms.The alkynyl is attached to the rest of the molecule by a single bond,for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and thelike. Unless stated otherwise specifically in the specification, analkynyl group is optionally substituted by one or more of the followingsubstituents: halo, cyano, nitro, oxo, thioxo, imino, oximo,trimethylsilanyl, —OR^(a), —SR^(a), —OC(O)R^(a), —N(R^(a))₂, —C(O)R^(a),—C(O)OR^(a), —C(O)N(R^(a))₂, —N(R^(a))C(O)OR^(f), —OC(O)—NR^(a)R^(f),—N(R^(a))C(O)R^(f), —N(R^(a))S(O)_(t)R^(f) (where t is 1 or 2),—S(O)_(t)OR^(a) (where t is 1 or 2), —S(O)_(t)R^(f) (where t is 1 or 2)and —S(O)_(t)N(R^(a))₂ (where t is 1 or 2) where each R^(a) isindependently hydrogen, alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl,heterocycloalkyl, or heteroaryl, and each R^(f) is independently alkyl,fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, or heteroaryl.

“Alkylene” or “alkylene chain” refers to a straight or branched divalenthydrocarbon chain linking the rest of the molecule to a radical group,consisting solely of carbon and hydrogen, containing no unsaturation andhaving from one to twelve carbon atoms, for example, methylene,ethylene, propylene, n-butylene, and the like. The alkylene chain isattached to the rest of the molecule through a single bond and to theradical group through a single bond. The points of attachment of thealkylene chain to the rest of the molecule and to the radical group arethrough one carbon in the alkylene chain or through any two carbonswithin the chain. In certain embodiments, an alkylene comprises one toeight carbon atoms (e.g., C₁-C₈ alkylene). In other embodiments, analkylene comprises one to five carbon atoms (e.g., C₁-C₅ alkylene). Inother embodiments, an alkylene comprises one to four carbon atoms (e.g.,C₁-C₄ alkylene). In other embodiments, an alkylene comprises one tothree carbon atoms (e.g., C₁-C₃ alkylene). In other embodiments, analkylene comprises one to two carbon atoms (e.g., C₁-C₂ alkylene). Inother embodiments, an alkylene comprises one carbon atom (e.g., C₁alkylene). In other embodiments, an alkylene comprises five to eightcarbon atoms (e.g., C₅-C₈ alkylene). In other embodiments, an alkylenecomprises two to five carbon atoms (e.g., C₂-C₅ alkylene). In otherembodiments, an alkylene comprises three to five carbon atoms (e.g.,C₃-C₅ alkylene). Unless stated otherwise specifically in thespecification, an alkylene chain is optionally substituted by one ormore of the following substituents: halo, cyano, nitro, oxo, thioxo,imino, oximo, trimethylsilanyl, —OR^(a), —SR^(a), —OC(O)—R^(a),—N(R^(a))₂, —C(O)R^(a), —C(O)OR^(a), —C(O)N(R^(a))₂,—N(R^(a))C(O)OR^(f), —OC(O)—NR^(a)R^(f), —N(R^(a))C(O)R,—N(R^(a))S(O)_(t)R^(f) (where t is 1 or 2), —S(O)_(t)OR^(a) (where t is1 or 2), —S(O)_(t)R^(f) (where t is 1 or 2) and —S(O)_(t)N(R^(a))₂(where t is 1 or 2) where each R^(a) is independently hydrogen, alkyl,fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, or heteroaryl,and each R^(f) is independently alkyl, fluoroalkyl, cycloalkyl, aryl,aralkyl, heterocycloalkyl, or heteroaryl.

“Aminoalkyl” refers to a radical of the formula —R^(c)—N(R^(a))₂ or—R^(c)—N(R^(a))—R^(c), where each R^(c) is independently an alkylenechain as defined above, for example, methylene, ethylene, and the like;and each R^(a) is independently hydrogen, alkyl, fluoroalkyl,cycloalkyl, aryl, aralkyl, heterocycloalkyl, or heteroaryl.

“Aryl” refers to a radical derived from an aromatic monocyclic ormulticyclic hydrocarbon ring system by removing a hydrogen atom from aring carbon atom. The aromatic monocyclic or multicyclic hydrocarbonring system contains only hydrogen and carbon from five to eighteencarbon atoms, where at least one of the rings in the ring system isfully unsaturated, i.e., it contains a cyclic, delocalized (4n+2)π-electron system in accordance with the Hückel theory. The ring systemfrom which aryl groups are derived include, but are not limited to,groups such as benzene, fluorene, indane, indene, tetralin andnaphthalene. Unless stated otherwise specifically in the specification,the term “aryl” or the prefix “ar-” (such as in “aralkyl”) is meant toinclude aryl radicals optionally substituted by one or more substituentsselected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, haloalkenyl,haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl,optionally substituted aralkyl, optionally substituted aralkenyl,optionally substituted aralkynyl, optionally substituted cycloalkyl,optionally substituted heterocycloalkyl, optionally substitutedheteroaryl, —R^(b)—OR^(a), —R^(b)—OC(O)—R^(a), —R^(b)—OC(O)—OR^(a),—R^(b)—OC(O)—N(R^(a))₂, —R^(b)—N(R^(a))₂, —R^(b)—C(O)R^(a),—R^(b)—C(O)OR^(a), —R^(b)—C(O)N(R^(a))₂, —R^(b)—O—R^(c)—C(O)N(R^(a))₂,—R^(b)—N(R^(a))C(O)OR^(a), —R^(b)—N(R^(a))C(O)R^(a),—R^(b)—N(R^(a))S(O)_(t)R^(a) (where t is 1 or 2), —R^(b)—S(O)_(t)OR^(a)(where t is 1 or 2), —R^(b)—S(O)_(t)R^(a) (where t is 1 or 2) and—R^(b)—S(O)_(t)N(R^(a))₂ (where t is 1 or 2), where each R^(a) isindependently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl,aryl, aralkyl, heterocycloalkyl, or heteroaryl, each R^(b) isindependently a direct bond or a straight or branched alkylene oralkenylene chain, and R^(c) is a straight or branched alkylene oralkenylene chain.

“Aryloxy” refers to a radical bonded through an oxygen atom of theformula —O-aryl, where aryl is as defined above.

“Aralkyl” refers to a radical of the formula —R^(c)-aryl where R^(c) isan alkylene chain as defined above, for example, methylene, ethylene,and the like. The alkylene chain part of the aralkyl radical isoptionally substituted as described above for an alkylene chain. Thearyl part of the aralkyl radical is optionally substituted as describedabove for an aryl group.

“Aralkenyl” refers to a radical of the formula —R^(d)-aryl where R^(d)is an alkenylene chain as defined above. The aryl part of the aralkenylradical is optionally substituted as described above for an aryl group.The alkenylene chain part of the aralkenyl radical is optionallysubstituted as defined above for an alkenylene group.

“Aralkynyl” refers to a radical of the formula —R^(e)-aryl, where R^(e)is an alkynylene chain as defined above. The aryl part of the aralkynylradical is optionally substituted as described above for an aryl group.The alkynylene chain part of the aralkynyl radical is optionallysubstituted as defined above for an alkynylene chain.

“Cycloalkyl” refers to a stable non-aromatic monocyclic or polycyclichydrocarbon radical consisting solely of carbon and hydrogen atoms,which includes fused or bridged ring systems, having from three tofifteen carbon atoms. In certain embodiments, a cycloalkyl comprisesthree to ten carbon atoms. In other embodiments, a cycloalkyl comprisesfive to seven carbon atoms. The cycloalkyl is attached to the rest ofthe molecule by a single bond. Cycloalkyl is fully saturated, (i.e.,containing single C—C bonds only) or partially unsaturated (i.e.,containing one or more double bonds). Examples of monocyclic cycloalkylsinclude, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl, and cyclooctyl. In certain embodiments, a cycloalkylcomprises three to eight carbon atoms (e.g., C₃-C₈ cycloalkyl). In otherembodiments, a cycloalkyl comprises three to seven carbon atoms (e.g.,C₃-C₇ cycloalkyl). In other embodiments, a cycloalkyl comprises three tosix carbon atoms (e.g., C₃-C₆ cycloalkyl). In other embodiments, acycloalkyl comprises three to five carbon atoms (e.g., C₃-C₅cycloalkyl). In other embodiments, a cycloalkyl comprises three to fourcarbon atoms (e.g., C₃-C₄ cycloalkyl). An partially unsaturatedcycloalkyl is also referred to as “cycloalkenyl.” Examples of monocycliccycloalkenyls include, e.g., cyclopentenyl, cyclohexenyl, cycloheptenyl,and cyclooctenyl. Polycyclic cycloalkyl radicals include, for example,adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptanyl), norbornenyl,decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unlessstated otherwise specifically in the specification, the term“cycloalkyl” is meant to include cycloalkyl radicals as defined abovethat are optionally substituted by one or more substituents selectedfrom alkyl, alkenyl, alkynyl, halo, fluoroalkyl, haloalkenyl,haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl,optionally substituted aralkyl, optionally substituted aralkenyl,optionally substituted aralkynyl, optionally substituted cycloalkyl,optionally substituted heterocycloalkyl, optionally substitutedheteroaryl, —R^(b)—OR^(a), —R^(b)—OC(O)—R^(a), —R^(b)—OC(O)—OR^(a),—R^(b)—OC(O)—N(R^(a))₂, —R^(b)—N(R^(a))₂, —R^(b)—C(O)R^(a),—R^(b)—C(O)OR^(a), —R^(b)—C(O)N(R^(a))₂, —R^(b)—O—R^(c)—C(O)N(R^(a))₂,—R^(b)—N(R^(a))C(O)OR^(a), —R^(b)—N(R^(a))C(O)R^(a),—R^(b)—N(R^(a))S(O)_(t)R^(a) (where t is 1 or 2), —R^(b)—S(O)_(t)OR^(a)(where t is 1 or 2), —R^(b)—S(O)_(t)R^(a) (where t is 1 or 2) and—R^(b)—S(O)_(t)N(R^(a))₂ (where t is 1 or 2), where each R^(a) isindependently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl,aryl, aralkyl, heterocycloalkyl, or heteroaryl, each R^(b) isindependently a direct bond or a straight or branched alkylene oralkenylene chain, and R^(c) is a straight or branched alkylene oralkenylene chain.

“Halo” or “halogen” refers to bromo, chloro, fluoro or iodosubstituents.

“Fluoroalkyl” refers to an alkyl radical, as defined above, that issubstituted by one or more fluoro radicals, as defined above, forexample, trifluoromethyl, difluoromethyl, fluoromethyl,2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, and the like. Insome embodiments, the alkyl part of the fluoroalkyl radical isoptionally substituted as defined above for an alkyl group.

“Haloalkyl” refers to an alkyl radical, as defined above, that issubstituted by one or more halogen radicals, as defined above, forexample, trifluoromethyl, chloroethyl, and the like. The alkyl part ofthe haloalkyl radical is optionally substituted as defined above for analkyl group.

“Heteroalkyl” refers to a straight or branched hydrocarbon chain alkylradical containing no unsaturation, having from one to fifteen carbonatoms (e.g., C₁-C₁₅ alkyl) consisting of carbon and hydrogen atoms andone or two heteroatoms selected from O, N, and S, wherein the nitrogenor sulfur atoms may be optionally oxidized and the nitrogen atom may bequaternized. The heteroatom(s) may be placed at any position of theheteroalkyl group including between the rest of the heteroalkyl groupand the fragment to which it is attached. The heteroalkyl is attached tothe rest of the molecule by a single bond. Unless stated otherwisespecifically in the specification, a heteroalkyl group is optionallysubstituted by one or more of the following substituents: halo, cyano,nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, —OR^(a), —SR^(a),—OC(O)R^(a), —N(R^(a))₂, —C(O)R^(a), —C(O)OR^(a), —C(O)N(R^(a))₂,—N(R^(a))C(O)OR^(f), —OC(O)—NR^(a)R^(f), —N(R^(a))C(O)R^(f),—N(R^(a))S(O)_(t)R^(f) (where t is 1 or 2), —S(O)_(t)OR^(a) (where t is1 or 2), —S(O)_(t)R^(f) (where t is 1 or 2) and —S(O)_(t)N(R^(a))₂(where t is 1 or 2) where each R^(a) is independently hydrogen, alkyl,fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, or heteroaryl,and each R^(f) is independently alkyl, fluoroalkyl, cycloalkyl, aryl,aralkyl, heterocycloalkyl, or heteroaryl.

“Heterocycloalkyl” refers to a stable 3- to 18-membered non-aromaticring radical that comprises two to twelve carbon atoms and from one tosix heteroatoms selected from nitrogen, oxygen and sulfur. Unless statedotherwise specifically in the specification, the heterocycloalkylradical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system,which includes fused, bridged, or spirocyclic ring systems. Theheteroatoms in the heterocycloalkyl radical are optionally oxidized. Oneor more nitrogen atoms, if present, are optionally quaternized. Theheterocycloalkyl radical is partially or fully saturated. In someembodiments, the heterocycloalkyl is attached to the rest of themolecule through any atom of the ring(s). Examples of suchheterocycloalkyl radicals include, but are not limited to, dioxolanyl,thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl,imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl,octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl,2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl,piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl,thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl,thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in thespecification, the term “heterocycloalkyl” is meant to includeheterocycloalkyl radicals as defined above that are optionallysubstituted by one or more substituents selected from alkyl, alkenyl,alkynyl, halo, fluoroalkyl, haloalkenyl, haloalkynyl, oxo, thioxo,cyano, nitro, optionally substituted aryl, optionally substitutedaralkyl, optionally substituted aralkenyl, optionally substitutedaralkynyl, optionally substituted cycloalkyl, optionally substitutedheterocycloalkyl, optionally substituted heteroaryl, —R^(b)—OR^(a),—R^(b)—OC(O)—R^(a), —R^(b)—OC(O)—OR^(a), —R^(b)—OC(O)—N(R^(a))₂,—R^(b)—N(R^(a))₂, —R^(b)—C(O)R^(a), —R^(b)—C(O)OR^(a),—R^(b)—C(O)N(R^(a))₂, —R^(b)—O—R^(c)—C(O)N(R^(a))₂,—R^(b)—N(R^(a))C(O)OR^(a), —R^(b)—N(R^(a))C(O)R^(a),—R^(b)—N(R^(a))S(O)_(t)R^(a) (where t is 1 or 2), —R^(b)—S(O)_(t)OR^(a)(where t is 1 or 2), —R^(b)—S(O)_(t)R^(a) (where t is 1 or 2) and—R^(b)—S(O)_(t)N(R^(a))₂ (where t is 1 or 2), where each R^(a) isindependently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl,aryl, aralkyl, heterocycloalkyl, or heteroaryl, each R^(b) isindependently a direct bond or a straight or branched alkylene oralkenylene chain, and R^(c) is a straight or branched alkylene oralkenylene chain.

“Heteroaryl” refers to a radical derived from a 3- to 18-memberedaromatic ring radical that comprises one to seventeen carbon atoms andfrom one to six heteroatoms selected from nitrogen, oxygen and sulfur.As used herein, the heteroaryl radical is a monocyclic, bicyclic,tricyclic or tetracyclic ring system, wherein at least one of the ringsin the ring system is fully unsaturated, i.e., it contains a cyclic,delocalized (4n+2) t-electron system in accordance with the Hickeltheory. Heteroaryl includes fused or bridged ring systems. Theheteroatom(s) in the heteroaryl radical is optionally oxidized. One ormore nitrogen atoms, if present, are optionally quaternized. Theheteroaryl is attached to the rest of the molecule through any atom ofthe ring(s). Examples of heteroaryls include, but are not limited to,azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl,benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl,benzo[b][1,4]dioxepinyl, benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl,benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl,benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl(benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl,benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl,cyclopenta[d]pyrimidinyl,6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl,5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl,6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl,dibenzothiophenyl, furanyl, furanonyl, furo[3,2-c]pyridinyl,5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl,5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl,5,6,7,8,9,10-hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl,indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl,isoquinolyl, indolizinyl, isoxazolyl,5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl,1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl,5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-1H-pyrrolyl,phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl,purinyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl,pyrido[3,2-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl,pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl,quinolinyl, isoquinolinyl, tetrahydroquinolinyl,5,6,7,8-tetrahydroquinazolinyl,5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl,6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidinyl,5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl,triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl,thieno[3,2-d]pyrimidinyl, thieno[2,3-c]pridinyl, and thiophenyl (i.e.thienyl). Unless stated otherwise specifically in the specification, theterm “heteroaryl” is meant to include heteroaryl radicals as definedabove that are optionally substituted by one or more substituentsselected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, haloalkenyl,haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl,optionally substituted aralkyl, optionally substituted aralkenyl,optionally substituted aralkynyl, optionally substituted cycloalkyl,optionally substituted heterocycloalkyl, optionally substitutedheteroaryl, —R^(b)—OR^(a), —R^(b)—OC(O)—R^(a), —R^(b)—OC(O)—OR^(a),—R^(b)—OC(O)—N(R^(a))₂, —R^(b)—N(R^(a))₂, —R^(b)—C(O)R^(a),—R^(b)—C(O)OR^(a), —R^(b)—C(O)N(R^(a))₂, —R^(b)—O—R^(c)—C(O)N(R^(a))₂,—R^(b)—N(R^(a))C(O)OR^(a), —R^(b)—N(R^(a))C(O)R^(a),—R^(b)—N(R^(a))S(O)_(t)R^(a) (where t is 1 or 2), —R^(b)—S(O)_(t)OR^(a)(where t is 1 or 2), —R^(b)—S(O)_(t)R^(a) (where t is 1 or 2) and—R^(b)—S(O)_(t)N(R^(a))₂ (where t is 1 or 2), where each R^(a) isindependently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl,aryl, aralkyl, heterocycloalkyl, or heteroaryl, each R^(b) isindependently a direct bond or a straight or branched alkylene oralkenylene chain, and R^(c) is a straight or branched alkylene oralkenylene chain.

“N-heteroaryl” refers to a heteroaryl radical as defined abovecontaining at least one nitrogen and where the point of attachment ofthe heteroaryl radical to the rest of the molecule is through a nitrogenatom in the heteroaryl radical. An N-heteroaryl radical is optionallysubstituted as described above for heteroaryl radicals.

“C-heteroaryl” refers to a heteroaryl radical as defined above and wherethe point of attachment of the heteroaryl radical to the rest of themolecule is through a carbon atom in the heteroaryl radical. AC-heteroaryl radical is optionally substituted as described above forheteroaryl radicals.

“Heteroaryloxy” refers to radical bonded through an oxygen atom of theformula —O-heteroaryl, where heteroaryl is as defined above.

“Heteroarylalkyl” refers to a radical of the formula —R^(c)-heteroaryl,where R^(c) is an alkylene chain as defined above. If the heteroaryl isa nitrogen-containing heteroaryl, the heteroaryl is optionally attachedto the alkyl radical at the nitrogen atom. The alkylene chain of theheteroarylalkyl radical is optionally substituted as defined above foran alkylene chain. The heteroaryl part of the heteroarylalkyl radical isoptionally substituted as defined above for a heteroaryl group.

“Heteroarylalkoxy” refers to a radical bonded through an oxygen atom ofthe formula —O—R^(c)-heteroaryl, where R^(c) is an alkylene chain asdefined above. If the heteroaryl is a nitrogen-containing heteroaryl,the heteroaryl is optionally attached to the alkyl radical at thenitrogen atom. The alkylene chain of the heteroarylalkoxy radical isoptionally substituted as defined above for an alkylene chain. Theheteroaryl part of the heteroarylalkoxy radical is optionallysubstituted as defined above for a heteroaryl group.

In some embodiments, the compounds disclosed herein contain one or moreasymmetric centers and thus give rise to enantiomers, diastereomers, andother stereoisomeric forms that are defined, in terms of absolutestereochemistry, as (R)- or (S)-. Unless stated otherwise, it isintended that all stereoisomeric forms of the compounds disclosed hereinare contemplated by this disclosure. When the compounds described hereincontain alkene double bonds, and unless specified otherwise, it isintended that this disclosure includes both E and Z geometric isomers(e.g., cis or trans.) Likewise, all possible isomers, as well as theirracemic and optically pure forms, and all tautomeric forms are alsointended to be included. The term “geometric isomer” refers to E or Zgeometric isomers (e.g., cis or trans) of an alkene double bond. Theterm “positional isomer” refers to structural isomers around a centralring, such as ortho-, meta-, and para-isomers around a benzene ring.

A “tautomer” refers to a molecule wherein a proton shift from one atomof a molecule to another atom of the same molecule is possible. Incertain embodiments, the compounds presented herein exist as tautomers.In circumstances where tautomerization is possible, a chemicalequilibrium of the tautomers will exist. The exact ratio of thetautomers depends on several factors, including physical state,temperature, solvent, and pH. Some examples of tautomeric equilibriuminclude:

“Optional” or “optionally” means that a subsequently described event orcircumstance may or may not occur and that the description includesinstances when the event or circumstance occurs and instances in whichit does not. For example, “optionally substituted aryl” means that thearyl radical may or may not be substituted and that the descriptionincludes both substituted aryl radicals and aryl radicals having nosubstitution. “Optionally substituted” and “substituted orunsubstituted” and “unsubstituted or substituted” are usedinterchangeably herein.

“Pharmaceutically acceptable salt” includes both acid and base additionsalts. A pharmaceutically acceptable salt of any one of the spirocyclecompounds described herein is intended to encompass any and allpharmaceutically suitable salt forms. Preferred pharmaceuticallyacceptable salts of the compounds described herein are pharmaceuticallyacceptable acid addition salts and pharmaceutically acceptable baseaddition salts.

“Pharmaceutically acceptable acid addition salt” refers to those saltswhich retain the biological effectiveness and properties of the freebases, which are not biologically or otherwise undesirable, and whichare formed with inorganic acids such as hydrochloric acid, hydrobromicacid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid,hydrofluoric acid, phosphorous acid, and the like. Also included aresalts that are formed with organic acids such as aliphatic mono- anddicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoicacids, alkanedioic acids, aromatic acids, aliphatic and aromaticsulfonic acids, etc. and include, for example, acetic acid,trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid,oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid,tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid,methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid,salicylic acid, and the like. Exemplary salts thus include sulfates,pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates,monohydrogenphosphates, dihydrogenphosphates, metaphosphates,pyrophosphates, chlorides, bromides, iodides, acetates,trifluoroacetates, propionates, caprylates, isobutyrates, oxalates,malonates, succinate suberates, sebacates, fumarates, maleates,mandelates, benzoates, chlorobenzoates, methylbenzoates,dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates,phenylacetates, citrates, lactates, malates, tartrates,methanesulfonates, and the like. Also contemplated are salts of aminoacids, such as arginates, gluconates, and galacturonates (see, forexample, Berge S. M. et al., “Pharmaceutical Salts,” Journal ofPharmaceutical Science, 66:1-19 (1997)). Acid addition salts of basiccompounds are prepared by contacting the free base forms with asufficient amount of the desired acid to produce the salt.

“Pharmaceutically acceptable base addition salt” refers to those saltsthat retain the biological effectiveness and properties of the freeacids, which are not biologically or otherwise undesirable. These saltsare prepared from addition of an inorganic base or an organic base tothe free acid. In some embodiments, pharmaceutically acceptable baseaddition salts are formed with metals or amines, such as alkali andalkaline earth metals or organic amines. Salts derived from inorganicbases include, but are not limited to, sodium, potassium, lithium,ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminumsalts and the like. Salts derived from organic bases include, but arenot limited to, salts of primary, secondary, and tertiary amines,substituted amines including naturally occurring substituted amines,cyclic amines and basic ion exchange resins, for example,isopropylamine, trimethylamine, diethylamine, triethylamine,tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol,2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine,caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine,hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline,N-methylglucamine, glucosamine, methylglucamine, theobromine, purines,piperazine, piperidine, N-ethylpiperidine, polyamine resins and thelike. See Berge et al., supra.

As used herein, “treatment” or “treating” or “palliating” or“ameliorating” are used interchangeably herein. These terms refers to anapproach for obtaining beneficial or desired results including but notlimited to therapeutic benefit and/or a prophylactic benefit. By“therapeutic benefit” is meant eradication or amelioration of theunderlying disorder being treated. Also, a therapeutic benefit isachieved with the eradication or amelioration of one or more of thephysiological symptoms associated with the underlying disorder such thatan improvement is observed in the patient, notwithstanding that thepatient is still afflicted with the underlying disorder. Forprophylactic benefit, the compositions are administered to a patient atrisk of developing a particular disease, or to a patient reporting oneor more of the physiological symptoms of a disease, even though adiagnosis of this disease has been made.

Compounds

Spirocycle compounds are described herein which are modulators of MAGLand/or ABHD6. These compounds, and compositions comprising thesecompounds, are useful for the treatment of pain. In some embodiments,the compounds described herein are useful for treating epilepsy/seizuredisorder, multiple sclerosis, neuromyelitis optica (NMO), Tourettesyndrome, Alzheimer's disease, or abdominal pain associated withirritable bowel syndrome.

In some embodiments is a compound having the structure of Formula (I):

-   -   wherein:    -   R¹ is H or optionally substituted C₁₋₆alkyl;    -   R² is H or optionally substituted C₁₋₆alkyl;    -   each R³ is independently selected from C₁₋₆alkyl, halogen, —CN,        C₁₋₆haloalkyl, aminoalkyl, —C₁₋₆ alkyl(heterocycloalkyl),        —NR⁵R⁶, —OR⁷, —CO₂R⁸, —C(O)R⁸, and —C(O)NR⁸R⁹; or two adjacent        R³ form a heterocycloalkyl ring optionally substituted with one,        two, or three R⁴;    -   each R⁴ is selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,        halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸,        —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   each R⁵ and R⁶ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, aminoalkyl, cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        optionally substituted heterocycloalkyl, optionally substituted        aryl, and optionally substituted heteroaryl; or R⁵ and R⁶,        together with the nitrogen to which they are attached, form a        heterocycloalkyl ring optionally substituted with one, two, or        three R¹⁰;    -   each R⁷ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, aminoalkyl, cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        optionally substituted heterocycloalkyl, optionally substituted        aryl, and optionally substituted heteroaryl;    -   each R⁸ and R⁹ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, cycloalkyl, aryl, and heteroaryl;    -   each R¹⁰ is selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,        halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸,        —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   p is 0, 1, 2, 3, 4, or 5;    -   n is 0 or 1; and    -   m is 1 or 2; provided that when n is 0, then m is 2; and when n        is 1, then m is 1;    -   or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or        pharmaceutically acceptable salt thereof.

In some embodiments is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein n is 0 and m is 2. In some embodiments is a compound ofFormula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein n is 1 and m is 1.

In some embodiments is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein R¹ is H. In some embodiments is a compound of Formula(I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein R² is H. In someembodiments is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein R¹ and R² are both H. In some embodiments is a compoundof Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer,or a pharmaceutically acceptable salt thereof, wherein R¹ is C₁₋₆alkyl.In some embodiments is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein R¹ is —CH₃. In some embodiments is a compound ofFormula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein R² is C₁₋₆alkyl. Insome embodiments is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein R² is —CH₃. In some embodiments is a compound ofFormula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein R¹ and R² are bothC₁₋₆alkyl. In some embodiments is a compound of Formula (I), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein R¹ and R² are both —CH₃.

In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 0, 1, 2, or 3. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 0. In another embodiment is a compound of Formula(I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2. In another embodiment is a compound of Formula(I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 3. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 4. In another embodiment is a compound of Formula(I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 5.

In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is selected fromC₁₋₆alkyl, halogen, C₁₋₆haloalkyl, —C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶,—OR⁷, —CO₂R⁸, and —C(O)NR⁸R⁹. In another embodiment is a compound ofFormula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein p is 1 and R³ isC₁₋₆alkyl. In another embodiment is a compound of Formula (I), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is halogen. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —Cl. In another embodiment is acompound of Formula (I), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1 and R³ is C₁₋₆haloalkyl. In another embodiment is a compound ofFormula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein p is 1 and R³ is—CF₃. In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is—C₁₋₆alkyl(heterocycloalkyl).

In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —NR⁵R⁶. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringoptionally substituted with one, two, or three R¹⁰. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form an unsubstitutedheterocycloalkyl ring. In another embodiment is a compound of Formula(I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶,and R⁵ and R⁶, together with the nitrogen to which they are attached,form a heterocycloalkyl ring substituted with one or two R¹⁰independently selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸.In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with two R¹⁰ independently selectedfrom C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸,—C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸. In another embodiment isa compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, R⁵ and R⁶, together with the nitrogen to which theyare attached, form a heterocycloalkyl ring substituted with two R¹⁰, andR⁰ is halogen. In another embodiment is a compound of Formula (I), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with two R¹⁰, and R¹⁰ is oxo. Inanother embodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰ selected from C₁₋₆alkyl, cycloalkyl,C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸,and —NR⁹SO₂R⁸. In another embodiment is a compound of Formula (I), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is C₁₋₆alkyl. Inanother embodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰, and R¹⁰ is cycloalkyl. In another embodimentis a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to whichthey are attached, form a heterocycloalkyl ring substituted with oneR¹⁰, and R¹⁰ is C₁₋₆haloalkyl. In another embodiment is a compound ofFormula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein p is 1, R³ is—NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to which they areattached, form a heterocycloalkyl ring substituted with one R¹⁰, and R¹⁰is halogen. In another embodiment is a compound of Formula (I), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —CO₂R⁸. Inanother embodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰, and R¹⁰ is —CO₂H. In another embodiment is acompound of Formula (I), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to whichthey are attached, form a heterocycloalkyl ring substituted with oneR¹⁰, and R¹⁰ is —C(O)R⁸. In another embodiment is a compound of Formula(I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶,and R⁵ and R⁶, together with the nitrogen to which they are attached,form a heterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is—C(O)CH₃. In another embodiment is a compound of Formula (I), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —C(O)NR⁸R⁹.In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —C(O)NH₂. Inanother embodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰, and R¹⁰ is —SO₂R⁸. In another embodiment is acompound of Formula (I), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to whichthey are attached, form a heterocycloalkyl ring substituted with oneR¹⁰, and R¹⁰ is —SO₂CH₃. In another embodiment is a compound of Formula(I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶,and R⁵ and R⁶, together with the nitrogen to which they are attached,form a heterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is—NR⁹C(O)R⁸. In another embodiment is a compound of Formula (I), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —NHC(O)CH₃.In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —NR⁹SO₂R⁸. Inanother embodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰, and R¹⁰ is —NHSO₂CH₃. In another embodiment isa compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to whichthey are attached, form a heterocycloalkyl ring selected from:

In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring selected from:

In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —OR⁷. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is independently selectedfrom C₁₋₆alkyl, C₁₋₆haloalkyl, aminoalkyl, —C₁₋₆alkyl(heterocycloalkyl),—C₁₋₆alkyl-C(O)(heterocycloalkyl), optionally substitutedheterocycloalkyl, and optionally substituted heteroaryl. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is C₁₋₆alkyl. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is C₁₋₆haloalkyl. Inanother embodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is aminoalkyl. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is—C₁₋₆alkyl(heterocycloalkyl). In another embodiment is a compound ofFormula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein p is 1 and R³ is—OR⁷, and R⁷ is —C₁₋₆alkyl-C(O)(heterocycloalkyl). In another embodimentis a compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1 and R³ is —OR⁷, and R⁷ is optionally substituted heterocycloalkyl.In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —OR⁷, and R⁷ isoptionally substituted heteroaryl.

In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —CO₂R⁸. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —CO₂H. In another embodiment is acompound of Formula (I), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1 and R³ is —C(O)NR⁸R⁹. In another embodiment is a compound ofFormula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein p is 1 and R³ is—C(O)NH₂.

In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2 and each R³ is independentlyselected from C₁₋₆alkyl, halogen, C₁₋₆haloalkyl,—C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶, —OR⁷, —CO₂R⁸, and —C(O)NR⁸R⁹. Inanother embodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is halogen, and one R³ is —OR⁷. Inanother embodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is —Cl, one R³ is —OR⁷, and R⁷ isC₁₋₆alkyl. In another embodiment is a compound of Formula (I), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is —Cl, one R³ is —OR⁷,and R⁷ is —C₁₋₆alkyl(heterocycloalkyl). In another embodiment is acompound of Formula (I), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 2, one R³ is halogen, and one R³ is —NR⁵R⁶. In another embodiment isa compound of Formula (I), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 2, one R³ is halogen, one R³ is —NR⁵R⁶, and R⁵ and R⁶, together withthe nitrogen to which they are attached, form an unsubstitutedheterocycloalkyl ring. In another embodiment is a compound of Formula(I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 2, one R³ ishalogen, one R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen towhich they are attached, form a heterocycloalkyl ring substituted withone or two R¹⁰ independently selected from C₁₋₆alkyl, cycloalkyl,C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸,and —NR⁹SO₂R⁸. In another embodiment is a compound of Formula (I), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is —Cl, and one R³ is—NR⁵R⁶. In another embodiment is a compound of Formula (I), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is —Cl, one R³ is—NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to which they areattached, form an unsubstituted heterocycloalkyl ring. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is —Cl, one R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one or two R¹⁰ independentlyselected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸,—C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is C₁₋₆haloalkyl, and one R³ is —NR⁵R⁶.In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is C₁₋₆haloalkyl, one R³is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to which they areattached, form an unsubstituted heterocycloalkyl ring. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is C₁₋₆haloalkyl, one R³ is —NR⁵R⁶, andR⁵ and R⁶, together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one or two R¹⁰ independentlyselected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸,—C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is —CF₃, and one R³ is —NR⁵R⁶. Inanother embodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is —CF₃, one R³ is —NR⁵R⁶, and R⁵ andR⁶, together with the nitrogen to which they are attached, form anunsubstituted heterocycloalkyl ring. In another embodiment is a compoundof Formula (I), or a solvate, hydrate, tautomer, N-oxide, stereoisomer,or a pharmaceutically acceptable salt thereof, wherein p is 2, one R³ is—CF₃, one R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen towhich they are attached, form a heterocycloalkyl ring substituted withone or two R¹⁰ independently selected from C₁₋₆alkyl, cycloalkyl,C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸,and —NR⁹SO₂R⁸.

In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is C₁₋₆alkyl, halogen,C₁₋₆haloalkyl, —C₁₋₆alkyl(heterocycloalkyl), —OR⁷, —CO₂R⁸, or—C(O)NR⁸R⁹, and one R³ is —NR⁵R⁶, wherein R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringselected from:

In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is C₁₋₆alkyl, halogen,C₁₋₆haloalkyl, —C₁₋₆alkyl(heterocycloalkyl), —OR⁷, —CO₂R⁸, or—C(O)NR⁸R⁹, and one R³ is —NR⁵R⁶, wherein R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringselected from:

In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein two adjacent R³ form a heterocycloalkylring optionally substituted with one, two, or three R⁴. In anotherembodiment is a compound of Formula (I), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein two adjacent R³ form an unsubstituted heterocycloalkylring. In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein two adjacent R³ form a heterocycloalkylring substituted with one, two, or three R⁴. In another embodiment is acompound of Formula (I), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein twoadjacent R³ form a heterocycloalkyl ring substituted with one or two R⁴.In another embodiment is a compound of Formula (I), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein two adjacent R³ form a heterocycloalkylring substituted with one or two R⁴ independently selected fromC₁₋₆alkyl, cycloalkyl, —C(O)R⁸, and —SO₂R⁸. In another embodiment is acompound of Formula (I), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein twoadjacent R³ form a heterocycloalkyl ring selected from:

In some embodiments is a compound having the structure of Formula (Ia):

-   -   wherein:    -   R¹ is H or C₁₋₆alkyl;    -   R² is H or C₁₋₆alkyl;    -   each R³ is independently selected from C₁₋₆alkyl, C₁₋₆alkenyl,        C₁₋₆alkynyl, halogen, —CN, C₁₋₆haloalkyl, C₁₋₆aminoalkyl,        heterocycloalkyl, —C₁₋₆alkyl(heterocycloalkyl), heteroaryl,        —SF₅, —NR⁵R⁶, —OR⁷, —CO₂R⁸, —C(O)R⁸, and —C(O)NR⁸R⁹, wherein        heterocycloalkyl and —C₁₋₆alkyl(heterocycloalkyl) are optionally        substituted with one or two R⁴; or two adjacent R³ form a        heterocycloalkyl ring, wherein the heterocycloalkyl ring and the        heteroaryl ring are optionally substituted with one, two, or        three R⁴;    -   each R⁴ is independently selected from C₁₋₆alkyl, C₁₋₆haloalkyl,        C₃₋₈cycloalkyl, halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹,        —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   each R⁵ and R⁶ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, C₁₋₆aminoalkyl, C₃₋₈cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        heterocycloalkyl, aryl, and heteroaryl; or R⁵ and R⁶, together        with the nitrogen to which they are attached, form a        heterocycloalkyl ring optionally substituted with one, two, or        three R¹⁰;    -   each R⁷ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, C₁₋₆aminoalkyl, C₃₋₈cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        heterocycloalkyl, aryl, and heteroaryl, wherein        heterocycloalkyl, aryl, and heteroaryl are optionally        substituted with one or two groups selected from oxo, C₁₋₆alkyl,        C₁₋₆haloalkyl, CO₂H, and C(O)NH₂;    -   each R⁸ and R⁹ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, C₃₋₈cycloalkyl, aryl, and heteroaryl; or R⁸ and        R⁹, together with the nitrogen to which they are attached, form        a heterocycloalkyl ring optionally substituted with one or two        groups selected from C₁₋₆alkyl, C₁₋₆ haloalkyl, CO₂H, and        C(O)NH₂;    -   each R¹⁰ is independently selected from C₁₋₆alkyl,        C₃₋₈cycloalkyl, C₁₋₆haloalkyl, halogen, oxo, —CN, —CO₂R⁸,        —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   p is 0, 1, 2, 3, 4, or 5;    -   n is 0 or 1; and    -   m is 1 or 2; provided that when n is 0, then m is 2; and when n        is 1, then m is 1;    -   or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or        pharmaceutically acceptable salt thereof.

In some embodiments is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein n is 0 and m is 2. In some embodimentsis a compound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein nis 1 and m is 1.

In some embodiments is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein R¹ is H. In some embodiments is acompound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R²is H. In some embodiments is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein R¹ and R² are both H. In someembodiments is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein R¹ is C₁₋₆alkyl. In some embodiments is a compound ofFormula (Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein R¹ is —CH₃. In someembodiments is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein R² is C₁₋₆alkyl. In some embodiments is a compound ofFormula (Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein R² is —CH₃. In someembodiments is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein R¹ and R² are both C₁₋₆alkyl. In some embodiments is acompound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R¹and R² are both —CH₃.

In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 0, 1, 2, or 3. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 0. In another embodiment is a compound of Formula(Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2. In another embodiment is a compound of Formula(Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 3. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 4. In another embodiment is a compound of Formula(Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 5.

In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is selected fromC₁₋₆alkyl, C₂₋₆alkynyl, halogen, —CN, C₁₋₆haloalkyl, heterocycloalkyl,—C₁₋₆alkyl(heterocycloalkyl), heteroaryl, —SF₅, —NR⁵R⁶, —OR⁷, —CO₂R⁸,—C(O)R⁸, and —C(O)NR⁸R⁹. In another embodiment is a compound of Formula(Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1 and R³ isselected from C₁₋₆alkyl, C₂₋₆alkynyl, halogen, C₁₋₆haloalkyl,—C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶, —OR⁷, —CO₂R⁸, and —C(O)NR⁸R⁹. Inanother embodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is selected from C₁₋₆alkyl, halogen,C₁₋₆haloalkyl, —C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶, —OR⁷, —CO₂R⁸, and—C(O)NR⁸R⁹. In another embodiment is a compound of Formula (Ia), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is C₁₋₆alkyl. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is C₂₋₆alkenyl. In another embodiment isa compound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1 and R³ is C₂₋₆alkynyl. In another embodiment is a compound ofFormula (Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein p is 1 and R³ ishalogen. In another embodiment is a compound of Formula (Ia), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —Cl. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is C₁₋₆haloalkyl. In another embodimentis a compound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1 and R³ is —CF₃. In another embodiment is a compound of Formula(Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1 and R³ is—C₁₋₆alkyl(heterocycloalkyl).

In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —NR⁵R⁶. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringoptionally substituted with one, two, or three R¹⁰. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form an unsubstitutedheterocycloalkyl ring. In another embodiment is a compound of Formula(Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶,and R⁵ and R⁶, together with the nitrogen to which they are attached,form a heterocycloalkyl ring substituted with one or two R¹⁰independently selected from C₁₋₆alkyl, C₃₋₈cycloalkyl, C₁₋₆haloalkyl,halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸.In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with two R¹⁰ independently selectedfrom C₁₋₆alkyl, C₃₋₈cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸,—C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸. In another embodiment isa compound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, R⁵ and R⁶, together with the nitrogen to which theyare attached, form a heterocycloalkyl ring substituted with two R¹⁰, andR¹⁰ is halogen. In another embodiment is a compound of Formula (Ia), ora solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶,R⁵ and R⁶, together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with two R¹⁰, and R¹⁰ is oxo. Inanother embodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰ selected from C₁₋₆alkyl, C₃₋₈cycloalkyl,C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸,and —NR⁹SO₂R⁸. In another embodiment is a compound of Formula (Ia), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is C₁₋₆alkyl. Inanother embodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰, and R¹⁰ is C₃₋₈cycloalkyl. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰, and R¹⁰ is C₁₋₆haloalkyl. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰, and R¹⁰ is halogen. In another embodiment is acompound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to whichthey are attached, form a heterocycloalkyl ring substituted with oneR¹⁰, and R¹⁰ is —CO₂R⁸. In another embodiment is a compound of Formula(Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶,and R⁵ and R⁶, together with the nitrogen to which they are attached,form a heterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —CO₂H.In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —C(O)R⁸. Inanother embodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰, and R¹⁰ is —C(O)CH₃. In another embodiment isa compound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to whichthey are attached, form a heterocycloalkyl ring substituted with oneR¹⁰, and R¹⁰ is —C(O)NR⁸R⁹. In another embodiment is a compound ofFormula (Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein p is 1, R³ is—NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to which they areattached, form a heterocycloalkyl ring substituted with one R¹⁰, and R¹⁰is —C(O)NH₂. In another embodiment is a compound of Formula (Ia), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —SO₂R⁸. Inanother embodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰, and R¹⁰ is —SO₂CH₃. In another embodiment is acompound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to whichthey are attached, form a heterocycloalkyl ring substituted with oneR¹⁰, and R¹⁰ is —NR⁹C(O)R⁸. In another embodiment is a compound ofFormula (Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein p is 1, R³ is—NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to which they areattached, form a heterocycloalkyl ring substituted with one R¹⁰, and R¹⁰is —NHC(O)CH₃. In another embodiment is a compound of Formula (Ia), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —NR⁹SO₂R⁸. Inanother embodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰, and R¹⁰ is —NHSO₂CH₃. In another embodiment isa compound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to whichthey are attached, form a heterocycloalkyl ring selected from:

In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring selected from:

In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —OR⁷. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is independently selectedfrom C₁₋₆alkyl, C₁₋₆haloalkyl, C₁₋₆aminoalkyl,—C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),heterocycloalkyl, aryl, and heteroaryl, wherein heterocycloalkyl, aryl,and heteroaryl are optionally substituted with one or two groupsselected from oxo, C₁₋₆alkyl, C₁₋₆haloalkyl, CO₂H, and C(O)NH₂. Inanother embodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is C₁₋₆alkyl. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is C₁₋₆haloalkyl. Inanother embodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is C₁₋₆aminoalkyl. Inanother embodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is—C₁₋₆alkyl(heterocycloalkyl). In another embodiment is a compound ofFormula (Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein p is 1 and R³ is—OR⁷, and R⁷ is —C₁₋₆alkyl-C(O)(heterocycloalkyl). In another embodimentis a compound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1 and R³ is —OR⁷, and R⁷ is heterocycloalkyl optionally substitutedwith one or two groups selected from oxo, C₁₋₆alkyl, C₁₋₆ haloalkyl,CO₂H, and C(O)NH₂. In another embodiment is a compound of Formula (Ia),or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1 and R³ is —OR⁷,and R⁷ is heteroaryl optionally substituted with one or two groupsselected from oxo, C₁₋₆alkyl, C₁₋₆haloalkyl, CO₂H, and C(O)NH₂.

In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —CO₂R⁸. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —CO₂H. In another embodiment is acompound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1 and R³ is —C(O)NR⁸R⁹. In another embodiment is a compound ofFormula (Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein p is 1 and R³ is—C(O)NH₂.

In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2 and each R³ is independentlyselected from C₁₋₆alkyl, C₂₋₆alkynyl, halogen, —CN, C₁₋₆haloalkyl,heterocycloalkyl, —C₁₋₆alkyl(heterocycloalkyl), heteroaryl, —SF₅,—NR⁵R⁶, —OR⁷, —CO₂R⁸, —C(O)R⁸, and —C(O)NR⁸R⁹. In another embodiment isa compound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 2 and each R³ is independently selected from C₁₋₆alkyl, C₂₋₆alkynyl,halogen, C₁₋₆haloalkyl, —C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶, —OR⁷,—CO₂R⁸, and —C(O)NR⁸R⁹. In another embodiment is a compound of Formula(Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 2 and each R³ isindependently selected from C₁₋₆alkyl, halogen, C₁₋₆haloalkyl,—C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶, —OR⁷, —CO₂R⁸, and —C(O)NR⁸R⁹. Inanother embodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is halogen, and one R³ is —OR⁷. Inanother embodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is —Cl, one R³ is —OR⁷, and R⁷ isC₁₋₆alkyl. In another embodiment is a compound of Formula (Ia), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is —Cl, one R³ is —OR⁷,and R⁷ is —C₁₋₆alkyl(heterocycloalkyl). In another embodiment is acompound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 2, one R³ is halogen, and one R³ is —NR⁵R⁶. In another embodiment isa compound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 2, one R³ is halogen, one R³ is —NR⁵R⁶, and R⁵ and R⁶, together withthe nitrogen to which they are attached, form an unsubstitutedheterocycloalkyl ring. In another embodiment is a compound of Formula(Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 2, one R³ ishalogen, one R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen towhich they are attached, form a heterocycloalkyl ring substituted withone or two R¹⁰ independently selected from C₁₋₆alkyl, C₃₋₈cycloalkyl,C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸,and —NR⁹SO₂R⁸. In another embodiment is a compound of Formula (Ia), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is —Cl, and one R³ is—NR⁵R⁶. In another embodiment is a compound of Formula (Ia), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is —Cl, one R³ is—NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to which they areattached, form an unsubstituted heterocycloalkyl ring. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is —Cl, one R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one or two R¹⁰ independentlyselected from C₁₋₆alkyl, C₃₋₈cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸,—C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is C₁₋₆haloalkyl, and one R³ is —NR⁵R⁶.In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is C₁₋₆haloalkyl, one R³is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to which they areattached, form an unsubstituted heterocycloalkyl ring. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is C₁₋₆haloalkyl, one R³ is —NR⁵R⁶, andR⁵ and R⁶, together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one or two R¹⁰ independentlyselected from C₁₋₆alkyl, C₃₋₈cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸,—C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is —CF₃, and one R³ is —NR⁵R⁶. Inanother embodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is —CF₃, one R³ is —NR⁵R⁶, and R⁵ andR⁶, together with the nitrogen to which they are attached, form anunsubstituted heterocycloalkyl ring. In another embodiment is a compoundof Formula (Ia), or a solvate, hydrate, tautomer, N-oxide, stereoisomer,or a pharmaceutically acceptable salt thereof, wherein p is 2, one R³ is—CF₃, one R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen towhich they are attached, form a heterocycloalkyl ring substituted withone or two R¹⁰ independently selected from C₁₋₆alkyl, C₃₋₈cycloalkyl,C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸,and —NR⁹SO₂R⁸.

In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is C₁₋₆alkyl, halogen,C₁₋₆haloalkyl, —C₁₋₆alkyl(heterocycloalkyl), —OR⁷, —CO₂R⁸, or—C(O)NR⁸R⁹, and one R³ is —NR⁵R⁶, wherein R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringselected from:

In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is C₁₋₆alkyl, halogen,C₁₋₆haloalkyl, —C₁₋₆alkyl(heterocycloalkyl), —OR⁷, —CO₂R⁸, or—C(O)NR⁸R⁹, and one R³ is —NR⁵R⁶, wherein R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringselected from:

In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein two adjacent R³ form a heterocycloalkylring optionally substituted with one, two, or three R⁴. In anotherembodiment is a compound of Formula (Ia), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein two adjacent R³ form an unsubstituted heterocycloalkylring. In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein two adjacent R³ form a heterocycloalkylring substituted with one, two, or three R⁴. In another embodiment is acompound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein twoadjacent R³ form a heterocycloalkyl ring substituted with one or two R⁴.In another embodiment is a compound of Formula (Ia), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein two adjacent R³ form a heterocycloalkylring substituted with one or two R⁴ independently selected fromC₁₋₆alkyl, C₃₋₈cycloalkyl, —C(O)R⁸, and —SO₂R⁸. In another embodiment isa compound of Formula (Ia), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein twoadjacent R³ form a heterocycloalkyl ring selected from:

In some embodiments is a compound having the structure of Formula (II):

-   -   wherein:    -   R¹ is H or optionally substituted C₁₋₆alkyl;    -   R² is H or optionally substituted C₁₋₆alkyl;    -   each R³ is independently selected from C₁₋₆alkyl, halogen, —CN,        C₁₋₆haloalkyl, aminoalkyl, —C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶,        —OR⁷, —CO₂R⁸, —C(O)R⁸, and —C(O)NR⁸R⁹; or two adjacent R³ form a        heterocycloalkyl ring optionally substituted with one, two, or        three R⁴;    -   each R⁴ is selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,        halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸,        —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   each R⁵ and R⁶ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, aminoalkyl, cycloalkyl, —C₁₋₆        alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        optionally substituted heterocycloalkyl, optionally substituted        aryl, and optionally substituted heteroaryl; or R⁵ and R⁶,        together with the nitrogen to which they are attached, form a        heterocycloalkyl ring optionally substituted with one, two, or        three R¹⁰;    -   each R⁷ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, aminoalkyl, cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        optionally substituted heterocycloalkyl, optionally substituted        aryl, and optionally substituted heteroaryl;    -   each R⁸ and R⁹ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, cycloalkyl, aryl, and heteroaryl;    -   each R¹⁰ is selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,        halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸,        —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸; and    -   p is 0, 1, 2, 3, 4, or 5;    -   or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or        pharmaceutically acceptable salt thereof.

In some embodiments is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein R¹ is H. In some embodiments is acompound of Formula (II), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R²is H. In some embodiments is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein R¹ and R² are both H. In someembodiments is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein R¹ is C₁₋₆alkyl. In some embodiments is a compound ofFormula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein R¹ is —CH₃. In someembodiments is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein R² is C₁₋₆alkyl. In some embodiments is a compound ofFormula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein R² is —CH₃. In someembodiments is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein R¹ and R² are both C₁₋₆alkyl. In some embodiments is acompound of Formula (II), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R¹and R² are both —CH₃.

In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 0, 1, 2, or 3. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 0. In another embodiment is a compound of Formula(II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2. In another embodiment is a compound of Formula(II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 3. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 4. In another embodiment is a compound of Formula(II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 5.

In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is selected fromC₁₋₆alkyl, halogen, C₁₋₆haloalkyl, —C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶,—OR⁷, —CO₂R⁸, and —C(O)NR⁸R⁹. In another embodiment is a compound ofFormula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein p is 1 and R³ isC₁₋₆alkyl. In another embodiment is a compound of Formula (II), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is halogen. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —Cl. In another embodiment is acompound of Formula (II), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1 and R³ is C₁₋₆haloalkyl. In another embodiment is a compound ofFormula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein p is 1 and R³ is—CF₃. In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is—C₁₋₆alkyl(heterocycloalkyl).

In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —NR⁵R⁶. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringoptionally substituted with one, two, or three R¹⁰. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form an unsubstitutedheterocycloalkyl ring. In another embodiment is a compound of Formula(II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶,and R⁵ and R⁶, together with the nitrogen to which they are attached,form a heterocycloalkyl ring substituted with one or two R¹⁰independently selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸.In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with two R¹⁰ independently selectedfrom C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸,—C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸. In another embodiment isa compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, R⁵ and R⁶, together with the nitrogen to which theyare attached, form a heterocycloalkyl ring substituted with two R¹⁰, andR¹⁰ is halogen. In another embodiment is a compound of Formula (II), ora solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶,R⁵ and R⁶, together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with two R¹⁰, and R¹⁰ is oxo. Inanother embodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰ selected from C₁₋₆alkyl, cycloalkyl,C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸,and —NR⁹SO₂R⁸. In another embodiment is a compound of Formula (II), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is C₁₋₆alkyl. Inanother embodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰, and R¹⁰ is cycloalkyl. In another embodimentis a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to whichthey are attached, form a heterocycloalkyl ring substituted with oneR¹⁰, and R¹⁰ is C₁₋₆haloalkyl. In another embodiment is a compound ofFormula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein p is 1, R³ is—NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to which they areattached, form a heterocycloalkyl ring substituted with one R¹⁰, and R¹⁰is halogen. In another embodiment is a compound of Formula (II), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —CO₂R⁸. Inanother embodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰, and R¹⁰ is —CO₂H. In another embodiment is acompound of Formula (II), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to whichthey are attached, form a heterocycloalkyl ring substituted with oneR¹⁰, and R¹⁰ is —C(O)R⁸. In another embodiment is a compound of Formula(II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶,and R⁵ and R⁶, together with the nitrogen to which they are attached,form a heterocycloalkyl ring substituted with one R¹⁰, and R⁰ is—C(O)CH₃. In another embodiment is a compound of Formula (II), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —C(O)NR⁸R⁹.In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —C(O)NH₂. Inanother embodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰, and R¹⁰ is —SO₂R⁸. In another embodiment is acompound of Formula (II), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to whichthey are attached, form a heterocycloalkyl ring substituted with oneR¹⁰, and R¹⁰ is —SO₂CH₃. In another embodiment is a compound of Formula(II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶,and R⁵ and R⁶, together with the nitrogen to which they are attached,form a heterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is—NR⁹C(O)R⁸. In another embodiment is a compound of Formula (II), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —NHC(O)CH₃.In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —NR⁹SO₂R⁸. Inanother embodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one R¹⁰, and R¹⁰ is —NHSO₂CH₃. In another embodiment isa compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to whichthey are attached, form a heterocycloalkyl ring selected from:

In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring selected from:

In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —OR⁷. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is independently selectedfrom C₁₋₆alkyl, C₁₋₆haloalkyl, aminoalkyl, —C₁₋₆alkyl(heterocycloalkyl),—C₁₋₆alkyl-C(O)(heterocycloalkyl), optionally substitutedheterocycloalkyl, and optionally substituted heteroaryl. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is C₁₋₆alkyl. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is C₁₋₆haloalkyl. Inanother embodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is aminoalkyl. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is—C₁₋₆alkyl(heterocycloalkyl). In another embodiment is a compound ofFormula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein p is 1 and R³ is—OR⁷, and R⁷ is —C₁₋₆alkyl-C(O)(heterocycloalkyl). In another embodimentis a compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1 and R³ is —OR⁷, and R⁷ is optionally substituted heterocycloalkyl.In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —OR⁷, and R⁷ isoptionally substituted heteroaryl.

In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —CO₂R⁸. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —CO₂H. In another embodiment is acompound of Formula (II), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1 and R³ is —C(O)NR⁸R⁹. In another embodiment is a compound ofFormula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, ora pharmaceutically acceptable salt thereof, wherein p is 1 and R³ is—C(O)NH₂.

In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2 and each R³ is independentlyselected from C₁₋₆alkyl, halogen, C₁₋₆haloalkyl,—C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶, —OR⁷, —CO₂R⁸, and —C(O)NR⁸R⁹. Inanother embodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is halogen, and one R³ is —OR⁷. Inanother embodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is —Cl, one R³ is —OR⁷, and R⁷ isC₁₋₆alkyl. In another embodiment is a compound of Formula (II), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is —Cl, one R³ is —OR⁷,and R⁷ is —C₁₋₆alkyl(heterocycloalkyl). In another embodiment is acompound of Formula (II), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 2, one R³ is halogen, and one R³ is —NR⁵R⁶. In another embodiment isa compound of Formula (II), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 2, one R³ is halogen, one R³ is —NR⁵R⁶, and R⁵ and R⁶, together withthe nitrogen to which they are attached, form an unsubstitutedheterocycloalkyl ring. In another embodiment is a compound of Formula(II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 2, one R³ ishalogen, one R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen towhich they are attached, form a heterocycloalkyl ring substituted withone or two R¹⁰ independently selected from C₁₋₆alkyl, cycloalkyl,C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸,and —NR⁹SO₂R⁸. In another embodiment is a compound of Formula (II), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is —Cl, and one R³ is—NR⁵R⁶. In another embodiment is a compound of Formula (II), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is —Cl, one R³ is—NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to which they areattached, form an unsubstituted heterocycloalkyl ring. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is —Cl, one R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one or two R¹⁰ independentlyselected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸,—C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is C₁₋₆haloalkyl, and one R³ is —NR⁵R⁶.In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is C₁₋₆haloalkyl, one R³is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to which they areattached, form an unsubstituted heterocycloalkyl ring. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is C₁₋₆haloalkyl, one R³ is —NR⁵R⁶, andR⁵ and R⁶, together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one or two R¹⁰ independentlyselected from C₁₋-6alkyl, cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸,—C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is —CF₃, and one R³ is —NR⁵R⁶. Inanother embodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is —CF₃, one R³ is —NR⁵R⁶, and R⁵ andR⁶, together with the nitrogen to which they are attached, form anunsubstituted heterocycloalkyl ring. In another embodiment is a compoundof Formula (II), or a solvate, hydrate, tautomer, N-oxide, stereoisomer,or a pharmaceutically acceptable salt thereof, wherein p is 2, one R³ is—CF₃, one R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen towhich they are attached, form a heterocycloalkyl ring substituted withone or two R¹⁰ independently selected from C₁₋₆alkyl, cycloalkyl,C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸,and —NR⁹SO₂R⁸.

In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is C₁₋₆alkyl, halogen,C₁₋₆haloalkyl, —C₁₋₆alkyl(heterocycloalkyl), —OR⁷, —CO₂R⁸, or—C(O)NR⁸R⁹, and one R³ is —NR⁵R⁶, wherein R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringselected from:

In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is C₁₋₆alkyl, halogen,C₁₋₆haloalkyl, —C₁₋₆alkyl(heterocycloalkyl), —OR⁷, —CO₂R⁸, or—C(O)NR⁸R⁹, and one R³ is —NR⁵R⁶, wherein R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringselected from:

In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein two adjacent R³ form a heterocycloalkylring optionally substituted with one, two, or three R⁴. In anotherembodiment is a compound of Formula (II), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein two adjacent R³ form an unsubstituted heterocycloalkylring. In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein two adjacent R³ form a heterocycloalkylring substituted with one, two, or three R⁴. In another embodiment is acompound of Formula (II), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein twoadjacent R³ form a heterocycloalkyl ring substituted with one or two R⁴.In another embodiment is a compound of Formula (II), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein two adjacent R³ form a heterocycloalkylring substituted with one or two R⁴ independently selected fromC₁₋₆alkyl, cycloalkyl, —C(O)R⁸, and —SO₂R⁸. In another embodiment is acompound of Formula (II), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein twoadjacent R³ form a heterocycloalkyl ring selected from:

In some embodiments is a compound having the structure of Formula (III):

-   -   wherein:    -   R¹ is H or optionally substituted C₁₋₆alkyl;    -   R² is H or optionally substituted C₁₋₆alkyl;    -   each R³ is independently selected from C₁₋₆alkyl, halogen, —CN,        C₁₋₆haloalkyl, aminoalkyl, —C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶,        —OR⁷, —CO₂R⁸, —C(O)R⁸, and —C(O)NR⁸R⁹; or two adjacent R³ form a        heterocycloalkyl ring optionally substituted with one, two, or        three R⁴;    -   each R⁴ is selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,        halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸,        —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;    -   each R⁵ and R⁶ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, aminoalkyl, cycloalkyl, —C₁₋₆        alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        optionally substituted heterocycloalkyl, optionally substituted        aryl, and optionally substituted heteroaryl; or R⁵ and R⁶,        together with the nitrogen to which they are attached, form a        heterocycloalkyl ring optionally substituted with one, two, or        three R¹⁰;    -   each R⁷ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, aminoalkyl, cycloalkyl,        —C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),        optionally substituted heterocycloalkyl, optionally substituted        aryl, and optionally substituted heteroaryl;    -   each R⁸ and R⁹ is independently selected from H, C₁₋₆alkyl,        C₁₋₆haloalkyl, cycloalkyl, aryl, and heteroaryl;    -   each R¹⁰ is selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,        halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸,        —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸; and    -   p is 0, 1, 2, 3, 4, or 5;    -   or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or        pharmaceutically acceptable salt thereof.

In some embodiments is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein R¹ is H. In some embodiments is acompound of Formula (III), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R²is H. In some embodiments is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein R¹ and R² are both H. In someembodiments is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein R¹ is C₁₋₆alkyl. In some embodiments is a compound ofFormula (III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer,or a pharmaceutically acceptable salt thereof, wherein R¹ is —CH₃. Insome embodiments is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein R² is C₁₋₆alkyl. In some embodiments is a compound ofFormula (III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer,or a pharmaceutically acceptable salt thereof, wherein R² is —CH₃. Insome embodiments is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein R¹ and R² are both C₁₋₆alkyl. In some embodiments is acompound of Formula (III), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R¹and R² are both —CH₃.

In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 0, 1, 2, or 3. In anotherembodiment is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 0. In another embodiment is a compound of Formula(III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1. In anotherembodiment is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2. In another embodiment is a compound of Formula(III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 3. In anotherembodiment is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 4. In another embodiment is a compound of Formula(III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 5.

In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is selected fromC₁₋₆alkyl, halogen, C₁₋₆haloalkyl, —C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶,—OR⁷, —CO₂R⁸, and —C(O)NR⁸R⁹. In another embodiment is a compound ofFormula (III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer,or a pharmaceutically acceptable salt thereof, wherein p is 1 and R³ isC₁₋₆alkyl. In another embodiment is a compound of Formula (III), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is halogen. In anotherembodiment is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —Cl. In another embodiment is acompound of Formula (III), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1 and R³ is C₁₋₆haloalkyl. In another embodiment is a compound ofFormula (III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer,or a pharmaceutically acceptable salt thereof, wherein p is 1 and R³ is—CF₃. In another embodiment is a compound of Formula (III), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is—C₁₋₆alkyl(heterocycloalkyl).

In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —NR⁵R⁶. In anotherembodiment is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringoptionally substituted with one, two, or three R¹⁰. In anotherembodiment is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form an unsubstitutedheterocycloalkyl ring. In another embodiment is a compound of Formula(III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶,and R⁵ and R⁶, together with the nitrogen to which they are attached,form a heterocycloalkyl ring substituted with one or two R¹⁰independently selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸.In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with two R¹⁰ independently selectedfrom C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸,—C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸. In another embodiment isa compound of Formula (III), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1, R³ is —NR⁵R⁶, R⁵ and R⁶, together with the nitrogen to which theyare attached, form a heterocycloalkyl ring substituted with two R¹⁰, andR¹⁰ is halogen. In another embodiment is a compound of Formula (III), ora solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶,R⁵ and R⁶, together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with two R¹⁰, and R¹⁰ is oxo. Inanother embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰ selected from C₁₋₆alkyl,cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸,—NR⁹C(O)R⁸, and —NR⁹SO₂R⁸. In another embodiment is a compound ofFormula (III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer,or a pharmaceutically acceptable salt thereof, wherein p is 1, R³ is—NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to which they areattached, form a heterocycloalkyl ring substituted with one R¹⁰, and R¹⁰is C₁₋₆alkyl. In another embodiment is a compound of Formula (III), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is cycloalkyl.In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ isC₁₋₆haloalkyl. In another embodiment is a compound of Formula (III), ora solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶,and R⁵ and R⁶, together with the nitrogen to which they are attached,form a heterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ ishalogen. In another embodiment is a compound of Formula (III), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —CO₂R⁸. Inanother embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —CO₂H. Inanother embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —C(O)R⁸. Inanother embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —C(O)CH₃. Inanother embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —C(O)NR⁸R⁹.In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —C(O)NH₂. Inanother embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —SO₂R⁸. Inanother embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —SO₂CH₃. Inanother embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —NR⁹C(O)R⁸.In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R¹⁰ is —NHC(O)CH₃.In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R⁰ is —NR⁹SO₂R⁸. Inanother embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one R¹⁰, and R⁰ is —NHSO₂CH₃. Inanother embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring selected from:

In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1, R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form aheterocycloalkyl ring selected from:

In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —OR⁷. In anotherembodiment is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is independently selectedfrom C₁₋₆alkyl, C₁₋₆haloalkyl, aminoalkyl, —C₁₋₆alkyl(heterocycloalkyl),—C₁₋₆alkyl-C(O)(heterocycloalkyl), optionally substitutedheterocycloalkyl, and optionally substituted heteroaryl. In anotherembodiment is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is C₁₋₆alkyl. In anotherembodiment is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is C₁₋₆haloalkyl. Inanother embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —OR⁷, and R⁷ isaminoalkyl. In another embodiment is a compound of Formula (III), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —OR⁷, and R⁷ is—C₁₋₆alkyl(heterocycloalkyl). In another embodiment is a compound ofFormula (III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer,or a pharmaceutically acceptable salt thereof, wherein p is 1 and R³ is—OR⁷, and R⁷ is —C₁₋₆alkyl-C(O)(heterocycloalkyl). In another embodimentis a compound of Formula (III), or a solvate, hydrate, tautomer,N-oxide, stereoisomer, or a pharmaceutically acceptable salt thereof,wherein p is 1 and R³ is —OR⁷, and R⁷ is optionally substitutedheterocycloalkyl. In another embodiment is a compound of Formula (III),or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 1 and R³ is —OR⁷,and R⁷ is optionally substituted heteroaryl.

In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 1 and R³ is —CO₂R⁸. In anotherembodiment is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 1 and R³ is —CO₂H. In another embodiment is acompound of Formula (III), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 1 and R³ is —C(O)NR⁸R⁹. In another embodiment is a compound ofFormula (III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer,or a pharmaceutically acceptable salt thereof, wherein p is 1 and R³ is—C(O)NH₂.

In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2 and each R³ is independentlyselected from C₁₋₆alkyl, halogen, C₁₋₆haloalkyl,—C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶, —OR⁷, —CO₂R⁸, and —C(O)NR⁸R⁹. Inanother embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is halogen, and one R³is —OR⁷. In another embodiment is a compound of Formula (III), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is —Cl, one R³ is —OR⁷,and R⁷ is C₁₋₆alkyl. In another embodiment is a compound of Formula(III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 2, one R³ is —Cl,one R³ is —OR⁷, and R⁷ is —C₁₋₆alkyl(heterocycloalkyl). In anotherembodiment is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is halogen, and one R³ is —NR⁵R⁶. Inanother embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is halogen, one R³ is—NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to which they areattached, form an unsubstituted heterocycloalkyl ring. In anotherembodiment is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is halogen, one R³ is —NR⁵R⁶, and R⁵ andR⁶, together with the nitrogen to which they are attached, form aheterocycloalkyl ring substituted with one or two R¹⁰ independentlyselected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸,—C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸. In anotherembodiment is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is —Cl, and one R³ is —NR⁵R⁶. In anotherembodiment is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein p is 2, one R³ is —Cl, one R³ is —NR⁵R⁶, and R⁵ and R⁶,together with the nitrogen to which they are attached, form anunsubstituted heterocycloalkyl ring. In another embodiment is a compoundof Formula (III), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 2, one R³ is —Cl, one R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one or two R¹⁰ independently selected from C₁₋₆alkyl,cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸,—NR⁹C(O)R⁸, and —NR⁹SO₂R⁸. In another embodiment is a compound ofFormula (III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer,or a pharmaceutically acceptable salt thereof, wherein p is 2, one R³ isC₁₋₆haloalkyl, and one R³ is —NR⁵R⁶. In another embodiment is a compoundof Formula (III), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein pis 2, one R³ is C₁₋₆haloalkyl, one R³ is —NR⁵R⁶, and R⁵ and R⁶, togetherwith the nitrogen to which they are attached, form an unsubstitutedheterocycloalkyl ring. In another embodiment is a compound of Formula(III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or apharmaceutically acceptable salt thereof, wherein p is 2, one R³ isC₁₋₆haloalkyl, one R³ is —NR⁵R⁶, and R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringsubstituted with one or two R¹⁰ independently selected from C₁₋₆alkyl,cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸,—NR⁹C(O)R⁸, and —NR⁹SO₂R⁸. In another embodiment is a compound ofFormula (III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer,or a pharmaceutically acceptable salt thereof, wherein p is 2, one R³ is—CF₃, and one R³ is —NR⁵R⁶. In another embodiment is a compound ofFormula (III), or a solvate, hydrate, tautomer, N-oxide, stereoisomer,or a pharmaceutically acceptable salt thereof, wherein p is 2, one R³ is—CF₃, one R³ is —NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen towhich they are attached, form an unsubstituted heterocycloalkyl ring. Inanother embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is —CF₃, one R³ is—NR⁵R⁶, and R⁵ and R⁶, together with the nitrogen to which they areattached, form a heterocycloalkyl ring substituted with one or two R¹⁰independently selected from C₁₋₆alkyl, cycloalkyl, C₁₋₆haloalkyl,halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸.

In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is C₁₋₆alkyl, halogen,C₁₋₆haloalkyl, —C₁₋₆alkyl(heterocycloalkyl), —OR⁷, —CO₂R⁸, or—C(O)NR⁸R⁹, and one R³ is —NR⁵R⁶, wherein R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringselected from:

In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein p is 2, one R³ is C₁₋₆alkyl, halogen,C₁₋₆haloalkyl, —C₁₋₆alkyl(heterocycloalkyl), —OR⁷, —CO₂R⁸, or—C(O)NR⁸R⁹, and one R³ is —NR⁵R⁶, wherein R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringselected from:

In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein two adjacent R³ form a heterocycloalkylring optionally substituted with one, two, or three R⁴. In anotherembodiment is a compound of Formula (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, wherein two adjacent R³ form an unsubstituted heterocycloalkylring. In another embodiment is a compound of Formula (III), or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein two adjacent R³ form a heterocycloalkylring substituted with one, two, or three R⁴. In another embodiment is acompound of Formula (III), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein twoadjacent R³ form a heterocycloalkyl ring substituted with one or two R⁴.In another embodiment is a compound of Formula (III), or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or a pharmaceuticallyacceptable salt thereof, wherein two adjacent R³ form a heterocycloalkylring substituted with one or two R⁴ independently selected fromC₁₋₆alkyl, cycloalkyl, —C(O)R⁸, and —SO₂R⁸. In another embodiment is acompound of Formula (III), or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or a pharmaceutically acceptable salt thereof, wherein twoadjacent R³ form a heterocycloalkyl ring selected from:

Further embodiments provided herein include combinations of one or moreof the particular embodiments set forth above.

In some embodiments, the compound disclosed herein has the structureprovided in Examples 1-281.

In another embodiment is a compound having the structure:

wherein R¹, R², R³, m, n, and p are defined as in Formula (I) describedherein, and x and y are at least one amino acid (aa).

In another embodiment is a compound having the structure:

wherein R¹, R², R³, m, n, and p are defined as in Formula (I) describedherein, and x and y are at least one amino acid (aa).

Described herein are inhibitors of monoacylglycerol lipase (MAGL) havingthe structure of Formula (I). In one embodiment, the inhibitors of MAGLare covalent inhibitors of MAGL, that is, the compounds of Formula (I)react with a serine residue of MAGL to form a modified serine residue,comprising the staying group of Formula (I); in such an embodiment, theleaving group of Formula (I) is removed from the compound of Formula(I). In a further embodiment, the covalent inhibitors of MAGL reactirreversibly with a serine residue of MAGL to form the modified serineresidue.

The staying group portion of the compounds of Formula (I) is:

The leaving group portion of the compounds of Formula (I) is:

In another embodiment is a compound having the structure:

wherein R¹, R², R³, m, n, and p are defined as in Formula (I) describedherein, and x and y are at least one amino acid (aa).

In another embodiment is a compound having the structure:

wherein R¹, R², R³, m, n, and p are defined as in Formula (Ia) describedherein, and x and y are at least one amino acid (aa).

Described herein are inhibitors of monoacylglycerol lipase (MAGL) havingthe structure of Formula (Ia). In one embodiment, the inhibitors of MAGLare covalent inhibitors of MAGL, that is, the compounds of Formula (Ia)react with a serine residue of MAGL to form a modified serine residue,comprising the staying group of Formula (Ia); in such an embodiment, theleaving group of Formula (Ia) is removed from the compound of Formula(Ia). In a further embodiment, the covalent inhibitors of MAGL reactirreversibly with a serine residue of MAGL to form the modified serineresidue.

The staying group portion of the compounds of Formula (Ia) is:

The leaving group portion of the compounds of Formula (Ia) is:

Preparation of the Compounds

The compounds used in the reactions described herein are made accordingto known organic synthesis techniques, starting from commerciallyavailable chemicals and/or from compounds described in the chemicalliterature. “Commercially available chemicals” are obtained fromstandard commercial sources including Acros Organics (Geel, Belgium),Aldrich Chemical (Milwaukee, Wis., including Sigma Chemical and Fluka),Apin Chemicals Ltd. (Milton Park, UK), Ark Pharm, Inc. (Libertyville,Ill.), Avocado Research (Lancashire, U.K.), BDH Inc. (Toronto, Canada),Bionet (Cornwall, U.K.), Chemservice Inc. (West Chester, Pa.),Combi-blocks (San Diego, Calif.), Crescent Chemical Co. (Hauppauge,N.Y.), eMolecules (San Diego, Calif.), Fisher Scientific Co.(Pittsburgh, Pa.), Fisons Chemicals (Leicestershire, UK), FrontierScientific (Logan, Utah), ICN Biomedicals, Inc. (Costa Mesa, Calif.),Key Organics (Cornwall, U.K.), Lancaster Synthesis (Windham, N.H.),Matrix Scientific, (Columbia, S.C.), Maybridge Chemical Co. Ltd.(Cornwall, U.K.), Parish Chemical Co. (Orem, Utah), Pfaltz & Bauer, Inc.(Waterbury, Conn.), Polyorganix (Houston, Tex.), Pierce Chemical Co.(Rockford, Ill.), Riedel de Haen AG (Hanover, Germany), Ryan Scientific,Inc. (Mount Pleasant, S.C.), Spectrum Chemicals (Gardena, Calif.),Sundia Meditech, (Shanghai, China), TCI America (Portland, Oreg.), TransWorld Chemicals, Inc. (Rockville, Md.), and WuXi (Shanghai, China).

Suitable reference books and treatises that detail the synthesis ofreactants useful in the preparation of compounds described herein, orprovide references to articles that describe the preparation, includefor example, “Synthetic Organic Chemistry”, John Wiley & Sons, Inc., NewYork; S. R. Sandler et al., “Organic Functional Group Preparations,” 2ndEd., Academic Press, New York, 1983; H. O. House, “Modern SyntheticReactions”, 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif. 1972; T. L.Gilchrist, “Heterocyclic Chemistry”, 2nd Ed., John Wiley & Sons, NewYork, 1992; J. March, “Advanced Organic Chemistry: Reactions, Mechanismsand Structure”, 4th Ed., Wiley-Interscience, New York, 1992. Additionalsuitable reference books and treatises that detail the synthesis ofreactants useful in the preparation of compounds described herein, orprovide references to articles that describe the preparation, includefor example, Fuhrhop, J. and Penzlin G. “Organic Synthesis: Concepts,Methods, Starting Materials”, Second, Revised and Enlarged Edition(1994) John Wiley & Sons ISBN: 3-527-29074-5; Hoffman, R. V. “OrganicChemistry, An Intermediate Text” (1996) Oxford University Press, ISBN0-19-509618-5; Larock, R. C. “Comprehensive Organic Transformations: AGuide to Functional Group Preparations” 2nd Edition (1999) Wiley-VCH,ISBN: 0-471-19031-4; March, J. “Advanced Organic Chemistry: Reactions,Mechanisms, and Structure” 4th Edition (1992) John Wiley & Sons, ISBN:0-471-60180-2; Otera, J. (editor) “Modern Carbonyl Chemistry” (2000)Wiley-VCH, ISBN: 3-527-29871-1; Patai, S. “Patai's 1992 Guide to theChemistry of Functional Groups” (1992) Interscience ISBN: 0-471-93022-9;Solomons, T. W. G. “Organic Chemistry” 7th Edition (2000) John Wiley &Sons, ISBN: 0-471-19095-0; Stowell, J. C., “Intermediate OrganicChemistry” 2nd Edition (1993) Wiley-Interscience, ISBN: 0-471-57456-2;“Industrial Organic Chemicals: Starting Materials and Intermediates: AnUllmann's Encyclopedia” (1999) John Wiley & Sons, ISBN: 3-527-29645-X,in 8 volumes; “Organic Reactions” (1942-2000) John Wiley & Sons, in over55 volumes; and “Chemistry of Functional Groups” John Wiley & Sons, in73 volumes.

Specific and analogous reactants are also identified through the indicesof known chemicals prepared by the Chemical Abstract Service of theAmerican Chemical Society, which are available in most public anduniversity libraries, as well as through on-line databases (the AmericanChemical Society, Washington, D.C., may be contacted for more details).Chemicals that are known but not commercially available in catalogs areoptionally prepared by custom chemical synthesis houses, where many ofthe standard chemical supply houses (e.g., those listed above) providecustom synthesis services. A reference for the preparation and selectionof pharmaceutical salts of the spirocycle compounds described herein isP. H. Stahl & C. G. Wermuth “Handbook of Pharmaceutical Salts”, VerlagHelvetica Chimica Acta, Zurich, 2002.

The compounds of Formula (I), (Ia), (II), or (III) described herein areprepared by the general synthetic routes described below in Schemes 1-3.

A method for preparing compounds of formula D is provided in Scheme 1.Reaction of spirocyclic amine A with appropriate reagents, such astriphosgene and HFIP, provides intermediate carbamate B. Removal of theBoc group with an acid such as trifluoroacetic acid or HCl leads toamine intermediate C. Reductive amination affords a spirocycle compoundD. In some embodiments, R¹ of compound D contains a protecting group. Infurther embodiments, the protecting group is removed and additionalfunctionalization of the compound is performed (e.g., N-alkylation,O-alkylation, acylation, or sulfonylation) to provide another spirocyclecompound of formula D. In some embodiments, N-alkylation of intermediateC using the appropriate electrophile provides a spirocycle compound offormula D. In some embodiments, acylation of intermediate C followed byamide reduction, using a reagent such as borane, provides a spirocyclecompound of formula D.

Another method for preparing compounds of formula D is provided inScheme 2. Reduction amination of spirocyclic amine E providesintermediate compound F. Removal of the Boc group with an acid, such astrifluoroacetic acid or HCl, affords intermediate G. Subsequent couplingwith a reagent such as hexafluoropropan-2-yl chloroformate affords aspirocycle compound of formula D. In some embodiments, N-alkylation ofspirocyclic amine E using the appropriate electrophile providesintermediate F.

A method of preparing compounds of formula L is provided in Scheme 3.Starting material H is alkylated under strongly basic conditions to formintermediate J. Reduction of the nitrile to the amine followed byreductive amination affords intermediate K. Cyclization to thespirocycle using appropriate reagents, such as a Pt(II) catalyst,followed by PMB group removal, and carbamate formation provides aspirocycle compound of formula L.

Further Forms of Compounds Isomers

Furthermore, in some embodiments, the compounds described herein existas geometric isomers. In some embodiments, the compounds describedherein possess one or more double bonds. The compounds presented hereininclude all cis, trans, syn, anti, entgegen (E), and zusammen (Z)isomers as well as the corresponding mixtures thereof. In somesituations, compounds exist as tautomers. The compounds described hereininclude all possible tautomers within the formulas described herein. Insome situations, the compounds described herein possess one or morechiral centers and each center exists in the R configuration, or Sconfiguration. The compounds described herein include alldiastereomeric, enantiomeric, and epimeric forms as well as thecorresponding mixtures thereof. In additional embodiments of thecompounds and methods provided herein, mixtures of enantiomers and/ordiastereoisomers, resulting from a single preparative step, combination,or interconversion are useful for the applications described herein. Insome embodiments, the compounds described herein are prepared as theirindividual stereoisomers by reacting a racemic mixture of the compoundwith an optically active resolving agent to form a pair ofdiastereoisomeric compounds, separating the diastereomers and recoveringthe optically pure enantiomers. In some embodiments, the compoundsdescribed herein are prepared as optically pure enantiomers by chiralchromatographic resolution of the racemic mixture. In some embodiments,dissociable complexes are preferred (e.g., crystalline diastereomericsalts). In some embodiments, the diastereomers have distinct physicalproperties (e.g., melting points, boiling points, solubilities,reactivity, etc.) and are separated by taking advantage of thesedissimilarities. In some embodiments, the diastereomers are separated bychiral chromatography, or preferably, by separation/resolutiontechniques based upon differences in solubility. In some embodiments,the optically pure enantiomer is then recovered, along with theresolving agent, by any practical means that would not result inracemization.

Labeled Compounds

In some embodiments, the compounds described herein exist in theirisotopically-labeled forms. In some embodiments, the methods disclosedherein include methods of treating diseases by administering suchisotopically-labeled compounds. In some embodiments, the methodsdisclosed herein include methods of treating diseases by administeringsuch isotopically-labeled compounds as pharmaceutical compositions.Thus, in some embodiments, the compounds disclosed herein includeisotopically-labeled compounds, which are identical to those recitedherein, but for the fact that one or more atoms are replaced by an atomhaving an atomic mass or mass number different from the atomic mass ormass number usually found in nature. Examples of isotopes that areincorporated into compounds described herein include isotopes ofhydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine andchloride, such as ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, ³¹P, ³²P, ³⁵S, ¹⁸F,and ³⁶Cl, respectively. Compounds described herein, and pharmaceuticallyacceptable salts, esters, solvate, hydrates or derivatives thereof whichcontain the aforementioned isotopes and/or other isotopes of other atomsare within the scope of this disclosure. Certain isotopically-labeledcompounds, for example those into which radioactive isotopes such as ³Hand ¹⁴C are incorporated, are useful in drug and/or substrate tissuedistribution assays. Tritiated, i. e., ³H and carbon-14, i. e., ¹⁴C,isotopes are particularly preferred for their ease of preparation anddetectability. Further, substitution with heavy isotopes such asdeuterium, i.e., ²H, produces certain therapeutic advantages resultingfrom greater metabolic stability, for example increased in vivohalf-life or reduced dosage requirements. In some embodiments, theisotopically labeled compounds, pharmaceutically acceptable salt, ester,solvate, hydrate or derivative thereof is prepared by any suitablemethod.

In some embodiments, the compounds described herein are labeled by othermeans, including, but not limited to, the use of chromophores orfluorescent moieties, bioluminescent labels, or chemiluminescent labels.

Pharmaceutically Acceptable Salts

In some embodiments, the compounds described herein exist as theirpharmaceutically acceptable salts. In some embodiments, the methodsdisclosed herein include methods of treating diseases by administeringsuch pharmaceutically acceptable salts. In some embodiments, the methodsdisclosed herein include methods of treating diseases by administeringsuch pharmaceutically acceptable salts as pharmaceutical compositions.

In some embodiments, the compounds described herein possess acidic orbasic groups and therefore react with any of a number of inorganic ororganic bases, and inorganic and organic acids, to form apharmaceutically acceptable salt. In some embodiments, these salts areprepared in situ during the final isolation and purification of thecompounds described herein, or by separately reacting a purifiedcompound in its free form with a suitable acid or base, and isolatingthe salt thus formed.

Solvates

In some embodiments, the compounds described herein exist as solvates.The disclosure described herein provides for methods of treatingdiseases by administering such solvates. The disclosure further providesfor methods of treating diseases by administering such solvates aspharmaceutical compositions.

Solvates contain either stoichiometric or non-stoichiometric amounts ofa solvent, and, in some embodiments, are formed during the process ofcrystallization with pharmaceutically acceptable solvents such as water,ethanol, and the like. Hydrates are formed when the solvent is water, oralcoholates are formed when the solvent is alcohol. Solvates of thecompounds described herein are conveniently prepared or formed duringthe processes described herein. By way of example only, hydrates of thecompounds described herein are conveniently prepared byrecrystallization from an aqueous/organic solvent mixture, using organicsolvents including, but not limited to, dioxane, tetrahydrofuran ormethanol. In addition, the compounds provided herein exist in unsolvatedas well as solvated forms. In general, the solvated forms are consideredequivalent to the unsolvated forms for the purposes of the compounds andmethods provided herein.

Pharmaceutical Compositions

In certain embodiments, the spirocycle compound as described herein isadministered as a pure chemical. In other embodiments, the spirocyclecompound described herein is combined with a pharmaceutically suitableor acceptable carrier (also referred to herein as a pharmaceuticallysuitable (or acceptable) excipient, physiologically suitable (oracceptable) excipient, or physiologically suitable (or acceptable)carrier) selected on the basis of a chosen route of administration andstandard pharmaceutical practice as described, for example, inRemington: The Science and Practice of Pharmacy (Gennaro, 21^(st) Ed.Mack Pub. Co., Easton, Pa. (2005)).

Accordingly, provided herein is a pharmaceutical composition comprisingat least one spirocycle compound described herein, or a stereoisomer,pharmaceutically acceptable salt, hydrate, solvate, or N-oxide thereof,together with one or more pharmaceutically acceptable carriers. Thecarrier(s) (or excipient(s)) is acceptable or suitable if the carrier iscompatible with the other ingredients of the composition and notdeleterious to the recipient (i.e., the subject) of the composition.

One embodiment provides a pharmaceutical composition comprising apharmaceutically acceptable carrier and a compound of Formula (I), or apharmaceutically acceptable salt thereof.

One embodiment provides a pharmaceutical composition comprising apharmaceutically acceptable carrier and a compound of Formula (Ia), or apharmaceutically acceptable salt thereof.

One embodiment provides a pharmaceutical composition comprising apharmaceutically acceptable carrier and a compound of Formula (II), or apharmaceutically acceptable salt thereof.

One embodiment provides a pharmaceutical composition comprising apharmaceutically acceptable carrier and a compound of Formula (III), ora pharmaceutically acceptable salt thereof.

Another embodiment provides a pharmaceutical composition consistingessentially of a pharmaceutically acceptable carrier and a compound ofFormula (I), or a pharmaceutically acceptable salt thereof. Anotherembodiment provides a pharmaceutical composition consisting essentiallyof a pharmaceutically acceptable carrier and a compound of Formula (Ia),or a pharmaceutically acceptable salt thereof. Another embodimentprovides a pharmaceutical composition consisting essentially of apharmaceutically acceptable carrier and a compound of Formula (II), or apharmaceutically acceptable salt thereof. Another embodiment provides apharmaceutical composition consisting essentially of a pharmaceuticallyacceptable carrier and a compound of Formula (III), or apharmaceutically acceptable salt thereof.

In certain embodiments, the spirocycle compound as described herein issubstantially pure, in that it contains less than about 5%, or less thanabout 1%, or less than about 0.1%, of other organic small molecules,such as contaminating intermediates or by-products that are created, forexample, in one or more of the steps of a synthesis method.

These formulations include those suitable for oral, rectal, topical,buccal, parenteral (e.g., subcutaneous, intramuscular, intradermal, orintravenous), rectal, vaginal, or aerosol administration. Methods

Disclosed herein are methods of modulating the activity of MAGL and/orABHD6. Contemplated methods, for example, comprise exposing said enzymeto a compound described herein. In some embodiments, the compoundutilized by one or more of the foregoing methods is one of the generic,subgeneric, or specific compounds described herein, such as a compoundof Formula (I), (Ia), (II), or (III). The ability of compounds describedherein to modulate or inhibit MAGL and/or ABHD6 is evaluated byprocedures known in the art and/or described herein. Another aspect ofthis disclosure provides methods of treating a disease associated withexpression or activity of MAGL and/or ABHD6 in a patient. For example,provided herein are compounds that are selective in inhibiting MAGL orABHD6, or both, as compared to inhibition of other serine hydrolasese.g., FAAH, e.g., 10, 100, 1000 or more fold inhibition of MAGL overFAAH. In other embodiments, disclosed compounds are more selective ininhibition of MAGL as compared to ABHD6.

In some embodiments is a method of treating pain in a patient,comprising administering a therapeutically effective amount of acompound of Formula (I), (Ia), (II), or (III), or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or a pharmaceutically acceptable saltthereof, to a patient in need thereof to treat said pain. In someembodiments is a method of treating pain in a patient, comprisingadministering a therapeutically effective amount of a compound ofFormula (I), (Ia), (II), or (III), or a solvate, hydrate, tautomer,N-oxide, stereoisomer, or a pharmaceutically acceptable salt thereof, toa patient in need thereof to treat said pain, wherein the pain isneuropathic pain.

Also disclosed herein are methods of treating and/or preventing in apatient in need thereof a disorder such as one or more of acute orchronic pain and neuropathy. Disclosed methods include administering apharmaceutically effective amount of a compound described herein.

In another embodiment is a method of treating a disease or disorder in apatient comprising administering to the patient in need thereof atherapeutically effective amount of a compound of Formula describedherein, or a pharmaceutically acceptable salt or solvate thereof,wherein the disease or disorder is selected from the group consisting ofepilepsy/seizure disorder, multiple sclerosis, neuromyelitis optica(NMO), Tourette syndrome, Alzheimer's disease, and abdominal painassociated with irritable bowel syndrome. In another embodiment is amethod of treating epilepsy/seizure disorder in a patient comprisingadministering to the patient in need thereof a therapeutically effectiveamount of a compound of Formula (I), (Ia), (II), or (III) describedherein, or a pharmaceutically acceptable salt or solvate thereof. Inanother embodiment is a method of treating multiple sclerosis in apatient comprising administering to the patient in need thereof atherapeutically effective amount of a compound of Formula (I), (Ia),(II), or (III) described herein, or a pharmaceutically acceptable saltor solvate thereof. In another embodiment is a method of treatingneuromyelitis optica (NMO) in a patient comprising administering to thepatient in need thereof a therapeutically effective amount of a compoundof Formula (I), (Ia), (II), or (III) described herein, or apharmaceutically acceptable salt or solvate thereof. In anotherembodiment is a method of treating Tourette syndrome in a patientcomprising administering to the patient in need thereof atherapeutically effective amount of a compound of Formula (I), (Ia),(II), or (III) described herein, or a pharmaceutically acceptable saltor solvate thereof. In another embodiment is a method of treatingAlzheimer's disease in a patient comprising administering to the patientin need thereof a therapeutically effective amount of a compound ofFormula (I), (Ia), (II), or (III) described herein, or apharmaceutically acceptable salt or solvate thereof. In anotherembodiment is a method of treating abdominal pain associated withirritable bowel syndrome in a patient comprising administering to thepatient in need thereof a therapeutically effective amount of a compoundof Formula (I), (Ia), (II), or (III) described herein, or apharmaceutically acceptable salt or solvate thereof.

In another embodiment is a method of treating acute pain, inflammatorypain, cancer pain, pain caused by peripheral neuropathy, central pain,fibromyalgia, migraine, vasoocclussive painful crises in sickle celldisease, spasticity or pain associated with multiple sclerosis,functional chest pain, rheumatoid arthritis, osteoarthritis, orfunctional dyspepsia in a patient in need thereof, comprisingadministering to the patient a therapeutically effective amount of acompound of Formula (I), (Ia), (II), or (III) described herein, or apharmaceutically acceptable salt or solvate thereof. In anotherembodiment is a method of treating acute pain in a patient in needthereof, comprising administering to the patient a therapeuticallyeffective amount of a compound of Formula (I), (Ia), (II), or (III)described herein, or a pharmaceutically acceptable salt or solvatethereof. In another embodiment is a method of treating inflammatory painin a patient in need thereof, comprising administering to the patient atherapeutically effective amount of a compound of Formula (I), (Ia),(II), or (III) described herein, or a pharmaceutically acceptable saltor solvate thereof. In another embodiment is a method of treating cancerpain in a patient in need thereof, comprising administering to thepatient a therapeutically effective amount of a compound of Formula (I),(Ia), (II), or (III) described herein, or a pharmaceutically acceptablesalt or solvate thereof. In another embodiment is a method of treatingpain caused by peripheral neuropathy in a patient in need thereof,comprising administering to the patient a therapeutically effectiveamount of a compound of Formula (I), (Ia), (II), or (III) describedherein, or a pharmaceutically acceptable salt or solvate thereof. Inanother embodiment is a method of treating central pain in a patient inneed thereof, comprising administering to the patient a therapeuticallyeffective amount of a compound of Formula (I), (Ia), (II), or (III)described herein, or a pharmaceutically acceptable salt or solvatethereof. In another embodiment is a method of treating fibromyalgia in apatient in need thereof, comprising administering to the patient atherapeutically effective amount of a compound of Formula (I), (Ia),(II), or (III) described herein, or a pharmaceutically acceptable saltor solvate thereof. In another embodiment is a method of treatingmigraine in a patient in need thereof, comprising administering to thepatient a therapeutically effective amount of a compound of Formula (I),(Ia), (II), or (III) described herein, or a pharmaceutically acceptablesalt or solvate thereof. In another embodiment is a method of treatingvasoocclussive painful crises in sickle cell disease in a patient inneed thereof, comprising administering to the patient a therapeuticallyeffective amount of a compound of Formula (I), (Ia), (II), or (III)described herein, or a pharmaceutically acceptable salt or solvatethereof. In another embodiment is a method of treating spasticity orpain associated with multiple sclerosis in a patient in need thereof,comprising administering to the patient a therapeutically effectiveamount of a compound of Formula (I), (Ia), (II), or (III) describedherein, or a pharmaceutically acceptable salt or solvate thereof. Inanother embodiment is a method of treating functional chest pain in apatient in need thereof, comprising administering to the patient atherapeutically effective amount of a compound of Formula (I), (Ia),(II), or (III) described herein, or a pharmaceutically acceptable saltor solvate thereof. In another embodiment is a method of treatingrheumatoid arthritis in a patient in need thereof, comprisingadministering to the patient a therapeutically effective amount of acompound of Formula (I), (Ia), (II), or (III) described herein, or apharmaceutically acceptable salt or solvate thereof. In anotherembodiment is a method of treating osteoarthritis in a patient in needthereof, comprising administering to the patient a therapeuticallyeffective amount of a compound of Formula (I), (Ia), (II), or (III)described herein, or a pharmaceutically acceptable salt or solvatethereof. In another embodiment is a method of treating functionaldyspepsia in a patient in need thereof, comprising administering to thepatient a therapeutically effective amount of a compound of Formula (I),(Ia), (II), or (III) described herein, or a pharmaceutically acceptablesalt or solvate thereof.

In some embodiments, disclosed herein is a method of treating PersistentMotor Tic Disorder in a patient in need thereof, comprisingadministering to the patient a therapeutically effective amount of acompound of Formula (I), (Ia), (II), or (III) described herein, or apharmaceutically acceptable salt or solvate thereof. In someembodiments, disclosed herein is a method of treating Persistent VocalTic Disorder in a patient in need thereof, comprising administering tothe patient a therapeutically effective amount of a compound of Formula(I), (Ia), (II), or (III) described herein, or a pharmaceuticallyacceptable salt or solvate thereof.

In some embodiments, disclosed herein is a method of treating PersistentMotor Tic Disorder in a patient in need thereof, comprisingadministering to the patient a therapeutically effective amount of acompound of Formula (I), (Ia), (II), or (III) described herein, or apharmaceutically acceptable salt or solvate thereof. In someembodiments, disclosed herein is a method of treating Persistent VocalTic Disorder in a patient in need thereof, comprising administering tothe patient a therapeutically effective amount of a compound of Formula(I), (Ia), (II), or (III) described herein, or a pharmaceuticallyacceptable salt or solvate thereof.

In another embodiment is a method of treating attention deficithyperactivity disorder (ADHD) in a patient in need thereof, comprisingadministering to the patient a therapeutically effective amount of acompound of Formula (I), (Ia), (II), or (III) described herein, or apharmaceutically acceptable salt or solvate thereof. In anotherembodiment is a method of treating obsessive-compulsive disorder (OCD)in a patient in need thereof, comprising administering to the patient atherapeutically effective amount of a compound of Formula (I), (Ia),(II), or (III) described herein, or a pharmaceutically acceptable saltor solvate thereof.

In another embodiment is a method of lowering intraocular eye pressure(IOP) in a patient in need thereof, comprising administering to thepatient a therapeutically effective amount of a compound of Formula (I),(Ia), (II), or (III) described herein, or a pharmaceutically acceptablesalt or solvate thereof. In another embodiment is a method of treatingglaucoma in a patient in need thereof, comprising administering to thepatient a therapeutically effective amount of a compound of Formula (I),(Ia), (II), or (III) described herein, or a pharmaceutically acceptablesalt or solvate thereof.

In another embodiment is a method of treating atopic dermatitis in apatient in need thereof, comprising administering to the patient atherapeutically effective amount of a compound of Formula (I), (Ia),(II), or (III) described herein, or a pharmaceutically acceptable saltor solvate thereof.

In another embodiment is a method of treating pruritis in a patient inneed thereof, comprising administering to the patient a therapeuticallyeffective amount of a compound of Formula (I), (Ia), (II), or (III)described herein, or a pharmaceutically acceptable salt or solvatethereof.

In another embodiment is a method of treating Down's syndrome in apatient in need thereof, comprising administering to the patient atherapeutically effective amount of a compound of Formula (I), (Ia),(II), or (III) described herein, or a pharmaceutically acceptable saltor solvate thereof.

In some embodiments, disclosed herein is a method of synergisticallypotentiating the activity of an opioid analgesic in a patient beingtreated with an opioid analgesic, comprising administering to thepatient a therapeutically effective amount of a compound of Formula (I),(Ia), (II), or (III) described herein, or a pharmaceutically acceptablesalt or solvate thereof. In some embodiments, disclosed herein is amethod of reducing the acute side-effects associated with an opioidanalgesic in a patient being treated with an opioid analgesic,comprising administering to the patient a therapeutically effectiveamount of a compound of Formula (I), (Ia), (II), or (III) describedherein, or a pharmaceutically acceptable salt or solvate thereof.

In certain embodiments, a disclosed compound utilized by one or more ofthe foregoing methods is one of the generic, subgeneric, or specificcompounds described herein, such as a compound of Formula (I), (Ia),(II), or (III).

Disclosed compounds are administered to patients (animals and humans) inneed of such treatment in dosages that will provide optimalpharmaceutical efficacy. It will be appreciated that the dose requiredfor use in any particular application will vary from patient to patient,not only with the particular compound or composition selected, but alsowith the route of administration, the nature of the condition beingtreated, the age and condition of the patient, concurrent medication orspecial diets then being followed by the patient, and other factors,with the appropriate dosage ultimately being at the discretion of theattendant physician. For treating clinical conditions and diseases notedabove, a contemplated compound disclosed herein is administered orally,subcutaneously, topically, parenterally, by inhalation spray or rectallyin dosage unit formulations containing conventional non-toxicpharmaceutically acceptable carriers, adjuvants and vehicles. Parenteraladministration include subcutaneous injections, intravenous orintramuscular injections or infusion techniques.

Also contemplated herein are combination therapies, for example,co-administering a disclosed compound and an additional active agent, aspart of a specific treatment regimen intended to provide the beneficialeffect from the co-action of these therapeutic agents. The beneficialeffect of the combination includes, but is not limited to,pharmacokinetic or pharmacodynamic co-action resulting from thecombination of therapeutic agents. Administration of these therapeuticagents in combination typically is carried out over a defined timeperiod (usually weeks, months or years depending upon the combinationselected). Combination therapy is intended to embrace administration ofmultiple therapeutic agents in a sequential manner, that is, whereineach therapeutic agent is administered at a different time, as well asadministration of these therapeutic agents, or at least two of thetherapeutic agents, in a substantially simultaneous manner.

Substantially simultaneous administration is accomplished, for example,by administering to the subject a single formulation or composition,(e.g., a tablet or capsule) having a fixed ratio of each therapeuticagent or in multiple, single formulations (e.g., capsules) for each ofthe therapeutic agents. Sequential or substantially simultaneousadministration of each therapeutic agent is effected by any appropriateroute including, but not limited to, oral routes, intravenous routes,intramuscular routes, and direct absorption through mucous membranetissues. The therapeutic agents are administered by the same route or bydifferent routes. For example, a first therapeutic agent of thecombination selected is administered by intravenous injection while theother therapeutic agents of the combination are administered orally.Alternatively, for example, all therapeutic agents are administeredorally or all therapeutic agents are administered by intravenousinjection.

Combination therapy also embraces the administration of the therapeuticagents as described above in further combination with other biologicallyactive ingredients and non-drug therapies. Where the combination therapyfurther comprises a non-drug treatment, the non-drug treatment isconducted at any suitable time so long as a beneficial effect from theco-action of the combination of the therapeutic agents and non-drugtreatment is achieved. For example, in appropriate cases, the beneficialeffect is still achieved when the non-drug treatment is temporallyremoved from the administration of the therapeutic agents, perhaps bydays or even weeks.

The components of the combination are administered to a patientsimultaneously or sequentially. It will be appreciated that thecomponents are present in the same pharmaceutically acceptable carrierand, therefore, are administered simultaneously. Alternatively, theactive ingredients are present in separate pharmaceutical carriers, suchas, conventional oral dosage forms, that are administered eithersimultaneously or sequentially.

For example, e.g., for contemplated treatment of pain, a disclosedcompound is co-administered with another therapeutic for pain such as anopioid, a cannabinoid receptor (CB-1 or CB-2) modulator, a COX-2inhibitor, acetaminophen, and/or a non-steroidal anti-inflammatoryagent. Additional therapeutics e.g., for the treatment of pain that areco-administered include morphine, codeine, hydromorphone, hydrocodone,oxymorphone, fentanyl, tramadol, and levorphanol.

Other contemplated therapeutics for co-administration include aspirin,naproxen, ibuprofen, salsalate, diflunisal, dexibuprofen, fenoprofen,ketoprofen, oxaprozin, loxoprofen, indomethacin, tolmetin, sulindac,etodolac, ketorolac, piroxicam, meloxicam, tenoxicam, droxicam,lornoxicam, celecoxib, parecoxib, rimonabant, and/or etoricoxib.

The following examples are provided merely as illustrative of variousembodiments and shall not be construed to limit the disclosure in anyway.

EXAMPLES List of Abbreviations

As used above, and throughout the description, the followingabbreviations, unless otherwise indicated, shall be understood to havethe following meanings:

-   -   ACN or MeCN acetonitrile    -   Bn benzyl    -   BOC or Boc tert-butyl carbamate    -   CDI 1,1′-carbonyldiimidazole    -   Cy cyclohexyl    -   DCE dichloroethane (ClCH₂CH₂Cl)    -   DCM dichloromethane (CH₂Cl₂)    -   DIPEA or DIEA diisopropylethylamine    -   DMAP 4-(N,N-dimethylamino)pyridine    -   DMF dimethylformamide    -   DMA N,N-dimethylacetamide    -   DMSO dimethylsulfoxide    -   equiv equivalent(s)    -   Et ethyl    -   EtOH ethanol    -   EtOAc ethyl acetate    -   HATU        1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium        3-oxid hexafluorophosphate    -   HFIP 1,1,1,3,3,3,3-hexafluoropropan-2-ol    -   HPLC high performance liquid chromatography    -   LAH lithium aluminum hydride    -   Me methyl    -   MeOH methanol    -   MS mass spectroscopy    -   NMM N-methylmorpholine    -   NMR nuclear magnetic resonance    -   PMB para-methoxybenzyl    -   TEA triethylamine    -   TFA trifluoroacetic acid    -   THF tetrahydrofuran    -   TLC thin layer chromatography

I. Chemical Synthesis

Unless otherwise noted, reagents and solvents were used as received fromcommercial suppliers. Anhydrous solvents and oven-dried glassware wereused for synthetic transformations sensitive to moisture and/or oxygen.Yields were not optimized. Reaction times are approximate and were notoptimized. Column chromatography and thin layer chromatography (TLC)were performed on silica gel unless otherwise noted. Spectra are givenin ppm (δ) and coupling constants, J are reported in Hertz. For protonspectra the solvent peak was used as the reference peak.

Example 1: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-methoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Preparation of bis(1,1,1,3,3,3-hexafluoropropan-2-yl) carbonate

A flask was charged with sodium hydride (60% dispersion, 8.16 g, 204mmol). Ether (100 mL) was added and the reaction was cooled to 0° C. Asolution of 1,1,1,3,3,3-hexafluoro-2-propanol (21 mL, 204 mmol) in 40 mLether was added via addition funnel over 10 min. The solution becameclear by the end of the addition. The reaction was stirred at 0° C. for20 min and then allowed to warm to rt and stirred for 20 min. Thesolution was transferred via cannula (˜10 mL/min) to a 0 OC solution oftriphosgene (10 g, 33.7 mmol) in ether (40 mL) resulting in anexothermic reaction and precipitate formation. The solution was stirredat rt for 2 h. The reaction was filtered and solids were washed with 50mL ether. The filtrate was carefully concentrated (bath 36° C., 500Torr) via rotary evaporation and yielded a cloudy solution, whichpartitioned into a top (organic) and bottom (fluorous) layer. The bottomlayer was retained and found to bebis(1,1,1,3,3,3-hexafluoropropan-2-yl) carbonate (8.00 g, 78% by weightsolution in ether, 51% yield) solution and stored and used as a solutionwithout further purification. ¹H NMR (400 MHz, Chloroform-d) δ 5.50(hept, J=5.7 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 151.6, 123.9, 121.0,118.2, 115.4, 72.5, 72.2, 71.8, 71.5, 71.1.

Step 2: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl1,8-diazaspiro[4.5]decane-1-carboxylate hydrochloride (3000 mg, 10.8mmol), DCM (20 mL), and TEA (1.88 mL, 13.0 mmol). The flask was cooledto 0° C. and bis(1,1,1,3,3,3-hexafluoropropan-2-yl) carbonate (4.34 mL,10.84 mmol) was added via syringe. The reaction was stirred at rt for 18h and concentrated. MeOH (50 mL) was added and the solution wasconcentrated to yield crude 1-(tert-butyl)8-(1,1,1,3,3,3-hexafluoropropan-2-yl)1,8-diazaspiro[4.5]decane-1,8-dicarboxylate as a white solid. The crudematerial was resuspended in DCM (20 mL). TFA (6 mL) was added and thereaction was stirred at rt for 4 h. The reaction was concentrated anddiluted in DCM (100 mL) and 1 N NaOH (100 mL, final pH>10). The aqueousphase was extracted with DCM (2×100 mL). The combined organic layerswere dried over anhydrous Na₂SO₄, filtered, and concentrated to yield1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate (3000 mg, 8.97 mmol, 82% yield)as an orange oil, which was carried on without further purification. ¹HNMR (400 MHz, Chloroform-d) δ 5.77 (hept, J=6.2 Hz, 1H), 3.67-3.51 (m,4H), 3.00 (t, J=6.9 Hz, 2H), 1.83 (p, J=7.2 Hz, 2H), 1.71-1.52 (m, 6H).LCMS (ESI, m/z): 335.1 [M+H]⁺.

Step 3: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-methoxybenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

A vial was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate (13 mg, 0.040 mmol) and DCM (2mL). 4-Methoxybenzaldehyde (5.3 mg, 0.040 mmol) and molecular sieves(100 mg) were added and the reaction was stirred at rt for 30 min.NaBH(OAc)₃ (16 mg, 0.080 mmol) was added and the reaction was stirred atrt for 18 h. The reaction was poured into brine (20 mL) and extractedDCM (3×40 mL). The combined organic layers were dried over anhydrousNa₂SO₄, filtered, and concentrated. The resulting oil was purified on asilica column (0 to 30% EtOAc in hexane) to yield1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-methoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate (18 mg,0.039 mmol, 99% yield) as a yellow oil. ¹H NMR (400 MHz, Chloroform-d) δ7.14 (d, J=8.5 Hz, 2H), 6.80-6.73 (m, 2H), 5.69 (hept, J=6.3 Hz, 1H),4.20-4.07 (m, 2H), 3.72 (s, 3H), 3.44 (d, J=2.1 Hz, 2H), 2.91 (dtd,J=22.4, 13.3, 2.5 Hz, 2H), 2.59 (t, J=6.0 Hz, 2H), 1.80-1.58 (m, 6H),1.45-1.36 (m, 2H). LCMS (ESI, m/z): 455.2 [M+H]⁺.

Example 2: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-methoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-methoxybenzaldehyde and 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 1, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-methoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as a whitesolid. ¹H NMR (400 MHz, Chloroform-d) δ 7.24 (td, J=8.1, 1.5 Hz, 1H),6.96-6.89 (m, 2H), 6.83-6.76 (m, 1H), 5.80 (hept, J=6.3 Hz, 1H),4.30-4.16 (m, 2H), 3.83 (d, J=1.5 Hz, 3H), 3.59 (s, 2H), 3.00 (dt,J=23.8, 12.9 Hz, 2H), 2.78-2.67 (m, 2H), 1.90-1.67 (m, 6H), 1.58-1.45(m, 2H). LCMS (ESI, m/z): 455.1 [M+H]⁺.

Example 3: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-methoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2-methoxybenzaldehyde and 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 1, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-methoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as a whitesolid. ¹H NMR (400 MHz, Chloroform-d) δ 7.40-7.33 (m, 1H), 7.24 (td,J=8.1, 1.6 Hz, 1H), 6.95 (t, J=7.4 Hz, 1H), 6.88 (d, J=8.2 Hz, 1H), 5.81(hept, J=6.2 Hz, 1H), 4.31-4.15 (m, 2H), 3.85 (s, 3H), 3.64 (s, 2H),3.00 (dtd, J=21.4, 13.3, 2.6 Hz, 2H), 2.84-2.74 (m, 2H), 1.92-1.74 (m,6H), 1.55-1.45 (m, 2H). LCMS (ESI, m/z): 455.1 [M+H]⁺.

Example 4: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-ethoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-ethoxybenzaldehyde and 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 1, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-ethoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as a whitesolid. ¹H NMR (400 MHz, Chloroform-d) δ 7.22 (d, J=8.5 Hz, 2H), 6.85 (d,J=8.6 Hz, 2H), 5.79 (hept, J=6.3 Hz, 1H), 4.30-4.16 (m, 2H), 4.04 (q,J=7.0 Hz, 2H), 3.59-3.46 (m, 2H), 3.08-2.91 (m, 2H), 2.72-2.64 (m, 2H),1.79 (ddt, J=22.8, 13.5, 8.2 Hz, 6H), 1.50 (td, J=8.3, 7.8, 3.9 Hz, 2H),1.43 (t, J=7.0 Hz, 3H). LCMS (ESI, m/z): 469.1 [M+H]⁺.

Example 5: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-ethoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-ethoxybenzaldehyde and 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 1, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-ethoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as a whitesolid. H NMR (400 MHz, Chloroform-d) δ 7.22 (t, J=7.8 Hz, 1H), 6.90 (d,J=7.4 Hz, 2H), 6.81-6.74 (m, 1H), 5.79 (hept, J=6.2 Hz, 1H), 4.30-4.16(m, 2H), 4.05 (q, J=7.0 Hz, 2H), 3.64-3.51 (m, 2H), 3.00 (dtd, J=22.5,13.3, 2.5 Hz, 2H), 2.78-2.67 (m, 2H), 1.90-1.66 (m, 6H), 1.55-1.39 (m,5H). LCMS (ESI, m/z): 469.2 [M+H]⁺.

Example 6: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-ethoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2-ethoxybenzaldehyde and 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 1, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-ethoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as a whitesolid. ¹H NMR (400 MHz, Chloroform-d) δ 7.35-7.29 (m, 1H), 7.25-7.17 (m,1H), 6.99-6.88 (m, 1H), 6.86 (d, J=8.2 Hz, 1H), 5.81 (hept, J=6.2 Hz,1H), 4.30-4.17 (m, 2H), 4.12-4.01 (m, 2H), 3.63 (q, J=13.4 Hz, 2H), 3.00(dtd, J=20.7, 13.3, 2.5 Hz, 2H), 2.86-2.74 (m, 2H), 1.93-1.78 (m, 6H),1.56-1.40 (m, 5H). LCMS (ESI, m/z): 469.2 [M+H]⁺.

Example 7: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-chloro-3-methoxybenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from commercially available2-chloro-3-methoxybenzaldehyde and 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 1, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-chloro-3-methoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate asa white solid. ¹H NMR (400 MHz, Chloroform-d) δ 7.20 (t, J=7.9 Hz, 1H),7.10 (d, J=7.5 Hz, 1H), 6.85 (d, J=7.9 Hz, 1H), 5.79 (hept, J=6.3 Hz,1H), 4.30-4.17 (m, 2H), 3.91 (s, 3H), 3.74 (s, 2H), 3.09-2.91 (m, 2H),2.76 (t, J=6.1 Hz, 2H), 1.80 (dd, J=20.8, 4.9 Hz, 6H), 1.57-1.47 (m,2H). LCMS (ESI, m/z): 489.1 [M+H]⁺.

Example 8: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(5-fluoro-2-methoxybenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from commercially available2-methoxy-5-fluorobenzaldehyde and 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 1, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-methoxy-5-fluorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate asa white solid. ¹H NMR (400 MHz, Chloroform-d) δ 7.06 (dd, J=9.3, 2.6 Hz,1H), 6.79 (td, J=8.5, 3.1 Hz, 1H), 6.68 (dd, J=8.9, 4.4 Hz, 1H), 5.69(hept, J=6.3 Hz, 1H), 4.19-4.06 (m, 2H), 3.72 (s, 3H), 3.51 (s, 2H),2.90 (dtd, J=22.3, 13.3, 2.5 Hz, 2H), 2.72-2.66 (m, 2H), 1.87-1.57 (m,6H), 1.45-1.35 (m, 2H). LCMS (ESI, m/z): 473.1 [M+H]⁺.

Example 9: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-2-methoxybenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from commercially available2-methoxy-4-chlorobenzaldehyde and 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 1, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-2-methoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate asa white solid. ¹H NMR (400 MHz, Chloroform-d) δ 7.28 (d, J=8.0 Hz, 1H),6.92 (dd, J=8.0, 1.9 Hz, 1H), 6.84 (d, J=1.9 Hz, 1H), 5.79 (hept, J=6.3Hz, 1H), 4.29-4.16 (m, 2H), 3.83 (s, 3H), 3.57 (s, 2H), 2.99 (dtd,J=22.3, 13.3, 2.5 Hz, 2H), 2.76 (s, 2H), 1.99-1.69 (m, 6H), 1.53-1.43(m, 2H). LCMS (ESI, m/z): 489.1 [M+H]⁺.

Example 10: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-chloro-2-methoxybenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from commercially available2-methoxy-3-chlorobenzaldehyde and 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 1, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-chloro-2-methoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate asa white solid. ¹H NMR (400 MHz, Chloroform-d) δ 7.34-7.25 (m, 2H), 7.03(t, J=7.8 Hz, 1H), 5.79 (hept, J=6.2 Hz, 1H), 4.31-4.18 (m, 2H), 3.87(s, 3H), 3.74-3.59 (m, 2H), 3.09-2.91 (m, 2H), 2.75-2.68 (m, 2H),1.90-1.73 (m, 6H), 1.56-1.47 (m, 2H). LCMS (ESI, m/z): 489.1 [M+H]⁺.

Example 11: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(2-(piperidin-1-yl)ethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-(2-(piperidin-1-yl)ethoxy)benzaldehyde and1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 1, Steps 1-3. The compound was purified bypreparative HPLC to give 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(2-(piperidin-1-yl)ethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateformate salt as a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 8.54 (s,1H), 7.22 (t, J=7.8 Hz, 1H), 6.94 (d, J=7.6 Hz, 1H), 6.88 (s, 1H), 6.77(d, J=8.2 Hz, 1H), 5.77 (hept, J=6.3 Hz, 1H), 4.31-4.25 (m, 2H),4.25-4.16 (m, 2H), 3.57 (d, J=3.1 Hz, 2H), 3.22 (t, J=4.9 Hz, 2H), 3.00(p, J=13.4 Hz, 6H), 2.70 (d, J=6.5 Hz, 2H), 1.78 (dtd, J=46.9, 13.2,12.6, 5.3 Hz, 10H), 1.58 (d, J=4.3 Hz, 4H). LCMS (ESI, m/z): 552.3[M+H]⁺.

Example 12: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(2-(pyrrolidin-1-yl)ethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-(2-(pyrrolidin-1-yl)ethoxy)benzaldehyde and1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 1, Steps 1-3. The compound was purified bypreparative HPLC to give 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(2-(pyrrolidin-1-yl)ethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateformate salt as a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 8.44 (brs, 1H), 7.26-7.14 (m, 1H), 7.02-6.85 (m, 2H), 6.81-6.63 (m, 1H),5.89-5.61 (m, 1H), 4.48-4.06 (m, 4H), 3.61 (s, 2H), 3.51-3.20 (m, 6H),3.10-2.86 (m, 2H), 2.73 (s, 2H), 2.06 (s, 4H), 1.94-1.67 (m, 6H),1.63-1.46 (m, 2H). LCMS (ESI, m/z): 538.3 [M+H]⁺.

Example 13: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(2-morpholinoethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-(2-morpholinoethoxy)benzaldehyde and 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 1, Steps 1-3. The compound was purified bypreparative HPLC to give 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(2-morpholinoethoxy)benzyl)-1,8-di azaspiro[4.5]decane-8-carboxylate formate salt as a clear oil. ¹H NMR (400 MHz,Chloroform-d) δ 8.5 (m, 1H), 7.23 (t, J=7.8 Hz, 1H), 7.01-6.87 (m, 2H),6.80 (dd, J=8.2, 2.2 Hz, 1H), 5.77 (hept, J=6.2 Hz, 1H), 4.37-4.05 (m,4H), 3.91-3.75 (m, 4H), 3.72-3.59 (m, 2H), 3.11-2.90 (m, 4H), 2.88-2.63(m, 6H), 2.03-1.69 (m, 6H), 1.67-1.47 (m, 2H). LCMS (ESI, m/z): 554.1[M+H]⁺.

Example 14: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-(2-morpholinoethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-(2-morpholinoethoxy)benzaldehyde and 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 1, Steps 1-3. The compound was purified bypreparative HPLC to give 1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-(2-morpholinoethoxy)benzyl)-1,8-di azaspiro[4.5]decane-8-carboxylate formate salt as a clear oil. ¹H NMR (400 MHz,Chloroform-d) δ 8.45 (s, 1H), 7.33 (d, J=2.0 Hz, 1H), 7.14 (dd, J=8.4,1.9 Hz, 1H), 6.85 (d, J=8.4 Hz, 1H), 5.76 (hept, J=6.2 Hz, 1H),4.48-4.33 (m, 2H), 4.30-4.12 (m, 2H), 3.51 (d, J=2.8 Hz, 2H), 3.45-3.37(m, 2H), 3.21 (br s, 4H), 3.07-2.88 (m, 2H), 2.73-2.59 (m, 2H),1.96-1.56 (m, 12H), 1.50 (d, J=11.1 Hz, 2H). LCMS (ESI, m/z): 586.2[M+H]⁺.

Example 15: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-chloro-4-(2-(piperidin-1-yl)ethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-chloro-4-(2-(piperidin-1-yl)ethoxy)benzaldehyde and1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 1, Steps 1-3. The compound was purified bypreparative HPLC to give 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-chloro-4-(2-(piperidin-1-yl)ethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateformate salt as a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 8.45 (s,1H), 7.33 (d, J=2.0 Hz, 1H), 7.14 (dd, J=8.4, 1.9 Hz, 1H), 6.85 (d,J=8.4 Hz, 1H), 5.76 (hept, J=6.2 Hz, 1H), 4.48-4.33 (m, 2H), 4.30-4.12(m, 2H), 3.51 (d, J=2.8 Hz, 2H), 3.45-3.37 (m, 2H), 3.21 (br s, 4H),3.07-2.88 (m, 2H), 2.73-2.59 (m, 2H), 1.96-1.56 (m, 12H), 1.50 (d,J=11.1 Hz, 2H). LCMS (ESI, m/z): 586.2 [M+H]⁺.

Example 16: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(4-(dimethylcarbamoyl)piperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Preparation of1-(2-formyl-5-(trifluoromethyl)phenyl)-N,N-dimethylpiperidine-4-carboxamide

A sealed tube was charged with 2-fluoro-4-(trifluoromethyl)benzaldehyde(520 mg, 2.71 mmol), N,N-dimethylpiperidine-4-carboxamide (507 mg, 73.2mmol), and potassium carbonate (1.2 g, 8.66 mmol). DMA (4 mL) was addedand the mixture was stirred at 140° C. for 20 h. The reaction was cooledto rt, then diluted with EtOAc (200 mL). The organic layer was washedwith brine (3×) and with sat. NH₄Cl (lx). The organic layer was driedover Na₂SO₄, filtered and concentrated to yield a solid. The solid waspurified by flash column chromatography to afford1-(2-formyl-5-(trifluoromethyl)phenyl)-N,N-dimethylpiperidine-4-carboxamideas a yellow solid (489 mg, 55% yield). ¹H NMR (400 MHz, Chloroform-d) δ10.31 (s, 1H), 7.90 (s, 1H), 7.40-7.32 (m, 2H), 3.47-3.38 (m, 2H), 3.12(s, 3H), 3.08-2.96 (m, 5H), 2.80-2.66 (m, 1H), 2.19-2.05 (m, 2H),1.96-1.85 (m, 2H).

Step 2: Preparation of tert-butyl1-(2-(4-(dimethylcarbamoyl)piperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A vial equipped was charged with1-(2-formyl-5-(trifluoromethyl)phenyl)-N,N-dimethylpiperidine-4-carboxamide(124 mg, 0.379 mmol) and tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate (109 mg, 0.455 mmol). DCM (5 mL)was added and the mixture was stirred until dissolved at rt. 4 ÅMolecular sieves (100 mg) were added and the vial was purged with N₂ andstirred at rt for 2 h. NaBH(OAc)₃ (88 mg, 0.417 mmol) was added. Thereaction was allowed to stir at rt overnight. The reaction was filteredover Celite and rinsed with MeOH, then concentrated and taken up inEtOAc. The organic layer was washed with saturated NaHCO₃ (3×), driedover Na₂SO₄ and concentrated to yield an oil. The oil was purified byflash column chromatography to afford tert-butyl1-(2-(4-(dimethylcarbamoyl)piperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(128 mg, 61% yield). ¹H NMR (400 MHz, Chloroform-d) δ 7.79-7.69 (m, 1H),7.34-7.24 (m, 2H), 4.23-4.03 (m, 2H), 3.75 (s, 2H), 3.18-3.09 (m, 5H),2.99 (s, 3H), 2.90-2.55 (m, 7H), 2.10-1.97 (m, 4H), 1.87-1.59 (m, 8H),1.47 (s, 9H).

Step 3: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-(dimethylcarbamoyl)piperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A vial was charged with tert-butyl1-(2-(4-(dimethylcarbamoyl)piperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(128 mg, 0.232 mmol). DCM (3 mL) was added and the mixture stirred at 0°C. for 10 min. 4 N HCl in dioxane was added dropwise via syringe (0.347mL, 1.39 mmol). The mixture stirred at rt overnight. MeOH was added andthe mixture was concentrated to yield a solid. The solid was dissolvedin DCM (3 mL) and DIEA (0.2 mL), and stirred at rt. A separate vial wascharged with triphosgene (241 mg, 0.814 mmol). To this vial was addedDCM (3 mL). The mixture was then purged with N₂ and stirred at rt for 5min. The vial was cooled to 0° C. and HFIP was added (444 mg, 2.64mmol), followed by DIEA (525 mg, 4.07 mmol). The mixture was allowed tostir at rt for 45 min. At that time, the contents of the first vial weretransferred to the HFIP mixture, dropwise via syringe, and the solutionwas stirred at rt overnight. The mixture was diluted with DCM, washedwith sat. NaHCO₃ (3×), dried over Na₂SO₄, and concentrated to yield aresidue. The residue was purified by flash column chromatography andpreparative HPLC to afford 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-(dimethylcarbamoyl)piperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil (61 mg, 20% yield). ¹H NMR (400 MHz, Chloroform-d) δ7.73-7.66 (m, 1H), 7.33-7.29 (m, 1H), 7.28-7.24 (m, 1H), 5.84-5.72 (m,1H), 4.30-4.13 (m, 2H), 3.75-3.63 (m, 2H), 3.21-3.09 (m, 5H), 3.08-2.92(m, 5H), 2.80-2.59 (m, 5H), 2.11-1.97 (m, 2H), 1.91-1.62 (m, 8H),1.57-1.46 (m, 2H). LCMS (ESI, m/z): 647.3 [M+H]⁺.

Example 17: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(4-chloro-2-(pyrrolidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde, pyrrolidine and tert-butyl2,8-diazaspiro[4.5] decane-8-carboxylate according to the representativeprocedure of Example 16, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-chloro-2-(pyrrolidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.29-7.26 (m, 1H),6.86-6.78 (m, 2H), 5.84-5.70 (m, 1H), 3.62-3.38 (m, 6H), 3.33-3.15 (m,4H), 2.70-2.56 (m, 2H), 2.44-2.31 (m, 2H), 2.03-1.88 (m, 4H), 1.75-1.53(m, 7H). LCMS (ESI, m/z): 528.2 [M+H]⁺.

Example 18: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-6-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-trifluoromethyl-2-fluorobenzaldehyde, andhexahydro-1H-furo[3,4-c]pyrrole and tert-butyl2,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 16, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl2-(2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-6-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.43 (dd, J=6.4, 2.6Hz, 1H), 7.33 (d, J=6.7 Hz, 2H), 5.76 (hept, J=6.3 Hz, 1H), 4.11-4.02(m, 2H), 3.85 (s, 2H), 3.65 (dd, J=8.5, 3.9 Hz, 2H), 3.55-3.45 (m, 2H),3.42 (dt, J=13.0, 6.1 Hz, 2H), 3.10 (dd, J=8.7, 5.6 Hz, 2H), 2.94 (d,J=8.1 Hz, 4H), 2.53 (q, J=6.7 Hz, 2H), 2.35 (q, J=8.8 Hz, 2H), 1.55 (dt,J=11.7, 6.1 Hz, 6H).

Example 19: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-2-(4-(2-fluoroethyl)piperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Preparation of tert-butyl4-(5-chloro-2-formylphenyl)piperazine-1-carboxylate

The title compound was prepared from commercially available4-chloro-2-fluorobenzaldehyde and tert-butyl piperazine-1-carboxylateaccording to the representative procedure of Example 16, Step 1, withthe exception that DMSO and 120° C. were used, and yielded tert-butyl4-(5-chloro-2-formylphenyl)piperazine-1-carboxylate as a yellow solid.¹H NMR (400 MHz, Chloroform-d) δ 10.25 (s, 1H), 7.77 (d, J=8.3 Hz, 1H),7.18-7.05 (m, 2H), 3.69-3.61 (m, 4H), 3.09-3.02 (m, 4H), 1.51 (s, 9H).LCMS (ESI, m/z): 586.2 [M+H]⁺.

Step 2: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-4-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A vial was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate (300 mg, 0.900 mmol), preparedas described in Example 1, Steps 1-2, and DCM (5 mL). Molecular sieves(300 mg) and tert-butyl4-(5-chloro-2-formyl-phenyl)piperazine-1-carboxylate (276 mg, 0.850mmol) were added and the reaction was stirred at rt for 10 min.NaBH(OAc)₃ (240 mg, 1.14 mmol) was added and the reaction was stirredfor 18 h. The reaction was poured into brine (30 mL) and extracted withDCM (3×50 mL). The combined organic layers were dried over anhydrousNa₂SO₄, filtered, and concentrated. The resulting oil was purified on asilica column (0 to 40% EtOAc in hexane) to yield1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-4-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(388 mg, 0.603 mmol, 67% yield) as a clear oil. ¹H NMR (400 MHz,Chloroform-d) δ 7.43 (d, J=8.2 Hz, 1H), 7.03 (dd, J=8.2, 2.0 Hz, 1H),7.00 (d, J=2.0 Hz, 1H), 5.77 (hept, J=6.2 Hz, 1H), 4.20 (t, J=15.9 Hz,2H), 3.62 (s, 2H), 3.55 (s, 4H), 3.06-2.89 (m, 2H), 2.83 (s, 4H), 2.65(t, J=6.6 Hz, 2H), 1.89-1.63 (m, 6H), 1.54-1.42 (m, 11H). LCMS (ESI,m/z): 643 [M+H]⁺.

Step 3: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-2-(piperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A vial was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-4-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(388 mg, 0.600 mmol) and DCM (16 mL). TFA (4 mL) was added and thereaction was stirred at rt for 3 h. The reaction mixture wasconcentrated, diluted in DCM (50 mL), poured into sat. Na₂CO₃ (40 mL)and extracted with DCM (3×50 mL). The combined organic layers were driedover anhydrous Na₂SO₄, filtered, and concentrated to yield1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-2-(piperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(300 mg, 0.552 mmol, 92% yield) which was used without furtherpurification. LCMS (ESI, m/z): 543.2 [M+H]⁺.

Step 4: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-2-(4-(2-fluoroethyl)piperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A thick walled tube was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-2-(piperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(60 mg, 0.110 mmol), potassium carbonate (61 mg, 0.440 mmol),2-fluoroethyl 4-methylbenzenesulfonate (24 mg, 0.110 mmol) in MeCN (3.6mL) and tert-butanol (8.4 mL). The reaction was heated to 120° C. for 8h. The reaction mixture was poured into sat. Na₂CO₃ (30 mL) andextracted with DCM (3×50 mL). The combined organic layers were driedover anhydrous Na₂SO₄, filtered, and concentrated. The resulting oil waspurified on a silica column to give 1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-2-(4-(2-fluoroethyl)piperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(45 mg, 0.076 mmol, 69% yield) as a clear oil. ¹H NMR (400 MHz,Chloroform-d) δ 7.48-7.41 (m, 1H), 7.04 (dd, J=6.4, 2.1 Hz, 2H), 5.79(hept, J=6.2 Hz, 1H), 4.74-4.66 (m, 1H), 4.62-4.54 (m, 1H), 4.29-4.16(m, 2H), 3.61 (s, 2H), 3.08-2.92 (m, 6H), 2.87-2.80 (m, 1H), 2.80-2.59(m, 7H), 1.90-1.66 (m, 6H), 1.48 (t, J=10.4 Hz, 2H). LCMS (ESI, m/z):589.2 [M+H]⁺.

Example 20: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(4-(2-fluoroethyl)piperazin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate and tert-butyl4-(2-formyl-5-(trifluoromethyl)phenyl)piperazine-1-carboxylate accordingto the representative procedure of Example 19, Steps 1-4 and yielded1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-(2-fluoroethyl)piperazin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas an orange oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.65 (d, J=8.3 Hz,1H), 7.32 (d, J=6.1 Hz, 2H), 5.79 (hept, J=6.3 Hz, 1H), 4.74-4.67 (m,1H), 4.63-4.55 (m, 1H), 4.30-4.17 (m, 2H), 3.69 (s, 2H), 3.09-2.93 (m,6H), 2.89-2.64 (m, 8H), 1.91-1.66 (m, 6H), 1.51 (t, J=10.6 Hz, 2H). LCMS(ESI, m/z): 623.2 [M+H]⁺.

Example 21: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(4-chloro-2-morpholinobenzyl)-2,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from4-chloro-2-morpholinobenzaldehyde (prepared from commercially available4-chloro-2-fluorobenzaldehyde and morpholine according to therepresentative procedure of Example 16, Step 1) and1,1,1,3,3,3-hexafluoropropan-2-yl 2,8-diazaspiro[4.5]decane-8-carboxylate (prepared from commercially available tert-butyl2,8-diazaspiro[4.5]decane-2-carboxylate according to the representativeprocedure of Example 1, Step 2) according to the representativeprocedure of Example 1, Step 3 to afford1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-chloro-2-morpholinobenzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.37-7.31 (m, 1H),7.08-7.02 (m, 2H), 5.84-5.70 (m, 1H), 3.92-3.83 (m, 4H), 3.65-3.52 (m,4H), 3.51-3.38 (m, 2H), 3.06-2.95 (m, 4H), 2.71-2.58 (m, 2H), 2.47-2.38(m, 2H), 1.73-1.51 (m, 8H). LCMS (ESI, m/z): 544.3 [M+H]⁺.

Example 22: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(2-morpholino-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from2-morpholino-4-(trifluoromethyl)benzaldehyde (prepared from commerciallyavailable 2-fluoro-4-(trifluoromethyl)benzaldehyde and morpholineaccording to the representative procedure of Example 16, Step 1) and1,1,1,3,3,3-hexafluoropropan-2-yl2,8-diazaspiro[4.5]decane-8-carboxylate (prepared from commerciallyavailable tert-butyl 2,8-diazaspiro[4.5] decane-2-carboxylate accordingto the representative procedure of Example 1, Step 2) according to therepresentative procedure of Example 1, Step 3 to afford1,1,1,3,3,3-hexafluoropropan-2-yl2-(2-morpholino-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.61-7.52 (m, 1H),7.36-7.31 (m, 1H), 7.29-7.28 (m, 1H), 5.82-5.71 (m, 1H), 3.94-3.82 (m,4H), 3.74-3.64 (m, 2H), 3.61-3.50 (m, 2H), 3.50-3.39 (m, 2H), 3.08-2.98(m, 4H), 2.73-2.60 (m, 2H), 2.50-2.40 (m, 2H), 1.75-1.54 (m, 8H). LCMS(ESI, m/z): 578.2 [M+H]⁺.

Example 23: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(2-(piperidin-1-yl)-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from2-(piperidin-1-yl)-4-(trifluoromethyl)benzaldehyde (prepared fromcommercially available 2-fluoro-4-(trifluoromethyl)benzaldehyde andpiperidine according to the representative procedure of Example 16,Step 1) and 1,1,1,3,3,3-hexafluoropropan-2-yl2,8-diazaspiro[4.5]decane-8-carboxylate (prepared from commerciallyavailable tert-butyl 2,8-diazaspiro[4.5] decane-2-carboxylate accordingto the representative procedure of Example 1, Step 2) according to therepresentative procedure of Example 1, Step 3 to afford1,1,1,3,3,3-hexafluoropropan-2-yl2-(2-(piperidin-1-yl)-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.59-7.54 (m, 1H),7.31-7.25 (m, 2H), 5.83-5.73 (m, 1H), 3.68 (s, 2H), 3.59-3.42 (m, 4H),2.97-2.88 (m, 4H), 2.72-2.63 (m, 2H), 2.52-2.41 (m, 2H), 1.79-1.68 (m,6H), 1.66-1.58 (m, 6H). LCMS (ESI, m/z): 576.2 [M+H]⁺.

Example 24: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(4-chloro-2-(piperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from4-chloro-2-(piperidin-1-yl)benzaldehyde (prepared from commerciallyavailable 4-chloro-2-fluorobenzaldehyde and piperidine according to therepresentative procedure of Example 16, Step 1) and1,1,1,3,3,3-hexafluoropropan-2-yl 2,8-diazaspiro[4.5]decane-8-carboxylate (prepared from commercially available tert-butyl2,8-diazaspiro[4.5]decane-2-carboxylate according to the representativeprocedure of Example 1, Step 2) according to the representativeprocedure of Example 1, Step 3 to afford1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-chloro-2-(piperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.37-7.31 (m, 1H),7.06-6.97 (m, 2H), 5.84-5.72 (m, 1H), 3.65-3.41 (m, 6H), 2.95-2.84 (m,4H), 2.71-2.58 (m, 2H), 2.50-2.39 (m, 2H), 1.81-1.41 (m, 12H). LCMS(ESI, m/z): 542.2 [M+H]⁺.

Example 25: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(4-chloro-2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from4-chloro-2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)benzaldehyde(prepared from commercially available 4-chloro-2-fluorobenzaldehyde andhexahydro-1H-furo[3,4-c]pyrrole according to the representativeprocedure of Example 16, Step 1) and 1,1,1,3,3,3-hexafluoropropan-2-yl2,8-diazaspiro[4.5]decane-8-carboxylate (prepared from commerciallyavailable tert-butyl 2,8-diazaspiro[4.5] decane-2-carboxylate accordingto the representative procedure of Example 1, Step 2) according to therepresentative procedure of Example 1, Step 3 to afford1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-chloro-2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.34 (s, 1H), 7.01-6.96(m, 2H), 5.83-5.71 (m, 1H), 4.12-4.03 (m, 2H), 3.65-3.50 (m, 6H),3.50-3.38 (m, 2H), 3.12-3.03 (m, 4H), 2.99-2.86 (m, J=4.6 Hz, 2H),2.68-2.57 (m, 2H), 2.44-2.35 (m, 2H), 1.73-1.64 (m, 2H), 1.64-1.56 (m,4H). LCMS (ESI, m/z): 570.3 [M+H]⁺.

Example 26: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-4-(trifluoromethyl)benzaldehyde(prepared from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde andhexahydro-1H-furo[3,4-c]pyrrole according to the representativeprocedure of Example 16, Step 1) and 1,1,1,3,3,3-hexafluoropropan-2-yl2,8-diazaspiro[4.5]decane-8-carboxylate (prepared from commerciallyavailable tert-butyl 2,8-diazaspiro[4.5]decane-2-carboxylate accordingto the representative procedure of Example 1, Step 2) according to therepresentative procedure of Example 1, Step 3 to afford1,1,1,3,3,3-hexafluoropropan-2-yl2-(2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.61-7.51 (m, 1H),7.31-7.17 (m, 2H), 5.84-5.69 (m, 1H), 4.14-4.02 (m, 2H), 3.73-3.61 (m,4H), 3.61-3.51 (m, 2H), 3.51-3.39 (m, 2H), 3.20-3.04 (m, 4H), 3.03-2.89(m, 2H), 2.73-2.59 (m, 2H), 2.48-2.36 (m, 2H), 1.75-1.56 (m, 6H). LCMS(ESI, m/z): 604.3 [M+H]⁺.

Example 27: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(2-fluoroethoxy)benzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

Step 1: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-hydroxybenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

A vial was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate (100 mg, 0.300 mmol, preparedaccording to Example 1, Steps 1-2), and DCM (2 mL).3-Hydroxybenzaldehyde (36 mg, 0.300 mmol) and molecular sieves wereadded and the reaction mixture was stirred at rt for 30 min. NaBH(OAc)₃(94 mg, 0.450 mmol) was added and the reaction was stirred at rt for 18h. The reaction mixture was poured into brine (30 mL) and extracted withDCM (3×50 mL). The combined organic layers were dried over anhydrousNa₂SO₄, filtered, and concentrated. The resulting oil was purified on asilica column (0 to 20% EtOAc in hexane) to yield1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-hydroxybenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate as a whitesolid. ¹H NMR (400 MHz, Chloroform-d) δ 7.13 (t, J=7.8 Hz, 1H), 6.85 (d,J=7.6 Hz, 1H), 6.77 (s, 1H), 6.64 (dd, J=8.0, 2.4 Hz, 1H), 6.23 (br s,1H), 5.80 (hept, J=6.2 Hz, 1H), 4.29-4.17 (m, 2H), 3.52 (d, J=2.7 Hz,2H), 3.08-2.91 (m, 2H), 2.71 (t, J=6.9 Hz, 2H), 1.77 (dddt, J=31.4,17.7, 13.2, 6.3 Hz, 6H), 1.50 (s, 2H). LCMS (ESI, m/z): 441.1 [M+H]⁺.

Step 2: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(2-fluoroethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A vial was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-hydroxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate (40 mg,0.090 mmol), cesium carbonate (57 mg, 0.180 mmol) and DMSO (0.50 mL).2-Fluoroethyl 4-methylbenzenesulfonate (19 mg, 0.090 mmol) was added andthe reaction was stirred at rt for 18 h. The reaction was poured intoEtOAc (100 mL) and washed with sat. Na₂CO₃ (3×25 mL). The organic layerwas dried over anhydrous Na₂SO₄, filtered, and concentrated. Theresulting oil was purified on a silica column with a gradient elution(EtOAc in hexane) to yield 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(2-fluoroethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate (13mg, 0.025 mmol, 28% yield). ¹H NMR (400 MHz, Chloroform-d) δ 7.24 (t,J=7.8 Hz, 1H), 6.95 (d, J=8.3 Hz, 2H), 6.85-6.77 (m, 1H), 5.80 (hept,J=6.3 Hz, 1H), 4.87-4.80 (m, 1H), 4.75-4.68 (m, 1H), 4.30-4.16 (m, 4H),3.59 (s, 2H), 3.00 (dtd, J=22.8, 13.3, 2.5 Hz, 2H), 2.77-2.66 (m, 2H),1.90-1.66 (m, 6H), 1.56-1.46 (m, 2H). LCMS (ESI, m/z): 487.1 [M+H]⁺.

Example 28: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-3-(2-fluoroethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Preparation of 4-chloro-3-(2-fluoroethoxy)benzaldehyde

A vial was charged with cesium carbonate (211 mg, 0.650 mmol) and DMSO(2 mL), and the reaction was stirred for 5 min at rt prior to additionof 2-fluoroethyl 4-methylbenzenesulfonate (71 mg, 0.330 mmol). Thereaction mixture was stirred at rt for 18 h. The resulting solution waspoured into EtOAc (150 mL) and washed with sat sodium carbonate (3×50mL). The organics were dried over anhydrous sodium sulfate, filtered,and concentrated under reduced pressure. The resulting oil waschromatographed on a silica column to afford[2,2,2-trifluoro-1-(trifluoromethyl)ethyl]1-[[4-chloro-3-(2-fluoroethoxy)phenyl]methyl]-1,8-diazaspiro[4.5]decane-8-carboxylate(10 mg, 0.017 mmol, 22% yield). ¹H NMR (400 MHz, Chloroform-d) δ 9.95(s, 1H), 7.62-7.54 (m, 1H), 7.49-7.41 (m, 2H), 4.95-4.87 (m, 1H),4.83-4.75 (m, 1H), 4.45-4.31 (m, 2H).

Step 2: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-3-(2-fluoroethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A vial was charged with 4-chloro-3-(2-fluoroethoxy)benzaldehyde (39 mg,0.190 mmol), 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate (64 mg, 0.190 mmol), DCM (1 mL)and molecular sieves. After stirring at rt for 5 min, NaBH(OAc)₃ (48 mg,0.230 mmol) was added and the reaction was stirred at rt overnight. Thereaction mixture was poured into brine (30 mL) and extracted with DCM(3×50 ml). The combined organic layers were dried over anhydrous Na₂SO₄,filtered, and concentrated. The resulting oil was purified on a silicacolumn with a gradient first using hexane/acetone and second using asilica column with DCM/MeOH and yielded1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-3-(2-fluoroethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate (64 mg, 0.120 mmol, 62% yield) as a clear oil. ¹HNMR (400 MHz, Chloroform-d) δ 7.28 (dd, J=8.0, 1.4 Hz, 1H), 6.95 (s,1H), 6.89 (d, J=8.1 Hz, 1H), 5.85-5.70 (m, 1H), 4.89-4.82 (m, 1H),4.78-4.70 (m, 1H), 4.35-4.15 (m, 4H), 3.55 (s, 2H), 2.98 (dt, J=24.9,12.7 Hz, 2H), 2.66 (t, J=6.4 Hz, 2H), 1.89-1.69 (m, 6H), 1.52-1.47 (m,2H). LCMS (ESI, m/z): 521.1 [M+H]⁺.

Example 29: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-fluoro-3-(2-fluoroethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from1,1,1,3,3,3-hexafluoropropan-2-yl 1,8-diazaspiro[4.5]decane-8-carboxylate and 4-fluoro-3-hydroxybenzaldehyde according to therepresentative procedure of Example 28, Steps 1-2 and yielded1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-fluoro-3-(2-fluoroethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.13-6.91 (m, 2H), 6.88(dq, J=6.2, 2.2 Hz, 1H), 5.90-5.67 (m, 1H), 4.94-4.63 (m, 2H), 4.44-4.10(m, 4H), 3.54 (s, 2H), 3.00 (dt, J=25.1, 13.1 Hz, 2H), 2.67 (t, J=6.1Hz, 2H), 1.76 (dtt, J=35.9, 13.0, 5.4 Hz, 6H), 1.59-1.41 (m, 2H). LCMS(ESI, m/z): 505.1 [M+H]⁺.

Example 30: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-2-(2-fluoroethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from1,1,1,3,3,3-hexafluoropropan-2-yl 1,8-diazaspiro[4.5]decane-8-carboxylate and 4-chloro-2-hydroxybenzaldehyde according to therepresentative procedure of Example 28, Steps 1-2 and yielded1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-2-(2-fluoroethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ7.22-7.15 (m, 1H), 6.85 (dd, J=8.1, 1.9 Hz, 1H), 6.73 (s, 1H), 5.70(hept, J=6.3 Hz, 1H), 4.77-4.70 (m, 1H), 4.65-4.58 (m, 1H), 4.19-4.05(m, 4H), 3.58-3.43 (m, 2H), 2.89 (dtd, J=21.7, 13.3, 2.4 Hz, 2H),2.69-2.61 (m, 2H), 1.74-1.68 (m, 5H), 1.44-1.34 (m, 2H). LCMS (ESI,m/z): 521.1 [M+H]⁺.

Example 31: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-(2-fluoroethoxy)benzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from1,1,1,3,3,3-hexafluoropropan-2-yl 1,8-diazaspiro[4.5]decane-8-carboxylate and 4-(2-fluoroethoxy)benzaldehyde according to therepresentative procedure of Example 28, Steps 1-2 and yielded1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-(2-fluoroethoxy)benzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate asa clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.24 (d, J=8.4 Hz, 2H),6.89 (d, J=8.6 Hz, 2H), 5.80 (p, J=6.2 Hz, 1H), 4.83 (ddd, J=4.3, 3.0,1.3 Hz, 1H), 4.74-4.67 (m, 1H), 4.29-4.13 (m, 4H), 3.60-3.48 (m, 2H),3.08-2.91 (m, 2H), 2.68 (t, J=6.7 Hz, 2H), 1.80 (ddq, J=22.9, 9.8, 5.9,4.6 Hz, 6H), 1.60-1.40 (m, 2H). LCMS (ESI, m/z): 487.1 [M+H]⁺.

Example 32: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-3-ethoxybenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate, ethyl iodide, and4-chloro-3-hydroxybenzaldehyde according to the representative procedureof Example 28, Steps 1-2 and yielded 1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-3-ethoxybenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as aclear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.31-7.22 (m, 1H), 6.92 (s,1H), 6.84 (d, J=8.0 Hz, 1H), 5.79 (hept, J=6.2 Hz, 1H), 4.30-4.16 (m,2H), 4.12 (q, J=7.0 Hz, 2H), 3.56 (s, 2H), 3.08-2.91 (m, 2H), 2.68 (t,J=6.6 Hz, 2H), 1.96-1.64 (m, 6H), 1.56-1.42 (m, 5H). LCMS (ESI, m/z):503.2 [M+H]⁺.

Example 33: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-chloro-5-morpholinobenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

Step 1: Preparation of tert-butyl1-(3-bromo-5-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A vial was charged with 3-bromo-5-chlorobenzaldehyde (207 mg, 0.943mmol). The solid was dissolved in DCM (5 mL) and stirred at rt.tert-Butyl 1,8-diazaspiro[4.5]decane-8-carboxylate (300 mg, 1.08 mmol)was added followed by 4 Å molecular sieves (300 mg). The vial was purgedwith N₂ and stirred at rt for 2 h. NaBH(OAc)₃ (219 mg, 1.03 mmol) wasadded and the reaction was allowed to stir at rt overnight. The reactionmixture was filtered over Celite and rinsed with MeOH. The mixture wasconcentrated, taken up in EtOAc, washed with sat. NaHCO₃, dried overNa₂SO₄ and concentrated to yield an oil. The oil was purified by flashcolumn chromatography to afford tert-butyl1-(3-bromo-5-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate (254mg, 60% yield). ¹H NMR (400 MHz, Chloroform-d) δ 7.38-7.35 (m, 2H),7.26-7.24 (m, 1H), 4.26-4.07 (m, 2H), 3.57-3.49 (m, 2H), 2.85-2.71 (m,2H), 2.68-2.61 (m, 2H), 1.85-1.74 (m, 4H), 1.65-1.57 (m, 2H), 1.47 (s,9H), 1.43-1.35 (m, 2H). LCMS (ESI, m/z): 451.2 [M+H]⁺.

Step 2: Preparation of tert-butyl1-(3-chloro-5-morpholinobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A vial was charged with tert-butyl1-(3-bromo-5-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate (129mg, 0.291 mmol). To this vial was added Pd(OAc)₂ (7 mg, 0.029 mmol),RuPhos (54 mg, 0.117 mmol), and t-BuONa (42 mg, 0.438 mmol). The vialwas then flushed with N₂ and evacuated 3 times. Morpholine (28 mg, 0.321mmol) was added to the vial, followed by anhydrous THF (3 mL). Theresulting stirred mixture was heated at 80° C. for 8 h. The reaction wasthen cooled to rt whereupon H₂O (5 mL) was added. The reaction mixturewas extracted with EtOAc (3×10 mL) and the combined organic layers weredried over Na₂SO₄, filtered and concentrated to yield an oil. The oilwas purified by flash column chromatography to afford tert-butyl1-(3-chloro-5-morpholinobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(45 mg, 34% yield). ¹H NMR (400 MHz, Chloroform-d) δ 6.73-6.64 (m, 1H),6.62-6.55 (m, 2H), 4.01 (s, 2H), 3.76-3.68 (m, 4H), 3.43-3.29 (m, 2H),3.08-2.93 (m, 4H), 2.72-2.45 (m, 4H), 1.75-1.57 (m, 4H), 1.56-1.43 (m,2H), 1.37-1.29 (m, 9H), 1.29-1.19 (m, 2H).

Step 3: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-chloro-5-morpholinobenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

A vial was charged with tert-butyl1-(3-chloro-5-morpholinobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(45 mg, 0.100 mmol). DCM (3 mL) was added and the mixture was stirred at0° C. for 10 min. 4 N HCl in dioxane was added dropwise via syringe(0.150 mL, 0.600 mmol). The mixture was stirred at rt overnight. MeOHwas added, and the mixture was concentrated to yield a solid. The solidwas dissolved in DCM (3 mL), DIEA (0.2 mL) was added, and the reactionwas stirred at rt. A separate vial was charged with triphosgene (87 mg,0.295 mmol). To this vial was added DCM (3 mL). The mixture was thenpurged with N₂ and stirred at rt for 5 min. The vial was cooled to 0° C.and HFIP was added (0.118 mL, 0.959 mmol), followed by DIEA (0.257 mL,1.47 mmol). The mixture was allowed to stir at rt for 45 min. At thattime, the contents of the first vial were transferred to the HFIPmixture dropwise via syringe, and the solution was stirred at rtovernight. The mixture was diluted with DCM, washed with sat. NaHCO₃(3×), dried over Na₂SO₄, and concentrated to yield a residue. Theresidue was purified by flash column chromatography and preparative HPLCto afford 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-chloro-5-morpholinobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(15 mg, 18% yield). ¹H NMR (400 MHz, Chloroform-d) δ 6.76 (s, 1H), 6.66(s, 2H), 5.76-5.61 (m, 1H), 4.25-4.07 (m, 2H), 3.86-3.69 (m, 4H),3.51-3.38 (m, 2H), 3.15-3.03 (m, 4H), 3.02-2.81 (m, 2H), 2.70-2.52 (m,2H), 1.85-1.51 (m, 6H), 1.47-1.32 (m, 2H). LCMS (ESI, m/z): 544.2[M+H]⁺.

Example 34: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-chloro-5-(pyrrolidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from pyrrolidine accordingto the representative procedure of Example 33, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-chloro-5-(pyrrolidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 6.68-6.62 (m, 1H),6.45-6.34 (m, 2H), 5.85-5.72 (m, 1H), 4.30-4.15 (m, 2H), 3.57-3.46 (m,2H), 3.32-3.23 (m, 4H), 3.10-2.91 (m, 2H), 2.79-2.65 (m, 2H), 2.08-1.94(m, 4H), 1.88-1.69 (m, 6H), 1.50 (ddt, J=13.2, 7.7, 2.3 Hz, 2H). LCMS(ESI, m/z): 528.2 [M+H]⁺.

Example 35: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-morpholino-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-5-(trifluoromethyl)benzaldehyde according to the representativeprocedure of Example 33, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-morpholino-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.03-6.86 (m, 3H),5.75-5.62 (m, 1H), 4.24-4.08 (m, 2H), 3.84-3.76 (m, 4H), 3.51 (s, 2H),3.12 (s, 4H), 3.00-2.82 (m, 2H), 2.65-2.54 (m, 2H), 1.81-1.60 (m, 6H),1.47-1.37 (m, 2H). LCMS (ESI, m/z): 578.2 [M+H]⁺.

Example 36: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(pyrrolidin-1-yl)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-5-(trifluoromethyl)benzaldehyde and pyrrolidine according to therepresentative procedure of Example 33, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(pyrrolidin-1-yl)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 6.78 (s, 1H), 6.54 (d,2H), 5.77-5.65 (m, 1H), 4.22-4.05 (m, 2H), 3.50 (s, 2H), 3.29-3.17 (m,4H), 3.01-2.82 (m, 2H), 2.70-2.58 (m, 2H), 2.02-1.90 (m, 4H), 1.83-1.57(m, 6H), 1.49-1.35 (m, 2H). LCMS (ESI, m/z): 562.2 [M+H]⁺.

Example 37: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-morpholino-5-(trifluoromethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-5-(trifluoromethoxy)benzaldehyde according to the representativeprocedure of Example 33, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-morpholino-5-(trifluoromethoxy)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 6.84-6.70 (m, 2H), 6.59(s, 1H), 5.86-5.71 (m, 1H), 4.33-4.16 (m, 2H), 3.94-3.80 (m, 4H), 3.57(s, 2H), 3.18 (s, 4H), 3.09-2.91 (m, 2H), 2.77-2.65 (m, 2H), 1.90-1.75(m, 4H), 1.75-1.67 (m, 2H), 1.55-1.45 (m, 2H). LCMS (ESI, m/z): 594.2[M+H]⁺.

Example 38: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-chloro-5-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially availablehexahydro-1H-furo[3,4-c]pyrrole according to the representativeprocedure of Example 33, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-chloro-5-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 6.71 (s, 1H), 6.47 (d,2H), 5.83-5.73 (m, 1H), 4.30-4.15 (m, 2H), 4.06-3.96 (m, 2H), 3.74-3.65(m, 2H), 3.58-3.48 (m, 2H), 3.49-3.40 (m, 2H), 3.28-3.19 (m, 2H),3.13-2.91 (m, 4H), 2.76-2.64 (m, 2H), 1.92-1.62 (m, 6H), 1.55-1.42 (m,2H). LCMS (ESI, m/z): 570.3 [M+H]⁺.

Example 39: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-chloro-5-(4-fluoropiperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-fluoropiperidine hydrochloride according to the representativeprocedure of Example 33, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-chloro-5-(4-fluoropiperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 6.72 (s, 1H), 6.68 (s,2H), 5.74-5.63 (m, 1H), 4.84-4.58 (m, 1H), 4.23-4.07 (m, 2H), 3.49-3.37(m, 2H), 3.33-3.23 (m, 2H), 3.17-3.05 (m, 2H), 3.00-2.82 (m, 2H),2.66-2.55 (m, 2H), 2.00-1.82 (m, 4H), 1.79-1.66 (m, 4H), 1.66-1.59 (m,2H), 1.47-1.35 (m, 2H). LCMS (ESI, m/z): 560.3 [M+H]⁺.

Example 40: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-chloro-5-(4-(methylsulfonyl)piperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available1-(methylsulfonyl)piperazine according to the representative procedureof Example 33, Steps 1-3 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-chloro-5-(4-(methylsulfonyl)piperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 6.92-6.84 (m, 1H),6.81-6.73 (m, 2H), 5.82-5.70 (m, 1H), 4.30-4.14 (m, 2H), 3.59-3.47 (m,2H), 3.43-3.35 (m, 4H), 3.33-3.25 (m, 4H), 3.08-2.90 (m, 2H), 2.85 (s,3H), 2.73-2.62 (m, 2H), 1.91-1.77 (m, 4H), 1.71-1.62 (m, 2H), 1.54-1.44(m, 2H). LCMS (ESI, m/z): 621.3 [M+H]⁺.

Example 41: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(4-cyclopropylpiperazin-1-yl)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available1-cyclopropylpiperazine and 3-bromo-5-(trifluoromethyl)benzaldehydeaccording to the representative procedure of Example 33, Steps 1-3 toprovide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(4-cyclopropylpiperazin-1-yl)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.09-7.02 (m, 2H), 6.99(s, 1H), 5.78 (hept, J=6.3 Hz, 1H), 4.31-4.14 (m, 2H), 3.66-3.52 (m,2H), 3.25-3.17 (m, 4H), 3.08-2.91 (m, 2H), 2.85-2.75 (m, 4H), 2.75-2.62(m, 2H), 1.95-1.67 (m, 7H), 1.57-1.46 (m, 2H), 0.56-0.44 (m, 4H). LCMS(ESI, m/z): 617.2 [M+H]⁺.

Example 42: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(1,1-dioxidothiomorpholino)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially availablethiomorpholine 1,1-dioxide and 3-bromo-5-(trifluoromethyl)benzaldehydeaccording to the representative procedure of Example 33, Steps 1-3 toprovide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(1,1-dioxidothiomorpholino)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.06 (s, 1H), 6.97 (s,1H), 6.90 (s, 1H), 5.75-5.62 (m, 1H), 4.22-4.07 (m, 2H), 3.86-3.74 (m,4H), 3.58-3.47 (m, 2H), 3.11-3.01 (m, 4H), 3.01-2.82 (m, 2H), 2.64-2.53(m, 2H), 1.85-1.69 (m, 4H), 1.61-1.54 (m, 2H), 1.48-1.35 (m, 2H). LCMS(ESI, m/z): 626.2 [M+H]⁺.

Example 43: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(4-(methylsulfonyl)piperazin-1-yl)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available1-(methyl sulfonyl)piperazine and3-bromo-5-(trifluoromethyl)benzaldehyde according to the representativeprocedure of Example 33, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(4-(methylsulfonyl)piperazin-1-yl)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.13(s, 1H), 7.06 (s, 1H), 7.01 (s, 1H), 5.83-5.72 (m, 1H), 4.30-4.15 (m,2H), 3.67-3.56 (m, 2H), 3.45-3.37 (m, 4H), 3.37-3.31 (m, 4H), 3.10-2.92(m, 2H), 2.88-2.81 (m, 3H), 2.73-2.63 (m, 2H), 1.94-1.76 (m, 4H),1.76-1.65 (m, 2H), 1.55-1.47 (m, 2H). LCMS (ESI, m/z): 655.2 [M+H]⁺.

Example 44: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(trifluoromethyl)-5-(4-(trifluoromethyl)piperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-(trifluoromethyl)piperidine hydrochloride and3-bromo-5-(trifluoromethyl)benzaldehyde according to the representativeprocedure of Example 33, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(trifluoromethyl)-5-(4-(trifluoromethyl)piperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.02-6.87 (m, 3H),5.75-5.62 (m, 1H), 4.22-4.05 (m, 2H), 3.78-3.63 (m, 2H), 3.57-3.44 (m,2H), 3.02-2.84 (m, 2H), 2.74-2.54 (m, 4H), 2.20-2.03 (m, 1H), 2.01-1.87(m, 2H), 1.83-1.51 (m, 7H), 1.46-1.34 (m, 2H). LCMS (ESI, m/z): 644.2[M+H]⁺.

Example 45: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(4-fluoropiperidin-1-yl)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-fluoropiperidine hydrochloride and3-bromo-5-(trifluoromethyl)benzaldehyde according to the representativeprocedure of Example 33, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(4-fluoropiperidin-1-yl)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.06 (s, 2H), 7.02 (s,1H), 5.84-5.72 (m, 1H), 4.98-4.73 (m, 1H), 4.33-4.17 (m, 2H), 3.60 (s,2H), 3.48-3.36 (m, 2H), 3.31-3.22 (m, 2H), 3.10-2.91 (m, 2H), 2.74-2.63(m, 2H), 2.13-1.95 (m, 4H), 1.91-1.69 (m, 6H), 1.58-1.44 (m, 2H). LCMS(ESI, m/z): 594.3 [M+H]⁺.

Example 46: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially availablehexahydro-1H-furo[3,4-c]pyrrole and3-bromo-5-(trifluoromethyl)benzaldehyde according to the representativeprocedure of Example 33, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 6.85 (s, 1H), 6.66-6.56(m, 2H), 5.74-5.62 (m, 1H), 4.21-4.05 (m, 2H), 3.97-3.86 (m, 2H),3.67-3.56 (m, 2H), 3.55-3.43 (m, 2H), 3.44-3.32 (m, 2H), 3.24-3.14 (m,2H), 3.05-2.80 (m, 4H), 2.65-2.51 (m, 2H), 1.81-1.67 (m, 4H), 1.68-1.59(m, 2H), 1.46-1.36 (m, 2H). LCMS (ESI, m/z): 604.2 [M+H]⁺.

Example 47: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(azetidin-1-yl)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially availableazetidine and 3-bromo-5-(trifluoromethyl)benzaldehyde according to therepresentative procedure of Example 16, Step 1 and Example 1, Steps 2-3to provide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(azetidin-1-yl)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 6.84 (s, 1H), 6.42 (s,2H), 5.74-5.60 (m, 1H), 4.21-4.06 (m, 2H), 3.89-3.76 (m, 4H), 3.53-3.39(m, 2H), 3.01-2.80 (m, 2H), 2.65-2.53 (m, 2H), 2.37-2.24 (m, 2H),1.84-1.59 (m, 6H), 1.45-1.35 (m, 2H). LCMS (ESI, m/z): 548.2 [M+H]⁺.

Example 48: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(4-chlorobenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5] decane-8-carboxylate

Step 1: Preparation of 1-(4-methoxybenzyl)piperidine-4-carbonitrile

A flask was charged with 4-methoxybenzaldehyde (2.5 g, 18.1 mmol),piperidine-4-carbonitrile (2.0 g, 18.2 mmol), DCM (50 mL), and molecularsieves (4 g). After stirring at rt for 30 min, NaBH(OAc)₃ (5.75 g, 27.2mmol) was added and the reaction was stirred at rt for 18 h. Thereaction was diluted in DCM (200 mL) and washed with aqueous sat. Na₂CO₃(2×100 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered,and concentrated. The resulting oil was purified on a silica column (0to 5% MeOH in DCM) to yield 1-(4-methoxybenzyl)piperidine-4-carbonitrile(4100 mg, 17.8 mmol, 98% yield) as a clear oil. ¹H NMR (400 MHz,Chloroform-d) δ 7.31-7.19 (m, 2H), 6.87 (dd, J=8.7, 1.3 Hz, 2H), 3.82(s, 3H), 3.46 (s, 2H), 2.66 (br s, 3H), 2.32 (br s, 2H), 2.00-1.81 (m,5H). LCMS (ESI, m/z): 231.2 [M+H]⁺.

Step 2: Preparation of1-(4-methoxybenzyl)-4-(2-methylallyl)piperidine-4-carbonitrile

A flask was charged with THF (20 mL) and DIPEA (3.2 mL, 23.1 mmol) andcooled to −78° C. The solution was treated with n-butyllithium (9.0 mL,21.4 mmol) and stirred at −78° C. for 15 min. A separate flask wascharged with 1-(4-methoxybenzyl)piperidine-4-carbonitrile and THF (40mL) and cooled to −78° C. LDA solution was added via syringe to thecyanopiperidine at −78° C. The solution became yellow and was stirred at−78° C. for 15 min. 3-Bromo-2-methyl-prop-1-ene (3.6 mL, 35.6 mmol) inTHF (10 mL) was added dropwise to the cyanopiperidine solution at −78°C. The reaction was stirred at −78° C. for 30 min. The reaction mixturewas poured into brine and EtOAc (100 mL). The organic layer was washedwith brine (2×75 mL), dried over anhydrous Na₂SO₄, filtered, andconcentrated. The resulting oil was purified on a silica column (0 to 5%MeOH in DCM) to yield1-(4-methoxybenzyl)-4-(2-methylallyl)piperidine-4-carbonitrile (3700 mg,13.0 mmol, 73% yield) as a white solid. ¹H NMR (400 MHz, Chloroform-d) δ7.23 (d, J=8.0 Hz, 2H), 6.91-6.83 (m, 2H), 5.01-4.95 (m, 1H), 4.88-4.83(m, 1H), 3.82 (s, 3H), 3.49 (s, 2H), 2.87 (d, J=12.3 Hz, 2H), 2.37-2.26(m, 4H), 1.97-1.89 (m, 5H), 1.64-1.52 (m, 2H). LCMS (ESI, m/z): 285.1[M+H]⁺.

Step 3: Preparation of(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine

A flask was charged with1-(4-methoxybenzyl)-4-(2-methylallyl)piperidine-4-carbonitrile (560 mg,1.97 mmol) and diethyl ether (10 mL). The reaction mixture was cooled to0° C. and LAH (2.4 M in THF, 3.3 mL, 7.88 mmol) was added dropwise. Thereaction stirred for 5 min at 0° C. and then at rt for 1 h. The solutionwas cooled to 0° C. and H₂O (250 μL) was added followed by 10% aq. NaOH(280 μL) and additional H₂O (840 μL). The reaction was allowed to warmto rt and stirred for 2 h. The solids were filtered and washed withether (2×20 mL). The filtrate was concentrated to yield(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine (560mg, 1.94 mmol, 98% yield) as a clear oil that was used without furtherpurification. ¹H NMR (400 MHz, Chloroform-d) δ 7.28-7.20 (m, 3H),6.91-6.82 (m, 3H), 4.89 (dd, J=2.3, 1.4 Hz, 1H), 4.73-4.67 (m, 1H), 3.82(s, 3H), 3.47 (d, J=9.3 Hz, 2H), 2.63 (s, 2H), 2.41 (dh, J=22.7, 5.7 Hz,4H), 2.08 (s, 2H), 1.80 (s, 3H), 1.50 (q, J=9.7, 7.4 Hz, 4H). LCMS (ESI,m/z): 289.2 [M+H]⁺.

Step 4: Preparation ofN-(4-chlorobenzyl)-1-(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine

A flask was charged with molecular sieves (1 g),(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine (288mg, 1.0 mmol) and MeOH (20 mL). 4-Chlorobenzaldehyde (140.5 mg, 1 mmol)was added and the reaction mixture was stirred for 1 h. The reaction wasfiltered and concentrated and resuspended in MeOH (20 mL) and cooled to0° C. Sodium borohydride (100 mg, 2.70 mmol) was added and the reactionmixture was stirred at 0° C. for 30 min. The reaction mixture was thenquenched at 0° C. with 1 N HCl (5 ml) and sat. Na₂CO₃ (30 mL), and thesolution was extracted with DCM (3×75 mL). The combined organic layerswere dried over anhydrous Na₂SO₄, filtered, and concentrated. Theresulting oil was purified on a silica column (0 to 10% NH₃ (2M MeOHic)in DCM) to yieldN-(4-chlorobenzyl)-1-(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine(358 mg, 0.867 mmol, 87% yield) as a clear oil. ¹H NMR (400 MHz,Chloroform-d) δ 7.34-7.20 (m, 6H), 6.90-6.83 (m, 2H), 4.86 (s, 1H), 4.67(s, 1H), 3.82 (d, J=1.5 Hz, 3H), 3.73 (s, 2H), 3.44 (s, 2H), 2.51-2.40(m, 4H), 2.34-2.28 (m, 2H), 2.13 (s, 2H), 1.78 (s, 3H), 1.54 (s, 4H).LCMS (ESI, m/z): 413.3 [M+H]⁺.

Step 5: Preparation of2-(4-chlorobenzyl)-8-(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane

A vial was charged withN-(4-chlorobenzyl)-1-(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine(220 mg, 0.530 mmol) and 1,4-dioxane (5 mL). Nitrogen was bubbledthrough the solution for 10 min. [Pt(II)Cl₂(C₂H₄)]₂ (34 mg, 0.110 mmol)and tBuXPhos (54 mg, 0.130 mmol) were added and the reaction was heatedto 110° C. for 8 h. The reaction mixture was poured into EtOAc (150 mL)and washed with aq. Na₂CO₃ (2×50 mL). The organic layer was dried overanhydrous Na₂SO₄, filtered, and concentrated. The resulting oil waspurified on a silica column (0 to 5% NH₃ (2M methanolic in DCM) to yield2-(4-chlorobenzyl)-8-(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane(119 mg, 0.288 mmol, 54% yield) as a white clear oil. ¹H NMR (400 MHz,Chloroform-d) δ 7.33-7.25 (m, 4H), 7.25-7.13 (m, 2H), 6.89-6.82 (m, 2H),3.81 (s, 3H), 3.48 (s, 2H), 3.38 (s, 2H), 2.49-2.18 (m, 6H), 1.57 (s,6H), 1.10 (d, J=1.5 Hz, 6H). LCMS (ESI, m/z): 413.3 [M+H]⁺.

Step 6: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-chlorobenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

A solution of 1-chloroethyl chloroformate (0.02 mL, 0.170 mmol) in DCM(1 mL) was added dropwise to a solution of2-(4-chlorobenzyl)-8-(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane(48 mg, 0.120 mmol) in DCM (1 mL) at 0° C. The reaction was stirred at0° C. for 20 min and concentrated. The crude material was resuspended inMeOH (5 mL) and heated to 60° C. for 1 h. The reaction mixture wasconcentrated, and DCM (3 mL) and TEA (100 μL) were added to the residue.The mixture was cooled to 0° C. Bis(1,1,1,3,3,3-hexafluoropropan-2-yl)carbonate (0.09 mL, 0.120 mmol) was added and the reaction mixture wasstirred at rt for 1 h. The reaction was quenched with MeOH (0.5 mL) andconcentrated. The resulting oil was purified on a silica column (0 to30% EtOAc in hexanes) to yield 1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-chlorobenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate(22 mg, 0.045 mmol, 39% yield) as a clear oil. ¹H NMR (400 MHz,Chloroform-d) δ 7.39-7.13 (m, 4H), 5.75 (hept, J=6.3, 1.5 Hz, 1H),3.63-3.29 (m, 6H), 2.59-2.36 (m, 2H), 1.73-1.51 (m, 6H), 1.25-1.06 (m,6H). LCMS (ESI, m/z): 487.2 [M+H]⁺.

Example 49: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(4-chloro-2-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was prepared from(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine and4-chloro-2-methoxybenzaldehyde according to the representative procedureof Example 48, Steps 4-6 and yielded 1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-chloro-2-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate.¹H NMR (400 MHz, Chloroform-d) δ 7.38 (d, J=7.9 Hz, 1H), 6.93 (dt,J=8.1, 2.1 Hz, 1H), 6.84 (t, J=2.2 Hz, 1H), 5.84-5.69 (m, 1H), 3.86-3.80(m, 3H), 3.53-3.37 (m, 6H), 2.60-2.47 (m, 2H), 1.72-1.53 (m, 6H), 1.13(s, 6H). LCMS (ESI, m/z): 517.1 [M+H]⁺.

Example 50: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(4-chloro-2-morpholinobenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was prepared from(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine and4-chloro-2-morpholinobenzaldehyde according to the representativeprocedure of Example 48, Steps 4-6 and yielded1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-chloro-2-morpholinobenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.37 (d, J=8.1 Hz, 1H),7.00-6.91 (m, 2H), 5.66 (dd, J=6.3 Hz, 1H), 3.76 (t, J=4.5 Hz, 4H), 3.47(s, 2H), 3.39-3.31 (m, 4H), 2.86 (q, J=3.7 Hz, 4H), 2.39 (s, 2H), 1.55(s, 2H), 1.53-1.43 (m, 4H), 1.06 (d, J=2.3 Hz, 6H). LCMS (ESI, m/z):572.1 [M+H]⁺.

Example 51: 1,1,1,3,3,3-Hexafluoropropan-2-yl3,3-dimethyl-2-(2-morpholino-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Preparation ofN-(4-methoxybenzyl)-1-(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine

The title compound was prepared from(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine and4-methoxybenzaldehyde according to the representative procedure ofExample 48, Step 4 and yieldedN-(4-methoxybenzyl)-1-(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine.LCMS (ESI, m/z): 409.1 [M+H]⁺.

Step 2: Preparation of2,8-bis(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane

The title compound was prepared fromN-(4-methoxybenzyl)-1-(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamineaccording to the representative procedure of Example 48, Step 5, exceptan 18 h reaction time was used. The reaction gave2,8-bis(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane. ¹H NMR(400 MHz, Chloroform-d) δ 7.26 (d, J=8.4 Hz, 2H), 6.86 (d, J=8.5 Hz,2H), 5.75 (hept, J=6.3 Hz, 1H), 3.83 (s, 3H), 3.54-3.36 (m, 6H), 2.48(s, 2H), 1.66-1.53 (m, 8H), 1.14 (d, J=3.1 Hz, 6H). LCMS (ESI, m/z):409.2 [M+H]⁺.

Step 3: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was prepared from2,8-bis(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decaneaccording to the representative procedure of Example 48, Step 6 andyielded 1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.26 (s, 2H), 6.93-6.83(m, 2H), 5.77 (hept, J=6.3 Hz, 1H), 3.83 (s, 3H), 3.56-3.34 (m, 6H),2.49 (d, J=1.6 Hz, 2H), 1.65 (s, 2H), 1.59 (dt, J=10.3, 5.5 Hz, 4H),1.15 (d, J=3.2 Hz, 6H). LCMS (ESI, m/z): 483.1 [M+H]⁺.

Step 4: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate(590 mg, 1.22 mmol), MeOH (20 mL), ammonium formate (385 mg, 6.11 mmol),and 10% palladium on carbon (250 mg, 0.060 mmol). The reaction washeated to 80° C. for 20 min. The reaction mixture was filtered,concentrated, diluted in DCM, washed with sat. Na₂CO₃ and extracted withDCM (3×). The combined organic layers were dried over anhydrous Na₂SO₄,filtered, and concentrated. The resulting oil was purified on a silicacolumn (0 to 100% acetone in hexane) to yield1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate (400 mg, 1.10 mmol,90% yield) as a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 5.73 (hept,J=6.2 Hz, 1H), 3.59-3.48 (m, 2H), 3.44-3.32 (m, 2H), 2.83 (s, 2H), 1.84(br s, 1H), 1.63-1.43 (m, 6H), 1.17 (s, 6H). LCMS (ESI, m/z): 363.1[M+H]⁺.

Step 5: Preparation of 4-(trifluoromethyl)-2-morpholinobenzaldehyde

The title compound was prepared from4-(trifluoromethyl)-2-fluorobenzaldehyde and morpholine according to therepresentative procedure of Example 16, Step 1, with the exception thatDMSO and 120° C. were used, and yielded4-(trifluoromethyl)-2-morpholinobenzaldehyde as a yellow solid. ¹H NMR(400 MHz, Chloroform-d) δ 10.21 (s, 1H), 7.73 (d, J=8.3 Hz, 1H),7.20-6.96 (m, 2H), 4.11-3.77 (m, 4H), 3.17-2.96 (m, 4H). LCMS (ESI,m/z): 226.0 [M+H]⁺.

Step 6: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2-(2-morpholino-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A vial was charged with 2-morpholino-4-(trifluoromethyl)benzaldehyde (42mg, 0.170 mmol), 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate, and DCM (2 mL).Molecular sieves (500 mg) and acetic acid (7 mg, 0.110 mmol) were addedand the reaction mixture was stirred for 30 min. NaBH(OAc)₃ (35 mg,0.170 mmol) was added and the mixture was stirred overnight at rt. Themixture was poured into brine (30 mL) and extracted with DCM (2×50 mL).The combined organic layers were dried over anhydrous Na₂SO₄, filtered,and concentrated. The resulting oil was purified on a silica column (0to 50% EtOAc in hexane) to yield 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2-(2-morpholino-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate(45 mg, 0.072 mmol, 66% yield) as a white solid. ¹H NMR (400 MHz,Chloroform-d) δ 7.67 (d, J=8.0 Hz, 1H), 7.36-7.25 (m, 2H), 5.81-5.67 (m,2H), 3.87 (t, J=3.7 Hz, 4H), 3.63 (s, 2H), 3.47-3.41 (m, 4H), 3.00-2.94(m, 4H), 2.49 (s, 2H), 1.72-1.64 (m, 2H), 1.64-1.54 (m, 4H), 1.16 (s,6H). LCMS (ESI, m/z): 606.1 [M+H]⁺.

Example 52: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(2-(8-oxa-2-azaspiro[4.5]decan-2-yl)-4-(trifluoromethyl)benzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was prepared from 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate, and2-fluoro-4-(trifluoromethyl)benzaldehyde according to the representativeprocedure of Example 51, Steps 5-6 and yielded1,1,1,3,3,3-hexafluoropropan-2-yl2-(2-(8-oxa-2-azaspiro[4.5]decan-2-yl)-4-(trifluoromethyl)benzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylateas a clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.68 (d, J=8.0 Hz, 1H),7.16 (d, J=8.0 Hz, 1H), 7.10 (s, 1H), 5.74 (hept, J=6.3 Hz, 1H), 3.71(h, J=7.5 Hz, 4H), 3.55 (s, 2H), 3.44 (qt, J=13.7, 7.0 Hz, 4H), 3.27(td, J=6.7, 4.5 Hz, 2H), 3.07 (s, 2H), 2.47-2.41 (m, 2H), 1.85 (t, J=7.0Hz, 2H), 1.77-1.66 (m, 5H), 1.59 (dt, J=10.5, 5.7 Hz, 5H), 1.15 (d,J=2.2 Hz, 6H). LCMS (ESI, m/z): 660.1 [M+H]⁺.

Example 53: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(2-(4-(methoxycarbonyl)piperidin-1-yl)-4-(trifluoromethyl)benzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was prepared from 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5] decane-8-carboxylate, methylpiperidine-4-carboxylate, and 2-fluoro-4-(trifluoromethyl)benzaldehydeaccording to the representative procedure of Example 51, Steps 5-6 andyielded 1,1,1,3,3,3-hexafluoropropan-2-yl2-(2-(4-(methoxycarbonyl)piperidin-1-yl)-4-(trifluoromethyl)benzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (400 MHz, Chloroform-d) δ 7.70 (d, J=8.0 Hz,1H), 7.35-7.28 (m, 1H), 7.26 (s, 1H), 5.76 (hept, J=5.9 Hz, 1H), 3.74(d, J=1.3 Hz, 3H), 3.61 (s, 2H), 3.45 (s, 4H), 3.16 (d, J=11.6 Hz, 2H),2.73 (q, J=10.7 Hz, 2H), 2.48 (s, 3H), 2.05 (d, J=12.2 Hz, 2H),2.00-1.86 (m, 2H), 1.72-1.51 (m, 6H), 1.17 (s, 6H). LCMS (ESI, m/z):662.1 [M+H]⁺.

Example 54: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(3-chloro-2-morpholinobenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was prepared from 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5] decane-8-carboxylate, morpholine, and2-fluoro-3-chlorobenzaldehyde according to the representative procedureof Example 51, Steps 5-6 and yielded 1,1,1,3,3,3-hexafluoropropan-2-yl2-(3-chloro-2-morpholinobenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. ¹H NMR (400 MHz, Chloroform-d) δ 7.43 (dd,J=7.6, 1.7 Hz, 1H), 7.20 (dd, J=7.9, 1.7 Hz, 1H), 7.08 (t, J=7.8 Hz,1H), 5.73 (hept, J=6.3 Hz, 1H), 3.88 (dt, J=10.7, 3.0 Hz, 2H), 3.79-3.58(m, 6H), 3.43 (dt, J=7.7, 4.0 Hz, 4H), 2.78-2.70 (m, 2H), 2.54-2.42 (m,2H), 1.67-1.63 (m, 2H), 1.64-1.53 (m, 4H), 1.14 (d, J=2.1 Hz, 6H). LCMS(ESI, m/z): 572.1 [M+H]⁺.

Example 55: 1,1,1,3,3,3-Hexafluoropropan-2-yl3,3-dimethyl-2-(2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was prepared from 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5] decane-8-carboxylate,hexahydro-1H-furo[3,4-c]pyrrole, and2-fluoro-4-(trifluoromethyl)benzaldehyde according to the representativeprocedure of Example 51, Steps 5-6 and yielded1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2-(2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate as a white solid. ¹H NMR (400 MHz, Chloroform-d) δ7.74 (d, J=8.0 Hz, 1H), 7.33-7.20 (m, 2H), 5.75 (hept, J=6.3 Hz, 1H),4.07 (dd, J=8.7, 6.3 Hz, 2H), 3.67-3.60 (m, 2H), 3.59 (s, 2H), 3.55-3.36(m, 4H), 3.20-3.09 (m, 2H), 3.02-2.93 (m, 4H), 2.46 (s, 2H), 1.68 (s,2H), 1.62 (dt, J=10.9, 5.7 Hz, 4H), 1.17 (d, J=2.4 Hz, 6H). LCMS (ESI,m/z): 632 [M+H]⁺.

Example 56: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(2-(8-oxa-2-azaspiro[4.5]decan-2-yl)-6-(trifluoromethyl)benzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was prepared from 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate,8-oxa-2-azaspiro[4.5]decane, and2-fluoro-6-(trifluoromethyl)benzaldehyde according to the representativeprocedure of Example 51, Steps 5-6 with the following modifications toStep 6: a vial was charged with2-(8-oxa-2-azaspiro[4.5]decan-2-yl)-6-(trifluoromethyl)benzaldehyde (100mg, 0.320 mmol) and 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate (80 mg, 0.220 mmol)and DCM (2.0 mL). Molecular sieves (500 mg) and acetic acid (15 mg,0.250 mmol) were added and the reaction was stirred for 30 min.NaBH(OAc)₃ (50 mg, 0.240 mmol) was added and the mixture was stirredovernight at rt. More2-(8-oxa-2-azaspiro[4.5]decan-2-yl)-6-(trifluoromethyl)benzaldehyde (100mg, 0.320 mmol) and NaBH(OAc)₃ (50 mg, 0.240 mmol) were added and themixture was stirred an additional 24 h. The mixture was poured intobrine (30 mL) and extracted with DCM (2×50 mL). The combined organiclayers were dried over anhydrous Na₂SO₄, filtered, and concentrated. Theresulting oil was purified on a silica column (0 to 50% EtOAc in hexane)to yield 1,1,1,3,3,3-hexafluoropropan-2-yl2-(2-(8-oxa-2-azaspiro[4.5]decan-2-yl)-6-(trifluoromethyl)benzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate(10 mg, 0.014 mmol, 7% yield) as a light yellow solid. ¹H NMR (400 MHz,Chloroform-d) δ 7.31-7.05 (m, 3H), 5.63 (hept, J=6.1 Hz, 1H), 3.75 (s,2H), 3.70-3.50 (m, J=4.2 Hz, 4H), 3.26 (s, 4H), 3.08 (td, J=7.1, 3.2 Hz,2H), 2.96-2.80 (m, 2H), 1.77 (t, J=6.9 Hz, 2H), 1.65-1.57 (m, 4H), 1.51(s, 2H), 1.45 (s, 2H), 1.38 (dt, J=11.3, 6.1 Hz, 4H), 0.98 (s, 6H). LCMS(ESI, m/z): 660.1 [M+H]⁺.

Example 57: 1,1,1,3,3,3-Hexafluoropropan-2-yl3,3-dimethyl-2-(2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-6-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was prepared from 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5] decane-8-carboxylate,hexahydro-1H-furo[3,4-c]pyrrole, and2-fluoro-6-(trifluoromethyl)benzaldehyde according to the representativeprocedure of Example 56, yielding 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2-(2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-6-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (400 MHz, Chloroform-d) δ 7.43 (dd, J=5.1, 4.0Hz, 1H), 7.35-7.27 (m, 2H), 5.74 (hept, J=6.1 Hz, 1H), 4.13-4.01 (m,1H), 3.89 (s, 2H), 3.74-3.58 (m, 2H), 3.49-3.24 (m, 4H), 3.21-3.02 (m,3H), 3.02-2.81 (m, 5H), 2.32 (s, 2H), 1.56 (s, 2H), 1.54-1.40 (m, 5H),1.10 (s, 6H). LCMS (ESI, m/z): 632 [M+H]⁺.

Example 58: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(3-(pyrrolidin-1-yl)benzyl)-2,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from commercially available3-(pyrrolidin-1-yl)benzaldehyde and commercially available tert-butyl2,8-diazaspiro[4.5] decane-2-carboxylate according to the representativeprocedure of Example 1, Steps 1-3 to provide1,1,1,3,3,3-hexafluoropropan-2-yl2-(3-(pyrrolidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate asa clear oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.23-7.11 (m, 1H),6.68-6.46 (m, 3H), 5.84-5.68 (m, 1H), 3.64-3.41 (m, 6H), 3.36-3.24 (m,4H), 2.75-2.60 (m, 2H), 2.49-2.36 (m, 2H), 2.07-1.95 (m, 4H), 1.72-1.66(m, 2H), 1.66-1.57 (m, 4H). LCMS (ESI, m/z): 494.2 [M+H]⁺.

Example 59: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Preparation of2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzaldehyde

A flask was charged with 2-fluoro-6-(trifluoromethyl)benzaldehyde (6.00g, 31.2 mmol, 1.00 equiv), pyrrolidine (3.33 g, 46.8 mmol, 1.50 equiv),potassium carbonate (10.8 g, 78.1 mmol, 2.50 equiv), and DMSO (50 mL)under nitrogen. The resulting solution was stirred overnight at 85° C.and diluted with H₂O (20 mL). The resulting solution was extracted withEtOAc (3×50 mL) and the organic layers were combined, washed with H₂O(2×20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. Theresidue was purified on a silica gel column (9:91 EtOAc/petroleum ether)to provide 5.98 g (79% yield) of2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzaldehyde as a yellow oil.LCMS (ESI, m/z): 244 [M+H]⁺.

Step 2: Preparation of tert-butyl2-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzaldehyde (200 mg, 0.820 mmol,1.00 equiv), tert-butyl 2,8-diazaspiro[4.5]decane-8-carboxylate (198 mg,0.820 mmol, 1.00 equiv), and DCE (10 mL). The resulting solution wasstirred for 30 min at rt and NaBH(OAc)₃ (523 mg, 2.47 mmol, 3.00 equiv)was added. The resulting solution was stirred overnight at rt andquenched with H₂O (10 mL). The resulting solution was extracted with DCM(3×15 mL) and the organic layers were combined, washed with brine (15mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residuewas purified on a silica gel column (1:1 EtOAc/petroleum ether) toprovide 230 mg (60% yield) of tert-butyl2-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a colorless oil. LCMS (ESI, m/z): 468 [M+H]⁺.

Step 3: Preparation of2-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane

A flask was charged with tert-butyl2-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate(230 mg, 0.490 mmol, 1.00 equiv), and DCM (8 mL). TFA (1 mL) was addedat 0° C. The resulting solution was stirred overnight at rt andconcentrated to provide 260 mg (crude) of2-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decaneas a yellow oil. LCMS (ESI, m/z): 368 [M+H]⁺.

Step 4: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl2-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with triphosgene (51.0 mg, 0.170 mmol, 0.17 equiv),and DCM (10 mL) under nitrogen. HFIP (166 mg, 0.990 mmol, 1.00 equiv)was added at 0° C., followed by DIEA (509 mg, 3.94 mmol, 3.99 equiv).The resulting solution was stirred for 1 h at 0° C., after which2-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane(181 mg, 0.490 mmol, 0.50 equiv) was added. The resulting solution wasstirred for 5 h at 0° C. and concentrated. The crude product waspurified by preparative HPLC to provide 24.0 mg (4% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl2-(2-(pyrrolidin-1-yl)-6-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.14-7.38 (m, 3H),5.67-5.80 (m, 1H), 3.79 (s, 2H), 3.36-3.49 (m, 4H), 3.13 (br, 4H),2.46-2.51 (t, J=6.8 Hz, 2H), 2.27 (s, 2H), 1.92 (br, 4H), 1.52-1.57 (m,6H). LCMS (ESI, m/z): 562 [M+H]⁺.

Example 60: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Preparation of tert-butyl 1-(2-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 2-chlorobenzaldehyde (1.00, 7.11 mmol, 1.00equiv), tert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate (2.00 g, 8.32mmol, 1.20 equiv), and DCE (20 mL). The mixture was stirred for 1 h atrt. NaBH(OAc)₃ (4.50 g, 21.2 mmol, 3.00 equiv) was added. The resultingsolution was stirred overnight at rt and then diluted with H₂O (20 mL).The resulting mixture was extracted with DCM (3×20 mL). The organiclayers were combined, washed with brine (lx 100 mL), dried overanhydrous Na₂SO₄, filtered and concentrated. The residue was purified ona silica gel column with EtOAc/petroleum ether (50/50) to provide 1.90 g(73% yield) of tert-butyl1-(2-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as acolorless oil. LCMS (ESI, m/z): 365 [M+H]⁺.

Step 2: Preparation of 1-(2-chlorobenzyl)-1,8-diazaspiro[4.5]decane

A flask was charged with tert-butyl1-(2-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate (470 mg, 1.29mmol, 1.00 equiv), TFA (4 mL), and DCM (10 mL). The resulting solutionwas stirred overnight at rt and concentrated to yield 300 mg (88% yield)of 1-(2-chlorobenzyl)-1,8-diazaspiro[4.5]decane as a yellow oil. LCMS(ESI, m/z): 265 [M+H]⁺.

Step 3: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-chlorobenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

A flask was charged with triphosgene (149 mg, 0.500 mmol, 0.70 equiv),and DCM (15 mL). HFIP (240 mg, 1.43 mmol, 2.00 equiv) and DIEA (740 mg,5.73 mmol, 8.00 equiv) were added at 0° C. The mixture was stirred for 2h at rt, after which 1-(2-chlorobenzyl)-1,8-diazaspiro[4.5]decane (190mg, 0.720 mmol, 1.00 equiv) was added. The resulting solution wasstirred overnight at rt, and diluted with H₂O (10 mL). The resultingmixture was extracted with DCM (3×10 mL). The organic layers werecombined, washed with brine (1×50 mL), dried over anhydrous Na₂SO₄,filtered and concentrated. The crude product was purified by preparativeHPLC to give 114.9 mg (35% yield) of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as a whitesolid. ¹H NMR (300 MHz, Chloroform-d) δ 7.42-7.59 (m, 1H), 7.32-7.34 (m,1H), 7.06-7.24 (m, 2H), 5.70-5.83 (m, 1H), 4.21 (t, J=12.4 Hz, 2H), 3.92(s, 2H), 2.91-3.05 (m, 2H), 2.63-2.76 (m, 2H), 1.72-1.82 (m, 6H),1.49-1.58 (m, 2H). LCMS (ESI, m/z): 459 [M+H]⁺.

Example 61: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-chlorobenzaldehyde according to the representative procedure ofExample 60 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-chlorobenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate as acolorless oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.32 (s, 1H), 7.16-7.28(m, 3H), 5.70-5.83 (m, 1H), 4.16-4.26 (m, 2H), 3.51-3.60 (m, 2H),2.90-3.05 (m, 2H), 2.64-2.76 (m, 2H), 1.64-1.87 (m, 6H), 1.43-1.47 (m,2H). LCMS (ESI, m/z): 459 [M+H]⁺.

Example 62: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chlorobenzaldehyde according to the representative procedure ofExample 60 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as a whitesolid. ¹H NMR (300 MHz, Chloroform-d) δ 7.25 (d, J=2.7 Hz, 4H),5.69-5.82 (m, 1H), 4.17-4.33 (m, 2H), 3.55 (s, 2H), 2.91-3.05 (m, 2H),2.64-2.66 (m, 2H), 1.60-1.99 (m, 6H), 1.46-1.50 (m, 2H). LCMS (ESI,m/z): 459 [M+H]⁺.

Example 63: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-benzyl-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially availablebenzaldehyde according to the representative procedure of Example 60 toprovide 1,1,1,3,3,3-hexafluoropropan-2-yl1-benzyl-1,8-diazaspiro[4.5]decane-8-carboxylate as a white solid. ¹HNMR (300 MHz, Chloroform-d) δ 7.22-7.31 (m, 5H), 5.70-5.82 (m, 1H), 4.21(t, J=13.0 Hz, 2H), 3.58 (s, 2H), 2.91-3.05 (m, 2H), 2.68-2.70 (m, 2H),1.69-1.80 (m, 6H), 1.47-1.51 (m, 2H). LCMS (ESI, m/z): 425 [M+H]⁺.

Example 64: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(3-chloro-2-(4,4-difluoropiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Preparation of 3-chloro-2-(4-hydroxypiperidin-1-yl)benzaldehyde

A flask was charged with 3-chloro-2-fluorobenzaldehyde (3.00 g, 18.9mmol, 1.00 equiv), piperidin-4-ol (2.86 g, 28.3 mmol, 1.49 equiv),potassium carbonate (7.81 g, 56.5 mmol, 2.99 equiv), and DMSO (30 mL)under nitrogen. The resulting solution was stirred overnight at 120° C.and diluted with H₂O (15 mL). The resulting solution was extracted withEtOAc (3×30 mL) and the organic layers were combined, dried overanhydrous Na₂SO₄, filtered and concentrated. The residue was purified ona silica gel column (27:63 EtOAc/petroleum ether) to provide 3.20 g (71%yield) of 3-chloro-2-(4-hydroxypiperidin-1-yl)benzaldehyde as a yellowoil. LCMS (ESI, m/z): 240 [M+H]⁺.

Step 2: Preparation of tert-butyl2-(3-chloro-2-(4-hydroxypiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with3-chloro-2-(4-hydroxypiperidin-1-yl)benzaldehyde (1.00 g, 4.17 mmol,1.00 equiv), tert-butyl 2,8-diazaspiro[4.5]decane-8-carboxylate (1.00 g,4.16 mmol, 1.00 equiv), and DCE (20 mL). The resulting solution wasstirred for 30 min at rt and NaBH(OAc)₃ (2.65 g, 12.5 mmol, 3.00 equiv)was added. The resulting solution was stirred overnight at rt andquenched with H₂O (15 mL). The mixture was extracted with DCM (3×20 mL)and the organic layers were combined, dried over anhydrous Na₂SO₄,filtered and concentrated. The residue was purified on a silica gelcolumn (30:70 EtOAc/petroleum ether) to provide 760 mg (39% yield) oftert-butyl2-(3-chloro-2-(4-hydroxypiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. LCMS (ESI, m/z): 464 [M+H]⁺.

Step 3: Preparation of tert-butyl2-(3-chloro-2-(4-oxopiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl2-(3-chloro-2-(4-hydroxypiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate(760 mg, 1.64 mmol, 1.00 equiv),(1,1,1-triacetoxy)-1,1-dihydro-1,2-benziodoxol-3(1H)-one (1.04 g, 2.45mmol, 1.50 equiv), and DCM (20 mL). The resulting solution was stirredovernight at rt and quenched with H₂O (15 mL). The mixture was extractedwith DCM (3×20 mL) and the organic layers were combined, dried overanhydrous Na₂SO₄, filtered and concentrated. The residue was purified ona silica gel column (45:55 EtOAc/petroleum ether) to provide 280 mg (37%yield) of tert-butyl2-(3-chloro-2-(4-oxopiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. LCMS (ESI, m/z): 462 [M+H]⁺.

Step 4: Preparation of tert-butyl2-(3-chloro-2-(4,4-difluoropiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl2-(3-chloro-2-(4-oxopiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate(280 mg, 0.610 mmol, 1.00 equiv) and DCM (10 mL) under nitrogen.Bis(2-methoxyethyl)aminosulfur trifluoride (403 mg, 1.82 mmol, 3.01equiv) was added at 0° C. The resulting solution was stirred overnightat rt and quenched with H₂O (10 mL). The mixture was extracted with DCM(3×15 mL) and the organic layers were combined, dried over anhydrousNa₂SO₄, filtered and concentrated. The crude product was purified bypreparative HPLC to provide 70.0 mg (24% yield) of tert-butyl2-(3-chloro-2-(4,4-difluoropiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. LCMS (ESI, m/z): 484 [M+H]⁺.

Step 5: Preparation of2-(3-chloro-2-(4,4-difluoropiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane

A flask was charged with tert-butyl2-(3-chloro-2-(4,4-difluoropiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate(70.0 mg, 0.140 mmol, 1.00 equiv), DCM (5 mL), and TFA (1 mL). Theresulting solution was stirred overnight at rt and concentrated toprovide 50.0 mg (90% yield) of2-(3-chloro-2-(4,4-difluoropiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decaneas a yellow oil. LCMS (ESI, m/z): 384 [M+H]⁺.

Step 6: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl2-(3-chloro-2-(4,4-difluoropiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with triphosgene (27.0 mg, 0.0900 mmol, 0.70 equiv)and DCM (10 mL). HFIP (44.0 mg, 0.260 mmol, 2.01 equiv) was added at 0°C., followed by DIEA (50.0 mg, 0.390 mmol, 2.97 equiv). The resultingsolution was stirred for 1 h at 0° C. and2-(3-chloro-2-(4,4-difluoropiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane(50.0 mg, 0.130 mmol, 1.00 equiv) was added. The resulting solution wasstirred overnight at rt and concentrated. The crude product was purifiedby preparative HPLC to provide 37.5 mg (50% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl2-(3-chloro-2-(4,4-difluoropiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.24-7.28 (m, 2H),7.06 (t, J=7.8 Hz, 1H), 5.68-5.81 (m, 1H), 3.37-3.64 (m, 8H), 3.00-3.04(m, 2H), 2.58 (br, 2H), 2.39 (br, 2H), 1.94-2.25 (m, 4H), 1.58-1.66 (m,6H). LCMS (ESI, m/z): 578 [M+H]⁺.

Example 65: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(3-chloro-2-(4-fluoropiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-chloro-2-fluorobenzaldehyde and 4-fluoropiperidine according to therepresentative procedure of Example 64, Steps 1, 2, 5, and 6 to provide1,1,1,3,3,3-hexafluoropropan-2-yl2-(3-chloro-2-(4-fluoropiperidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.21-7.24 (m, 2H),7.04 (t, J=7.6 Hz, 1H), 5.70-5.79 (m, 1H), 4.60-4.80 (m, 1H), 3.33-3.66(m, 8H), 3.01-3.06 (m, 1H), 2.75-2.80 (m, 1H), 2.60 (br, 2H), 2.41 (br,2H), 1.80-2.12 (m, 4H), 1.58-1.68 (m, 6H). LCMS (ESI, m/z): 560 [M+H]⁺.

Example 66: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Preparation of2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzaldehyde

A flask was charged with 2-fluoro-4-(trifluoromethyl)benzaldehyde (6.00g, 31.2 mmol, 1.00 equiv), pyrrolidine (3.30 g, 46.4 mmol, 1.50 equiv),potassium carbonate (12.9 g, 93.3 mmol, 3.00 equiv), and DMSO (50 mL)under nitrogen. The resulting solution was stirred overnight at 90° C.and diluted with H₂O (20 mL). The mixture was extracted with DCM (3×50mL) and the organic layers were combined, washed with brine (3×10 mL),dried over anhydrous Na₂SO₄, filtered and concentrated. The residue waspurified on a silica gel column (1:20 EtOAc/petroleum ether) to provide6.00 g (79% yield) of2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzaldehyde as a yellow oil.LCMS (ESI, m/z): 244 [M+H]⁺.

Step 2: Preparation of tert-butyl1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate (500 mg, 2.08 mmol, 1.00 equiv),DCE (10 mL), TEA (630 mg, 6.23 mmol, 3.00 equiv), and2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzaldehyde (505 mg, 2.08 mmol,1.00 equiv). The resulting solution was stirred for 1 h at rt.NaBH(OAc)₃ (1.32 mg, 6.24 mmol, 3.00 equiv) was added. The resultingsolution was stirred overnight at rt and diluted with H₂O (20 mL). Themixture was extracted with DCM (3×30 mL) and the organic layers werecombined, washed with brine (3×10 mL), dried over anhydrous Na₂SO₄,filtered and concentrated. The residue was purified on a silica gelcolumn (3:7 EtOAc/petroleum ether) to provide 770 mg (79% yield) oftert-butyl1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. LCMS (ESI, m/z): 468 [M+H]⁺.

Step 3: Preparation of1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane

A flask was charged with tert-butyl1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(770 mg, 1.65 mmol, 1.00 equiv), 1,4-dioxane (15 mL), and hydrochloricacid (3 mL). The resulting solution was stirred for 3 h at rt andconcentrated to provide 600 mg (99% yield) of1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decaneas a yellow oil. LCMS (ESI, m/z): 368 [M+H]⁺.

Step 4: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with triphosgene (85.0 mg, 0.290 mmol, 0.70 equiv),and DCM (10 mL). HFIP (138 mg, 0.820 mmol, 2.00 equiv) was added at 0°C., followed by DIEA (264 mg, 2.04 mmol, 5.00 equiv). The resultingsolution was stirred for 2 h at rt.1-(2-(Pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane(150 mg, 0.410 mmol, 1.00 equiv) was added. The resulting solution wasstirred 2 h at rt and concentrated. The crude product was purified bypreparative HPLC to provide 84.9 mg (37% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.67 (d, J=7.8Hz, 1H), 7.12-7.42 (m, 2H), 5.70-5.82 (m, 1H), 4.16-4.30 (m, 2H), 3.63(s, 2H), 3.14-3.18 (m, 4H), 2.92-3.06 (m, 2H), 2.61-2.65 (m, 2H),1.91-2.07 (m, 4H), 1.68-1.88 (m, 6H), 1.45-1.60 (m, 2H). LCMS (ESI,m/z): 562 [M+H]⁺.

Example 67: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-morpholino-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially availablemorpholine according to the representative procedure of Example 66 toprovide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-morpholino-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.62 (d, J=8.7Hz, 1H), 7.26-7.58 (m, 2H), 5.70-5.82 (m, 1H), 4.17-4.32 (m, 2H), 3.85(t, J=9.0 Hz, 4H), 3.70 (s, 2H), 2.91-3.00 (m, 6H), 2.59-2.68 (m, 2H),1.60-2.01 (m, 6H), 1.26-1.56 (m, 2H). LCMS (ESI, m/z): 578 [M+H]⁺.

Example 68: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-((1-methyl-1,2,3,4-tetrahydroquinolin-7-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Preparation of 7-bromo-1-methyl-1,2,3,4-tetrahydroquinoline

A flask was charged with 7-bromo-1,2,3,4-tetrahydroquinoline (2.50 g,11.8 mmol, 1.00 equiv), paraformaldehyde (1.10 g, 35.4 mmol, 3.00equiv), and DCE (30 mL). The resulting solution was stirred for 1 h atrt. NaBH(OAc)₃ (7.50 g, 35.4 mmol, 3.00 equiv) was added, and thesolution was stirred overnight at 40° C. Water (20 mL) was added, andthe mixture was extracted with DCM (3×30 mL); the organic layers werecombined, washed with brine (3×10 mL), dried over anhydrous Na₂SO₄,filtered, and concentrated. The residue was purified on a silica gelcolumn (1:5 EtOAc/petroleum ether) to provide (67% yield) of7-bromo-1-methyl-1,2,3,4-tetrahydroquinoline as a yellow oil. LCMS (ESI,m/z): 226 [M+H]⁺.

Step 2: Preparation of1-methyl-1,2,3,4-tetrahydroquinoline-7-carbaldehyde

A flask was charged with 7-bromo-1-methyl-1,2,3,4-tetrahydroquinoline(800 mg, 3.54 mmol, 1.00 equiv) and THF (10 mL) under nitrogen.n-Butyllithium (2.5 M in THF, 1.6 mL, 3.92 mmol, 1.10 equiv) was addeddropwise at −78° C. The resulting solution was stirred for 30 min at−78° C., after which DMF (1.04 g, 14.2 mmol, 4.00 equiv) was added. Theresulting solution was stirred for 30 min at −78° C. and then for 2 h atrt. The resulting mixture was diluted with H₂O (20 mL), and the mixturewas extracted with DCM (3×30 mL). The organic layers were combined,washed with H₂O (3×10 mL), dried over anhydrous Na₂SO₄, filtered, andconcentrated. The residue was purified on a silica gel column (2:23EtOAc/petroleum ether) to provide 283 mg (46% yield) of1-methyl-1,2,3,4-tetrahydroquinoline-7-carbaldehyde as a light yellowoil. LCMS (ESI, m/z): 176 [M+H]⁺.

Step 3: Preparation of tert-butyl1-((1-methyl-1,2,3,4-tetrahydroquinolin-7-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate (160 mg, 0.670 mmol, 1.00equiv), DCE (5 mL), TEA (203 mg, 2.01 mmol, 3.00 equiv), and1-methyl-1,2,3,4-tetrahydroquinoline-7-carbaldehyde (120 mg, 0.680 mmol,1.03 equiv). The resulting solution was stirred for 1 h at rt.NaBH(OAc)₃ (426 mg, 2.01 mmol, 3.00 equiv) was added, and the resultingsolution was stirred overnight at rt before diluting with H₂O (20 mL).The mixture was extracted with DCM (3×30 mL) and the organic layers werecombined, washed with brine (3×10 mL), dried over anhydrous Na₂SO₄,filtered and concentrated. The residue was purified on a silica gelcolumn (EtOAc/petroleum ether) to provide 200 mg (75% yield) oftert-butyl1-((1-methyl-1,2,3,4-tetrahydroquinolin-7-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow oil. LCMS (ESI, m/z): 400 [M+H]⁺.

Step 4: Preparation of1-((1-methyl-1,2,3,4-tetrahydroquinolin-7-yl)methyl)-1,8-diazaspiro[4.5]decane

A flask was charged with tert-butyl1-((1-methyl-1,2,3,4-tetrahydroquinolin-7-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(200 mg, 0.500 mmol, 1.00 equiv), 1,4-dioxane (10 mL), and hydrochloricacid (2 mL). The resulting solution was stirred for 2 h at rt andconcentrated to provide 150 mg (100% yield) of1-((1-methyl-1,2,3,4-tetrahydroquinolin-7-yl)methyl)-1,8-diazaspiro[4.5]decaneas a light yellow oil. LCMS (ESI, m/z): 300 [M+H]⁺.

Step 5: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1-methyl-1,2,3,4-tetrahydroquinolin-7-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with triphosgene (104 mg, 0.350 mmol, 0.70 equiv),and DCM (10 mL). HFIP (168 mg, 1.00 mmol, 2.00 equiv) was added dropwiseat 0° C., followed by DIEA (323 mg, 2.50 mmol, 4.99 equiv). Theresulting solution stirred for 2 h at rt.1-((1-Methyl-1,2,3,4-tetrahydroquinolin-7-yl)methyl)-1,8-diazaspiro[4.5]decane(150 mg, 0.500 mmol, 1.00 equiv) was added. The resulting solution wasstirred for 2 h at rt and concentrated. The crude product was purifiedby preparative HPLC to provide 124.0 mg (50% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl1-((1-methyl-1,2,3,4-tetrahydroquinolin-7-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 6.87 (d, J=7.5Hz, 1H), 6.54-6.56 (m, 2H), 5.71-5.82 (m, 1H), 4.15-4.24 (m, 2H), 3.50(s, 2H), 3.18-3.22 (m, 2H), 2.88-3.22 (m, 5H), 2.65-2.76 (m, 4H),1.92-2.00 (m, 2H), 1.59-1.79 (m, 6H), 1.26-1.49 (m, 2H). LCMS (ESI,m/z): 494 [M+H]⁺.

Example 69: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-morpholinobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from3-morpholinobenzaldehyde according to the representative procedure ofExample 60 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-morpholinobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as alight yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.18-7.23 (m, 1H),6.76-6.91 (m, 3H), 5.69-5.80 (m, 1H), 4.16-4.25 (m, 2H), 3.85-3.94 (m,4H), 3.50-3.60 (m, 2H), 3.14-3.29 (m, 4H), 2.91-3.05 (m, 2H), 2.66-2.71(m, 2H), 1.62-1.86 (m, 6H), 1.46-1.56 (m, 2H). LCMS (ESI, m/z): 510[M+H]⁺.

Example 70: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-((1-acetyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Preparation of tert-butyl2-(1,2,3,4-tetrahydroquinolin-8-ylmethyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,2,3,4-tetrahydroquinoline-8-carbaldehyde(1.00 g, 6.20 mmol, 1.00 equiv), tert-butyl2,8-diazaspiro[4.5]decane-8-carboxylate (1.64 g, 6.82 mmol, 1.10 equiv),and DCE (25 mL). The resulting solution was stirred for 1 h at rt, andNaBH(OAc)₃ (3.95 g, 18.6 mmol, 3.00 equiv) was added. The resultingsolution was stirred overnight at rt and quenched with H₂O (15 mL)before extracting with DCM (3×20 mL). The organic layers were combined,dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue waspurified on a silica gel column with EtOAc/petroleum ether (22/78) toprovide 1.17 g (49% yield) of tert-butyl2-(1,2,3,4-tetrahydroquinolin-8-ylmethyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. LCMS (ESI, m/z): 386 [M+H]⁺.

Step 2: Preparation of tert-butyl2-((1-acetyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl2-(1,2,3,4-tetrahydroquinolin-8-ylmethyl)-2,8-diazaspiro[4.5]decane-8-carboxylate(500 mg, 1.30 mmol, 1.00 equiv), acetyl chloride (152 mg, 1.94 mmol,1.49 equiv), DCM (10 mL), and TEA (392 mg, 3.87 mmol, 2.99 equiv). Theresulting solution was stirred overnight at rt and quenched with H₂O (10mL). The resulting solution was extracted with DCM (3×15 mL) and theorganic layers were combined, dried over anhydrous Na₂SO₄, filtered andconcentrated. The residue was purified on a silica gel column (85:15EtOAc/petroleum ether) to provide 410 mg (74% yield) of tert-butyl2-((1-acetyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. LCMS (ESI, m/z): 428 [M+H]⁺.

Step 3: Preparation of1-(8-((2,8-diazaspiro[4.5]decan-2-yl)methyl)-3,4-dihydroquinolin-1(2H)-yl)ethan-1-one

A flask was charged with tert-butyl2-((1-acetyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate(410 mg, 0.960 mmol, 1.00 equiv), DCM (9 mL), and TFA (1.5 mL). Theresulting solution was stirred overnight at rt and concentrated toprovide 300 mg (96% yield) of1-(8-((2,8-diazaspiro[4.5]decan-2-yl)methyl)-3,4-dihydroquinolin-1(2H)-yl)ethan-1-oneas a yellow oil. LCMS (ESI, m/z): 328 [M+H]⁺.

Step 4: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl2-((1-acetyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with triphosgene (95.0 mg, 0.320 mmol, 0.70 equiv)and DCM (10 mL). HFIP (154 mg, 0.920 mmol, 2.00 equiv) was added at 0°C., followed by DIEA (178 mg, 1.38 mmol, 3.01 equiv). The resultingsolution was stirred for 2 h at rt and1-(8-((2,8-diazaspiro[4.5]decan-2-yl)methyl)-3,4-dihydroquinolin-1(2H)-yl)ethan-1-one(150 mg, 0.460 mmol, 1.00 equiv) was added. The resulting solution wasstirred overnight at rt and concentrated. The crude product was purifiedby preparative HPLC to provide 62.0 mg (26% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl2-((1-acetyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.30-7.33 (m, 1H),7.09-7.14 (m, 2H), 6.21-6.34 (m, 1H), 3.89-4.91 (m, 1H), 3.16-3.48 (m,8H), 2.62 (br, 2H), 2.32 (br, 2H), 1.78-2.12 (m, 5H), 1.49-1.61 (m, 7H).LCMS (ESI, m/z): 522 [M+H]⁺.

Example 71: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-((1-ethyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Preparation of tert-butyl2-(1,2,3,4-tetrahydroquinolin-8-ylmethyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,2,3,4-tetrahydroquinoline-8-carbaldehyde(1.00 g, 6.20 mmol, 1.00 equiv), tert-butyl2,8-diazaspiro[4.5]decane-8-carboxylate (1.64 g, 6.82 mmol, 1.10 equiv),and DCE (25 mL). The resulting solution was stirred for 1 h at rt andNaBH(OAc)₃ (3.95 g, 18.6 mmol, 3.00 equiv) was added. The resultingsolution was stirred overnight at rt and quenched with H₂O (15 mL) andextracted with DCM (3×20 mL). The combined organic layers were driedover anhydrous Na₂SO₄, filtered, and concentrated. The residue waspurified on a silica gel column (22:78 EtOAc/petroleum ether) to provide1.17 g (49% yield) of tert-butyl2-(1,2,3,4-tetrahydroquinolin-8-ylmethyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. LCMS (ESI, m/z): 386 [M+H]⁺.

Step 2: Preparation of tert-butyl2-((1-ethyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl2-(1,2,3,4-tetrahydroquinolin-8-ylmethyl)-2,8-diazaspiro[4.5]decane-8-carboxylate(500 mg, 1.30 mmol, 1.00 equiv), acetaldehyde (171 mg, 3.88 mmol, 2.99equiv), and DCE (10 mL). The resulting solution was stirred for 1 h atrt and NaBH(OAc)₃ (824 mg, 3.89 mmol, 3.00 equiv) was added. Theresulting solution was stirred overnight at 50° C. and quenched with H₂O(10 mL). The resulting solution was extracted with DCM (3×15 mL) and thecombined organic layers were dried over anhydrous Na₂SO₄, filtered, andconcentrated. The residue was purified on a silica gel column (85:15EtOAc/petroleum ether) to provide 230 mg (43% yield) of tert-butyl2-((1-ethyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. LCMS (ESI, m/z): 414 [M+H]⁺.

Step 3: Preparation of2-((1-ethyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane

A flask was charged with tert-butyl2-((1-ethyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate(230 mg, 0.560 mmol, 1.00 equiv), DCM (6 mL), and TFA (1 mL). Theresulting solution was stirred overnight at rt and concentrated toprovide 170 mg (98% yield) of2-((1-ethyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decaneas a yellow oil. LCMS (ESI, m/z): 314 [M+H]⁺.

Step 4: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl2-((1-ethyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with triphosgene (56.0 mg, 0.190 mmol, 0.70 equiv)and DCM (10 mL). HFIP (91.0 mg, 0.540 mmol, 2.00 equiv) was added at 0°C., followed by DIEA (105 mg, 0.810 mmol, 3.00 equiv). The resultingsolution was stirred for 1 h at 0° C. and2-((1-ethyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane(85.0 mg, 0.270 mmol, 1.00 equiv) was added. The resulting solution wasstirred overnight at rt and concentrated. The crude product was purifiedby preparative HPLC to provide 51.7 mg (38% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl2-((1-ethyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.23-7.26 (m, 1H),6.84-6.95 (m, 2H), 5.68-5.81 (m, 1H), 3.42-3.56 (m, 6H), 2.94-3.07 (m,4H), 2.66-2.82 (m, 4H), 2.45 (br, 2H), 1.75-1.83 (m, 2H), 1.58-1.68 (m,6H), 1.21 (t, J=6.0 Hz, 3H). LCMS (ESI, m/z): 508 [M+H]⁺.

Example 72: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde and pyrrolidine in Step 1 andtert-butyl 2,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 accordingto the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl2-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.47-7.50 (m, 1H),7.06-7.17 (m, 2H), 5.68-5.78 (m, 1H), 3.33-3.72 (m, 6H), 3.25 (br, 4H),2.63 (br, 2H), 2.40 (br, 2H), 1.94 (br, 4H), 1.62-1.67 (m, 6H). LCMS(ESI, m/z): 562 [M+H]⁺.

Example 73: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde and8-oxa-3-azabicyclo[3.2.1]octane in Step 1 and tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 according to therepresentative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.69 (d, J=9.0 Hz,1H), 7.26-7.33 (m, 2H), 5.70-5.82 (m, 1H), 4.42 (br, 2H), 4.18-4.32 (m,2H), 3.73 (s, 2H), 2.93-3.18 (m, 4H), 2.62-2.71 (m, 4H), 1.89-2.10 (m,4H), 1.63-1.84 (m, 6H), 1.49-1.58 (m, 2H). LCMS (ESI, m/z): 604 [M+H]⁺.

Example 74: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-2-(piperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde and piperidine in Step 1 and tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 according to therepresentative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-2-(piperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas an off-white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.42 (d, J=9.0Hz, 1H), 6.97-7.00 (m, 2H), 5.70-5.82 (m, 1H), 4.15-4.24 (m, 2H), 3.59(s, 2H), 2.91-3.04 (m, 2H), 2.64-2.80 (m, 6H), 1.65-1.79 (m, 10H),1.48-1.57 (m, 4H). LCMS (ESI, m/z): 542 [M+H]⁺.

Example 75: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde and 8-oxa-3-azabicyclo[3.2.1]octane inStep 1 and tert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2according to the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.48 (d, J=9.0 Hz,1H), 7.03-7.06 (m, 2H), 5.70-5.80 (m, 1H), 4.40 (br, 2H), 4.17-4.24 (m,2H), 3.70 (s, 2H), 2.92-3.06 (m, 4H), 2.61-2.69 (m, 4H), 1.94-2.10 (m,4H), 1.61-1.90 (m, 6H), 1.41-1.58 (m, 2H). LCMS (ESI, m/z): 570 [M+H]⁺.

Example 76: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-2-(pyrrolidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde and pyrrolidine in Step 1 and tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 according to therepresentative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-2-(pyrrolidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.46 (d, J=8.4Hz, 1H), 6.85-6.91 (m, 2H), 5.70-5.82 (m, 1H), 4.15-4.24 (m, 2H), 3.56(s, 2H), 2.92-3.14 (m, 6H), 2.63-2.65 (m, 2H), 1.80-1.97 (m, 4H),1.65-1.78 (m, 6H), 1.40-1.55 (m, 2H). LCMS (ESI, m/z): 528 [M+H]⁺.

Example 77: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-2-morpholinobenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde and morpholine in Step 1 and tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 according to therepresentative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-2-morpholinobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.43 (d, J=8.4 Hz,1H), 7.03-7.09 (m, 2H), 5.70-5.82 (m, 1H), 4.17-4.25 (m, 2H), 3.81-3.84(m, 4H), 3.62 (s, 2H), 2.88-3.05 (m, 6H), 2.63-2.72 (m, 2H), 1.66-1.85(m, 6H), 1.44-1.56 (m, 2H). LCMS (ESI, m/z): 544 [M+H]⁺.

Example 78: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(piperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde and piperidine in Step 1 andtert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 accordingto the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(piperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.62 (d, J=8.4 Hz,1H), 7.25-7.27 (m, 2H), 5.70-5.83 (m, 1H), 4.17-4.25 (m, 2H), 3.67 (s,2H), 2.92-3.05 (m, 2H), 2.81-2.84 (m, 4H), 2.60-2.69 (m, 2H), 1.69-1.86(m, 10H), 1.45-1.58 (m, 4H). LCMS (ESI, m/z): 576 [M+H]⁺.

Example 79: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-chloro-3-morpholinobenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

Step 1: Preparation of tert-butyl1-(3-bromo-2-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 3-bromo-2-chlorobenzaldehyde (2.18 g, 9.93mmol, 1.00 equiv) in DCE (20 mL), tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate (3.60 g, 15.0 mmol, 1.51 equiv),and TEA (3.03 g, 30.0 mmol, 3.02 equiv); the resulting solution wasstirred for 30 min at rt. NaBH(OAc)₃ (6.36 g, 30.0 mmol, 3.02 equiv) wasadded, after which the solution was stirred overnight at rt. Thereaction was then quenched with H₂O (10 mL) and extracted with DCM (3×10mL). The combined organic layers were washed with brine (2×10 mL), driedover anhydrous Na₂SO₄, filtered, and concentrated. The residue waspurified on a silica gel column (20:1 DCM/MeOH) to yield 3.00 g (68%yield) of tert-butyl 1-(3-bromo-2-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as a light yellow solid. LCMS (ESI, m/z): 445[M+H]⁺.

Step 2: Preparation of tert-butyl1-(2-chloro-3-morpholinobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl1-(3-bromo-2-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate (800mg, 1.80 mmol, 1.00 equiv) in toluene (20 mL), morpholine (235 mg, 2.70mmol, 1.50 equiv), tris(dibenzylideneacetone)dipalladium (82.5 mg,0.0900 mmol, 0.05 equiv), 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl(168 mg, 0.270 mmol, 0.15 equiv), and cesium carbonate (881 mg, 2.70mmol, 1.50 equiv) under nitrogen. The resulting solution was stirredovernight at 100° C. The reaction was then quenched with H₂O (20 mL).The resulting solution was extracted with EtOAc (3×20 mL) and theorganic layers were combined, washed with brine (2×20 mL), dried overNa₂SO₄, filtered and concentrated. The residue was purified on a silicagel column (1:4 EtOAc/petroleum ether) to provide 650 mg (80% yield) oftert-butyl1-(2-chloro-3-morpholinobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. LCMS (ESI, m/z): 450 [M+H]⁺.

Step 3: Preparation of4-(3-((1,8-diazaspiro[4.5]decan-1-yl)methyl)-2-chlorophenyl)morpholine

A flask was charged with tert-butyl1-(2-chloro-3-morpholinobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(650 mg, 1.44 mmol, 1.00 equiv), DCM (10 mL), and TFA (2.5 mL). Theresulting solution was stirred overnight at rt and then concentrated toprovide 500 mg (99% yield) of4-(3-((1,8-diazaspiro[4.5]decan-1-yl)methyl)-2-chlorophenyl)morpholineas a yellow oil. LCMS (ESI, m/z): 350 [M+H]⁺.

Step 4: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-chloro-3-morpholinobenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

A flask was charged with triphosgene (74.5 mg, 0.250 mmol, 0.35 equiv)in DCM (5 mL) and HFIP (181 mg, 1.08 mmol, 1.51 equiv) under nitrogen.DIEA (277 mg, 2.15 mmol, 3.01 equiv) was added dropwise at 0° C. Theresulting solution was stirred for 2 h at 0° C. A solution of4-(3-((1,8-diazaspiro[4.5]decan-1-yl)methyl)-2-chlorophenyl)morpholine(250 mg, 0.710 mmol, 1.00 equiv) in DCM (5 mL) was added dropwise at 0°C. The resulting solution was stirred for 3 h at 0° C. and then quenchedwith H₂O (10 mL). The mixture was extracted with DCM (3×10 mL) and theorganic layers were combined, washed with brine (2×10 mL), dried overanhydrous Na₂SO₄, filtered and concentrated. The crude product waspurified by preparative HPLC to give 163.9 mg (42% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-chloro-3-morpholinobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.18-7.27 (m, 2H),6.94-6.98 (m, 1H), 5.71-5.83 (m, 1H), 4.18-4.34 (m, 2H), 3.88-3.94 (m,4H), 3.73 (s, 2H), 2.92-3.06 (m, 6H), 2.75-2.77 (m, 2H), 1.72-1.88 (m,6H), 1.52-1.58 (m, 2H). LCMS (ESI, m/z): 544 [M+H]⁺.

Example 80: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-chloro-3-(piperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially availablepiperidine in Step 2 according to the representative procedure ofExample 79 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-chloro-3-(piperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.13-7.18 (m, 2H),6.93-6.97 (m, 1H), 5.72-5.81 (m, 1H), 4.16-4.24 (m, 2H), 3.71 (s, 2H),2.94-3.03 (m, 6H), 2.72-2.75 (m, 2H), 1.71-1.85 (m, 10H), 1.47-1.64 (m,4H). LCMS (ESI, m/z): 542 [M+H]⁺.

Example 81: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-chloro-3-(pyrrolidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially availablepyrrolidine in Step 2 according to the representative procedure ofExample 79 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-chloro-3-(pyrrolidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.02-7.14 (m, 2H),6.85-6.91 (m, 1H), 5.70-5.82 (m, 1H), 4.16-4.24 (m, 2H), 3.72 (s, 2H),3.30-3.34 (m, 4H), 2.91-3.09 (m, 2H), 2.76-2.78 (m, 2H), 1.89-1.98 (m,4H), 1.65-1.82 (m, 6H), 1.39-1.56 (m, 2H). LCMS (ESI, m/z): 528 [M+H]⁺.

Example 82: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available8-oxa-3-azabicyclo[3.2.1]octane in Step 2 according to therepresentative procedure of Example 79 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.14-7.19 (m, 2H),6.94-6.98 (m, 1H), 5.72-5.80 (m, 1H), 4.39-4.40 (m, 2H), 4.16-4.25 (m,2H), 3.70 (s, 2H), 2.91-3.02 (m, 6H), 2.75-2.77 (m, 2H), 2.24-2.30 (m,2H), 1.91-2.02 (m, 2H), 1.71-1.88 (m, 6H), 1.51-1.60 (m, 2H). LCMS (ESI,m/z): 570 [M+H]⁺.

Example 83: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-methyl-3-morpholinobenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-2-methylbenzaldehyde in Step 1 and morpholine in Step 2according to the representative procedure of Example 79 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-methyl-3-morpholinobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.06-7.15 (m, 2H),6.96 (d, J=7.8 Hz, 1H), 5.72-5.81 (m, 1H), 4.17-4.25 (m, 2H), 3.84-3.87(m, 4H), 3.57 (s, 2H), 2.86-3.05 (m, 6H), 2.64-2.68 (m, 2H), 2.31 (s,3H), 1.72-1.83 (m, 6H), 1.47-1.57 (m, 2H). LCMS (ESI, m/z): 524 [M+H]⁺.

Example 84: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-methyl-3-(piperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-2-methylbenzaldehyde in Step 1 and piperidine in Step 2according to the representative procedure of Example 79 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-methyl-3-(piperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.07-7.12 (m, 1H),7.00-7.02 (m, 1H), 6.92-6.95 (m, 1H), 5.72-5.81 (m, 1H), 4.16-4.24 (m,2H), 3.56 (s, 2H), 2.91-3.04 (m, 2H), 2.80 (br, 4H), 2.64-2.68 (m, 2H),2.29 (s, 3H), 1.67-1.86 (m, 10H), 1.47-1.56 (m, 4H). LCMS (ESI, m/z):522 [M+H]⁺.

Example 85: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-methyl-3-(pyrrolidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-2-methylbenzaldehyde in Step 1 and pyrrolidine in Step 2according to the representative procedure of Example 79 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-methyl-3-(pyrrolidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.04-7.09 (m, 1H),6.90-6.96 (m, 2H), 5.72-5.81 (m, 1H), 4.16-4.25 (m, 2H), 3.58 (s, 2H),2.91-3.10 (m, 6H), 2.64-2.69 (m, 2H), 2.27 (s, 3H), 1.71-1.96 (m, 10H),1.51-1.56 (m, 2H). LCMS (ESI, m/z): 508 [M+H]⁺.

Example 86: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-methylbenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-2-methylbenzaldehyde in Step 1 and8-oxa-3-azabicyclo[3.2.1]octane in Step 2 according to therepresentative procedure of Example 79 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-methylbenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas an off-white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.00-7.19 (m,3H), 5.74-5.81 (m, 1H), 4.40 (br, 2H), 4.16-4.25 (m, 2H), 3.56 (s, 2H),2.91-3.05 (m, 4H), 2.64-2.74 (m, 4H), 2.33 (s, 3H), 2.14-2.21 (m, 2H),1.94-2.11 (m, 2H), 1.70-1.85 (m, 6H), 1.49-1.56 (m, 2H). LCMS (ESI,m/z): 550 [M+H]⁺.

Example 87: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(4-ethylpiperazin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde and 1-ethylpiperazine in Step 1and tert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2according to the representative procedure of Example 79 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-ethylpiperazin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.63 (d, J=8.1 Hz,1H), 7.29-7.40 (m, 2H), 5.70-5.83 (m, 1H), 4.17-4.26 (m, 2H), 3.67 (s,2H), 2.92-3.24 (m, 6H), 2.43-2.85 (m, 8H), 1.74-1.87 (m, 6H), 1.44-1.53(m, 2H), 1.05-1.25 (m, 3H). LCMS (ESI, m/z): 605 [M+H]⁺.

Example 88: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(4-acetylpiperazin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde and1-(piperazin-1-yl)ethan-1-one in Step 1 and tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 according to therepresentative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-acetylpiperazin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.65 (d, J=8.1Hz, 1H), 7.34 (d, J=8.4 Hz, 1H), 7.26 (s, 1H), 5.72-5.80 (m, 1H),4.17-4.26 (m, 2H), 3.71-3.76 (m, 4H), 3.60-3.63 (m, 2H), 2.89-3.06 (m,6H), 2.64-2.69 (m, 2H), 2.15 (s, 3H), 1.66-1.88 (m, 6H), 1.47-1.51 (m,2H). LCMS (ESI, m/z): 619 [M+H]⁺.

Example 89: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(4-(methylsulfonyl)piperazin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde and 1-methanesulfonylpiperazinein Step 1 and tert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step2 according to the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-(methylsulfonyl)piperazin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.66 (d, J=8.1 Hz,1H), 7.30-7.37 (m, 2H), 5.72-5.80 (m, 1H), 4.17-4.26 (m, 2H), 3.68 (s,2H), 3.38-3.41 (m, 4H), 2.87-3.10 (m, 9H), 2.66-2.68 (m, 2H), 1.64-1.88(m, 6H), 1.51-1.55 (m, 2H). LCMS (ESI, m/z): 655 [M+H]⁺.

Example 90: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(4,4-difluoropiperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde and 4,4-difluoropiperidine inStep 1 and tert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2according to the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4,4-difluoropiperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow semi-solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.62 (d,J=10.8 Hz, 1H), 7.30-7.34 (m, 2H), 5.70-5.82 (m, 1H), 4.18-4.26 (m, 2H),3.68 (s, 2H), 2.92-3.04 (m, 6H), 2.60-2.68 (m, 2H), 2.07-2.20 (m, 4H),1.63-1.88 (m, 6H), 1.48-1.59 (m, 2H). LCMS (ESI, m/z): 612 [M+H]⁺.

Example 91: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(4-fluoropiperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde and 4-fluoropiperidine in Step1 and tert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2according to the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-fluoropiperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow semi-solid. ¹H NMR (300 MHz, Chloroform-d) 6 7.62 (d,J=9.0 Hz, 1H), 7.29-7.31 (m, 2H), 5.72-5.80 (m, 1H), 4.72-4.90 (m, 1H),4.16-4.26 (m, 2H), 3.68 (s, 2H), 2.83-3.11 (m, 4H), 2.79-2.81 (m, 2H),2.64-2.68 (m, 2H), 1.96-2.09 (m, 4H), 1.64-1.86 (m, 6H), 1.45-1.55 (m,2H). LCMS (ESI, m/z): 594 [M+H]⁺.

Example 92: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(1,1-dioxidothiomorpholino)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Preparation of 2-thiomorpholino-4-(trifluoromethyl)benzaldehyde

A flask was charged with 2-fluoro-4-(trifluoromethyl)benzaldehyde (300mg, 1.56 mmol, 1.00 equiv) in DMSO (10 mL), thiomorpholine (241 mg, 2.34mmol, 1.49 equiv), and potassium carbonate (647 mg, 4.69 mmol, 3.01equiv) under nitrogen. The resulting solution was stirred overnight at80° C. and then quenched with H₂O (10 mL). The resulting solution wasextracted with EtOAc (3×10 mL) and the organic layers were combined,washed with brine (2×10 mL), dried over Na₂SO₄, filtered andconcentrated. The residue was purified on a silica gel column (1:4EtOAc/petroleum ether) to provide 210 mg (49% yield) of2-thiomorpholino-4-(trifluoromethyl)benzaldehyde as a light-yellowsolid. LCMS (ESI, m/z): 276 [M+H]⁺.

Step 2: Preparation of tert-butyl1-(2-thiomorpholino-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with2-thiomorpholino-4-(trifluoromethyl)benzaldehyde (210 mg, 0.760 mmol,1.00 equiv) in DCE (10 mL), tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate (275 mg, 1.14 mmol, 1.50 equiv),and TEA (231 mg, 2.29 mmol, 3.00 equiv), and the resulting solution wasstirred for 30 min at rt. NaBH(OAc)₃ (486 mg, 2.29 mmol, 3.01 equiv) wasadded, after which the mixture was stirred overnight at rt. The reactionwas then quenched with H₂O (10 mL) and extracted with DCM (3×10 mL). Thecombined organic layers were washed with brine (2×10 mL), dried overanhydrous Na₂SO₄, filtered and concentrated. The residue was purified ona silica gel column (20:1 DCM/MeOH) to yield 350 mg (92% yield) oftert-butyl1-(2-thiomorpholino-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. LCMS (ESI, m/z): 500 [M+H]⁺.

Step 3: Preparation of tert-butyl1-(2-(1,1-dioxidothiomorpholino)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl1-(2-thiomorpholino-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(350 mg, 0.700 mmol, 1.00 equiv) in DCM (10 mL), and3-chlorobenzoperoxoic acid (241 mg, 1.40 mmol, 1.99 equiv). Theresulting solution was stirred for 2 h at 0° C. The reaction was thenquenched with H₂O (10 mL) and extracted with DCM (3×10 mL). The combinedorganic layers were washed with brine (2×10 mL), dried over anhydrousNa₂SO₄, filtered, and concentrated. The residue was purified on a silicagel column (1:1 DCM/MeOH) to yield 300 mg (81% yield) of tert-butyl1-(2-(1,1-dioxidothiomorpholino)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. LCMS (ESI, m/z): 532 [M+H]⁺.

Step 4: Preparation of4-(2-((1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)thiomorpholine1,1-dioxide

A flask was charged with tert-butyl1-(2-(1,1-dioxidothiomorpholino)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(300 mg, 0.560 mmol, 1.00 equiv) in DCM (10 mL), and TFA (2.5 mL). Theresulting solution was stirred overnight at rt and then concentrated toyield 240 mg (99% yield) of4-(2-((1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)thiomorpholine1,1-dioxide as a yellow oil. LCMS (ESI, m/z): 432 [M+H]⁺.

Step 5: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(1,1-dioxidothiomorpholino)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with triphosgene (29.0 mg, 0.100 mmol, 0.35 equiv)in DCM (5 mL) and HFIP (70.0 mg, 0.420 mmol, 1.50 equiv) under nitrogen.DIEA (108 mg, 0.840 mmol, 3.01 equiv) was added dropwise at 0° C. Theresulting solution was stirred for 2 h at 0° C. A solution of4-(2-((1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)thiomorpholine1,1-dioxide (120 mg, 0.280 mmol, 1.00 equiv) in DCM (5 mL) was addeddropwise at 0° C. The resulting solution was stirred for 3 h at 0° C.and then quenched with H₂O (10 mL). The mixture was extracted with DCM(3×10 mL) and the organic layers were combined, washed with brine (2×10mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The crudeproduct was purified by preparative HPLC to give 62.4 mg (36% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(1,1-dioxidothiomorpholino)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.64 (d, J=7.8 Hz,1H), 7.38-7.42 (m, 2H), 5.72-5.84 (m, 1H), 5.36-5.42 (m, 1H), 4.96 (br,1H), 3.92-3.98 (m, 4H), 3.60-3.75 (m, 4H), 3.11-3.17 (m, 2H), 2.92-3.02(m, 4H), 2.76-2.81 (m, 2H), 2.10 (br, 4H), 1.72-1.82 (m, 2H). LCMS (ESI,m/z): 626 [M+H]⁺.

Example 93: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(4-acetamidopiperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde and N-(piperidin-4-yl)acetamidein Step 1 and tert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step2 according to the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-acetamidopiperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.59 (d, J=7.8 Hz,1H), 7.26-7.30 (m, 2H), 5.72-5.80 (m, 1H), 5.45-5.48 (m, 1H), 4.17-4.26(m, 2H), 3.91-4.01 (m, 1H), 3.58-3.73 (m, 2H), 2.92-3.09 (m, 4H),2.80-2.84 (m, 2H), 2.67-2.76 (m, 2H), 2.01-2.07 (m, 5H), 1.62-1.87 (m,10H). LCMS (ESI, m/z): 633 [M+H]⁺.

Example 94: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(4-(methylsulfonamido)piperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde andN-(piperidin-4-yl)methanesulfonamide in Step 1 and tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 according to therepresentative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl 1-(2-(4-(methylsulfonamido)piperidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.62 (d, J=8.1Hz, 1H), 7.29-7.32 (m, 2H), 5.74-5.83 (m, 1H), 4.45-4.47 (m, 1H),4.18-4.26 (m, 2H), 3.46-3.74 (m, 3H), 2.92-3.07 (m, 7H), 2.68-2.84 (m,4H), 2.11-2.14 (m, 2H), 1.65-1.87 (m, 8H), 1.46-1.51 (m, 2H). LCMS (ESI,m/z): 669 [M+H]⁺.

Example 95: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(azepan-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde and azepane in Step 1 andtert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 accordingto the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(azepan-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.63 (d, J=8.1Hz, 1H), 7.30 (s, 1H), 7.22-7.25 (m, 1H), 5.72-5.80 (m, 1H), 4.16-4.25(m, 2H), 3.70 (s, 2H), 2.92-3.06 (m, 6H), 2.65-2.70 (m, 2H), 1.64-1.88(m, 14H), 1.49-1.52 (m, 2H). LCMS (ESI, m/z): 590 [M+H]⁺.

Example 96: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(azetidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde and azetidine in Step 1 andtert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 accordingto the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(azetidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.58 (d, J=8.1 Hz,1H), 7.04-7.07 (m, 1H), 6.68 (s, 1H), 5.69-5.82 (m, 1H), 4.15-4.24 (m,2H), 3.90-3.95 (m, 4H), 3.53 (s, 2H), 2.92-3.05 (m, 2H), 2.66-2.68 (m,2H), 2.27-2.37 (m, 2H), 1.84-1.89 (m, 4H), 1.61-1.77 (m, 2H), 1.44-1.51(m, 2H). LCMS (ESI, m/z): 548 [M+H]⁺.

Example 97: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde andhexahydro-1H-furo[3,4-c]pyrrole in Step 1 and tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 according to therepresentative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.69 (d, J=8.1 Hz,1H), 7.22-7.25 (m, 2H), 5.70-5.83 (m, 1H), 4.16-4.25 (m, 2H), 4.00-4.04(m, 2H), 3.60-3.65 (m, 4H), 3.14 (br, 2H), 2.89-3.06 (m, 6H), 2.60-2.64(m, 2H), 1.78-1.89 (m, 4H), 1.62-1.75 (m, 2H), 1.53-1.58 (m, 2H). LCMS(ESI, m/z): 604 [M+H]⁺.

Example 98: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-2-(4-ethylpiperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde and 1-ethylpiperazine in Step 1 andtert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 accordingto the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-2-(4-ethylpiperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.42 (d, J=8.1 Hz,1H), 7.00-7.03 (m, 2H), 5.70-5.83 (m, 1H), 4.16-4.25 (m, 2H), 3.60 (s,2H), 2.93-3.05 (m, 6H), 2.47-2.68 (m, 8H), 1.67-1.85 (m, 6H), 1.48 (br,2H), 1.23 (t, J=8.1 Hz, 3H). LCMS (ESI, m/z): 571 [M+H]⁺.

Example 99: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(4-acetylpiperazin-1-yl)-4-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde and 1-(piperazin-1-yl)ethan-1-one in Step1 and tert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2according to the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-acetylpiperazin-1-yl)-4-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.43 (d, J=8.4Hz, 1H), 7.00-7.07 (m, 2H), 5.72-5.81 (m, 1H), 4.16-4.25 (m, 2H), 3.74(br, 2H), 3.57-3.63 (m, 4H), 2.87-3.05 (m, 6H), 2.63-2.68 (m, 2H), 2.14(s, 3H), 1.67-1.86 (m, 6H), 1.45-1.49 (m, 2H). LCMS (ESI, m/z): 585[M+H]⁺.

Example 100: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-2-(4-(methylsulfonyl)piperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde and 1-methanesulfonylpiperazine in Step 1and tert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2according to the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-2-(4-(methylsulfonyl)piperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.44 (d, J=8.4Hz, 1H), 7.04-7.08 (m, 2H), 5.72-5.80 (m, 1H), 4.16-4.25 (m, 2H), 3.60(br, 2H), 3.35-3.38 (m, 4H), 2.91-3.09 (m, 6H), 2.86 (s, 3H), 2.65-2.67(m, 2H), 1.65-1.86 (m, 6H), 1.44-1.48 (m, 2H). LCMS (ESI, m/z): 621[M+H]⁺.

Example 101: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-2-(4,4-difluoropiperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde and 4,4-difluoropiperidine in Step 1 andtert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 accordingto the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-2-(4,4-difluoropiperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as an off-white solid. ¹H NMR (300 MHz,Chloroform-d) δ 7.44 (d, J=8.7 Hz, 1H), 7.04-7.07 (m, 2H), 5.70-5.82 (m,1H), 4.16-4.25 (m, 2H), 3.60 (s, 2H), 2.91-3.05 (m, 6H), 2.62-2.67 (m,2H), 2.01-2.18 (m, 4H), 1.64-1.86 (m, 6H), 1.38-1.62 (m, 2H). LCMS (ESI,m/z): 578 [M+H]⁺.

Example 102: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-2-(4-fluoropiperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde and 4-fluoropiperidine in Step 1 andtert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 accordingto the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-2-(4-fluoropiperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.42 (d, J=9.0Hz, 1H), 7.00-7.03 (m, 2H), 5.72-5.80 (m, 1H), 4.70-4.89 (m, 1H),4.16-4.24 (m, 2H), 3.60 (s, 2H), 2.91-3.07 (m, 4H), 2.63-2.80 (m, 4H),1.94-2.07 (m, 4H), 1.65-1.83 (m, 6H), 1.45-1.56 (m, 2H). LCMS (ESI,m/z): 560 [M+H]⁺.

Example 103: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-2-(1,1-dioxidothiomorpholino)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized from commercially available4-chloro-2-fluorobenzaldehyde according to the representative procedureof Example 92 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(1,1-dioxidothiomorpholino)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.42 (d, J=8.1 Hz,1H), 7.10-7.16 (m, 2H), 5.72-5.84 (m, 1H), 5.36-5.40 (m, 1H), 4.92 (br,1H), 3.98 (br, 2H), 3.85 (s, 2H), 3.59-3.71 (m, 4H), 3.11-3.15 (m, 2H),2.91-2.98 (m, 4H), 2.73-2.77 (m, 2H), 2.08-2.10 (m, 4H), 1.70-1.80 (m,2H). LCMS (ESI, m/z): 592 [M+H]⁺.

Example 104: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(4-acetamidopiperidin-1-yl)-4-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde and N-(piperidin-4-yl)acetamide in Step 1and tert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2according to the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-acetamidopiperidin-1-yl)-4-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.38 (d, J=8.7Hz, 1H), 7.00-7.02 (m, 2H), 5.72-5.80 (m, 1H), 5.52-5.54 (m, 1H),4.16-4.25 (m, 2H), 3.88-3.98 (m, 1H), 3.50-3.66 (m, 2H), 2.91-3.08 (m,4H), 2.69-2.78 (m, 4H), 2.00-2.09 (m, 5H), 1.66-1.88 (m, 6H), 1.42-1.61(m, 4H). LCMS (ESI, m/z): 599 [M+H]⁺.

Example 105: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-2-(4-(methylsulfonamido)piperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde and N-(piperidin-4-yl)methanesulfonamidein Step 1 and tert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step2 according to the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl 1-(4-chloro-2-(4-(methylsulfonamido)piperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.40 (d, J=8.1 Hz,1H), 7.00-7.05 (m, 2H), 5.74-5.83 (m, 1H), 4.39-4.41 (m, 1H), 4.17-4.25(m, 2H), 3.62-3.66 (m, 1H), 3.43-3.52 (m, 2H), 2.91-3.05 (m, 7H),2.64-2.79 (m, 4H), 2.08-2.12 (m, 2H), 1.63-1.89 (m, 8H), 1.40-1.48 (m,2H). LCMS (ESI, m/z): 635 [M+H]⁺.

Example 106: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(azepan-1-yl)-4-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde and azepane in Step 1 and tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 according to therepresentative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(azepan-1-yl)-4-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.43 (d, J=8.4 Hz,1H), 6.95-7.04 (m, 2H), 5.72-5.80 (m, 1H), 4.16-4.24 (m, 2H), 3.63 (s,2H), 2.91-3.02 (m, 6H), 2.65-2.69 (m, 2H), 1.72-1.86 (m, 14H), 1.46-1.50(m, 2H). LCMS (ESI, m/z): 556 [M+H]⁺.

Example 107: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(azetidin-1-yl)-4-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde and azetidine in Step 1 and tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2 according to therepresentative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(azetidin-1-yl)-4-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.37 (d, J=8.1Hz, 1H), 6.76-6.79 (m, 1H), 6.45 (d, J=1.8 Hz, 1H), 5.69-5.82 (m, 1H),4.14-4.23 (m, 2H), 3.86-3.91 (m, 4H), 3.46 (s, 2H), 2.91-3.04 (m, 2H),2.63-2.67 (m, 2H), 2.24-2.34 (m, 2H), 1.75-1.87 (m, 4H), 1.60-1.69 (m,2H), 1.50-1.57 (m, 2H). LCMS (ESI, m/z): 514 [M+H]⁺.

Example 108: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde and hexahydro-1H-furo[3,4-c]pyrrole inStep 1 and tert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate in Step 2according to the representative procedure of Example 66 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-2-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.48 (d, J=8.1 Hz,1H), 6.97-7.00 (m, 2H), 5.70-5.82 (m, 1H), 4.15-4.24 (m, 2H), 3.99-4.03(m, 2H), 3.58-3.61 (m, 4H), 2.86-3.09 (m, 8H), 2.59-2.63 (m, 2H),1.63-1.86 (m, 6H), 1.46-1.50 (m, 2H). LCMS (ESI, m/z): 570 [M+H]⁺.

Example 109: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-2-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-2-chlorobenzaldehyde in Step 1 and3-oxa-8-azabicyclo[3.2.1]octane in Step 2 according to therepresentative procedure of Example 79 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-2-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.09-7.14 (m, 2H),6.77-6.80 (m, 1H), 5.70-5.82 (m, 1H), 4.16-4.25 (m, 2H), 3.93-4.02 (m,2H), 3.82 (2H), 3.65-3.71 (m, 4H), 2.91-3.05 (m, 2H), 2.75-2.77 (m, 2H),1.94-2.12 (m, 4H), 1.71-1.82 (m, 6H), 1.52-1.58 (m, 2H). LCMS (ESI,m/z): 570 [M+H]⁺.

Example 110: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-chloro-3-(4-fluoropiperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-2-chlorobenzaldehyde in Step 1 and 4-fluoropiperidine in Step 2according to the representative procedure of Example 79 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-chloro-3-(4-fluoropiperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.14-7.18 (m, 2H),6.95-6.98 (m, 1H), 5.70-5.82 (m, 1H), 4.72-4.93 (m, 1H), 4.16-4.24 (m,2H), 3.72 (s, 2H), 3.12-3.18 (m, 2H), 2.92-3.05 (m, 4H), 2.74-2.76 (m,2H), 1.96-2.17 (m, 4H), 1.71-1.82 (m, 6H), 1.52-1.56 (m, 2H). LCMS (ESI,m/z): 560 [M+H]⁺.

Example 111: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-chloro-3-(4,4-difluoropiperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-2-chlorobenzaldehyde in Step 1 and 4,4-difluoropiperidine inStep 2 according to the representative procedure of Example 79 toprovide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-chloro-3-(4,4-difluoropiperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.15-7.21 (m, 2H),6.95-6.98 (m, 1H), 5.70-5.82 (m, 1H), 4.17-4.25 (m, 2H), 3.72 (s, 2H),2.91-3.13 (m, 6H), 2.74-2.76 (m, 2H), 2.10-2.23 (m, 4H), 1.69-1.87 (m,6H), 1.52-1.57 (m, 2H). LCMS (ESI, m/z): 578 [M+H]⁺.

Example 112: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-chloro-3-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-2-chlorobenzaldehyde in Step 1 andhexahydro-1H-furo[3,4-c]pyrrole in Step 2 according to therepresentative procedure of Example 79 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-chloro-3-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.14-7.22 (m, 2H),6.90-6.95 (m, 1H), 5.70-5.82 (m, 1H), 4.16-4.24 (m, 2H), 3.95-4.05 (m,2H), 3.63-3.71 (m, 4H), 3.12-3.23 (m, 4H), 2.87-3.05 (m, 4H), 2.75-2.77(m, 2H), 1.71-1.82 (m, 6H), 1.51-1.58 (m, 2H). LCMS (ESI, m/z): 570[M+H]⁺.

Example 113: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-chloro-3-(4-(methylsulfonyl)piperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-2-chlorobenzaldehyde in Step 1 and 1-methanesulfonylpiperazinein Step 2 according to the representative procedure of Example 79 toprovide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-chloro-3-(4-(methylsulfonyl)piperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.18-7.25 (m,2H), 6.94-6.97 (m, 1H), 5.70-5.82 (m, 1H), 4.16-4.24 (m, 2H), 3.72 (s,2H), 3.40-3.43 (m, 4H), 3.11-3.14 (m, 4H), 2.91-3.07 (m, 2H), 2.85 (s,3H), 2.74-2.76 (m, 2H), 1.70-1.88 (m, 6H), 1.52-1.58 (m, 2H). LCMS (ESI,m/z): 621 [M+H]⁺.

Example 114: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(4-acetylpiperazin-1-yl)-2-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-2-chlorobenzaldehyde in Step 1 and 1-(piperazin-1-yl)ethan-1-onein Step 2 according to the representative procedure of Example 79 toprovide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(4-acetylpiperazin-1-yl)-2-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.16-7.23 (m, 2H),6.91-6.94 (m, 1H), 5.70-5.83 (m, 1H), 4.17-4.25 (m, 2H), 3.72-3.80 (m,4H), 3.62-3.65 (m, 2H), 2.91-3.03 (m, 6H), 2.75-2.76 (m, 2H), 2.14 (s,3H), 1.73-1.93 (m, 6H), 1.45-1.55 (m, 2H). LCMS (ESI, m/z): 585 [M+H]⁺.

Example 115: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-chloro-3-(4-cyclopropylpiperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-2-chlorobenzaldehyde in Step 1 and 1-cyclopropylpiperazine inStep 2 according to the representative procedure of Example 79 toprovide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-chloro-3-(4-cyclopropylpiperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.14-7.18 (m,2H), 6.92-6.97 (m, 1H), 5.70-5.82 (m, 1H), 4.16-4.25 (m, 2H), 3.72 (s,2H), 2.74-3.03 (m, 12H), 1.71-1.82 (m, 7H), 1.44-1.56 (m, 2H), 0.41-0.50(m, 4H). LCMS (ESI, m/z): 583 [M+H]⁺.

Example 116: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-chloro-3-(4-ethylpiperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-2-chlorobenzaldehyde in Step 1 and 1-ethylpiperazine in Step 2according to the representative procedure of Example 79 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-chloro-3-(4-ethylpiperazin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow semi-solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.15-7.22 (m,2H), 6.95-7.00 (m, 1H), 5.70-5.80 (m, 1H), 4.16-4.24 (m, 2H), 3.71 (s,2H), 2.91-3.10 (m, 6H), 2.68-2.76 (m, 6H), 2.49-2.56 (m, 2H), 1.71-1.82(m, 6H), 1.44-1.58 (m, 2H), 1.15 (t, J=7.2 Hz, 3H). LCMS (ESI, m/z): 571[M+H]⁺.

Example 117: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-chloro-3-(8-oxa-2-azaspiro[4.5]decan-2-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available3-bromo-2-chlorobenzaldehyde in Step 1 and 8-oxa-2-azaspiro[4.5]decanein Step 2 according to the representative procedure of Example 79 toprovide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-chloro-3-(8-oxa-2-azaspiro[4.5]decan-2-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.03-7.14 (m, 2H),6.83-6.85 (m, 1H), 5.72-5.80 (m, 1H), 4.16-4.24 (m, 2H), 3.62-3.77 (m,6H), 3.38-3.43 (m, 2H), 3.22 (s, 2H), 2.91-3.05 (m, 2H), 2.76-2.78 (m,2H), 1.65-1.86 (m, 12H), 1.44-1.58 (m, 2H). LCMS (ESI, m/z): 598 [M+H]⁺.

Example 118:1-(5-Chloro-2-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-2,8-diazaspiro[4.5]decan-2-yl)methyl)phenyl)piperidine-4-carboxylic acid

Step 1: Preparation of ethyl 1-(5-chloro-2-formylphenyl)piperidine-4-carboxylate

A flask was charged with 4-chloro-2-fluorobenzaldehyde (2.40 g, 15.1mmol, 1.00 equiv), ethyl piperidine-4-carboxylate (2.60 g, 16.5 mmol,1.20 equiv), potassium carbonate (6.20 g, 44.9 mmol, 3.00 equiv), andDMSO (25 mL). The resulting solution was stirred overnight at 90° C. andthen diluted with H₂O (20 mL). The mixture was extracted with DCM (3×50mL), and the organic layers were combined, washed with brine (3×50 mL),dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue waspurified on a silica gel column (2:8 EtOAc/petroleum ether) to provide4.00 g (89% yield) of ethyl 1-(5-chloro-2-formylphenyl)piperidine-4-carboxylate as a yellow oil. LCMS (ESI, m/z): 296 [M+H]⁺.

Step 2: Preparation of tert-butyl2-(2-(4-(ethoxycarbonyl)piperidin-1-yl)-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with ethyl1-(5-chloro-2-formylphenyl)piperidine-4-carboxylate (1.33 g, 4.50 mmol,1.00 equiv), tert-butyl 2,8-diazaspiro[4.5]decane-8-carboxylate (1.18 g,4.91 mmol, 1.10 equiv), and DCE (10 mL). The resulting solution wasstirred for 1 h at rt and then NaBH(OAc)₃ (2.86 g, 13.5 mmol, 3.00equiv) was added. The resulting solution was stirred for 3 h at rt anddiluted with H₂O (20 mL). The mixture was extracted with DCM (3×50 mL)and the organic layers were combined, washed with brine (3×50 mL), driedover anhydrous Na₂SO₄, filtered and concentrated. The residue waspurified on a silica gel column (3:7 EtOAc/petroleum ether) to provide1.54 g (66% yield) of tert-butyl2-(2-(4-(ethoxycarbonyl)piperidin-1-yl)-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate as a colorless oil. LCMS (ESI, m/z): 520 [M+H]⁺.

Step 3: Preparation of1-(2-((8-(tert-butoxycarbonyl)-2,8-diazaspiro[4.5]decan-2-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-4-carboxylicacid

A flask was charged with tert-butyl2-(2-(4-(ethoxycarbonyl)piperidin-1-yl)-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate(1.54 g, 2.96 mmol, 1.00 equiv), MeOH (10 mL), H₂O (5 mL), and lithiumhydroxide (0.356 g, 14.9 mmol, 5.00 equiv). The resulting solution wasstirred for 3 h at rt. The pH value of the solution was adjusted to 7with hydrochloric acid (1 M, 1.5 mL). The mixture was extracted with DCM(3×50 mL) and the organic layers were combined, washed with brine (3×50mL), dried over anhydrous Na₂SO₄, filtered and concentrated to provide0.978 g (67% yield) of1-(2-((8-(tert-butoxycarbonyl)-2,8-diazaspiro[4.5]decan-2-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-4-carboxylicacid as a light yellow solid. LCMS (ESI, m/z): 492 [M+H]⁺.

Step 4: Preparation of1-(2-((2,8-diazaspiro[4.5]decan-2-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-4-carboxylicacid

A flask was charged with1-(2-((8-(tert-butoxycarbonyl)-2,8-diazaspiro[4.5]decan-2-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-4-carboxylicacid (246 mg, 0.470 mmol, 1.00 equiv), DCM (7 mL), and TFA (1 mL). Theresulting solution was stirred overnight at rt and concentrated toprovide 196 mg (98% yield) of1-(2-((2,8-diazaspiro[4.5]decan-2-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-4-carboxylicacid as a light yellow solid. LCMS (ESI, m/z): 392 [M+H]⁺.

Step 5: Preparation of1-(5-chloro-2-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-2,8-diazaspiro[4.5]decan-2-yl)methyl)phenyl)piperidine-4-carboxylic acid

A flask was charged with triphosgene (59.4 mg, 0.201 mmol, 0.400 equiv)and DCM (5 mL). HFIP (100 mg, 0.603 mmol, 1.20 equiv) and DIEA (194 mg,1.50 mmol, 3.00 equiv) were each added dropwise at 0° C. The resultingsolution was stirred for 2 h at rt.1-(2-((2,8-Diazaspiro[4.5]decan-2-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-4-carboxylicacid (196 mg, 0.462 mmol, 1.00 equiv) was added, and the mixture wasstirred for 3 h at rt before diluting with H₂O (20 mL). The mixture wasextracted with DCM (3×30 mL), and the organic layers were combined,washed with brine (3×30 mL), dried over anhydrous Na₂SO₄, filtered, andconcentrated. The crude product was purified by preparative HPLC toprovide 55.5 mg (21% yield) of1-(5-chloro-2-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-2,8-diazaspiro[4.5]decan-2-yl)methyl)phenyl)piperidine-4-carboxylicacid as a light yellow solid. ¹H NMR (400 MHz, Chloroform-d) δ 7.27-7.38(m, 1H), 7.05 (br, 2H), 5.67-5.76 (m, 1H), 3.50-3.60 (m, 4H), 3.29 (d,J=10.4 Hz, 2H), 3.17 (br, 2H), 2.69-2.72 (m, 7H), 2.05 (d, J=10.4 Hz,2H), 1.88-1.96 (m, 2H), 1.76-1.82 (m, 2H), 1.61 (br, 4H). LCMS (ESI,m/z): 586 [M+H]⁺.

Example 119:1-(2-((8-(((1,1,1,3,3,3-Hexafluoropropan-2-yl)oxy)carbonyl)-2,8-diazaspiro[4.5]decan-2-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-4-carboxylicacid

The title compound was synthesized directly from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde according to the representativeprocedure of Example 118 to provide1-(2-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-2,8-diazaspiro[4.5]decan-2-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-4-carboxylicacid as a white solid. ¹H NMR (300 MHz, Chloroform-d) 6 7.58 (br, 1H),7.29-7.49 (m, 2H), 5.69-5.78 (m, 1H), 3.57-3.80 (m, 2H), 3.35-3.57 (m,4H), 3.19-3.35 (m, 2H), 2.66-2.79 (m, 4H), 2.40-2.55 (m, 3H), 1.87-2.09(m, 4H), 1.62-1.81 (m, 2H), 1.60-1.72 (m, 4H). LCMS (ESI, m/z): 620[M+H]⁺.

Example 120:1-(5-Chloro-2-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)phenyl)piperidine-4-carboxylic acid

The title compound was synthesized directly from commercially available4-chloro-2-fluorobenzaldehyde according to the representative procedureof Example 118 to provide1-(5-chloro-2-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)phenyl)piperidine-4-carboxylicacid as a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.43 (br, 1H),6.91-7.08 (m, 2H), 5.69-5.80 (m, 1H), 4.16-4.36 (m, 2H), 3.61 (br, 2H),2.91-3.08 (m, 4H), 2.52-2.72 (m, 4H), 2.43-2.50 (m, 1H), 1.95-2.07 (m,2H), 1.67-1.94 (m, 8H), 1.37-1.67 (m, 2H). LCMS (ESI, m/z): 586 [M+H]⁺.

Example 121:1-(2-((8-(((1,1,1,3,3,3-Hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-4-carboxylicacid

The title compound was synthesized directly from commercially available2-fluoro-4-(trifluoromethyl)benzaldehyde according to the representativeprocedure of Example 118 to provide1-(2-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-4-carboxylicacid as a white solid. ¹H NMR (300 MHz, Chloroform-d) 6 7.60-7.64 (m,1H), 7.26-7.37 (m, 2H), 5.70-5.82 (m, 1H), 4.16-4.26 (m, 2H), 3.67 (br,2H), 3.07-3.11 (m, 2H), 2.96-3.01 (m, 2H), 2.55-2.77 (m, 4H), 2.46-2.55(m, 1H), 2.05-2.09 (m, 2H), 1.90-1.98 (m, 2H), 1.70-1.82 (m, 6H),1.38-1.66 (m, 2H). LCMS (ESI, m/z): 620 [M+H]⁺.

Example 122:1-(3-Chloro-5-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)phenyl)piperidine-4-carboxylic acid

Step 1: Preparation of tert-butyl1-(3-bromo-5-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 3-bromo-5-chlorobenzaldehyde (1.09 g, 4.97mmol, 1.00 equiv), tert-butyl 1,8-diazaspiro[4.5]decane-8-carboxylate(1.32 g, 5.49 mmol, 1.10 equiv), and DCE (10 mL). The resulting solutionwas stirred for 1 h at rt. NaBH(OAc)₃ (3.18 g, 15.0 mmol, 3.00 equiv)was added, and the reaction was stirred for 3 h at rt before dilutingwith H₂O (20 mL). The mixture was extracted with DCM (3×50 mL) and theorganic layers were combined, washed with brine (3×50 mL), dried overanhydrous Na₂SO₄, filtered, and concentrated. The residue was purifiedon a silica gel column (3:7 EtOAc/petroleum ether) to provide 1.00 g(45% yield) of tert-butyl1-(3-bromo-5-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as acolorless oil. LCMS (ESI, m/z): 443 [M+H]⁺.

Step 2: Preparation of tert-butyl1-(3-chloro-5-(4-(ethoxycarbonyl)piperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask purged and maintained with an inert atmosphere of nitrogen wascharged with tert-butyl1-(3-bromo-5-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate (1.02g, 2.25 mmol, 1.00 equiv), ethyl piperidine-4-carboxylate (0.531 g, 3.38mmol, 1.50 equiv), tris(dibenzylideneacetone)dipalladium (0.103 g, 0.112mmol, 0.05 equiv), 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (0.210 g,0.341 mmol, 0.15 equiv), sodium tert-butoxide (0.324 g, 3.38 mmol, 1.50equiv), and toluene (15 mL). The resulting solution was stirredovernight at 80° C. and diluted with H₂O (20 mL). The mixture wasextracted with DCM (3×50 mL) and the organic layers were combined,washed with brine (3×50 mL), dried over anhydrous Na₂SO₄, filtered, andconcentrated. The residue was purified on a silica gel column (2:8EtOAc/petroleum ether) to provide 0.511 g (44% yield) of tert-butyl1-(3-chloro-5-(4-(ethoxycarbonyl)piperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. LCMS (ESI, m/z): 520 [M+H]⁺.

Step 3: Preparation of1-(3-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-chlorophenyl)piperidine-4-carboxylic acid

A flask was charged with tert-butyl1-(3-chloro-5-(4-(ethoxycarbonyl)piperidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(511 mg, 0.982 mmol, 1.00 equiv), lithium hydroxide (117 mg, 4.89 mmol,5.00 equiv), MeOH (10 mL), and H₂O (5 mL). The resulting solution wasstirred for 3 h at rt. The pH value of the solution was adjusted to 7with hydrochloric acid (1 M, 1.5 mL). The mixture was extracted with DCM(3×50 mL) and the organic layers were combined, washed with brine (3×50mL), dried over anhydrous Na₂SO₄, filtered, and concentrated to provide330 mg (68% yield) of1-(3-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-chlorophenyl)piperidine-4-carboxylicacid as a yellow oil. LCMS (ESI, m/z): 492 [M+H]⁺.

Step 4: Preparation of1-(3-((1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-chlorophenyl)piperidine-4-carboxylicacid

A flask was charged with1-(3-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-chlorophenyl)piperidine-4-carboxylicacid (330 mg, 0.631 mmol, 1.00 equiv), TFA (1 mL), and DCM (5 mL). Theresulting solution was stirred overnight at rt and concentrated toprovide 262 mg (98% yield) of1-(3-((1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-chlorophenyl)piperidine-4-carboxylicacid as a yellow oil. LCMS (ESI, m/z): 392 [M+H]⁺.

Step 5: Preparation of1-(3-chloro-5-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)phenyl)piperidine-4-carboxylic acid

A flask was charged with triphosgene (78.4 mg, 0.262 mmol, 0.400 equiv),and DCM (5 mL). HFIP (135 mg, 0.802 mmol, 1.20 equiv) and DIEA (260 mg,2.01 mmol, 3.00 equiv) were each added dropwise at 0° C. The resultingsolution was stirred for 2 h at rt.1-(3-((1,8-Diazaspiro[4.5]decan-1-yl)methyl)-5-chlorophenyl)piperidine-4-carboxylicacid (262 mg, 0.621 mmol, 1.00 equiv) was added, and the reaction wasstirred for 3 h at rt before diluting with H₂O (20 mL). The mixture wasextracted with DCM (3×50 mL) and the organic layers were combined,washed with brine (3×50 mL), dried over anhydrous Na₂SO₄, filtered, andconcentrated. The crude product was purified by preparative HPLC toprovide 14.3 mg (4% yield) of1-(3-chloro-5-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)phenyl)piperidine-4-carboxylicacid as a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 6.76 (br, 3H),5.71-5.79 (m, 1H), 4.13-4.25 (m, 2H), 3.60-3.73 (m, 2H), 3.48-3.60 (m,2H), 2.90-3.05 (m, 2H), 2.71-2.90 (m, 4H), 2.43-2.56 (m, 1H), 2.03-2.07(m, 2H), 1.70-1.92 (m, 8H), 1.40-1.70 (m, 2H). LCMS (ESI, m/z): 586[M+H]⁺.

Example 123:1-(3-((8-(((1,1,1,3,3,3-Hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-4-carboxylicacid

The title compound was synthesized directly from commercially available3-bromo-5-(trifluoromethyl)benzaldehyde according to the representativeprocedure of Example 122 to provide1-(3-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-4-carboxylicacid as a white solid. ¹H NMR (300 MHz, Chloroform-d) 6 6.91-7.07 (br,3H), 5.71-5.79 (m, 1H), 4.19-4.23 (m, 2H), 3.41-3.87 (m, 4H), 2.82-3.06(m, 4H), 2.58-2.82 (m, 2H), 2.48-2.58 (m, 1H), 2.04-2.92 (m, 2H),2.66-2.96 (m, 8H), 1.44-1.76 (m, 2H). LCMS (ESI, m/z): 620 [M+H]⁺.

Example 124: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-3-methylbenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

Step 1: Preparation of 1-tert-butyl8-(1,1,1,3,3,3-hexafluoropropan-2-yl)1,8-diazaspiro[4.5]decane-1,8-dicarboxylate

A flask was charged with triphosgene (2.60 g, 8.75 mmol, 0.70 equiv) andDCM (40 mL). HFIP (4.20 g, 25.0 mmol, 2.00 equiv) and DIEA (4.84 g, 37.5mmol, 3.00 equiv) were each added dropwise at 0° C. The mixture wasstirred for 1 h at rt. tert-Butyl1,8-diazaspiro[4.5]decane-1-carboxylate (3.00 g, 12.5 mmol, 1.00 equiv)was added, and the reaction was stirred overnight at rt before dilutingwith H₂O (80 mL). The resulting solution was extracted with DCM (2×100mL) and the organic layers were combined, dried over anhydrous Na₂SO₄,filtered, and concentrated. The residue was purified on a silica gelcolumn (1:3 EtOAc/petroleum ether) to provide 1.80 g (33% yield) of1-tert-butyl 8-(1,1,1,3,3,3-hexafluoropropan-2-yl)1,8-diazaspiro[4.5]decane-1,8-dicarboxylate as a white solid. LCMS (ESI,m/z): 435 [M+H]⁺.

Step 2: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1-tert-butyl8-(1,1,1,3,3,3-hexafluoropropan-2-yl)1,8-diazaspiro[4.5]decane-1,8-dicarboxylate (1.00 g, 2.30 mmol, 1.00equiv), DCM (15 mL), and TFA (3.0 mL). The resulting solution wasstirred overnight at rt and concentrated to provide 769 mg (crude) of1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate as a light yellow oil. LCMS(ESI, m/z): 335 [M+H]⁺.

Step 3: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-3-methylbenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate (160 mg, 0.480 mmol, 1.00equiv), DCE (10 mL), 4-chloro-3-methylbenzaldehyde (74.0 mg, 0.480 mmol,1.00 equiv), and TEA (145 mg, 1.43 mmol, 3.00 equiv). The mixture wasstirred for 1 h at rt. NaBH(OAc)₃ (305 mg, 1.44 mmol, 3.00 equiv) wasadded, and the reaction was stirred overnight at rt before diluting withH₂O (30 mL). The resulting solution was extracted with DCM (2×50 mL),and the organic layers were combined, dried over anhydrous Na₂SO₄,filtered, and concentrated. The crude product was purified bypreparative HPLC to provide 81.9 mg (36% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-3-methylbenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as awhite solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.23 (s, 1H), 7.14 (s,1H), 7.06 (d, J=7.8 Hz, 1H), 5.72-5.80 (m, 1H), 4.16-4.25 (m, 2H), 3.51(s, 2H), 2.91-3.04 (m, 2H), 2.65 (t, J=6.4 Hz, 2H), 2.35 (s, 3H),1.65-1.86 (m, 6H), 1.45-1.49 (m, 2H). LCMS (ESI, m/z): 473 [M+H]⁺.

Example 125: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-chloro-4-methylbenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from commercially available3-chloro-4-methylbenzaldehyde in Step 3 according to the representativeprocedure of Example 124 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-chloro-4-methylbenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as awhite solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.29 (s, 1H), 7.06-7.15(m, 2H), 5.71-5.80 (m, 1H), 4.16-4.25 (m, 2H), 3.52 (s, 2H), 2.91-3.04(m, 2H), 2.66-2.68 (m, 2H), 2.34 (s, 3H), 1.65-1.80 (m, 6H), 1.46-1.50(m, 2H). LCMS (ESI, m/z): 473 [M+H]⁺.

Example 126: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2,3-dihydro-1,4-benzodioxine-6-carbaldehyde in Step 3 according to therepresentative procedure of Example 124 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 6.74-6.84 (m, 3H),5.71-5.80 (m, 1H), 4.24 (s, 4H), 4.15-4.20 (m, 2H), 3.47 (s, 2H),2.90-3.04 (m, 2H), 2.67-2.69 (m, 2H), 1.65-1.79 (m, 6H), 1.44-1.48 (m,2H). LCMS (ESI, m/z): 483 [M+H]⁺.

Example 127: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-chloro-4-morpholinobenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from3-chloro-4-morpholinobenzaldehyde (synthesized as described in Step 1 ofExample 59) in Step 3 according to the representative procedure ofExample 124 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-chloro-4-morpholinobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.33 (s, 1H), 7.14(d, J=8.1 Hz, 1H), 6.96 (d, J=8.4 Hz, 1H), 5.69-5.82 (m, 1H), 4.16-4.24(m, 2H), 3.86-3.89 (m, 4H), 3.51 (s, 2H), 2.91-3.05 (m, 6H), 2.66 (t,J=6.0 Hz, 2H), 1.65-1.80 (m, 6H), 1.45-1.50 (m, 2H). LCMS (ESI, m/z):544 [M+H]⁺.

Example 128: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-chloro-4-(pyrrolidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from3-chloro-4-(pyrrolidin-1-yl)benzaldehyde (synthesized as described inStep 1 of Example 59) in Step 3 according to the representativeprocedure of Example 124 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-chloro-4-(pyrrolidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.24 (s, 1H),7.03-7.06 (m, 1H), 6.83 (d, J=8.1 Hz, 1H), 5.69-5.82 (m, 1H), 4.16-4.24(m, 2H), 3.47 (s, 2H), 3.34 (t, J=6.3 Hz, 4H), 2.90-3.04 (m, 2H),2.66-2.68 (m, 2H) 1.88-1.98 (m, 4H), 1.66-1.79 (m, 6H), 1.47-1.58 (m,2H). LCMS (ESI, m/z): 528 [M+H]⁺.

Example 129: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-morpholino-3-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from4-morpholino-3-(trifluoromethyl)benzaldehyde (synthesized as describedin Step 1 of Example 59) in Step 3 according to the representativeprocedure of Example 124 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-morpholino-3-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.55 (s, 1H), 7.46 (d,J=8.1 Hz, 1H), 7.30 (d, J=8.1 Hz, 1H), 5.69-5.82 (m, 1H), 4.17-4.26 (m,2H), 3.81-3.84 (m, 4H), 3.58 (s, 2H), 2.83-3.05 (m, 6H), 2.66-2.68 (m,2H), 1.64-1.82 (m, 6H), 1.47-1.51 (m, 2H). LCMS (ESI, m/z): 578 [M+H]⁺.

Example 130: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-(pyrrolidin-1-yl)-3-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from4-(pyrrolidin-1-yl)-3-(trifluoromethyl)benzaldehyde (synthesized asdescribed in Step 1 of Example 59) in Step 3 according to therepresentative procedure of Example 124 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-(pyrrolidin-1-yl)-3-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as a light yellow oil. ¹H NMR (300 MHz,Chloroform-d) δ 7.47 (s, 1H), 7.28-7.31 (m, 1H), 6.94 (d, J=8.7 Hz, 1H),5.69-5.82 (m, 1H), 4.17-4.25 (m, 2H), 3.51 (s, 2H), 3.29 (br, 4H),2.91-3.05 (m, 2H), 2.66 (br, 2H) 1.89-1.90 (m, 4H), 1.72-1.80 (m, 6H),1.46-1.50 (m, 2H). LCMS (ESI, m/z): 562 [M+H]⁺.

Example 131: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-3-morpholinobenzyl)-1,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from4-chloro-3-morpholinobenzaldehyde (synthesized as described in Step 2 ofExample 79) in Step 3 according to the representative procedure ofExample 124 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-3-morpholinobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.30 (s, 1H),6.91-7.00 (m, 2H), 5.71-5.81 (m, 1H), 4.17-4.21 (m, 2H), 3.86-3.89 (m,4H), 3.54 (s, 2H), 2.82-3.05 (m, 6H), 2.66 (br, 2H), 1.41-1.81 (m, 8H).LCMS (ESI, m/z): 544 [M+H]⁺.

Example 132: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-3-(pyrrolidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from4-chloro-3-(pyrrolidin-1-yl)benzaldehyde (synthesized as described inStep 2 of Example 79) in Step 3 according to the representativeprocedure of Example 124 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-3-(pyrrolidin-1-yl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 6.20 (d, J=8.1 Hz,1H), 6.82 (s, 1H), 6.72-6.75 (m, 1H), 5.69-5.82 (m, 1H), 4.16-4.25 (m,2H), 3.51 (s, 2H), 3.37 (t, J=6.3 Hz, 4H), 2.91-3.04 (m, 2H), 2.66-2.70(m, 2H) 1.88-1.99 (m, 4H), 1.66-1.80 (m, 6H), 1.45-1.50 (m, 2H). LCMS(ESI, m/z): 528 [M+H]⁺.

Example 133: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-morpholino-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from3-morpholino-4-(trifluoromethyl)benzaldehyde (synthesized as describedin Step 2 of Example 79) in Step 3 according to the representativeprocedure of Example 124 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-morpholino-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas an off-white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.55 (d, J=7.8Hz, 1H), 7.31 (s, 1H), 7.18 (d, J=7.8 Hz, 1H), 5.69-5.80 (m, 1H),4.18-4.26 (m, 2H), 3.82-3.84 (m, 4H), 3.62 (s, 2H), 2.92-3.06 (m, 6H),2.67-2.69 (m, 2H), 1.56-1.92 (m, 8H). LCMS (ESI, m/z): [M+H]⁺.

Example 134: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from3-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzaldehyde (synthesized asdescribed in Step 2 of Example 79) in Step 3 according to therepresentative procedure of Example 124 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as a light yellow oil. ¹H NMR (300 MHz,Chloroform-d) δ 7.49 (d, J=8.1 Hz, 1H), 6.92 (s, 1H), 6.80 (d, J=8.1 Hz,1H), 5.69-5.80 (m, 1H), 4.17-4.25 (m, 2H), 3.56 (s, 2H), 3.32 (s, 4H),2.91-3.05 (m, 2H), 2.70-2.72 (m, 2H), 1.88-2.00 (m, 4H), 1.65-1.81 (m,6H), 1.41-1.50 (m, 2H). LCMS (ESI, m/z): 562 [M+H]⁺.

Example 135: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(4-chloro-3-methylbenzyl)-2,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from commercially available4-chloro-3-methylbenzaldehyde and tert-butyl2,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 60 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-chloro-3-methylbenzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate as ayellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.27 (d, J=8.1 Hz, 1H),7.08 (d, J=8.1 Hz, 1H), 7.18 (s, 1H), 5.70-5.78 (m, 1H), 3.39-3.55 (m,6H), 2.61 (br, 2H), 2.38 (br, 2H), 2.36 (s, 3H), 1.68 (t, J=6.8 Hz, 2H),1.57-1.63 (m, 4H). LCMS (ESI, m z): 473 [M+H]⁺.

Example 136: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(3-chloro-4-methylbenzyl)-2,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from commercially available3-chloro-4-methylbenzaldehyde and tert-butyl 2,8-diazaspiro[4.5]decane-8-carboxylate according to the representative procedure ofExample 60 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl2-(3-chloro-4-methylbenzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate as ayellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.30 (s, 1H), 7.10-7.18 (m,2H), 5.70-5.78 (m, 1H), 3.39-3.54 (m, 6H), 2.62 (br, 2H), 2.40 (br, 2H),2.35 (s, 3H), 1.68 (t, J=6.9 Hz, 2H), 1.57-1.63 (m, 4H). LCMS (ESI,m/z): 473 [M+H]⁺.

Example 137: 1,1,1,3,3,3-Hexafluoropropan-2-yl 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from commercially available2,3-dihydro-1,4-benzodioxine-6-carbaldehyde and tert-butyl2,8-diazaspiro[4.5] decane-8-carboxylate according to the representativeprocedure of Example 60 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate as ayellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 6.75-6.83 (m, 3H),5.70-5.79 (m, 1H), 4.25 (s, 4H), 3.39-3.54 (m, 6H), 2.58-2.63 (m, 2H),2.34-2.41 (m, 2H), 1.56-1.68 (m, 6H). LCMS (ESI, m/z): 483 [M+H]⁺.

Example 138: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(3-chloro-4-morpholinobenzyl)-2,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized directly from3-chloro-4-morpholinobenzaldehyde (synthesized as described in Step 1 ofExample 59) and tert-butyl 2,8-diazaspiro[4.5]decane-8-carboxylateaccording to the representative procedure of Example 60 to provide1,1,1,3,3,3-hexafluoropropan-2-yl2-(3-chloro-4-morpholinobenzyl)-2,8-diazaspiro[4.5] decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.34 (s, 1H),7.16-7.18 (m, 1H), 7.00 (d, J=7.8 Hz, 1H), 5.70-5.78 (m, 1H), 3.88 (t,J=4.5 Hz, 4H), 3.32-3.56 (m, 6H), 3.05 (t, J=4.5 Hz, 4H), 2.61 (br, 2H),2.39 (br, 2H), 1.59-1.81 (m, 6H). LCMS (ESI, m/z): 544 [M+H]⁺.

Example 139: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(3-chloro-4-(pyrrolidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from3-chloro-4-(pyrrolidin-1-yl)benzaldehyde (synthesized as described inStep 1 of Example 59) and tert-butyl2,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 60 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl2-(3-chloro-4-(pyrrolidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.25 (s, 1H), 7.09 (d,J=7.8 Hz, 1H), 6.83 (d, J=8.4 Hz, 1H), 5.68-5.80 (m, 1H), 3.41-3.61 (m,6H), 3.36 (t, J=6.4 Hz, 4H), 2.62 (br, 2H), 2.40 (br, 2H), 1.89-1.98 (m,4H), 1.61-1.70 (m, 6H). LCMS (ESI, m/z): 528 [M+H]⁺.

Example 140: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(4-morpholino-3-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from4-morpholino-3-(trifluoromethyl)benzaldehyde (synthesized as describedin Step 1 of Example 59) and tert-butyl2,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 60 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-morpholino-3-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a colorless oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.57 (s, 1H), 7.49(br, 1H), 7.31 (d, J=8.1 Hz, 1H), 5.68-5.81 (m, 1H), 3.83 (t, J=4.5 Hz,4H), 3.40-3.60 (m, 6H), 2.92 (t, J=4.5 Hz, 4H), 2.78 (br, 2H), 2.40 (br,2H), 1.60-1.70 (m, 6H). LCMS (ESI, m/z): 578 [M+H]⁺.

Example 141: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(4-(pyrrolidin-1-yl)-3-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized directly from4-(pyrrolidin-1-yl)-3-(trifluoromethyl)benzaldehyde (synthesized asdescribed in Step 1 of Example 59) and tert-butyl2,8-diazaspiro[4.5]decane-8-carboxylate according to the representativeprocedure of Example 60 to provide 1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-(pyrrolidin-1-yl)-3-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas pink oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.56 (s, 1H), 7.36-7.37(m, 1H), 6.94 (d, J=8.7 Hz, 1H), 5.68-5.80 (m, 1H), 3.39-3.57 (m, 6H),3.32 (t, J=4.5 Hz, 4H), 2.67 (br, 2H), 2.43 (br, 2H), 1.88-1.97 (m, 4H),1.71 (br, 2H), 1.60-1.62 (m, 4H). LCMS (ESI, m/z): 562 [M+H]⁺.

Example 142: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-((1-acetyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Preparation of 1-tert-butyl8-(1,1,1,3,3,3-hexafluoropropan-2-yl)1,8-diazaspiro[4.5]decane-1,8-dicarboxylate

A flask was charged with triphosgene (2.46 g, 8.29 mmol, 0.50 equiv),DCM (100 mL) and HFIP (4.21 g, 24.9 mmol, 1.50 equiv). DIEA (6.45 g,49.7 mmol, 3.00 equiv) was added dropwise at 0° C. The reaction mixturewas stirred for 2 h at 0° C. tert-Butyl1,8-diazaspiro[4.5]decane-1-carboxylate (4.01 g, 16.6 mmol, 1.00 equiv)was added, and the reaction was stirred for 3 h at 0° C. beforequenching with H₂O (50 mL). The mixture was extracted with DCM (3×50 mL)and the organic layers were combined, washed with H₂O (3×100 mL), driedover anhydrous Na₂SO₄, filtered, and concentrated. The residue waspurified on a silica gel column (1:2 EtOAc/petroleum ether) to provide4.34 g (60% yield) of 1-tert-butyl 8-(1,1,1,3,3,3-hexafluoropropan-2-yl)1,8-diazaspiro[4.5]decane-1,8-dicarboxylate as a white solid. LCMS (ESI,m/z): 435 [M+H]⁺.

Step 2: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1-tert-butyl8-(1,1,1,3,3,3-hexafluoropropan-2-yl)1,8-diazaspiro[4.5]decane-1,8-dicarboxylate (4.34 g, 9.99 mmol, 1.00equiv), DCM (20 mL), and TFA (10 mL). The resulting solution was stirredfor 1 h at rt and concentrated to provide 3.34 g (crude) of1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate as a yellow oil. LCMS (ESI,m/z): 335 [M+H]⁺.

Step 3: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1,2,3,4-tetrahydroquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,2,3,4-tetrahydroquinoline-8-carbaldehyde (161mg, 1.01 mmol, 1.00 equiv), 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate (400 mg, 1.20 mmol, 1.20 equiv),DCE (10 mL) and NaBH(OAc)₃ (424 mg, 2.02 mmol, 2.00 equiv). Theresulting solution was stirred overnight at rt and diluted with DCM (50mL). The mixture was washed with H₂O (3×50 mL), dried over anhydrousNa₂SO₄, filtered, and concentrated. The residue was purified on a silicagel column (1:2 EtOAc/petroleum ether) to provide 240 mg (50% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl1-((1,2,3,4-tetrahydroquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. LCMS (ESI, m/z): 480 [M+H]⁺.

Step 4: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1-acetyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1,2,3,4-tetrahydroquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(133 mg, 0.281 mmol, 1.00 equiv), DCM (20 mL), and TEA (56.1 mg, 0.556mmol, 2.00 equiv). Acetyl acetate (42.6 mg, 0.421 mmol, 1.50 equiv) wasadded at rt. The resulting solution was stirred for 1 h at rt anddiluted with DCM (20 mL). The mixture was washed with H₂O (3×20 mL),dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue waspurified by preparative HPLC to provide 39.5 mg (27% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl1-((1-acetyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas an off-white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.39 (d, J=7.1Hz, 1H), 6.96-7.23 (m, 2H), 5.71-5.77 (m, 1H), 4.71-4.87 (m, 1H),4.10-4.31 (m, 2H), 3.45-3.68 (m, 2H), 2.83-3.05 (m, 2H), 2.58-2.81 (m,3H), 2.35-2.55 (m, 2H), 2.12-2.34 (m, 2H), 1.81-2.01 (m, 4H), 1.63-1.80(m, 4H), 1.27-1.63 (m, 3H). LCMS (ESI, m/z): 522 [M+H]⁺.

Example 143: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-((1-methanesulfonyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1-(1,2,3,4-tetrahydroquinolin-8-ylmethyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(from Example 142, Step 3, 133 mg, 0.278 mmol, 1.00 equiv), DCM (20 mL),and TEA (56.2 mg, 0.556 mmol, 2.00 equiv). Methanesulfonyl chloride(48.1 mg, 0.420 mmol, 1.50 equiv) was added at rt. The resultingsolution was stirred for 1 h at rt and diluted with DCM (20 mL). Themixture was washed with H₂O (3×20 mL), dried over anhydrous Na₂SO₄,filtered, and concentrated. The residue was purified by preparative HPLCto provide 36.4 mg (24% yield) of 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1-methanesulfonyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ7.53 (d, J=7.7 Hz, 1H), 7.22 (t, J=7.5 Hz, 1H), 7.04 (d, J=7.4 Hz, 1H),5.69-5.82 (m, 1H), 4.01-4.31 (m, 3H), 3.70-3.89 (m, 2H), 3.21-3.35 (m,1H), 2.87-3.11 (m, 5H), 2.75-2.86 (m, 2H), 2.61-2.75 (m, 1H), 2.35-2.56(m, 2H), 1.65-2.03 (m, 7H), 1.40-1.51 (m, 2H). LCMS (ESI, m/z): 558[M+H]⁺.

Example 144: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-((2-ethyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Preparation of tert-butyl8-formyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate

A flask was charged with tert-butyl8-bromo-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (3.11 g, 9.93 mmol,1.00 equiv) and THF (50 mL) under nitrogen. The reaction mixture wascooled to −78° C. and n-butyllithium (2.5 M in hexane, 6 mL, 15.1 mmol,1.50 equiv) was added dropwise. The reaction mixture was stirred at −78°C. for 2 h, then DMF (1.46 g, 19.9 mmol, 2.00 equiv) was added dropwise.The resulting solution was stirred for 2 h at −78° C., quenched with aq.NH₄Cl (10 mL) and diluted with EtOAc (100 mL). The mixture was washedwith H₂O (3×100 mL), dried over anhydrous Na₂SO₄, filtered, andconcentrated. The residue was purified on a silica gel column (1:5EtOAc/petroleum ether) to provide 1.81 g (69% yield) of tert-butyl8-formyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate as a yellow solid.LCMS (ESI, m/z): 262 [M+H]⁺.

Step 2: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-((2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl8-formyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (1.81 g, 6.89mmol, 1.00 equiv), 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate (2.71 g, 8.08 mmol, 1.20 equiv),DCE (50 mL), and NaBH(OAc)₃ (4.41 g, 20.7 mmol, 3.00 equiv). Theresulting solution was stirred overnight at rt and diluted with DCM (50mL). The mixture was washed with H₂O (3×50 mL), dried over anhydrousNa₂SO₄, filtered, and concentrated. The residue was purified on a silicagel column (1:1 EtOAc/petroleum ether) to provide 500 mg (13% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl1-((2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow solid. LCMS (ESI, m/z): 580 [M+H]⁺.

Step 3: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1-((2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(500 mg, 0.860 mmol, 1.00 equiv), DCM (10 mL) and TFA (5 mL). Theresulting solution was stirred for 2 h at rt and concentrated to provide414 mg (crude) of 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. LCMS (ESI, m/z): 480 [M+H]⁺.

Step 4: Preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl1-((2-ethyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(165 mg, 0.340 mmol, 1.00 equiv), acetaldehyde (76.2 mg, 1.73 mmol, 5.00equiv), DCE (20 mL), and NaBH(OAc)₃ (212 mg, 1.02 mmol, 3.00 equiv). Theresulting solution was stirred overnight at rt and diluted with DCM (20mL). The mixture was washed with H₂O (3×20 mL), dried over anhydrousNa₂SO₄, filtered, and concentrated. The residue was purified bypreparative HPLC to provide 52.3 mg (30% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl1-((2-ethyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.05-7.12 (m, 2H),6.99-7.04 (m, 1H), 5.70-5.83 (m, 1H), 4.21 (t, J=12.6 Hz, 2H), 3.78 (s,2H), 3.52 (s, 2H), 2.86-3.04 (m, 4H), 2.75 (s, 2H), 2.55-2.70 (m, 4H),1.65-1.90 (m, 6H), 1.41-1.55 (m, 2H), 1.20-1.24 (m, 3H). LCMS (ESI,m/z): 508 [M+H]⁺.

Example 145: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-((2-acetyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(from Example 144, Step 3, 138 mg, 0.290 mmol, 1.00 equiv), DCM (20 mL)and TEA (88.1 mg, 0.870 mmol, 3.00 equiv). Acetyl acetate (59.1 mg,0.580 mmol, 2.00 equiv) was added at rt at rt. The resulting solutionwas stirred for 2 h at rt and diluted with DCM (20 mL). The mixture waswashed with H₂O (3×20 mL), dried over anhydrous Na₂SO₄, filtered, andconcentrated. The residue was purified by preparative HPLC to provide112.9 mg (75% yield) of 1,1,1,3,3,3-hexafluoropropan-2-yl1-((2-acetyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.03-7.27 (m, 3H),5.73-5.82 (m, 1H), 4.77-4.91 (m, 2H), 4.24 (t, J=12.6 Hz, 2H), 3.81 (t,J=6.0 Hz, 1H), 3.52-3.74 (m, 3H), 2.80-3.12 (m, 4H), 2.62 (q, J=6.7 Hz,2H), 2.17 (s, 3H), 1.65-1.93 (m, 6H), 1.42-1.65 (m, 2H). LCMS (ESI,m/z): 522 [M+H]⁺.

Example 146: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-((2-methanesulfonyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(from Example 144, Step 3, 138 mg, 0.290 mmol, 1.00 equiv), DCM (20 mL)and TEA (88.1 mg, 0.871 mmol, 3.00 equiv). Methanesulfonyl chloride(66.2 mg, 0.590 mmol, 2.00 equiv) was added at rt. The resultingsolution was stirred for 2 h and diluted with DCM (20 mL). The mixturewas washed with H₂O (3×20 mL), dried over anhydrous Na₂SO₄, filtered,and concentrated. The residue was purified by preparative HPLC toprovide 65.8 mg (41% yield) of 1,1,1,3,3,3-hexafluoropropan-2-yl1-((2-methanesulfonyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas an off-white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.11-7.17 (m,2H), 7.03-7.10 (m, 1H), 5.71-5.85 (m, 1H), 4.64 (s, 2H), 4.24 (t, J=11.4Hz, 2H), 3.51-3.58 (m, 4H), 2.89-3.11 (m, 4H), 2.81 (s, 3H), 2.58 (t,J=6.9 Hz, 2H), 1.65-1.89 (m, 6H), 1.56 (s, 2H). LCMS (ESI, m/z): 558[M+H]⁺.

Example 147: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-((2-isopropyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized using acetone in Step 4 according tothe representative procedure of Example 144 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-((2-isopropyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate formate as a yellow oil. ¹H NMR (400 MHz,Chloroform-d) δ 8.37 (s, 1H), 7.61-8.32 (br, 1H), 7.05-7.21 (m, 3H),5.71-5.85 (m, 1H), 4.42 (s, 2H), 4.25 (t, J=14.4 Hz, 2H), 3.62 (s, 3H),3.33 (s, 2H), 3.19 (s, 2H), 2.85-3.10 (m, 2H), 2.57 (t, J=6.7 Hz, 2H),1.62-1.95 (m, 6H), 1.28-1.61 (m, 8H). LCMS (ESI, m/z): 522 [M+H]⁺.

Example 148: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-((2-cyclopropyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(from Example 144, Step 3, 165 mg, 0.340 mmol, 1.00 equiv), MeOH (10mL), THF (10 mL), (1-ethoxycyclopropoxy)trimethylsilane (174 mg, 1.01mmol, 3.00 equiv), acetic acid (80.1 mg, 1.33 mmol, 4.00 equiv) andsodium cyanoborohydride (63.2 mg, 1.01 mmol, 3.00 equiv). The resultingsolution was stirred overnight at 60° C. and diluted with DCM (50 mL).The mixture was washed with H₂O (3×50 mL), dried over anhydrous Na₂SO₄,filtered, and concentrated. The residue was purified by preparative HPLCto provide 72.6 mg (41% yield) of 1,1,1,3,3,3-hexafluoropropan-2-yl1-((2-cyclopropyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.05-7.12 (m, 2H),7.00 (d, J=6.8 Hz, 1H), 5.70-5.81 (m, 1H), 4.22 (t, J=16.8 Hz, 2H), 3.97(s, 2H), 3.54 (s, 2H), 2.85-3.11 (m, 6H), 2.61 (t, J=6.8 Hz, 2H),1.65-1.97 (m, 7H), 1.40-1.56 (m, 2H) 0.45-0.78 (m, 4H). LCMS (ESI, m/z):520 [M+H]⁺.

Example 149: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-((2-(2-methylpropyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized using 2-methylpropanal in Step 4according to the representative procedure of Example 144 to provide1,1,1,3,3,3-hexafluoropropan-2-yl1-((2-(2-methylpropyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas an off-white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.03-7.15 (m,2H), 6.95-7.03 (m, 1H), 5.71-5.85 (m, 1H), 4.20 (t, J=13.0 Hz, 2H), 3.67(s, 2H), 3.51 (s, 2H), 2.85-3.09 (m, 4H), 2.55-2.76 (m, 4H), 2.29 (s,2H), 1.89-2.03 (m, 1H), 1.67-1.83 (m, 6H), 1.40-1.52 (m, 2H), 0.95 (d,J=7.0 Hz, 6H). LCMS (ESI, m/z): 536 [M+H]⁺.

Example 150: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-ethyl-4-fluorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Synthesis of 1-tert-butyl 8-(1,1,1,3,3,3-hexafluoropropan-2-yl)1,8-diazaspiro[4.5]decane-1,8-dicarboxylate

A flask was charged with triphosgene (2.60 g, 8.75 mmol, 0.70 equiv),and DCM (40 mL). HFIP (4.20 g, 25.0 mmol, 2.00 equiv) and DIPEA (4.84 g,37.5 mmol, 3.00 equiv) were each added dropwise at 0° C. The mixture wasstirred for 1 h at rt. tert-Butyl1,8-diazaspiro[4.5]decane-1-carboxylate (3.00 g, 12.5 mmol, 1.00 equiv)was added, and the reaction was stirred overnight at rt before quenchingwith water (80 mL). The resulting solution was extracted with DCM (2×100mL) and the organic layers were combined, dried over anhydrous sodiumsulfate, filtered, and concentrated. The residue was chromatographed ona silica gel column with EtOAc/petroleum ether (1/3) to provide 1.80 g(33% yield) of 1-tert-butyl 8-(1,1,1,3,3,3-hexafluoropropan-2-yl)1,8-diazaspiro[4.5]decane-1,8-dicarboxylate as a white solid. LCMS (ESI,m/z): 435 [M+H]⁺.

Step 2: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1-tert-butyl8-(1,1,1,3,3,3-hexafluoropropan-2-yl)1,8-diazaspiro[4.5]decane-1,8-dicarboxylate (1.00 g, 2.30 mmol, 1.00equiv), DCM (15 mL), and TFA (3 mL). The resulting solution was stirredovernight at rt and concentrated to provide 769 mg (crude) of1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate as a light yellow oil. LCMS(ESI, m/z): 335 [M+H]⁺.

Step 3: Synthesis of 3-ethyl-4-fluorobenzaldehyde

A flask was charged with 4-bromo-2-ethyl-1-fluorobenzene (2.00 g, 9.85mmol, 1.00 equiv), and THF (25 mL) under nitrogen. The mixture wascooled to −78° C. n-Butyllithium (2.5 M in hexane, 4.80 mL, 11.8 mmol,1.20 equiv) was added dropwise at −78° C. The mixture was stirred for 1h at −78° C. and DMF (2.17 g, 29.6 mmol, 3.00 equiv) was added. Theresulting solution was stirred for 1 h at −78° C. and quenched withsaturated NH₄Cl solution (30 mL). The resulting solution was extractedwith EtOAc (2×100 mL) and the organic layers were combined, dried overanhydrous sodium sulfate, filtered, and concentrated. The residue waschromatographed on a silica gel column with EtOAc/petroleum ether (1/9)to provide 1.20 g (80% yield) of 3-ethyl-4-fluorobenzaldehyde as a lightyellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 9.94 (s, 1H), 7.71-7.82 (m,2H), 7.16 (t, J=8.8 Hz, 1H), 2.68-2.78 (m, 2H), 1.28 (t, J=6.4 Hz, 3H).

Step 4: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-ethyl-4-fluorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 3-ethyl-4-fluorobenzaldehyde (68.0 mg, 0.450mmol, 1.00 equiv), DCE (10 mL), 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate (150 mg, 0.450 mmol, 1.00equiv), and TEA (136 mg, 1.34 mmol, 3.00 equiv). The mixture was stirredfor 1 h at rt. Sodium triacetoxyborohydride (286 mg, 1.35 mmol, 3.00equiv) was added, and the reaction was stirred overnight at rt beforequenching with water (30 mL). The resulting solution was extracted withDCM (2×50 mL) and the organic layers were combined, dried over anhydroussodium sulfate, filtered, and concentrated. The crude product waspurified by preparative HPLC to give 78.9 mg (38% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-ethyl-4-fluorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as alight yellow oil. ¹H NMR (400 MHz, DMSO-d₆) δ 7.17 (d, J=5.6 Hz, 1H),7.10-7.15 (m, 1H), 7.03 (t, J=5.0 Hz, 1H), 6.52-6.57 (m, 1H), 4.16-4.25(m, 2H), 3.51 (s, 2H), 2.98-3.11 (m, 2H), 2.51-2.62 (m, 4H), 1.77-1.80(m, 2H), 1.56-1.71 (m, 4H), 1.48 (d, J=12.8 Hz, 2H), 1.16 (t, J=7.6 Hz,3H). LCMS (ESI, m/z): 471 [M+H]⁺.

Example 151: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-((1,3-dihydroisobenzofuran-5-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Synthesis of (4-bromo-1,2-phenylene)dimethanol

A flask was charged with 5-bromoisobenzofuran-1,3-dione (8.00 g, 35.2mmol, 1.00 equiv), and THF (100 mL). LAH (2.69 g, 70.9 mmol, 2.00 equiv)was added at 0° C. The resulting solution was stirred for 2 h at 10° C.and quenched with EtOAc (50 mL) and diluted with water (100 mL). The pHvalue of the solution was adjusted to 3 with 1 M HCl. The resultingsolution was extracted with EtOAc (2×100 mL) and the organic layers werecombined, dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue was chromatographed on a silica gel columnwith EtOAc/petroleum ether (1/2) to provide 4.00 g (52% yield) of(4-bromo-1,2-phenylene)dimethanol as a white solid. ¹H NMR (300 MHz,Chloroform-d) δ 7.66-7.70 (m, 1H), 7.43-7.47 (m, 1H), 7.23 (d, J=7.8 Hz,1H), 4.71 (s, 4H), 2.62 (br, 2H).

Step 2: Synthesis of (5-bromo-2-(chloromethyl)phenyl)methanol

A flask was charged with (4-bromo-1,2-phenylene)dimethanol (4.00 g, 18.4mmol, 1.00 equiv) and hydrochloric acid (25 mL). The resulting solutionwas stirred for 15 min at 70° C. and quenched with water (50 mL). Themixture was extracted with EtOAc (2×80 mL) and the organic layers werecombined, dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue was chromatographed on a silica gel columnwith EtOAc/petroleum ether (1/8) to provide 2.70 g (62% yield) of(5-bromo-2-(chloromethyl)phenyl)methanol as an off-white solid. ¹H NMR(300 MHz, DMSO-d₆) δ 7.64-7.66 (m, 1H), 7.45-7.49 (m, 1H), 7.36 (d,J=8.1 Hz, 1H), 5.40-5.45 (m, 1H), 4.78 (s, 2H), 4.66 (d, J=4.5 Hz, 2H).

Step 3: Synthesis 5-bromo-1,3-dihydroisobenzofuran

A flask was charged with (5-bromo-2-(chloromethyl)phenyl)methanol (2.50g, 10.7 mmol, 1.00 equiv), and THF (40 mL). Sodium hydride (60% inmineral oil, 856 mg, 21.4 mmol, 2.00 equiv) was added at 0° C. Thereaction mixture was stirred for 2 h at 45° C. and quenched with water(80 mL). The resulting solution was extracted with EtOAc (2×100 mL) andthe organic layers were combined, dried over anhydrous sodium sulfate,filtered, and concentrated. The residue was chromatographed on a silicagel column with EtOAc/petroleum ether (7/93) to provide 1.90 g (90%yield) of 5-bromo-1,3-dihydroisobenzofuran as an off-white solid. ¹H NMR(300 MHz, DMSO-d₆) δ 7.54 (s, 1H), 7.45 (d, J=8.1 Hz, 1H), 7.28 (d,J=8.1 Hz, 1H), 4.95-4.98 (m, 1H).

Step 4: Synthesis of 1,3-dihydroisobenzofuran-5-carbaldehyde

A flask was charged with 5-bromo-1,3-dihydroisobenzofuran (1.60 g, 8.08mmol, 1.00 equiv), and THF (25 mL) under nitrogen. n-Butyllithium (2.5 Min hexane, 3.90 mL, 9.70 mmol, 1.20 equiv) was added dropwise at −78° C.The mixture was stirred at −78° C. for 1 h and DMF (1.77 g, 24.2 mmol,3.00 equiv) was added. The resulting solution was stirred for 1 h at−78° C. and quenched with saturated NH₄Cl solution (50 mL). Theresulting solution was extracted with EtOAc (2×80 mL) and the organiclayers were combined, dried over anhydrous sodium sulfate, filtered andconcentrated. The residue was chromatographed on a silica gel columnwith EtOAc/petroleum ether (1/9) to provide 900 mg (76% yield) of1,3-dihydroisobenzofuran-5-carbaldehyde as a white solid. ¹H NMR (300MHz, Chloroform-d) δ 10.0 (s, 1H), 7.77-7.82 (m, 2H), 7.40 (d, J=7.5 Hz,1H), 5.16 (s, 4H).

Step 5: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1,3-dihydroisobenzofuran-5-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,3-dihydroisobenzofuran-5-carbaldehyde (66.0mg, 0.450 mmol, 1.00 equiv), DCE (10 mL),1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate (150 mg, 0.450 mmol, 1.00equiv), and TEA (136 mg, 1.34 mmol, 3.00 equiv). The mixture was stirredfor 1 h at rt. Sodium triacetoxyborohydride (286 mg, 1.35 mmol, 3.00equiv) was added, and the reaction was stirred overnight at rt beforequenching with water (30 mL). The resulting solution was extracted withDCM (2×50 mL) and the organic layers were combined, dried over anhydroussodium sulfate, filtered, and concentrated. The crude product waspurified by preparative HPLC to give 127.1 mg (61% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl1-((1,3-dihydroisobenzofuran-5-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow oil. ¹H NMR (400 MHz, DMSO-d₆) δ 7.16-7.22 (m, 3H),6.53-6.60 (m, 1H), 4.97 (s, 4H), 3.97-4.06 (m, 2H), 3.55 (s, 2H),2.98-3.33 (m, 2H), 2.57 (t, J=6.8 Hz, 2H), 1.77-1.81 (m, 2H), 1.58-1.71(m, 4H), 1.41-1.42 (m, 2H). LCMS (ESI, m/z): 467 [M+H]⁺.

Example 152: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(3-ethyl-4-fluorobenzyl)-2,8-diazaspiro[4.5] decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 150 using 3-ethyl-4-fluorobenzaldehyde andtert-butyl 2,8-diazaspiro[4.5] decane-2-carboxylate. Purificationresulted in 85.9 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl2-(3-ethyl-4-fluorobenzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate as alight yellow oil. ¹H NMR (400 MHz, DMSO-d₆) δ 7.19-7.22 (m, 1H),7.12-7.16 (m, 1H), 7.03-7.08 (m, 1H), 6.52-6.58 (m, 1H), 3.41-3.50 (m,4H), 3.33-3.39 (m, 2H), 2.58-2.64 (m, 2H), 2.52-2.53 (m, 2H), 3.34 (s,2H), 1.60 (t, J=7.0 Hz, 2H), 1.46-1.52 (m, 4H), 1.16 (t, J=7.6 Hz, 3H).LCMS (ESI, m/z): 471 [M+H]⁺.

Example 153: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-((1,3-dihydroisobenzofuran-5-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 151 using 1,3-dihydroisobenzofuran-5-carbaldehydeand tert-butyl 2,8-diazaspiro[4.5]decane-2-carboxylate. Purificationresulted in 160.3 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl2-((1,3-dihydroisobenzofuran-5-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.16-7.22 (m,3H), 5.70-5.79 (m, 1H), 5.10 (s, 4H), 3.58-3.60 (m, 2H), 3.39-3.54 (m,4H), 2.59-2.64 (m, 2H), 2.36-2.43 (m, 2H), 1.68 (t, J=6.9 Hz, 2H),1.56-1.63 (m, 4H). LCMS (ESI, m/z): 467 [M+H]⁺.

Example 154: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(4-chloro-3-morpholinobenzyl)-2,8-diazaspiro[4.5] decane-8-carboxylate

Step 1: Synthesis of 4-chloro-3-morpholinobenzaldehyde

A flask was charged with 3-bromo-4-chlorobenzaldehyde (2.00 g, 9.11mmol, 1.00 equiv), tris(dibenzylideneacetone)dipalladium (0.420 g, 0.460mmol, 0.05 equiv), cesium carbonate (8.97 g, 27.5 mmol, 3.00 equiv),2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (0.856 g, 1.37 mmol, 0.15equiv), morpholine (1.20 g, 13.8 mmol, 1.50 equiv), and toluene (40 mL)under nitrogen. The reaction mixture was stirred overnight at 85° C. andquenched with water (100 mL). The resulting solution was extracted withEtOAc (2×150 mL) and the organic layers were combined, dried overanhydrous sodium sulfate, filtered, and concentrated. The residue waschromatographed on a silica gel column with EtOAc/petroleum ether (1/8)to provide 1.60 g (78% yield) of 4-chloro-3-morpholinobenzaldehyde as ayellow oil. LCMS (ESI, m/z): 226 [M+H]⁺.

Step 2: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-chloro-3-morpholinobenzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 4-chloro-3-morpholinobenzaldehyde (101 mg,0.450 mmol, 1.00 equiv), DCE (10 mL), TEA (136 mg, 1.34 mmol, 3.00equiv), and 1,1,1,3,3,3-hexafluoropropan-2-yl2,8-diazaspiro[4.5]decane-8-carboxylate (150 mg, 0.450 mmol, 1.00equiv). The mixture was stirred for 1 h at rt. Sodiumtriacetoxyborohydride (286 mg, 1.35 mmol, 3.00 equiv) was added, and thereaction was stirred overnight at rt before quenching with water (30mL). The resulting solution was extracted with DCM (2×50 mL) and theorganic layers were combined, dried over anhydrous sodium sulfate,filtered, and concentrated. The crude product was purified bypreparative HPLC to give 199.1 mg (82% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-chloro-3-morpholinobenzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.29 (d, J=7.8 Hz,1H), 7.01 (br, 1H), 6.94 (d, J=7.8 Hz, 1H), 5.68-5.81 (m, 1H), 3.88 (t,J=4.5 Hz, 4H), 3.39-3.62 (m, 6H), 3.08 (t, J=4.6 Hz, 4H), 2.62 (br, 2H),2.37 (br, 2H), 1.59-1.70 (m, 6H). LCMS (ESI, m/z): 544 [M+H]⁺.

Example 155: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(4-chloro-3-(pyrrolidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 154 using pyrrolidine in Step 1. Purificationresulted in 179.5 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-chloro-3-(pyrrolidin-1-yl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.21 (d, J=8.1 Hz,1H), 6.86 (br, 1H), 6.70-6.73 (m, 1H), 5.68-5.81 (m, 1H), 3.44-3.55 (m,6H), 3.36-3.40 (m, 4H), 2.62 (br, 2H), 2.38 (br, 2H), 1.89-2.00 (m, 4H),1.61-1.68 (m, 6H). LCMS (ESI, m/z): 528 [M+H]⁺.

Example 156: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(3-morpholino-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 154 using 3-bromo-4-(trifluoromethyl)benzaldehydeand morpholine in Step 1. Purification resulted in 174.5 mg of1,1,1,3,3,3-hexafluoropropan-2-yl2-(3-morpholino-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.55-7.58 (m, 1H),7.33 (s, 1H), 7.16-7.18 (m, 1H), 5.70-5.78 (m, 1H), 3.84 (t, J=4.4 Hz,4H), 3.42-3.70 (m, 6H), 2.93 (br, 4H), 2.61-2.66 (m, 2H), 2.38 (br, 2H),1.49-1.72 (m, 6H). LCMS (ESI, m/z): 578 [M+H]⁺.

Example 157: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(3-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 154 using 3-bromo-4-(trifluoromethyl)benzaldehydeand pyrrolidine in Step 1. Purification resulted in 91.5 mg of1,1,1,3,3,3-hexafluoropropan-2-yl2-(3-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.52 (d, J=8.4 Hz,1H), 6.97 (br, 1H), 6.81 (d, J=8.0 Hz, 1H), 5.72-5.80 (m, 1H), 3.45-3.70(m, 6H), 3.36 (br, 4H), 2.66 (br, 2H), 2.42 (br, 2H), 1.97 (br, 4H),1.62-1.71 (m, 6H). LCMS (ESI, m/z): 562 [M+H]⁺.

Example 158: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-((1-ethyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1,2,3,4-tetrahydroquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,2,3,4-tetrahydroquinoline-8-carbaldehyde (161mg, 1.01 mmol, 1.00 equiv), 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate (400 mg, 1.20 mmol, 1.20 equiv),DCE (10 mL) and sodium triacetoxyborohydride (424 mg, 2.02 mmol, 2.00equiv). The resulting solution was stirred overnight at rt and quenchedwith water (20 mL). The mixture was extracted with DCM (3×20 mL) and theorganic layers were combined, washed with water (3×100 mL), dried overanhydrous sodium sulfate, filtered, and concentrated. The residue waschromatographed on a silica gel column with EtOAc/petroleum ether (1/2)to provide 240 mg (50% yield) of 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1,2,3,4-tetrahydroquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. LCMS (ESI, m/z): 480 [M+H]⁺.

Step 2: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1-ethyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1-((1,2,3,4-tetrahydroquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(240 mg, 0.50 mmol, 1.00 equiv), acetaldehyde (110 mg, 5.00 equiv), DCE(10 mL) and sodium triacetoxyborohydride (318 mg, 1.50 mmol, 3.00equiv). The resulting solution was stirred overnight at rt and quenchedwith water (20 mL). The mixture was extracted with DCM (3×20 mL) and theorganic layers were combined, washed with water (3×100 mL), dried overanhydrous sodium sulfate, filtered, and concentrated. The residue waspurified by preparative HPLC to give 75.7 mg (27% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl1-((1-ethyl-1,2,3,4-tetrahydroquinolin-8-yl)methyl)-1,8-diazaspiro[4.5]decane-8-carboxylateformic acid salt as a yellow solid. ¹H NMR (400 MHz, Chloroform-d) δ11.11 (s, 1H), 8.42 (s, 1H), 7.53 (d, J=6.8 Hz, 1H), 6.95-7.03 (m, 2H),5.71-5.77 (m, 1H), 4.16-4.27 (m, 2H), 4.06 (s, 2H), 3.22 (s, 2H),2.95-3.22 (m, 4H), 2.75-2.81 (m, 4H), 2.12 (d, J=6.8 Hz, 2H), 1.91-2.09(m, 4H), 1.74-1.90 (m, 4H), 1.22 (t, J=6.8 Hz, 3H). LCMS (ESI, m/z): 508[M+H−HCOOH]⁺.

Example 159: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-((2-ethyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Synthesis of tert-butyl8-formyl-3,4-dihydroisoquinoline-2(1H)-carboxylate

A 3-necked flask was charged with tert-butyl8-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate (3.11 g, 9.93 mmol,1.00 equiv) and THF (50 mL) under nitrogen. The reaction mixture wascooled to −78° C. and n-butyllithium (2.5 M in hexane, 6 mL, 15.1 mmol,1.50 equiv) was added dropwise. The reaction mixture was stirred at −78°C. for 2 h, and DMF (1.46 g, 19.9 mmol, 2.00 equiv) was added dropwise.The resulting solution was stirred for 2 h at −78° C., quenched withaqueous ammonium chloride (10 mL) and diluted with EtOAc (100 mL). Theresulting mixture was washed with water (3×100 mL), dried over anhydroussodium sulfate, filtered, and concentrated. The residue waschromatographed on a silica gel column with EtOAc/petroleum ether (1/5)to provide 1.81 g (69% yield) of tert-butyl8-formyl-3,4-dihydroisoquinoline-2(1H)-carboxylate as a yellow solid.LCMS (ESI, m/z): 262 [M+H]⁺.

Step 2: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl2-((2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl8-formyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (1.38 g, 5.28 mmol,1.00 equiv), DCE (20 mL), 1,1,1,3,3,3-hexafluoropropan-2-yl2,8-diazaspiro[4.5]decane-8-carboxylate (1.77 g, 5.30 mmol, 1.00 equiv)and sodium triacetoxyborohydride (2.25 g, 10.6 mmol, 2.00 equiv). Theresulting solution was stirred overnight at rt and diluted with DCM (100mL). The mixture was washed with water (3×100 mL), dried over anhydroussodium sulfate, filtered and concentrated. The residue waschromatographed on a silica gel column with EtOAc/petroleum ether (1/2)to provide 2.20 g (65% yield) of tert-butyl8-((8-((1,1,1,3,3,3-hexafluoropropan-2-yloxy)carbonyl)-2,8-diazaspiro[4.5]decan-2-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylateas a yellow oil. LCMS (ESI, m/z): 580 [M+H]⁺.

Step 3: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl2-((1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl8-((8-((1,1,1,3,3,3-hexafluoropropan-2-yloxy)carbonyl)-2,8-diazaspiro[4.5]decan-2-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate(2.20 g, 3.80 mmol, 1.00 equiv), DCM (20 mL), and TFA (10 mL). Theresulting solution was stirred for 2 h at rt and concentrated to provide3.00 g (crude) of 1,1,1,3,3,3-hexafluoropropan-2-yl2-((1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate as a yellow oil. LCMS (ESI, m/z): 480 [M+H]⁺.

Step 4: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl2-((2-ethyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl2-((1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate(479 mg, 1.01 mmol, 1.00 equiv), DCE (10 mL), acetaldehyde (220 mg, 5.01mmol, 5.00 equiv) and sodium triacetoxyborohydride (636 mg, 3.01 mmol,3.00 equiv). The resulting solution was stirred overnight at rt anddiluted with DCM (50 mL). The resulting solution was washed with water(3×50 mL), dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue was purified by preparative HPLC to give 123mg (24% yield) of 1,1,1,3,3,3-hexafluoropropan-2-yl2-((2-ethyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.00-7.12 (m, 3H),5.71-5.78 (m, 1H), 3.69-3.92 (br, 2H), 3.32-3.59 (m, 6H), 2.97 (s, 2H),2.60-2.91 (m, 4H), 2.57 (t, J=6.0 Hz, 2H), 2.37 (s, 2H), 1.50-1.69 (m,6H), 1.25 (s, 3H). LCMS (ESI, m/z): 508 [M+H]⁺.

Example 160: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-((2-acetyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl2-((1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate(240 mg, 0.501 mmol, 1.00 equiv), DCM (10 mL) and TEA (150 mg, 1.48mmol, 3.00 equiv). Acetic anhydride (102 mg, 1.01 mmol, 2.00 equiv) wasadded dropwise. The reaction mixture was stirred for 2 h at rt anddiluted with DCM (50 mL). The resulting solution was washed with water(3×50 mL), dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue was purified by preparative HPLC to give 154.1mg (59% yield) of 1,1,1,3,3,3-hexafluoropropan-2-yl2-((2-acetyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow solid. ¹H NMR (400 MHz, Chloroform-d) δ 7.02-7.21 (m, 3H),5.71-5.77 (m, 1H), 4.75-4.87 (m, 2H), 3.64-3.87 (m, 2H), 3.46-3.64 (m,4H), 3.32-3.48 (m, 2H), 3.81-3.98 (m, 2H), 2.51-2.68 (br, 2H), 2.29-2.47(m, 2H), 2.18 (s, 3H), 1.52-1.71 (m, 6H). LCMS (ESI, m/z): 522 [M+H]⁺.

Example 161: 1,1,1,3,3,3-hexafluoropropan-2-yl2-((2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-Hexafluoropropan-2-yl2-((1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate(240 mg, 0.501 mmol, 1.00 equiv), DCM (10 mL), TEA (150 mg, 1.48 mmol,3.00 equiv) and methanesulfonyl chloride (115 mg, 1.01 mmol, 2.00equiv). The resulting solution was stirred for 2 h at rt and dilutedwith DCM (50 mL). The resulting mixture was washed with water (3×50 mL),dried over anhydrous sodium sulfate, filtered, and concentrated. Theresidue was purified by preparative HPLC to give 171.1 mg (61% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl2-((2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas an off-white solid. ¹H NMR (400 MHz, Chloroform-d) δ 7.01-7.19 (m,3H), 5.71-5.77 (m, 1H), 4.62 (s, 2H), 3.50-3.59 (m, 6H), 3.35-3.46 (m,2H), 2.94-3.06 (m, 2H), 2.82 (s, 3H), 2.46-2.64 (m, 2H), 2.25-2.46 (m,2H), 1.49-1.71 (m, 6H). LCMS (ESI, m/z): 558 [M+H]⁺.

Example 162: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-((2-isopropyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 159 using 1,1,1,3,3,3-hexafluoropropan-2-yl2-((1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylateand acetone in Step 4. Purification resulted in 88.2 mg of1,1,1,3,3,3-hexafluoropropan-2-yl2-((2-isopropyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (400 MHz, Chloroform-d) δ 6.98-7.12 (m, 3H),5.73-5.82 (m, 1H), 3.86 (s, 2H), 3.36-3.59 (m, 6H), 2.89-2.97 (m, 3H),2.78 (t, J=6.0 Hz, 2H), 2.58 (t, J=7.0 Hz, 2H), 2.41 (s, 2H), 1.51-1.71(m, 6H), 1.28 (d, J=6.0 Hz, 6H). LCMS (ESI, m/z): 522 [M+H]⁺.

Example 163: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-((2-cyclopropyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl2-(1,2,3,4-tetrahydroisoquinolin-8-ylmethyl)-2,8-diazaspiro[4.5]decane-8-carboxylate(479 mg, 1.01 mmol, 1.00 equiv), MeOH (20 mL), THF (20 mL),(1-ethoxycyclopropoxy)trimethylsilane (522 mg, 2.99 mmol, 3.00 equiv),acetic acid (240 mg, 4.01 mmol, 4.00 equiv) and sodium cyanoborohydride(190 mg, 3.01 mmol, 3.00 equiv). The resulting solution was stirredovernight at 60° C. and quenched with water (50 mL). The mixture wasextracted with DCM (3×50 mL) and the organic layers were combined,washed with water (3×100 mL), dried over anhydrous sodium sulfate,filtered, and concentrated. The residue was purified by preparative HPLCto give 78.8 mg (15% yield) of 1,1,1,3,3,3-hexafluoropropan-2-yl2-((2-cyclopropyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (400 MHz, Chloroform-d) δ 6.98-7.12 (m, 3H),5.73-5.82 (m, 1H), 3.91 (s, 2H), 3.36-3.62 (m, 6H), 2.94 (s, 4H), 2.61(s, 2H), 2.43 (s, 2H), 1.86 (s, 1H), 1.51-1.75 (m, 6H), 0.58 (s, 4H).LCMS (ESI, m/z): 520 [M+H]⁺.

Example 164: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-((2-isobutyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 159 using 1,1,1,3,3,3-hexafluoropropan-2-yl2-((1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylateand 2-methylpropanal in Step 4. Purification resulted in 345.8 mg of1,1,1,3,3,3-hexafluoropropan-2-yl2-((2-isobutyl-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (400 MHz, Chloroform-d) δ 6.98-7.15 (m, 3H),5.71-5.82 (m, 1H), 3.70 (s, 2H), 3.36-3.59 (m, 6H), 2.95 (s, 2H), 2.71(s, 2H), 2.60 (t, J=7.0 Hz, 2H), 2.21-2.48 (m, 4H), 1.95 (s, 1H),1.51-1.72 (m, 6H), 0.78-1.15 (m, 6H). LCMS (ESI, m/z): 536 [M+H]⁺.

Example 165: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(1-methylpiperidin-4-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Synthesis of 1-methylpiperidin-4-yl methanesulfonate

A flask was charged with 1-methylpiperidin-4-ol (2.00 g, 17.4 mmol, 1.00equiv), TEA (5.27 g, 52.1 mmol, 3.00 equiv), and DCM (30 mL).Methanesulfonyl chloride (2.97 g, 26.1 mmol, 1.50 equiv) was added at 0°C. The resulting solution was stirred overnight at rt and quenched withH₂O (50 mL). The mixture was extracted with DCM (3×70 mL) and theorganic layers were combined, washed with brine (100 mL), dried overanhydrous sodium sulfate, filtered, and concentrated to provide 2.60 g(77% yield) of 1-methylpiperidin-4-yl methanesulfonate as a light yellowoil. LCMS (ESI, m/z): 194 [M+H]⁺.

Step 2: Synthesis of 2-hydroxy-4-(trifluoromethyl)benzaldehyde

A flask was charged with 2-fluoro-4-(trifluoromethyl)benzaldehyde (5.00g, 26.0 mmol, 1.00 equiv), water (5 mL), potassium carbonate (10.8 g,78.1 mmol, 3.00 equiv), and DMSO (50 mL) under nitrogen. The resultingsolution was stirred overnight at 100° C. and quenched with H₂O (70 mL).The mixture was extracted with DCM (3×100 mL) and the organic layerswere combined, washed with brine (200 mL), dried over anhydrous sodiumsulfate, filtered, and concentrated. The residue was chromatographed ona silica gel column with EtOAc/petroleum ether (6/94) to provide 3.07 g(62% yield) of 2-hydroxy-4-(trifluoromethyl)benzaldehyde as a yellowoil.

Step 3: Synthesis of tert-butyl1-(2-hydroxy-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 2-hydroxy-4-(trifluoromethyl)benzaldehyde (1.00g, 5.26 mmol, 1.00 equiv), tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate (1.89 g, 7.86 mmol, 1.50 equiv),acetic acid (0.948 g, 15.8 mmol, 3.00 equiv), and MeOH (30 mL). Themixture was stirred for 1 h at rt. Sodium cyanoborohydride (0.995 g,15.8 mmol, 3.00 equiv) was added, and the reaction was stirred overnightat rt before quenching with H₂O (50 mL). The mixture was extracted withDCM (3×70 mL) and the organic layers were combined, washed with brine(100 mL), dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue was chromatographed on a silica gel columnwith EtOAc/petroleum ether (14/86) to provide 1.60 g (73% yield) oftert-butyl1-(2-hydroxy-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow solid. LCMS (ESI, m/z): 415 [M+H]⁺.

Step 4: Synthesis of tert-butyl1-(2-(1-methylpiperidin-4-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl1-(2-hydroxy-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(200 mg, 0.483 mmol, 1.00 equiv), 1-methylpiperidin-4-ylmethanesulfonate (280 mg, 1.45 mmol, 3.00 equiv), cesium carbonate (630mg, 1.93 mmol, 4.00 equiv), and DMF (10 mL). The resulting solution wasstirred overnight at 80° C. and quenched with H₂O (20 mL). The mixturewas extracted with DCM (3×50 mL) and the organic layers were combined,washed with brine (100 mL), dried over anhydrous sodium sulfate,filtered, and concentrated. The residue was chromatographed on a silicagel column with MeOH/DCM (7/93) to provide 220 mg (89% yield) oftert-butyl1-(2-(1-methylpiperidin-4-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow oil. LCMS (ESI, m/z): 512 [M+H]⁺.

Step 5: Synthesis of1-(2-(1-methylpiperidin-4-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane

A flask was charged with tert-butyl1-(2-(1-methylpiperidin-4-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(220 mg, 0.430 mmol, 1.00 equiv), DCM (5 mL), and TFA (1 mL). Theresulting solution was stirred overnight at rt and concentrated toprovide 300 mg (crude) of1-(2-(1-methylpiperidin-4-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decaneas a light yellow solid. LCMS (ESI, m/z): 412 [M+H]⁺.

Step 6: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(1-methylpiperidin-4-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with triphosgene (89.4 mg, 0.301 mmol, 0.70 equiv),and DCM (10 mL). HFIP (144 mg, 0.860 mmol, 2.00 equiv) was added at 0°C., followed by DIEA (222 mg, 1.72 mmol, 4.00 equiv). The mixture wasstirred for 2 h at rt.1-(2-(1-Methylpiperidin-4-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane(177 mg, 0.430 mmol, 1.00 equiv) was added, and the reaction was stirredovernight at rt before quenching with H₂O (10 mL). The mixture wasextracted with DCM (3×30 mL) and the organic layers were combined,washed with brine (30 mL), dried over anhydrous sodium sulfate,filtered, and concentrated. The crude product was purified bypreparative HPLC to give 54.0 mg (21% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(1-methylpiperidin-4-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.52 (d, J=7.8 Hz,1H), 7.19 (d, J=8.4 Hz, 1H), 7.05 (s, 1H), 5.73-5.86 (m, 1H), 4.46 (br,1H), 4.20-4.29 (m, 2H), 3.67 (s, 2H), 2.94-3.08 (m, 2H), 2.76-2.78 (m,4H), 2.38-2.44 (m, 5H), 2.10 (br, 2H), 1.64-1.94 (m, 8H), 1.48-1.55 (m,2H). LCMS (ESI, m/z): 606 [M+H]⁺.

Example 166: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(1-methylpiperidin-4-yloxy)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 165 using 3-hydroxy-5-(trifluoromethyl)benzaldehydeas the starting material in Step 3. Purification resulted in 28.9 mg of1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(1-methylpiperidin-4-yloxy)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.15 (s, 1H),7.04 (s, 1H), 6.98 (s, 1H), 5.71-5.79 (m, 1H), 4.44 (br, 1H), 4.17-4.25(m, 2H), 3.60 (s, 2H), 2.91-3.05 (m, 2H), 2.82 (br, 2H), 2.51-2.69 (m,4H), 2.45 (s, 3H), 2.14 (br, 2H), 1.63-2.00 (m, 8H), 1.48-1.51 (m, 2H).LCMS (ESI, m/z): 606 [M+H]⁺.

Example 167: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(2-oxo-2-(pyrrolidin-1-yl)ethoxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Synthesis of 2-chloro-1-(pyrrolidin-1-yl)ethanone

A flask was charged with pyrrolidine (0.500 g, 7.03 mmol, 1.00 equiv),DCM (20 mL), and TEA (2.13 g, 21.1 mmol, 3.00 equiv). 2-Chloroacetylchloride (1.18 g, 10.4 mmol, 1.50 equiv) was added at 0° C. Theresulting solution was stirred for 1 h at rt and concentrated. Theresidue was chromatographed on a silica gel column with EtOAc/petroleumether (1/3) to provide 0.902 g (87% yield) of2-chloro-1-(pyrrolidin-1-yl)ethanone as a yellow solid. LCMS (ESI, m/z):148 [M+H]⁺.

Step 2: Synthesis of tert-butyl1-(2-(2-oxo-2-(pyrrolidin-1-yl)ethoxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl1-(2-hydroxy-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(200 mg, 0.480 mmol, 1.00 equiv),2-chloro-1-(pyrrolidin-1-yl)ethan-1-one (213 mg, 1.44 mmol, 3.00 equiv),potassium carbonate (200 mg, 1.45 mmol, 3.00 equiv), and MeCN (10 mL).The resulting solution was stirred overnight at 80° C. and quenched withH₂O (10 mL). The mixture was extracted with DCM (3×30 mL) and theorganic layers were combined, washed with brine (30 mL), dried overanhydrous sodium sulfate, filtered, and concentrated. The residue waschromatographed on a silica gel column with EtOAc/petroleum ether(75/25) to provide 220 mg (87% yield) of tert-butyl1-(2-(2-oxo-2-(pyrrolidin-1-yl)ethoxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow oil. LCMS (ESI, m/z): 526 [M+H]⁺.

Step 3: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(2-oxo-2-(pyrrolidin-1-yl)ethoxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 167 using tert-butyl1-(2-(2-oxo-2-(pyrrolidin-1-yl)ethoxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas the starting material to yield 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(2-oxo-2-(pyrrolidin-1-yl)ethoxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.55 (d, J=7.8 Hz,1H), 7.23-7.29 (m, 1H), 7.04 (s, 1H), 5.72-5.85 (m, 1H), 4.76 (s, 2H),4.19-4.26 (m, 2H), 3.75 (s, 2H), 3.51-3.60 (m, 4H), 2.93-3.07 (m, 2H),2.77 (br, 2H), 2.00-2.07 (m, 2H), 1.70-1.99 (m, 8H), 1.45-1.52 (m, 2H).LCMS (ESI, m/z): 620 [M+H]⁺.

Example 168: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(2-oxo-2-(pyrrolidin-1-yl)ethoxy)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 167 using 3-hydroxy-5-(trifluoromethyl)benzaldehydeas the starting material. Purification resulted in 61.5 mg of1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(2-oxo-2-(pyrrolidin-1-yl)ethoxy)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.27 (br, 2H),7.03 (br, 1H), 5.70-5.82 (m, 1H), 4.66 (br, 2H), 4.19-4.26 (m, 2H), 3.63(br, 2H), 3.51-3.57 (m, 4H), 2.92-3.06 (m, 2H), 2.68 (br, 2H), 1.98-2.08(m, 2H), 1.68-1.96 (m, 8H), 1.53 (br, 2H). LCMS (ESI, m/z): 620 [M+H]⁺.

Example 169: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(tetrahydro-2H-pyran-4-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 165 using 4-bromotetrahydro-2H-pyran in Step 4.Purification resulted in 37.4 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(tetrahydro-2H-pyran-4-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow semi-solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.49 (d,J=7.8 Hz, 1H), 7.17 (d, J=8.1 Hz, 1H), 7.03 (s, 1H), 5.72-5.83 (m, 1H),4.53-4.61 (m, 1H), 4.17-4.25 (m, 2H), 3.94-4.02 (m, 2H), 3.57-3.65 (m,4H), 2.91-3.05 (m, 2H), 2.73-2.75 (m, 2H), 2.04-2.07 (m, 2H), 1.68-1.86(m, 8H), 1.40-1.55 (m, 2H). LCMS (ESI, m/z): 593 [M+H]⁺.

Example 170: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(tetrahydro-2H-pyran-4-yloxy)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 166 using 4-bromotetrahydro-2H-pyran as thestarting material. Purification resulted in 16.4 mg of1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(tetrahydro-2H-pyran-4-yloxy)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.15 (s, 1H),7.05 (s, 1H), 6.99 (s, 1H), 5.71-5.79 (m, 1H), 4.53 (br, 1H), 4.17-4.26(m, 2H), 3.95-4.02 (m, 2H), 3.51-3.72 (m, 4H), 2.91-3.06 (m, 2H),2.67-2.69 (m, 2H), 2.01-2.06 (m, 2H), 1.48-1.82 (m, 10H). LCMS (ESI,m/z): 593 [M+H]⁺.

Example 171: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(benzo[d]thiazol-2-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 165 using 2-chlorobenzo[d]thiazole in Step 4.Purification resulted in 122.8 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(benzo[d]thiazol-2-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow semi-solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.65-7.81(m, 4H), 7.56 (d, J=8.1 Hz, 1H), 7.44 (t, J=7.5 Hz, 1H), 7.33 (t, J=7.5Hz, 1H), 5.68-5.80 (m, 1H), 4.16-4.38 (m, 2H), 3.75 (s, 2H), 2.89-3.02(m, 2H), 2.72 (br, 2H), 1.69-1.75 (m, 6H), 1.44-1.48 (m, 2H). LCMS (ESI,m/z): 642 [M+H]⁺.

Example 172: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(benzo[d]thiazol-2-yloxy)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 166 using 2-chlorobenzo[d]thiazole as the startingmaterial. Purification resulted in 79.9 mg of1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(benzo[d]thiazol-2-yloxy)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.70-7.76 (m,2H), 7.52-7.59 (m, 3H), 7.40-7.46 (m, 1H), 7.29-7.35 (m, 1H), 5.70-5.82(m, 1H), 4.19-4.28 (m, 2H), 3.72 (br, 2H), 2.92-3.06 (m, 2H), 2.74 (br,2H), 1.60-1.86 (m, 6H), 1.54 (br, 2H). LCMS (ESI, m/z): 642 [M+H]⁺.

Example 173: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(pyridin-3-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Synthesis of tert-butyl1-(2-(pyridin-3-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl1-(2-hydroxy-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(200 mg, 0.480 mmol, 1.00 equiv), 3-bromopyridine (228 mg, 1.44 mmol,3.00 equiv), copper(I) iodide (18.5 mg, 0.100 mmol, 0.20 equiv),L-proline (22.4 mg, 0.193 mmol, 0.40 equiv), cesium carbonate (346 mg,1.06 mmol, 2.20 equiv), and DMF (6 mL) under nitrogen. The resultingsolution was stirred overnight at 110° C. and quenched with H₂O (20 mL).The mixture was extracted with DCM (3×50 mL) and the organic layers werecombined, washed with brine (50 mL), dried over anhydrous sodiumsulfate, filtered, and concentrated. The residue was chromatographed ona silica gel column with DCM/MeOH (98/2) to provide 200 mg (84% yield)of tert-butyl1-(2-(pyridin-3-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate as a yellow oil. LCMS (ESI, m/z): 491 [M+H]⁺.

Step 2: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(pyridin-3-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 165, Steps 5-6. Purification resulted in 60.2 mg of1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(pyridin-3-yloxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 8.02-8.34 (m, 2H),7.74 (d, J=8.1 Hz, 1H), 7.39-7.54 (m, 3H), 7.21 (s, 1H), 6.06-6.19 (m,1H), 4.12 (br, 2H), 3.75 (s, 2H), 2.94-3.18 (m, 2H), 2.75 (t, J=5.7 Hz,2H), 1.63-1.81 (m, 6H), 1.32-1.41 (m, 2H). LCMS (ESI, m/z): 586 [M+H]⁺.

Example 174: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-(pyridin-3-yloxy)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 166. Purification resulted in 104.0 mg of1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-(pyridin-3-yloxy)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 8.42 (s, 2H),7.53-7.61 (m, 3H), 7.10-7.26 (m, 2H), 5.69-5.79 (m, 1H), 4.16-4.38 (m,2H), 3.63 (s, 2H), 2.90-3.04 (m, 2H), 2.67-2.69 (m, 2H), 1.82 (br, 4H),1.49-1.73 (m, 4H). LCMS (ESI, m/z): 586 [M+H]⁺.

Example 175: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)oxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Synthesis of 1,1-dioxidotetrahydro-2H-thiopyran-4-ylmethanesulfonate

A flask was charged with 4-hydroxytetrahydro-2H-thiopyran 1,1-dioxide(3.50 g, 23.3 mmol, 1.00 equiv), methanesulfonyl chloride (5.30 g, 46.5mmol, 2.00 equiv), TEA (7.10 g, 70.2 mmol, 3.00 equiv), and DCM (40 mL).The resulting solution was stirred overnight at rt and quenched with H₂O(40 mL). The resulting mixture was extracted with DCM (3×30 mL) and theorganic layers were combined, washed with brine (200 mL), dried overanhydrous sodium sulfate, filtered, and concentrated. The residue waschromatographed on a silica gel column with EtOAc/petroleum ether (10/1)to provide 4.00 g (75% yield) of 1,1-dioxidotetrahydro-2H-thiopyran-4-ylmethanesulfonate as a white solid.

Step 2: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)oxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 165 using 1,1-dioxidotetrahydro-2H-thiopyran-4-ylmethanesulfonate in Step 4. Purification resulted in 139.7 mg of1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)oxy)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.58 (d, J=7.8 Hz,1H), 7.29 (s, 1H), 7.06 (s, 1H), 5.73-5.85 (m, 1H), 4.78 (br, 1H),4.21-4.30 (m, 2H), 3.70 (br, 2H), 3.38-3.41 (m, 2H), 2.95-3.09 (m, 4H),2.71 (br, 2H), 2.40-2.64 (m, 4H), 1.73-2.04 (m, 6H), 1.54 (br, 2H). LCMS(ESI, m/z): 641 [M+H]⁺.

Example 176: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)oxy)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 166 using 1,1-dioxo-thian-4-yl methanesulfonate asthe starting material. Purification resulted in 77.8 mg of1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)oxy)-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.27 (s, 1H),7.09 (s, 1H), 7.01 (s, 1H), 5.71-5.82 (m, 1H), 4.70 (br, 1H), 4.19-4.28(m, 2H), 3.62 (br, 2H), 3.36-3.46 (m, 2H), 2.95-3.06 (m, 4H), 2.68 (br,2H), 2.29-2.51 (m, 4H), 1.60-2.00 (m, 6H), 1.53 (br, 2H). LCMS (ESI,m/z): 641 [M+H]⁺.

Example 177: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-methyl-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 150 using 3-methyl-4-(trifluoromethyl)benzaldehydeand 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate. Purification resulted in 101.5mg (45% yield) of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-methyl-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.52 (d, J=7.8 Hz,1H), 7.21 (br, 2H), 5.69-5.82 (m, 1H), 4.18-4.26 (m, 2H), 3.58 (s, 2H),2.92-3.05 (m, 2H), 2.66 (br, 2H), 2.46 (s, 3H), 1.66-1.82 (m, 6H),1.48-1.51 (m, 2H). LCMS (ESI, m/z): 507 [M+H]⁺.

Example 178: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-carbamoyl-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Synthesis of methyl 5-formyl-2-(trifluoromethyl)benzoate

A flask was charged with 3-bromo-4-(trifluoromethyl)benzaldehyde (3.00g, 11.9 mmol, 1.00 equiv), MeOH (50 mL),1,1′-bis(diphenylphosphino)ferrocenepalladiumdichloride (870 mg, 1.19mmol, 0.10 equiv), and TEA (3.61 g, 35.7 mmol, 3.00 equiv). Carbonmonoxide (10 atm) was introduced, and the reaction was stirred overnightat 100° C. before quenching with water (50 mL). The resulting solutionwas extracted with EtOAc (2×80 mL) and the organic layers were combined,dried over anhydrous sodium sulfate, filtered, and concentrated. Theresidue was chromatographed on a silica gel column with EtOAc/petroleumether (8/92) to provide 2.2 g (80% yield) of methyl5-formyl-2-(trifluoromethyl)benzoate as an off-white semi-solid. ¹H NMR(400 MHz, Chloroform-d) δ 10.1 (s, 1H), 8.31 (s, 1H), 8.12-8.15 (m, 1H),7.97 (d, J=8.0 Hz, 1H), 4.00 (s, 3H).

Step 2: Synthesis of tert-butyl1-(3-(methoxycarbonyl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with methyl 5-formyl-2-(trifluoromethyl)benzoate(2.20 g, 9.48 mmol, 1.00 equiv), DCE (50 mL), and tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate (2.27 g, 9.44 mmol, 1.00 equiv).The mixture was stirred for 1 h at rt. Sodium triacetoxyborohydride(6.02 g, 28.4 mmol, 3.00 equiv) was added, and the reaction was stirredovernight at rt before quenching with water (80 mL). The resultingsolution was extracted with DCM (2×150 mL) and the organic layers werecombined, dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue was chromatographed on a silica gel columnwith DCM/MeOH (96/4) to provide 3.1 g (72% yield) of tert-butyl1-(3-(methoxycarbonyl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. LCMS (ESI, m/z): 457 [M+H]⁺.

Step 3: Synthesis of5-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-2-(trifluoromethyl)benzoicacid

A flask was charged with tert-butyl1-(3-(methoxycarbonyl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(1.50 g, 3.29 mmol, 1.00 equiv), THF (10 mL), MeOH (10 mL), water (20mL), and lithium hydroxide (1.38 g, 32.9 mmol, 10.0 equiv). Theresulting solution was stirred overnight at rt. The pH of the solutionwas adjusted to 5 with hydrochloric acid (1 M). The resulting solutionwas extracted with DCM (2×80 mL) and the organic layers were combined,dried over anhydrous sodium sulfate, filtered, and concentrated to yield800 mg (55%) of5-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-2-(trifluoromethyl)benzoicacid as a light yellow solid. LCMS (ESI, m/z): 443 [M+H]⁺.

Step 4: Synthesis of tert-butyl1-(3-carbamoyl-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 5-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-2-(trifluoromethyl)benzoic acid (600 mg, 1.36 mmol,1.00 equiv), DMF (15 mL), 1-hydroxybenzotriazole (275 mg, 2.04 mmol,1.50 equiv), and 3-(ethyliminomethyleneamino)-N,N-dimethylpropan-1-amine(392 mg, 2.04 mmol, 1.50 equiv). The resulting solution was stirred for1 h at rt. A saturated solution of NH₃ in dioxane (2 mL) was added. Thereaction mixture was stirred overnight at rt before quenching with water(30 mL). The resulting solution was extracted with EtOAc (2×50 mL) andthe organic layers were combined, dried over anhydrous sodium sulfate,filtered and concentrated. The residue was chromatographed on a silicagel column with EtOAc/petroleum ether (4/1) to 120 mg (20% yield) oftert-butyl1-(3-carbamoyl-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow solid. LCMS (ESI, m/z): 442 [M+H]⁺.

Step 5. Synthesis of5-(1,8-diazaspiro[4.5]decan-1-ylmethyl)-2-(trifluoromethyl)benzamide

A flask was charged with tert-butyl1-(3-carbamoyl-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(120 mg, 0.270 mmol, 1.00 equiv), dioxane (10 mL), and hydrochloric acid(2 mL). The resulting solution was stirred overnight at rt andconcentrated to provide 90 mg (crude) of5-(1,8-diazaspiro[4.5]decan-1-ylmethyl)-2-(trifluoromethyl)benzamide asa yellow oil. LCMS (ESI, m/z): 342 [M+H]⁺.

Step 6: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-carbamoyl-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with triphosgene (20.0 mg, 0.070 mmol, 0.50 equiv),and DCM (10 mL). HFIP (44.0 mg, 0.260 mmol, 2.00 equiv) and DIPEA (51.0mg, 0.390 mmol, 3.00 equiv) were each added dropwise at 0° C. Themixture was stirred for 1 h at rt.5-(1,8-Diazaspiro[4.5]decan-1-ylmethyl)-2-(trifluoromethyl)benzamide(45.0 mg, 0.130 mmol, 1.00 equiv) was added, and the reaction wasstirred overnight at rt before quenching with water (30 mL). Theresulting solution was extracted with DCM (2×50 mL) and the organiclayers were combined, dried over anhydrous sodium sulfate, filtered, andconcentrated. The crude product was purified by preparative HPLC toyield 11.6 mg (16%) of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-carbamoyl-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.61-7.66 (m, 2H),7.48-7.51 (m, 1H), 5.64-5.81 (m, 3H), 4.20-4.28 (m, 2H), 3.69 (br, 2H),2.85-3.07 (m, 2H), 2.69 (br, 2H), 1.40-1.85 (m, 8H). LCMS (ESI, m/z):536 [M+H]⁺.

Example 179:5-((8-((1,1,1,3,3,3-Hexafluoropropan-2-yloxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-2-(trifluoromethyl)benzoicacid

The title compound was synthesized according to the representativeprocedure of Example 178, Steps 1-3 and 5. Purification resulted in 96.4mg of5-((8-((1,1,1,3,3,3-hexafluoropropan-2-yloxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-2-(trifluoromethyl)benzoicacid as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 13.6 (br, 1H), 7.74(d, J=8.0 Hz, 1H), 7.67 (s, 1H), 7.59 (d, J=8.4 Hz, 1H), 6.51-6.59 (m,1H), 3.98-4.06 (m, 2H), 3.69 (s, 2H), 2.99-3.19 (m, 2H), 2.57-2.60 (m,2H), 1.75-1.83 (m, 2H), 1.58-1.73 (m, 4H), 1.44-1.47 (m, 2H). LCMS (ESI,m/z): 537 [M+H]⁺.

Example 180: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-methyl-3-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 150 using 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate and4-methyl-3-(trifluoromethyl)benzaldehyde. Purification resulted in 118.1mg of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-methyl-3-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.53 (s, 1H), 7.35(d, J=7.8 Hz, 1H), 7.20 (d, J=7.8 Hz, 1H), 5.70-5.82 (m, 1H), 4.17-4.26(m, 2H), 3.53-3.63 (m, 2H), 2.90-3.06 (m, 2H), 2.64 (t, J=6.4 Hz, 2H),2.45 (s, 3H), 1.60-1.87 (m, 6H), 1.42-1.50 (m, 2H). LCMS (ESI, m/z): 507[M+H]⁺.

Example 181: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-carbamoyl-3-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 178 using 4-bromo-3-(trifluoromethyl)benzaldehydein Step 1. Purification resulted in 57.6 mg of1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-carbamoyl-3-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.67 (s, 1H), 7.56(br, 2H), 5.69-5.96 (m, 3H), 4.19-4.27 (m, 2H), 3.68 (br, 2H), 2.92-3.06(m, 2H), 2.66 (br, 2H), 1.85 (br, 4H), 1.66-1.74 (m, 2H), 1.55 (br, 2H).LCMS (ESI, m/z): 536 [M+H]⁺.

Example 182:4-((8-((1,1,1,3,3,3-Hexafluoropropan-2-yloxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-2-(trifluoromethyl)benzoicacid

The title compound was synthesized according to the representativeprocedure of Example 178, Steps 1-3, and 5 using4-bromo-3-(trifluoromethyl)benzaldehyde as the starting material.Purification resulted in 59.6 mg of4-((8-((1,1,1,3,3,3-hexafluoropropan-2-yloxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-2-(trifluoromethyl)benzoicacid as a white solid. ¹H NMR (300 MHz, DMSO-d₆) δ 7.60-7.99 (m, 3H),6.47-6.58 (m, 1H), 3.97-4.06 (m, 2H), 3.68 (s, 2H), 2.97-3.16 (m, 2H),2.56-2.60 (m, 2H), 1.56-1.81 (m, 6H), 1.42-1.48 (m, 2H). LCMS (ESI,m/z): 537 [M+H]⁺.

Example 183: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(3-chloro-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 150 using 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate and3-chloro-4-(trifluoromethyl)benzaldehyde. Purification resulted in 100.5mg of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-chloro-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.60 (d, J=8.1 Hz,1H), 7.48 (s, 1H), 7.27-7.30 (m, 1H), 5.69-5.82 (m, 1H), 4.18-4.26 (m,2H), 3.57-3.66 (m, 2H), 2.91-3.05 (m, 2H), 2.64-2.68 (m, 2H), 1.84 (br,4H), 1.61-1.77 (m, 2H), 1.48-1.52 (m, 2H). LCMS (ESI, m/z): 527 [M+H]⁺.

Example 184: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(4-chloro-3-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 150 using 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate and4-chloro-3-(trifluoromethyl)benzaldehyde. Purification resulted in 64.1mg of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(4-chloro-3-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (300 MHz, Chloroform-d) δ 7.62 (s, 1H),7.39-7.42 (m, 2H), 5.69-5.82 (m, 1H), 4.17-4.26 (m, 2H), 3.55-3.65 (m,2H), 2.90-3.06 (m, 2H), 2.60 (t, J=6.4 Hz, 2H), 1.75-1.88 (m, 4H),1.62-1.72 (m, 2H), 1.47-1.53 (m, 2H). LCMS (ESI, m/z): 527 [M+H]⁺.

Example 185: 1,1,1,3,3,3Hhexafluoropropan-2-yl2-(2-chloro-3-morpholinobenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Synthesis of 2-chloro-3-morpholinobenzaldehyde

A flask was charged with 3-bromo-2-chlorobenzaldehyde (218 mg, 0.990mmol, 1.00 equiv), toluene (8 mL), morpholine (104 mg, 1.19 mmol, 1.20equiv), cesium carbonate (652 mg, 2.00 mmol, 2.00 equiv),tris(dibenzylideneacetone)dipalladium (52.0 mg, 0.050 mmol, 0.050 equiv)and 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (93.0 mg, 0.150 mmol,0.150 equiv) under nitrogen. The reaction mixture was stirred overnightat 90° C. and quenched with water (40 mL). The resulting solution wasextracted with DCM (3×80 mL) and the organic layers were combined,washed with water (3×20 mL), dried over anhydrous sodium sulfate,filtered, and concentrated. The residue was chromatographed on a silicagel column with EtOAc/petroleum ether (1/3) to afford 150 mg (67% yield)of 2-chloro-3-morpholinobenzaldehyde as a yellow solid. LCMS (ESI, m/z):226 [M+H]⁺.

Step 2: Synthesis of 1-(4-methoxybenzyl)piperidine-4-carbonitrile

A flask was charged with piperidine-4-carbonitrile (5.00 g, 45.4 mmol,1.00 equiv), DCE (50 mL) and 4-methoxybenzaldehyde (6.18 g, 45.4 mmol,1.00 equiv). After 30 min, sodium triacetoxyborohydride (19.3 g, 91.1mmol, 2.00 equiv) was added, and the reaction was stirred overnight atrt before quenching with water (40 mL). The mixture was extracted withDCM (3×80 mL) and the organic layers were combined, washed with water(3×20 mL), dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue was chromatographed on a silica gel columnwith DCM/MeOH (20/1) to provide 7.55 g (72% yield) of1-(4-methoxybenzyl)piperidine-4-carbonitrile as a light yellow oil. LCMS(ESI, m/z): 231 [M+H]⁺.

Step 3: Synthesis of1-(4-methoxybenzyl)-4-(2-methylallyl)piperidine-4-carbonitrile

A 3-necked round-bottom flask was charged with1-(4-methoxybenzyl)piperidine-4-carbonitrile (1.00 g, 4.34 mmol, 1.00equiv) and THF (20 mL) under nitrogen. Lithium diisopropylamide (2.80mL, 1.30 equiv, 2.0 M in THF) was added dropwise at −78° C. The solutionwas stirred for 30 min at −78° C., then 3-bromo-2-methylprop-1-ene (1.16g, 8.59 mmol, 2.00 equiv) was added dropwise at −78° C. The resultingsolution was stirred for 1 h at −78° C. and quenched with brine (20 mL).The resulting solution was extracted with EtOAc (2×80 mL) and theorganic layers were combined, washed with brine (80 mL), dried overanhydrous sodium sulfate, filtered, and concentrated. The residue waschromatographed on a silica gel column with EtOAc/petroleum ether (1/2)to provide 790 mg (64% yield) of1-(4-methoxybenzyl)-4-(2-methylallyl)piperidine-4-carbonitrile as alight yellow oil. LCMS (ESI, m/z): 285 [M+H]⁺.

Step 4: Synthesis of(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine

A flask was charged with1-(4-methoxybenzyl)-4-(2-methylallyl)piperidine-4-carbonitrile (500 mg,1.76 mmol, 1.00 equiv) and THF (10 mL). LAH (753 mg, 19.8 mmol, 4.00equiv) was added in portions at 0° C. The resulting solution was stirredovernight at rt. The solution was cooled to 0° C. and water (753 mg) wasadded, followed by 15% aq. NaOH (2.26 g), followed by water (753 mg).The solids were filtered and washed with THF (2×20 mL). The filtrate wasconcentrated to provide 540 mg (crude) of(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine as acolorless oil. LCMS (ESI, m/z): 289 [M+H]⁺.

Step 5: Synthesis ofN-(4-methoxybenzyl)-1-(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine

A flask was charged with 4-methoxybenzaldehyde (1.06 g, 7.79 mmol, 1.00equiv), MeOH (20 mL) and(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine (500mg, 1.73 mmol, 1.00 equiv). Sodium triacetoxyborohydride (178 mg, 4.71mmol, 2.70 equiv) was added in portions at 0° C. The resulting solutionwas stirred for 30 min at 0° C., quenched with hydrogen chloride (5 mL,1 moL/L), and diluted with saturated sodium carbonate (30 mL). Theresulting solution was extracted with DCM (3×80 mL) and the organiclayers were combined, washed with water (3×20 mL), dried over anhydroussodium sulfate, filtered, and concentrated. The residue waschromatographed on a silica gel column with DCM/MeOH (10/1) to provide600 mg (19%) ofN-(4-methoxybenzyl)-1-(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamineas a light yellow oil. LCMS (ESI, m/z): 409 [M+H]⁺.

Step 6: Synthesis of2,8-bis(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane

A 3-necked flask purged and maintained with an inert atmosphere ofnitrogen, was charged withN-(4-methoxybenzyl)-1-(1-(4-methoxybenzyl)-4-(2-methylallyl)piperidin-4-yl)methanamine(4.56 g, 11.2 mmol, 1.00 equiv), dioxane (50 mL), [Pt(II)Cl₂(C₂H₄)]₂(590 mg, 1.12 mmol, 0.100 equiv) anddi-tert-butyl(2′,4′,6′-triisopropyl-[1,1′-biphenyl]-2-yl)phosphane (1.14g, 2.69 mmol, 0.240 equiv). The resulting solution was stirred overnightat 110° C. and quenched with water (40 mL). The mixture was extractedwith DCM (3×80 mL) and the organic layers were combined, washed withwater (3×20 mL), dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue was chromatographed on a silica gel columnwith EtOAc/petroleum ether (4/1) to provide 2.71 g (59% yield) of2,8-bis(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane as abrown oil. LCMS (ESI, m/z): 409 [M+H]⁺.

Step 7: Synthesis of2-(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane

A flask was charged with2,8-bis(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane (1.48 g,3.62 mmol, 1.00 equiv) and DCM (20 mL). 1-Chloroethyl chloroformate (721mg, 5.04 mmol, 1.40 equiv) was added dropwise at 0° C. The resultingsolution was stirred for 30 min at 0° C. and concentrated. MeOH (20 mL)was added, and the resulting solution was stirred for 1 h at 65° C. andconcentrated to provide 1.08 g (crude) of2-(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane as anoff-white solid. LCMS (ESI, m/z): 289 [M+H]⁺.

Step 8: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with triphosgene (206 mg, 0.690 mmol, 0.500 equiv),THF (10 mL) and HFIP (350 mg, 2.08 mmol, 1.50 equiv). DIPEA (573 mg,4.43 mmol, 3.00 equiv) was added dropwise at 0° C. The resultingsolution was stirred for 1 h at rt, after which2-(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane (400 mg, 1.39mmol, 1.00 equiv) and DMAP (34.0 mg, 0.280 mmol, 0.200 equiv) wereadded. The reaction mixture was stirred overnight at 60° C. and quenchedwith water (40 mL). The resulting solution was extracted with DCM (3×80mL) and the organic layers were combined, washed with water (3×20 mL),dried over anhydrous sodium sulfate, filtered, and concentrated. Theresidue was chromatographed on a silica gel column with EtOAc/petroleumether (1/2) to provide 1.73 g (crude) of1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow oil. LCMS (ESI, m/z): 483 [M+H]⁺.

Step 9: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl2-(4-methoxybenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate(1.20 g, 2.49 mmol, 1.00 equiv), MeOH (20 mL), ammonium formate (784 mg,12.4 mmol, 5.00 equiv) and 10% palladium on carbon (1.00 g). Theresulting solution was stirred for 30 min at 80° C. The solids werefiltered and washed with MeOH (2×20 mL). The filtrate was concentratedto provide 1.0 g (crude) of 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate as a light yellowoil. LCMS (ESI, m/z): 363 [M+H]⁺.

Step 10: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl2-(2-chloro-3-morpholinobenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 2-chloro-3-morpholinobenzaldehyde (62.0 mg,0.270 mmol, 1.00 equiv), DCE (5 mL), 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate (100 mg, 0.280mmol, 1.00 equiv) and sodium triacetoxyborohydride (175 mg, 0.830 mmol,3.00 equiv). The reaction mixture was stirred overnight at rt andquenched with water (40 mL). The resulting solution was extracted withDCM (3×80 mL) and the organic layers were combined, washed with water(3×20 mL), dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue was purified by preparative HPLC to yield112.8 mg (72%) of 1,1,1,3,3,3-hexafluoropropan-2-yl2-(2-chloro-3-morpholinobenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylateas a colorless oil. ¹H NMR (400 MHz, Chloroform-d) δ 7.21-7.30 (m, 2H),6.91-6.99 (m, 1H), 5.73-5.79 (m, 1H), 3.91 (t, J=4.6 Hz, 4H), 3.67 (s,2H), 3.42-3.50 (m, 4H), 3.05-3.10 (m, 4H), 2.58 (s, 2H), 1.60-1.67 (m,6H), 1.65 (s, 6H). LCMS (ESI, m/z): 572 [M+H]⁺.

Example 186: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(3-chloro-5-morpholinobenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 185 using 3-bromo-5-chlorobenzaldehyde as thestarting material in Step 1 and 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate as the startingmaterial in Step 10. Purification resulted in 84.2 mg (54% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl2-(3-chloro-5-morpholinobenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 6.85 (s, 1H),6.74-6.78 (m, 2H), 5.70-5.78 (m, 1H), 3.86 (t, J=4.8 Hz, 4H), 3.39-3.51(m, 6H), 3.15 (t, J=4.9 Hz, 4H), 2.49 (s, 2H), 1.55-1.64 (m, 6H), 1.12(s, 6H). LCMS (ESI, m/z): 572 [M+H]⁺.

Example 187: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(5-chloro-2-morpholinobenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 185 using 2-bromo-5-chlorobenzaldehyde as thestarting material in Step 1 and 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate as the startingmaterial in Step 10. Purification resulted in 88.7 mg of1,1,1,3,3,3-hexafluoropropan-2-yl2-(5-chloro-2-morpholinobenzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylateas a white solid. ¹H NMR (400 MHz, Chloroform-d) δ 7.53 (d, J=2.4 Hz,1H), 7.18-7.21 (m, 1H), 7.01 (d, J=8.4 Hz, 1H), 5.73-5.79 (m, 1H),3.84-3.86 (m, 4H), 3.59 (s, 2H), 3.40-3.51 (m, 4H), 2.85-3.00 (m, 4H),2.51 (s, 2H), 1.58-1.67 (m, 6H), 1.16 (s, 6H). LCMS (ESI, m/z): 572[M+H]⁺.

Example 188: 1,1,1,3,3,3-Hexafluoropropan-2-yl3,3-dimethyl-2-(3-morpholino-5-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 185 using 3-bromo-5-(trifluoromethyl)benzaldehydeas the starting material in Step 1 and 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate as the startingmaterial in Step 10. Purification resulted in 92.8 mg of1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2-(3-morpholino-5-(trifluoromethyl)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylateas a light yellow oil. ¹H NMR (300 MHz, Chloroform-d) δ 7.12 (s, 1H),7.07 (s, 1H), 6.98 (s, 1H), 5.70-5.78 (m, 1H), 3.88 (t, J=4.8 Hz, 4H),3.36-3.54 (m, 6H), 3.20 (t, J=4.8 Hz, 4H), 2.49 (s, 2H), 1.55-1.66 (m,6H), 1.14 (s, 6H). LCMS (ESI, m/z): 606 [M+H]⁺.

Example 189: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(3-chloro-2-(4-methylpiperazin-1-yl)benzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 185 using 2-bromo-3-chlorobenzaldehyde and1-methylpiperazine in Step 1 and 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate in Step 10.Purification resulted in 86.0 mg of 1,1,1,3,3,3-hexafluoropropan-2-yl2-(3-chloro-2-(4-methylpiperazin-1-yl)benzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylateas a yellow oil. ¹H NMR (400 MHz, Chloroform-d) 6 7.45 (d, J=7.6 Hz,1H), 7.21 (d, J=6.8 Hz, 1H), 7.09 (t, J=7.6 Hz, 1H), 5.72-5.78 (m, 1H),3.61-3.67 (m, 4H), 3.40-3.51 (m, 4H), 2.76-2.90 (m, 5H), 2.30-2.55 (m,6H), 1.58-1.66 (m, 6H), 1.16 (s, 6H). LCMS (ESI, m/z): 585 [M+H]⁺.

Example 190: 1,1,1,3,3,3-Hexafluoropropan-2-yl3,3-dimethyl-2-(2-morpholino-3-(trifluoromethoxy)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Synthesis of 2-morpholino-3-(trifluoromethoxy)benzaldehyde

A flask was charged with 2-fluoro-3-(trifluoromethoxy)benzaldehyde (208mg, 1.00 mmol, 1.00 equiv), DMSO (5 mL), morpholine (174 mg, 2.00 mmol,2.00 equiv) and potassium carbonate (414 mg, 3.00 mmol, 3.00 equiv)under nitrogen. The reaction mixture was stirred overnight at 80° C. andquenched with water (40 mL). The resulting solution was extracted withDCM (3×80 mL) and the organic layers were combined, washed with water(3×20 mL), dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue was chromatographed on a silica gel columnwith EtOAc/petroleum ether (1/5) to provide 50 mg (18% yield) of2-morpholino-3-(trifluoromethoxy)benzaldehyde as a light yellow oil.

Step 2: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2-(2-morpholino-3-(trifluoromethoxy)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate (66.0 mg, 0.180mmol, 1.00 equiv), and DCE (3 mL),2-morpholino-3-(trifluoromethoxy)benzaldehyde (50.0 mg, 0.180 mmol, 1.00equiv). The mixture was stirred for 1 h at rt, followed by addition ofsodium triacetoxyborohydride (115 mg, 0.540 mmol, 3.00 equiv). Thereaction mixture was stirred overnight at rt before quenching with water(40 mL). The resulting solution was extracted with DCM (3×80 mL) and theorganic layers were combined, washed with water (3×20 mL), dried overanhydrous sodium sulfate, filtered, and concentrated. The residue waspurified by preparative HPLC to give 8.1 mg (7% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2-(2-morpholino-3-(trifluoromethoxy)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate as a colorless oil. ¹H NMR (300 MHz, Chloroform-d)δ 7.44-7.47 (m, 1H), 7.09-7.17 (m, 2H), 5.69-5.77 (m, 1H), 3.67-3.90 (m,6H), 3.20-3.50 (m, 6H), 2.60-3.00 (m, 2H), 2.48 (s, 2H), 1.56-1.65 (m,6H), 1.14 (s, 6H). LCMS (ESI, m/z): 622 [M+H]⁺.

Example 191: 1,1,1,3,3,3-Hexafluoropropan-2-yl2-(2-fluoro-3-(morpholinomethyl)benzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Synthesis of 2-fluoro-3-(morpholinomethyl)benzaldehyde

A flask was charged with 3-bromo-2-fluorobenzaldehyde (202 mg, 1.00mmol, 1.00 equiv), THF (12 mL), water (3 mL), potassium(morpholin-4-yl)methyltrifluoroborate (248 mg, 1.20 mmol, 1.20 equiv),palladium acetate (7.00 mg, 0.030 mmol, 0.03 equiv), XPhos (29.0 mg,0.0600 mmol, 0.06 equiv), and cesium carbonate (987 mg, 3.03 mmol, 3.00equiv) under nitrogen. The reaction mixture was stirred overnight at 80°C. and quenched with water (40 mL). The resulting solution was extractedwith DCM (3×80 mL) and the organic layers were combined, washed withwater (3×20 mL), dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue was chromatographed on a silica gel columnwith EtOAc/petroleum ether (1/3) to provide 150 mg (68% yield) of2-fluoro-3-(morpholinomethyl)benzaldehyde as a light yellow oil.

Step 2: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl2-(2-fluoro-3-(morpholinomethyl)benzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 2-fluoro-3-(morpholinomethyl)benzaldehyde (49.0mg, 0.220 mmol, 1.00 equiv), DCE (10 mL) and1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate (80.0 mg, 0.220mmol, 1.00 equiv). The mixture was stirred for 1 h at rt, followed byaddition of sodium triacetoxyborohydride (141 mg, 0.670 mmol, 3.00equiv). The reaction mixture was stirred overnight at rt beforequenching with water (40 mL). The resulting solution was extracted withDCM (3×80 mL) and the organic layers were combined, washed with water(3×20 mL), dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue was purified by preparative HPLC to give 56.3mg (45% yield) of 1,1,1,3,3,3-hexafluoropropan-2-yl2-(2-fluoro-3-(morpholinomethyl)benzyl)-3,3-dimethyl-2,8-diazaspiro[4.5]decane-8-carboxylate as a light brown oil. ¹H NMR (300 MHz,Chloroform-d) δ 7.26-7.32 (m, 1H), 7.21-7.25 (m, 1H), 7.04-7.09 (m, 1H),5.68-5.77 (m, 1H), 3.70-3.73 (m, 4H), 3.55-3.65 (m, 4H), 3.35-3.50 (m,4H), 2.49-2.54 (m, 6H), 1.50-1.70 (m, 6H), 1.05-1.20 (s, 6H). LCMS (ESI,m/z): 570 [M+H]⁺.

Example 192: 1,1,1,3,3,3-Hexafluoropropan-2-yl3,3-dimethyl-2-(5-(morpholinomethyl)-2-(trifluoromethoxy)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Synthesis of 4-(3-bromo-4-(trifluoromethoxy)benzyl)morpholine

A flask was charged with 3-bromo-4-(trifluoromethoxy)benzaldehyde (804mg, 2.99 mmol, 1.00 equiv), DCE (10 mL) and morpholine (261 mg, 3.00mmol, 1.10 equiv). The resulting solution was stirred for 1 h at rt,followed by the addition of sodium triacetoxyborohydride (1.91 g, 9.01mmol, 3.00 equiv). The mixture was stirred overnight at rt and quenchedwith water (40 mL). The resulting solution was extracted with DCM (3×40mL) and the organic layers were combined, washed with water (3×20 mL),dried over anhydrous sodium sulfate, filtered, and concentrated. Theresidue was chromatographed on a silica gel column with EtOAc/petroleumether (1/3) to provide 920 mg (91% yield) of4-(3-bromo-4-(trifluoromethoxy)benzyl)morpholine as a colorless oil.LCMS (ESI, m/z): 340 [M+H]⁺.

Step 2: Synthesis of5-(morpholinomethyl)-2-(trifluoromethoxy)benzaldehyde

A 3-necked round-bottom flask was charged with4-(3-bromo-4-(trifluoromethoxy)benzyl)morpholine (200 mg, 0.590 mmol,1.00 equiv) and THF (5 mL) under nitrogen. Then n-butyllithium (0.501mL, 2.0 M in hexane, 1.50 equiv) was added dropwise at −78° C. Theresulting solution was stirred for 30 min at −78° C., and DMF (86.0 mg,1.18 mmol, 2.00 equiv) was added. The resulting solution was stirred for1 h at −78° C. and quenched with saturated ammonium chloride (20 mL).The mixture was extracted with DCM (3×50 mL) and the organic layers werecombined, washed with water (3×20 mL), dried over anhydrous sodiumsulfate, filtered, and concentrated. The residue was chromatographed ona silica gel column with EtOAc/petroleum ether (1/1) to provide 80.0 mg(47% yield) of 5-(morpholinomethyl)-2-(trifluoromethoxy)benzaldehyde asa light yellow oil. LCMS (ESI, m/z): 290 [M+H]⁺.

Step 3: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2-(5-(morpholinomethyl)-2-(trifluoromethoxy)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate

The title compound was synthesized according to the representativeprocedure of Example 185, Steps 2-10, using5-(morpholinomethyl)-2-(trifluoromethoxy)benzaldehyde in Step 10 toafford 18.4 mg (10% yield) of 1,1,1,3,3,3-hexafluoropropan-2-yl3,3-dimethyl-2-(5-(morpholinomethyl)-2-(trifluoromethoxy)benzyl)-2,8-diazaspiro[4.5]decane-8-carboxylate as a light yellow oil. ¹H NMR (300 MHz,Chloroform-d) δ 7.47 (s, 1H), 7.12-7.26 (m, 2H), 5.66-5.78 (m, 1H),3.71-3.80 (m, 4H), 3.36-3.57 (m, 8H), 2.30-2.60 (m, 6H), 1.40-1.80 (m,6H), 1.00-1.25 (m, 6H). LCMS (ESI, m/z): 636 [M+H]⁺.

Example 193: 1,1,1,3,3,3-Hexafluoropropan-2-yl1-(2-(3-(methylsulfonyl)pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

Step 1: Synthesis of sodium(2-fluoro-4-(trifluoromethyl)phenyl)(hydroxy)methanesulfonate

A flask was charged with 2-fluoro-4-(trifluoromethyl)benzaldehyde (2.00g, 10.4 mmol, 1.00 equiv), EtOH (30 mL), saturated sodium bisulfiteaqueous solution (2.5 mL), and water. The resulting solution was stirredfor 48 h at rt and cooled to 0° C. and tert-butyl methyl ether wasadded. The solids were collected by filtration to provide 2.45 g (79%yield) of sodium(2-fluoro-4-(trifluoromethyl)phenyl)(hydroxy)methanesulfonate as a whitesolid. LCMS (ESI, m/z): 297 [M+H]⁺.

Step 2: Synthesis of2-(3-(methylsulfonyl)pyrrolidin-1-yl)-4-(trifluoromethyl)benzaldehyde

A flask was charged with sodium(2-fluoro-4-(trifluoromethyl)phenyl)(hydroxy)methanesulfonate (500 mg,1.69 mmol, 1.00 equiv), 3-methanesulfonylpyrrolidine (378 mg, 2.53 mmol,1.50 equiv), potassium carbonate (932 mg, 6.74 mmol, 4.00 equiv), andDMSO (5 mL) under nitrogen. The reaction mixture was stirred overnightat 100° C. before quenching with water (50 mL). The resulting solutionwas extracted with EtOAc (3×50 mL) and the organic layers were combined,washed with brine (50 mL), dried over anhydrous sodium sulfate, filteredand concentrated. The residue was chromatographed on a silica gel columnto provide 190 mg (35% yield) of2-(3-methanesulfonylpyrrolidin-1-yl)-4-(trifluoromethyl)benzaldehyde.LCMS (ESI, m/z): 322 [M+H]⁺.

Step 3: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(3-(methylsulfonyl)pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with2-(3-methanesulfonylpyrrolidin-1-yl)-4-(trifluoromethyl)benzaldehyde(90.0 mg, 0.280 mmol, 1.00 equiv), 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate (140 mg, 0.420 mmol, 1.50equiv), and DCE (3 mL). The resulting solution was stirred for 1 h at rtprior to addition of sodium triacetoxyborohydride (238 mg, 1.12 mmol,4.00 equiv). The reaction mixture was stirred overnight at rt andquenched with water (20 mL). The resulting mixture was extracted withDCM (3×20 mL) and the organic layers were combined, washed with brine(20 mL), dried over anhydrous sodium sulfate, filtered and concentrated.The residue was purified by preparative HPLC to yield 69.4 mg (39%yield) of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(3-(methylsulfonyl)pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate.¹H NMR (300 MHz, Chloroform-d) δ 7.67-7.70 (m, 1H), 7.28-7.31 (m, 1H),7.24 (br, 1H), 5.72-5.80 (m, 1H), 4.17-4.26 (m, 2H), 3.57-3.77 (m, 4H),3.44-3.50 (m, 1H), 3.22-3.32 (m, 2H), 2.94-3.06 (m, 5H), 2.63-2.65 (m,2H), 2.40-2.49 (m, 2H), 1.65-1.88 (m, 5H), 1.53-1.56 (m, 3H). LCMS (ESI,m/z): 640 [M+H]⁺.

Example 194:1-(3-Chloro-5-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)benzyl)piperidine-4-carboxylic acid

Step 1: Synthesis of potassium((4-(tert-butoxycarbonyl)piperidin-1-yl)methyl)trifluoroborate

A flask was charged with tert-butyl piperidine-4-carboxylate (7.00 g,37.8 mmol, 1.00 equiv), potassium (bromomethyl)trifluoroboranate (7.60g, 37.8 mmol, 1.00 equiv), and THF (70 mL). The reaction mixture wasstirred overnight at 80° C. and concentrated. Acetone (70 mL) andpotassium carbonate (5.22 g, 37.8 mmol, 1.00 equiv) were added. Theresulting solution was stirred for 1.5 h at rt before the solids werefiltered. The filtrate was concentrated and then triturated withacetone/hexane to provide 6.50 g (56% yield) of potassium((4-(tert-butoxycarbonyl)piperidin-1-yl)methyl)trifluoroborate as ayellow semi-solid. LCMS (ESI, m/z): 266 [M−K]⁻.

Step 2: Synthesis of tert-butyl1-(3-chloro-5-formylbenzyl)piperidine-4-carboxylate

A flask was placed 3-bromo-5-chlorobenzaldehyde (431 mg, 1.96 mmol, 1.20equiv), potassium((4-(tert-butoxycarbonyl)piperidin-1-yl)methyl)trifluoroborate (500 mg,1.64 mmol, 1.00 equiv), cesium carbonate (1.60 g, 4.91 mmol, 3.00equiv), palladium acetate (11.1 mg, 0.0493 mmol, 0.03 equiv), XPhos(46.9 mg, 0.0983 mmol, 0.06 equiv), THF (8 mL), and water (2 mL) undernitrogen. The reaction mixture was stirred overnight at 80° C. andquenched with water (10 mL). The resulting solution was extracted withDCM (3×20 mL) and the organic layers were combined, washed with brine(2×5 mL), dried over anhydrous sodium sulfate, filtered andconcentrated. The residue was chromatographed on a silica gel column toprovide 260 mg (47% yield) of tert-butyl1-(3-chloro-5-formylbenzyl)piperidine-4-carboxylate. LCMS (ESI, m/z):338 [M+H]⁺.

Step 3: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-((4-(tert-butoxycarbonyl)piperidin-1-yl)methyl)-5-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with tert-butyl1-(3-chloro-5-formylbenzyl)piperidine-4-carboxylate (260 mg, 0.769 mmol,1.50 equiv), 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate (173 mg, 0.518 mmol, 1.00equiv), TEA (157 mg, 1.55 mmol, 3.00 equiv), and DCE (5 mL). Thereaction mixture was stirred for 30 min at rt prior to addition ofsodium triacetoxyborohydride (329 mg, 1.55 mmol, 3.00 equiv). Theresulting solution was stirred overnight at rt and quenched with water(5 mL). The mixture was extracted with DCM (3×10 mL) and the organiclayers were combined, washed with brine (2×5 mL), dried over anhydroussodium sulfate, filtered and concentrated. The residue waschromatographed on a silica gel column to provide 168 mg (49% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-((4-(tert-butoxycarbonyl)piperidin-1-yl)methyl)-5-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate.LCMS (ESI, m/z): 656 [M+H]⁺.

Step 4: Synthesis of1-(3-chloro-5-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)benzyl)piperidine-4-carboxylic acid

A flask was charged with 1,1,1,3,3,3-hexafluoropropan-2-yl1-(3-((4-(tert-butoxycarbonyl)piperidin-1-yl)methyl)-5-chlorobenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(168 mg, 0.256 mmol, 1.00 equiv), DCM (4 mL), and TFA (1 mL). Theresulting solution was stirred overnight at rt and concentrated. Theresidue was diluted with sodium bicarbonate (20% aqueous, 5 mL), and theresulting solution was extracted with DCM (3×10 mL). Organic layers werecombined, washed with brine (2×5 mL), dried over anhydrous sodiumsulfate, filtered and concentrated. The residue was purified bypreparative HPLC to afford 57.8 mg (38% yield) of1-(3-chloro-5-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)benzyl)piperidine-4-carboxylicacid as a white semi-solid. ¹H NMR (300 MHz, Methanol-d₄) δ 7.36-7.39(m, 3H), 6.10-6.14 (m, 1H), 4.16-4.20 (m, 2H), 3.98 (br, 2H), 3.66 (br,2H), 3.04-3.32 (m, 4H), 2.65-2.74 (m, 4H), 2.32 (br, 1H), 1.73-2.03 (m,10H), 1.53-1.58 (m, 2H). LCMS (ESI, m/z): 600 [M+H]⁺.

Example 195:4-(3-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-methylmorpholine-2-carboxylicacid

Step 1: Synthesis of 4-(tert-butyl) 2-ethyl2-methylmorpholine-2,4-dicarboxylate

A flask was charged with 4-tert-butyl 2-ethylmorpholine-2,4-dicarboxylate (8.00 g, 31.0 mmol, 1.00 equiv) and THF (80mL) under nitrogen. Lithium bis(trimethylsilyl)amide (93.0 mL, 93.0mmol, 3.00 equiv, 1M in THF) was added dropwise over 1 h at −78° C. Themixture was stirred for 30 min at −78° C. and iodomethane (13.2 g, 93.0mmol, 3.00 equiv) was added dropwise over 20 min. The reaction mixturewas stirred overnight at rt and quenched with saturated NH₄Cl solution(50 ml). The resulting solution was extracted with EtOAc (2×80 mL) andthe organic layers were combined, washed with brine (2×50 mL), driedover anhydrous sodium sulfate, filtered and concentrated. The residuewas chromatographed on a silica gel column to provide 5.00 g (59% yield)of 4-(tert-butyl) 2-ethyl 2-methylmorpholine-2,4-dicarboxylate. LCMS(ESI, m/z): 274 [M+H]⁺.

Step 2: Synthesis of ethyl 2-methylmorpholine-2-carboxylate

A flask was charged with 4-tert-butyl 2-ethyl2-methylmorpholine-2,4-dicarboxylate (3.00 g, 11.0 mmol, 1.00 equiv),1,4-dioxane (15 mL), and concentrated hydrochloric acid (4 mL). Theresulting solution was stirred overnight at rt and concentrated toprovide 2.50 g (crude) of ethyl 2-methylmorpholine-2-carboxylate. LCMS(ESI, m/z): 174 [M+H]⁺.

Step 3: Synthesis of ethyl4-(3-formyl-5-(trifluoromethyl)phenyl)-2-methylmorpholine-2-carboxylate

A flask was charged with 3-bromo-5-(trifluoromethyl)benzaldehyde (1.30g, 5.16 mmol, 1.00 equiv), toluene (15 mL), ethyl2-methylmorpholine-2-carboxylate (1.78 g, 10.3 mmol, 2.00 equiv),tris(dibenzylideneacetone)dipalladium (0.708 g, 0.774 mmol, 0.15 equiv),2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (1.44 g, 2.32 mmol, 0.45equiv), and cesium carbonate (5.05 g, 15.5 mmol, 3.00 equiv) undernitrogen. The reaction mixture was stirred overnight at 100° C. andquenched with water (50 mL). The resulting mixture was extracted withDCM (2×80 mL) and the organic layers were combined, washed with brine(2×50 mL), dried over anhydrous sodium sulfate, filtered andconcentrated. The residue was chromatographed on a silica gel column toprovide 0.640 g (36% yield) of ethyl4-(3-formyl-5-(trifluoromethyl)phenyl)-2-methylmorpholine-2-carboxylate.LCMS (ESI, m/z): 346 [M+H]⁺.

Step 4: Synthesis of ethyl4-(3-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-methylmorpholine-2-carboxylate

A flask was charged with ethyl4-(3-formyl-5-(trifluoromethyl)phenyl)-2-methylmorpholine-2-carboxylate(0.840 g, 2.43 mmol, 1.00 equiv), DCE (20 mL), and tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate (0.700 g, 2.91 mmol, 1.20equiv). The mixture was stirred for 1 h at rt prior to the addition ofsodium triacetoxyborohydride (1.55 g, 7.29 mmol, 3.00 equiv). Thereaction mixture was stirred overnight at rt and quenched with water (50mL). The resulting solution was extracted with DCM (2×80 mL) and theorganic layers were combined, washed with brine (2×50 mL), dried overanhydrous sodium sulfate, filtered and concentrated. The residue waschromatographed on a silica gel column to provide 1.20 g (87% yield) ofethyl4-(3-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-methylmorpholine-2-carboxylate.LCMS (ESI, m/z): 570 [M+H]⁺.

Step 5: Synthesis of4-(3-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-methylmorpholine-2-carboxylicacid

A flask was charged with ethyl4-(3-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-methylmorpholine-2-carboxylate(1.20 g, 2.11 mmol, 1.00 equiv), THF (10 mL), water (10 mL), and lithiumhydroxide (0.761 g, 31.7 mmol, 15.0 equiv). The reaction mixture wasstirred overnight at 60° C. The pH value of the solution was adjusted to5 with hydrochloric acid (1 M). The resulting solution was extractedwith DCM (2×50 mL) and the organic layers were combined, washed withbrine (2×30 mL), dried over anhydrous sodium sulfate, filtered andconcentrated to provide 1.00 g (88% yield) of4-(3-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-methylmorpholine-2-carboxylicacid. LCMS (ESI, m/z): 542 [M+H]⁺.

Step 6: Synthesis of4-(3-((1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-methylmorpholine-2-carboxylicacid

A flask was charged with4-(3-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-methylmorpholine-2-carboxylicacid (1.00 g, 1.85 mmol, 1.00 equiv), 1,4-dioxane (10 mL), andconcentrated hydrochloric acid (3 mL). The resulting solution wasstirred overnight at rt and concentrated to provide 1.20 g (crude) of4-(3-((1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-methylmorpholine-2-carboxylicacid. LCMS (ESI, m/z): 442 [M+H]⁺.

Step 7: Synthesis of4-(3-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-methylmorpholine-2-carboxylicacid

A flask was charged with triphosgene (377 mg, 1.27 mmol, 0.70 equiv),DCM (15 mL), and HFIP (608 mg, 3.62 mmol, 2.00 equiv). DIPEA (700 mg,5.43 mmol, 3.00 equiv) was added at 0° C. The mixture was stirred for 1h at rt.4-(3-((1,8-Diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-methylmorpholine-2-carboxylicacid (800 mg, 1.81 mmol, 1.00 equiv) was added. The reaction mixture wasstirred overnight at rt and quenched with water (30 mL). The resultingsolution was extracted with DCM (2×50 mL) and the organic layers werecombined, washed with brine (2×30 mL), dried over anhydrous sodiumsulfate, filtered and concentrated. The residue was purified bypreparative HPLC to afford 258.1 mg (22% yield) of4-(3-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-methylmorpholine-2-carboxylicacid as a white solid. ¹H NMR (300 MHz, Methanol-d₄) δ 7.24 (s, 1H),7.12 (br, 2H), 6.13-6.17 (m, 1H), 4.06-4.23 (m, 4H), 3.93 (s, 2H),3.80-3.84 (m, 1H), 3.32-3.35 (m, 1H), 2.70-3.15 (m, 6H), 1.93-2.10 (m,6H), 1.68-1.73 (m, 2H), 1.39 (s, 3H). LCMS (ESI, m/z): 636 [M+H]⁺.

Example 196:(S)-1-(3-((8-(((1,1,1,3,3,3-Hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-2-carboxylicacid

Step 1: Synthesis of tert-butyl1-(3-bromo-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A flask was charged with 3-bromo-5-(trifluoromethyl)benzaldehyde (2.00g, 7.94 mmol, 1.00 equiv), DCE (20 mL), and tert-butyl1,8-diazaspiro[4.5]decane-8-carboxylate (1.90 g, 7.94 mmol, 1.00 equiv).The reaction mixture was stirred for 1 h at rt prior to addition ofsodium triacetoxyborohydride (5.05 g, 23.8 mmol, 3.00 equiv). Theresulting solution was stirred overnight at rt and quenched with water(30 mL). The mixture was extracted with DCM (2×50 mL) and the organiclayers were combined, washed with brine (2×30 mL), dried over anhydroussodium sulfate, filtered and concentrated. The residue waschromatographed on a silica gel column to provide 1.40 g (37% yield) oftert-butyl1-(3-bromo-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate.LCMS (ESI, m/z): 477 [M+H]⁺.

Step 2: Synthesis of(S)-1-(3-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-2-carboxylicacid

A flask was charged with tert-butyl1-(3-bromo-5-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(600 mg, 1.26 mmol, 1.00 equiv), DMF (10 mL),(2S)-piperidine-2-carboxylic acid (325 mg, 2.52 mmol, 2.00 equiv),potassium carbonate (696 mg, 5.04 mmol, 4.00 equiv), and copper(I)iodide (48.0 mg, 0.252 mmol, 0.20 equiv) under nitrogen. The reactionmixture was stirred overnight at 100° C. and quenched with water (30mL). The resulting solution was extracted with DCM (2×50 mL) and theorganic layers were combined, washed with brine (2×30 mL), dried overanhydrous sodium sulfate, filtered and concentrated. The residue waschromatographed on a silica gel column to provide 450 mg (68% yield) of(S)-1-(3-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-2-carboxylicacid. LCMS (ESI, m/z): 526 [M+H]⁺.

Step 3: Synthesis of(S)-1-(3-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-2-carboxylicacid

A flask was charged with(S)-1-(3-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-2-carboxylicacid (450 mg, 0.857 mmol, 1.00 equiv), 1,4-dioxane (10 mL), andconcentrated hydrochloric acid (3 mL). The resulting solution wasstirred overnight at rt and concentrated to provide 600 mg (crude) of(S)-1-(3-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-2-carboxylicacid. LCMS (ESI, m/z): 426 [M+H]⁺.

Step 4: Synthesis of(S)-1-(3-((1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-2-carboxylicacid

A flask was charged with triphosgene (171 mg, 0.577 mmol, 0.70 equiv),DCM (10 mL), and HFIP 277 mg, 1.65 mmol, 2.00 equiv). DIPEA (319 mg,2.47 mmol, 3.00 equiv) was added at 0° C. and the mixture was stirredfor 1 h at rt prior to addition of(S)-1-(3-((8-(tert-butoxycarbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-2-carboxylicacid (350 mg, 0.824 mmol, 1.00 equiv). The reaction mixture was stirredovernight at rt and quenched with water (30 mL). The resulting solutionwas extracted with DCM (2×50 mL) and the organic layers were combined,washed with brine (2×30 mL), dried over anhydrous sodium sulfate,filtered and concentrated. The residue was purified by preparative HPLCto afford 242.4 mg (48% yield) of(S)-1-(3-((1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)piperidine-2-carboxylicacid. ¹H NMR (300 MHz, Methanol-d₄) δ 7.10-7.11 (m, 2H), 7.02 (s, 1H),6.13-6.17 (m, 1H), 4.41 (br, 1H), 4.24 (br, 2H), 3.95 (s, 2H), 3.31-3.53(m, 2H), 3.04-3.16 (m, 4H), 2.25 (br, 1H), 1.94-2.08 (m, 8H), 1.55-1.73(m, 5H). LCMS (ESI, m/z): 620 [M+H]⁺.

Example 197:4-(2-((8-(((1,1,1,3,3,3-Hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)morpholine-2-carboxylicacid

Step 1: Synthesis of methyl4-(2-formyl-5-(trifluoromethyl)phenyl)morpholine-2-carboxylate

A flask was charged with 2-bromo-4-(trifluoromethyl)benzaldehyde (1.20g, 4.74 mmol, 1.00 equiv), methyl morpholine-2-carboxylate (1.38 g, 9.51mmol, 2.00 equiv), tris(dibenzylideneacetone)dipalladium (0.218 g, 0.240mmol, 0.05 equiv),dicyclohexyl(2′,6′-diisopropoxybiphenyl-2-yl)phosphine (0.445 g, 0.950mmol, 0.20 equiv), cesium carbonate (4.66 g, 14.3 mmol, 3.00 equiv), andtoluene (30 mL) under nitrogen. The reaction mixture was stirredovernight at 100° C. and then quenched with water (50 mL). The resultingsolution was extracted with EtOAc (3×50 mL) and the organic layers werecombined, washed with brine (3×100 mL), dried over anhydrous sodiumsulfate, filtered and concentrated. The residue was chromatographed on asilica gel column to provide 0.432 g (25% yield) of methyl4-(2-formyl-5-(trifluoromethyl)phenyl)morpholine-2-carboxylate. LCMS(ESI, m/z): 318 [M+H]⁺.

Step 2: Synthesis of4-(2-formyl-5-(trifluoromethyl)phenyl)morpholine-2-carboxylic acid

A flask was charged with methyl4-(2-formyl-5-(trifluoromethyl)phenyl)morpholine-2-carboxylate (432 mg,1.36 mmol, 1.00 equiv), THF (10 mL), lithium hydroxide (98.0 mg, 4.09mmol, 3.00 equiv), and water (5 mL). The reaction mixture was stirredfor 2 h at rt and quenched with water (5 mL). The pH of the solution wasadjusted to 5 with hydrochloric acid (1M, 4 mL). The resulting solutionwas extracted with DCM (3×20 mL) and the organic layers were combined,washed with brine (2×20 mL), dried over anhydrous sodium sulfate,filtered and concentrated to provide 410 mg (99% yield) of4-(2-formyl-5-(trifluoromethyl)phenyl)morpholine-2-carboxylic acid. LCMS(ESI, m/z): 304 [M+H]⁺.

Step 3: Synthesis of4-(2-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)morpholine-2-carboxylicacid

A flask was charged with4-(2-formyl-5-(trifluoromethyl)phenyl)morpholine-2-carboxylic acid (136mg, 0.450 mmol, 1.00 equiv), 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate (180 mg, 0.540 mmol, 1.20equiv), and DCM (20 mL). The mixture was stirred for 2 h at rt prior toaddition of sodium triacetoxyborohydride (286 mg, 1.35 mmol, 3.00equiv). The reaction mixture was stirred overnight at rt and quenchedwith water (20 mL). The resulting solution was extracted with DCM (3×20mL) and the organic layers were combined, washed with brine (1×100 mL),dried over anhydrous sodium sulfate, filtered and concentrated. Thecrude residue was purified by preparative HPLC to afford 8.7 mg (3%yield) of4-(2-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)-5-(trifluoromethyl)phenyl)morpholine-2-carboxylicacid. ¹H NMR (300 MHz, Methanol-d₄) δ 7.73-7.75 (m, 1H), 7.63 (s, 1H),7.54-7.57 (m, 1H), 6.14-6.23 (m, 1H), 4.11-4.44 (m, 6H), 3.85 (br, 1H),3.19 (br, 6H), 2.97 (br, 2H), 1.87-2.32 (br, 8H). LCMS (ESI, m/z): 622[M+H]⁺.

Example 198:1-{5-Ethynyl-2-[(8-{[(1,1,1,3,3,3-hexafluoropropan-2-yl)oxy]carbonyl}-1,8-diazaspiro[4.5]decan-1-yl)methyl] phenyl}piperidine-4-carboxylic acid

Step 1: Synthesis of tert-butyl1-(2-formyl-5-((trimethylsilyl)ethynyl)phenyl)piperidine-4-carboxylate

A 50-mL round-bottom flask was charged with tert-butyl1-(2-formyl-5-iodophenyl)piperidine-4-carboxylate (660 mg, 1.59 mmol,1.00 equiv), tetrahydrofuran (10 mL), ethynyltrimethylsilane (187 mg,1.91 mmol, 1.20 equiv), bis(triphenylphosphine)palladium(II) chloride(22.3 mg, 0.0320 mmol, 0.02 equiv), copper(I) iodide (12.1 mg, 0.0640mmol, 0.04 equiv), and triethylamine (321 mg, 3.18 mmol, 2.00 equiv)under nitrogen. The reaction mixture was stirred overnight at 50° C. andquenched with water (50 mL). The resulting solution was extracted withdichloromethane (3×50 mL) and the organic layers were combined, washedwith brine (1×50 mL), dried over anhydrous sodium sulfate, filtered andconcentrated under reduced pressure. The residue was chromatographed ona silica gel column to provide 580 mg (95% yield) of tert-butyl1-(2-formyl-5-((trimethyl silyl)ethynyl)phenyl)piperidine-4-carboxylate.LCMS (ESI, m/z): 386 [M+H]⁺.

Step 2: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-(tert-butoxycarbonyl)piperidin-1-yl)-4-((trimethylsilyl)ethynyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A 50-mL round-bottom flask was charged with tert-butyl1-(2-formyl-5-((trimethylsilyl)ethynyl)phenyl)piperidine-4-carboxylate(180 mg, 0.468 mmol, 1.00 equiv), 1,1,1,3,3,3-hexafluoropropan-2-yl1,8-diazaspiro[4.5]decane-8-carboxylate (234 mg, 0.701 mmol, 1.50equiv), and 1,2-dichloroethane (5 mL). The resulting solution wasstirred for 1.5 h at room temperature prior to addition of sodiumtriacetoxyborohydride (396 mg, 1.87 mmol, 4.00 equiv). The reactionmixture was stirred overnight at room temperature and then quenched withwater (50 mL). The resulting solution was extracted with dichloromethane(3×50 mL) and the organic layers were combined, washed with brine (50mL), dried over anhydrous sodium sulfate, filtered and concentratedunder reduced pressure. The residue was chromatographed on a silica gelcolumn to provide 317 mg (96% yield) of1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-(tert-butoxycarbonyl)piperidin-1-yl)-4-((trimethylsilyl)ethynyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate.LCMS (ESI, m/z): 704 [M+H]⁺.

Step 3: Synthesis of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-(tert-butoxycarbonyl)piperidin-1-yl)-4-ethynylbenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate

A 50-mL round-bottom flask was charged with1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-(tert-butoxycarbonyl)piperidin-1-yl)-4-((trimethylsilyl)ethynyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(277 mg, 0.394 mmol, 1.00 equiv), and tetrahydrofuran (5 mL).Tetrabutylammonium fluoride (1.97 mL, 1M in tetrahydrofuran, 1.97 mmol,5.00 equiv) was added. The reaction mixture was stirred overnight atroom temperature and concentrated under reduced pressure. The residuewas chromatographed on a silica gel column to provide 170 mg (68% yield)of 1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-(tert-butoxycarbonyl)piperidin-1-yl)-4-ethynylbenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate.LCMS (ESI, m/z): 632 [M+H]⁺.

Step 4: Synthesis of1-(5-ethynyl-2-((8-(((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)phenyl)piperidine-4-carboxylic acid

A 100-mL round-bottom flask was charged with1,1,1,3,3,3-hexafluoropropan-2-yl1-(2-(4-(tert-butoxycarbonyl)piperidin-1-yl)-4-ethynylbenzyl)-1,8-diazaspiro[4.5]decane-8-carboxylate(157 mg, 0.249 mmol, 1.00 equiv), dichloromethane (5 mL), andtrifluoroacetic acid (2 mL). The resulting solution was stirredovernight at room temperature and then concentrated under reducedpressure. The crude product (250 mg) was purified by preparative HPLC toprovide 76.7 mg (54% yield) of1-(5-ethynyl-2-((8-(((,1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)carbonyl)-1,8-diazaspiro[4.5]decan-1-yl)methyl)phenyl)piperidine-4-carboxylic acid. ¹H NMR (300 MHz,Methanol-d₄) δ 7.43-7.46 (m, 1H), 7.29-7.30 (m, 1H), 7.20-7.23 (m, 1H),6.10-6.17 (m, 1H), 4.18-4.26 (m, 2H), 4.00 (br, 2H), 3.50 (s, 1H),2.99-3.14 (m, 6H), 2.70-2.77 (m, 2H), 2.31-2.36 (m, 1H), 1.90-2.09 (m,10H), 1.66-1.73 (m, 2H). LCMS (ESI, m/z): 576 [M+H]⁺.

Examples 199-281 (Table 1) were prepared by similar procedures asdescribed in Examples 1-198.

TABLE 1 NMR (¹H NMR, 300 MHz or 400 MHz MS Ex Structure Methanol-d4)[M + H]⁺ 199

δ 7.70-7.73 (m, 1H), 7.17-7.22 (m, 2H), 6.10- 6.19 (m, 1H), 4.19 (br,2H), 3.78-3.80 (m, 2H), 3.40-3.48 (m, 2H), 3.14-3.29 (m, 2H), 3.03- 3.06(m, 3H), 2.67-2.75 (m, 2H), 2.21-2.23 (m, 2H), 1.81-1.97 (m, 6H),1.57-1.62 (m, 2H). 606 200

δ 7.07-7.12 (m, 3H), 6.10-6.23 (m, 1H), 4.40- 4.44 (m, 1H), 4.19-4.28(m, 3H), 3.91-4.05 (m, 3H), 3.80-3.88 (m, 1H), 3.65-3.79 (m, 1H), 3.48-3.63 (m, 1H), 3.39-3.50 (m, 1H), 3.05-3.21 (m, 4H), 1.82-2.17 (m, 6H),1.71-1.74 (m, 2H). 622 201

δ 7.53-7.56 (m, 2H), 7.41-7.43 (m, 1H), 6.07- 6.14 (m, 1H), 4.67-4.72(m, 1H), 4.37-4.42 (m, 1H), 3.60-3.68 (m, 3H), 3.36-3.51 (m, 4H), 3.30-3.31 (m, 1H), 3.01-3.16 (m, 4H), 2.85-2.90 (m, 1H), 2.41-2.45 (m, 1H),2.05-2.18 (m, 3H), 1.70- 1.73 (m, 4H). 606 202

δ 7.03 (br, 1H), 6.94 (s, 1H), 6.78 (s, 1H), 6.08- 6.19 (m, 1H),4.14-4.28 (m, 2H), 3.41-3.58 (m, 7H), 3.38 (s, 1H), 3.25-3.31 (m, 2H),3.12-3.23 (m, 3H), 2.24-2.35 (m, 2H), 1.91-1.99 (m, 2H), 1.65 (br, 4H).606 203

δ 6.92 (s, 1H), 6.84 (s, 1H), 6.70 (s, 1H), 6.09- 6.22 (m, 1H),4.13-4.32 (m, 2H), 3.90 (s, 2H), 3.53-3.55 (m, 2H), 3.39-3.44 (m, 2H),3.08- 3.20 (m, 3H), 2.90-3.03 (m, 2H), 2.25-2.29 (m, 2H), 2.02-2.09 (m,2H), 1.82-1.97 (m, 4H), 1.62- 1.72 (m, 2H). 606 204

δ 7.22 (s, 1H), 7.13 (s, 2H), 6.10-6.21 (m, 1H), 4.04-4.22 (m, 4H),3.68-3.95 (m, 4H), 3.42- 3.48 (m, 1H), 3.03-3.19 (m, 2H), 2.80-2.91 (m,4H), 1.86-204 (m, 6H), 1.63-1.67 (m, 2H). 622 205

(Chloroform-d) δ 9.20 (br, 1H), 8.69 (s, 1H), 8.37 (s, 1H), 7.60 (s,1H), 5.71-5.79 (m, 1H), 4.28- 4.31 (m, 2H), 4.02-4.08 (m, 2H), 2.97-3.11(m, 4H), 2.22-2.27 (m, 2H), 2.09-2.12 (m, 2H), 1.84- 1.98 (m, 4H). 561206

(Chloroform-d) δ 8.65 (s, 1H), 8.25 (s, 1H), 7.65 (s, 1H), 5.70-5.85 (m,1H), 4.25-4.35 (m, 2H), 3.88-3.90 (m, 2H), 2.85-3.15 (m, 4H), 2.15- 2.30(m, 2H), 1.85-2.15 (m, 6H). 537 207

δ 6.95 (s, 1H), 6.78 (s, 2H), 6.10-6.20 (m, 1H), 4.19 (br, 2H),3.60-3.81 (m, 4H), 2.98-3.18 (m, 2H), 2.77-2.91 (m, 4H), 2.35-2.49 (m,1H), 1.95- 2.09 (m, 4H), 1.71-1.90 (m, 6H), 1.53-1.67 (m, 2H). 636 208

(Chloroform-d) δ 7.36 (s, 1H), 7.07 (s, 1H), 6.88 (s, 1H), 5.69-5.78 (m,1H), 3.93-3.98 (m, 1H), 3.74-3.88 (m, 2H), 3.42-3.55 (m, 5H), 3.08- 3.14(m, 1H), 2.73-2.97 (m, 5H), 2.56-2.60 (m, 1H), 2.03-2.05 (m, 1H),1.75-1.85 (m, 3H), 1.62- 1.78 (m, 6H). 620 209

δ 7.67-7.70 (m, 2H), 7.56-7.58 (m, 1H), 6.10- 6.19 (m, 1H), 4.38-4.53(m, 2H), 4.22-4.24 (m, 1H), 3.80-3.84 (m, 1H), 3.80-3.84 (m, 1H), 3.39-3.66 (m, 6H), 3.19-3.27 (m, 3H), 3.06-3.12 (m, 2H), 2.92-2.96 (m, 1H),2.08-2.10 (m, 2H), 1.76- 1.78 (m, 4H). 622 210

δ 7.26 (s, 1H), 7.17 (s, 1H), 7.11 (s, 1H), 6.12- 6.21 (m, 1H),4.19-4.24 (m, 2H), 3.69-3.77 (m, 4H), 3.04-3.18 (m, 2H), 2.79-2.90 (m,4H), 2.43- 2.49 (m, 1H), 1.97-2.04 (m, 4H), 1.80-1.91 (m, 6H), 1.57-1.65(m, 2H). 577 211

δ 7.62-7.64 (m, 2H), 7.51-7.53 (m, 1H), 6.10- 6.19 (m, 1H), 4.49 (br,1H), 4.20-4.23 (m, 1H), 3.46-3.66 (m, 4H), 3.32-3.34 (m, 1H), 3.22- 3.24(m, 2H), 3.04-3.10 (m, 4H), 2.80-2.82 (m, 1H), 2.64 (br, 1H), 2.11-2.13(m, 3H), 1.76-1.96 (m, 7H). 620 212

(Chloroform-d) δ 7.23 (br, 1H), 7.02 (s, 2H), 5.70- 5.80 (m, 1H),4.11-4.28 (m, 2H), 3.60-3.68 (m, 3H), 3.42-3.45 (m, 1H), 3.22-3.24 (m,1H), 2.93- 3.02 (m, 3H), 2.62-2.81 (m, 3H), 1.66-1.98 (m, 12H). 620 213

(Chloroform-d) δ 7.36 (br, 1H), 7.05-7.16 (m, 2H), 5.72-5.78 (m, 1H),4.14-4.39 (m, 2H), 3.48- 3.72 (m, 4H), 3.30-3.39 (m, 1H), 2.66-3.00 (m,6H), 1.50-2.14 (m, 12H). 620 214

(Chloroform-d) δ 7.62 (br, 1H), 7.32-7.34 (m, 2H), 5.73-5.79 (m, 1H),4.17-4.26 (m, 2H), 3.66- 3.75 (m, 2H), 3.13-3.21 (m, 1H), 2.96-3.05 (m,3H), 2.84-2.91 (m, 1H), 2.72-2.74 (m, 4H), 1.50- 2.00 (m, 12 H). 620 215

δ 7.62-7.67 (m, 2H), 7.53-7.56 (m, 1H), 6.10- 6.18 (m, 1H), 4.54-4.58(m, 1H), 4.24-4.28 (m, 1H), 3.33-3.64 (m, 6H), 3.17-3.30 (m, 2H), 3.06-3.10 (m, 3H), 2.75-2.82 (m, 1H), 2.66 (br, 1H), 2.11-2.29 (m, 3H),1.76-1.96 (m, 7H). 620 216

δ 7.63-7.65 (m, 2H), 7.54-7.57 (m, 1H), 6.10- 6.19 (m, 1H),4.60-4.64 (m,1H), 4.14-4.19 (m, 1H), 3.52-3.66 (m, 5H), 3.25-3.34 (m, 3H), 3.04- 3.10(m, 2H), 2.62-2.70 (m, 2H), 2.12-2.37 (m, 3H), 1.73-1.84 (m, 6H),1.20-1.28 (m, 1H), 1.18 (s, 3H). 634 217

δ 7.62-7.69 (m, 2H), 7.48-7.51 (m, 1H), 6.13- 6.22 (m, 1H), 4.21-4.45(m, 3H), 3.98-4.05 (m, 1H), 3.00-3.18 (m, 7H), 2.66-2.67 (m, 2H), 2.34-2.45 (m, 2H), 2.07-2.12 (m, 5H), 1.72-1.93 (m, 5H). 620 218

δ 7.73 (s, 1H), 7.67 (d, J = 8.1 Hz, 1H), 7.60 (d, J = 8.1 Hz, 1H),6.11-6.19 (m, 1H), 4.63-4.68 (m, 1H), 4.31-4.36 (m, 1H), 3.95-4.02 (m,1H), 3.81- 3.85 (m, 1H), 3.34-3.65 (m, 8H), 3.09-3.13 (m 1H), 2.88-2.99(m, 2H), 2.77-2.81 (m, 1H), 2.11- 2.22 (m, 2H), 1.78-1.82 (m, 4H), 1.36(s, 3H). 636 219

δ 7.49 (br, 2H), 7.35-7.38 (m, 1H), 6.06-6.14 (m, 1H), 4.64-4.86 (m,1H), 4.36-4.59 (m, 1H), 3.59-3.73 (m, 3H), 3.38-3.44 (m, 4H), 3.16- 3.30(m, 2H), 2.90-3.03 (m, 2H), 2.63-2.66 (m, 1H), 2.34-2.44 (m, 1H),2.04-2.17 (m, 2H), 1.85- 1.99 (m, 1H), 1.70 (br, 4H), 1.35 (s, 3H). 620220

(Chloroform-d) δ 7.68 (s, 1H), 7.46-7.49 (m, 1H), 7.38-7.40 (m, 1H),5.69-5.77 (m, 1H), 4.65- 4.69 (m, 1H), 4.33-4.38 (m, 1H), 4.09-4.13 (m,1H), 3.92-4.00 (m, 1H), 3.62-3.78 (m, 3H), 3.24- 3.58 (m, 6H), 2.86-3.02(m, 3H), 2.69-2.73 (m, 1H), 1.84-2.18 (m, 3H), 1.62-1.78 (m, 3H). 622221

δ 7.20 (s, 1H), 7.03-7.08 (m, 2H), 6.11-6.15 (m, 1H), 4.17-4.19 (m, 2H),3.85-3.89 (m, 1H), 3.71 (s, 2H), 3.36-3.40 (m, 1H), 3.05-3.12 (m, 2H),2.77-2.93 (m, 3H), 2.68-2.71 (m, 1H), 2.14- 2.20 (m, 1H), 1.91-1.99 (m,2H), 1.68-1.88 (m, 6H), 1.55-1.61 (m, 2H), 1.29-1.38 (m, 1H), 1.21 (s,3H). 634 222

(Chloroform-d) δ 7.28 (s, 1H), 7.14 (s, 1H), 7.08 (s, 1H), 6.09-6.13 (m,1H), 3.96 (br, 2H), 3.81- 3.85 (m, 1H), 3.46-3.64 (m, 5H), 2.85-3.09 (m,6H), 2.53 (br, 1H), 2.03 (br, 1H), 1.85-1.89 (m, 3H), 1.64-1.66 (m, 6H).620 223

δ 7.27 (s, 1H), 7.14 (s, 1H), 7.06 (s, 1H), 6.07- 6.13 (m, 1H),3.88-3.93 (m, 3H), 3.40-3.57 (m, 5H), 2.81-2.95 (m, 3H), 2.70-2.78 (m,3H), 2.16- 2.20 (m, 1H), 1.72-1.84 (m, 4H), 1.58-1.63 (m, 4H), 1.30-1.40(m, 1H), 1.19 (s, 3H). 634 224

δ 7.64-7.69 (m, 2H), 7.55 (d, J = 8.1 Hz, 1H), 6.12-6.20 (m, 1H),4.77-4.81 (m, 1H), 3.93- 3.97 (m, 1H), 3.72-3.81 (m, 3H), 3.62 (br, 1H),3.34-3.50 (m, 3H), 3.21-3.28 (m, 2H), 2.99- 3.03 (m, 1H), 2.58-2.67 (m,1H), 1.90-2.22 (m, 4H), 1.51-1.89 (m, 8H). 620 225

δ 7.17-7.24 (m, 2H), 7.04 (s, 1H), 6.11-6.20 (m, 1H), 4.46 (br, 1H),4.12-4.23 (m, 2H), 3.34-3.59 (m, 6H), 3.23-3.28 (m, 2H), 3.03-3.16 (m,2H), 2.32-2.36 (m, 1H), 1.85-1.98 (m, 4H), 1.56- 1.68 (m, 7H). 620 226

δ 7.10-7.14 (m, 2H), 7.04 (s, 1H), 6.14-6.23 (m, 1H), 4.41-4.44 (m, 1H),4.23-4.26 (m, 2H), 3.96 (s, 2H), 3.53-3.58 (m, 1H), 3.34-3.45 (m, 1H),3.05-3.22 (m, 4H), 2.28-2.32 (m, 1H), 2.11- 2.27 (m, 2H), 1.85-2.00 (m,6H), 1.52-1.75 (m, 5H). 620 227

δ 7.80 (s, 1H), 7.70-7.73 (m, 1H), 7.60-7.63 (m, 1H), 6.22-6.28 (m, 1H),4.98 (s, 1H), 4.29-4.58 (m, 2H), 4.18-4.22 (m, 1H), 4.04-4.11 (m, 1H),3.90-3.96 (m, 1H), 3.74-3.86 (m, 2H), 3.55- 3.68 (m, 1H), 3.22-3.28 (m,2H), 3.09-3.18 (m, 2H), 2.92-2.97 (m, 1H), 2.80-2.88 (m, 1H), 2.45- 2.62(m, 2H), 1.94-2.16 (m, 6H). 622 228

δ 7.69 (s, 1H), 7.60-7.63 (m, 1H), 7.44-7.47 (m, 1H), 6.07-6.16 (m, 1H),3.89 (s, 2H), 3.41-3.61 (m, 4H), 3.03-3.06 (m, 2H), 2.91-2.94 (m, 2H),2.75-2.89 (m, 4H), 2.31-2.40 (m, 1H), 1.80- 1.98 (m, 6H), 1.62-1.66 (m,4H). 620 229

δ 6.94 (br, 2H), 6.75 (br, 1H), 6.10-6.19 (m, 1H), 4.11 (br, 2H),3.84-3.87 (m, 1H), 3.41-3.63 (m, 6H), 3.14-3.18 (m, 3H), 3.02 (br, 2H),2.49-2.57 (m, 1H), 1.90-1.97 (m, 3H), 1.68-1.70 (m, 4H), 1.41 (s, 3H).620 230

δ 7.60-7.62 (m, 1H), 7.45 (s, 1H), 7.33-7.36 (m, 1H), 6.14-6.18 (m, 1H),4.09-4.38 (m, 4H), 3.56- 3.60 (m, 1H), 3.32-3.44 (m, 1H), 3.01-3.18 (m,6H), 2.48-2.57 (m, 1H), 2.27-2.30 (m, 2H), 1.77- 2.04 (m, 7H), 1.43 (s,3H). 620 231

δ 6.91 (s, 1H), 6.80 (s, 1H), 6.68 (s, 1H), 6.14- 6.20 (m, 1H),4.21-4.26 (m, 2H), 3.80-3.88 (m, 3H), 3.40-3.44 (m, 2H), 3.05-3.19 (m,3H), 2.94- 2.98 (m, 2H), 2.49-2.55 (m, 1H), 2.03-2.07 (m, 2H), 1.86-1.96(m, 5H), 1.65-1.74 (m, 2H), 1.42 (s, 3H). 620 232

δ 6.93 (s, 1H), 6.91 (s, 1H),6.84 (s, 1H), 6.10- 6.12 (m, 1H), 3.95 (s,2H), 3.62-3.74 (m, 2H), 3.46-3.60 (m, 4H), 3.10-3.30 (m, 2H), 2.94 (s,2H), 2.76-2.84 (m, 2H), 2.32-2.37 (m, 1H), 1.91- 2.03 (m, 4H), 1.66-1.89(m, 6H). 586 233

δ 6.93 (s, 1H), 6.75-6.79 (m, 1H), 6.64-6.67 (m, 1H), 6.13-6.17 (m, 1H),4.92 (s, 2H), 3.63-3.79 (m, 2H), 3.51-3.56 (m, 2H), 3.35-3.49 (m, 4H),3.25-3.32 (m, 2H), 2.87-2.91 (m, 2H), 2.46- 2.50 (m, 1H), 2.00-2.08 (m,4H), 1.75-1.85 (m, 6H). 570 234

δ 7.60 (d, J = 8.1 Hz, 1H), 7.50 (s, 1H), 1.21 (d, J = 7.8 Hz, 1H),6.07-6.15 (m, 1H), 3.84 (br, 2H), 3.43-3.60 (m, 4H), 3.04-3.08 (m, 2H),2.67- 2.84 (m, 6H), 2.36-2.43 (m, 1H), 1.82-2.00 (m, 6H), 1.61-1.68 (m,4H). 620 235

δ 7.49-7.52 (m, 1H), 7.07-7,12 (m, 1H), 6.92- 6.99 (m, 1H), 6.18-6.22(m, 1H), 4.21-4.29 (m, 4H), 3.31-3.33 (m, 2H), 3.09-3.29 (m, 4H), 2.74-2.82 (m, 2H), 2.41-2.42 (m, 1H), 2.02-2.24 (m, 8H), 1.82-1.94 (m, 4H).570 236

δ 6.63 (s, 1H), 6.54-6.60 (m, 2H), 6.13-6.19 (m, 1H), 4.22 (br, 2H),3.70-3.74 (m, 4H), 3.08-3.34 (m, 2H), 2.77-2.93 (m, 4H), 2.39-2.40 (m,1H), 1.77-2.04 (m, 10H), 1.61-1.65 (m, 2H). 570 237

δ 7.46-7.49 (m, 1H), 7.04-7.09 (m, 1H), 6.90- 6.96 (m, 1H), 6.13-6.17(m, 1H), 4.91 (s, 2H), 3.61-3.67 (m, 2H), 3.49-3.54 (m, 2H), 3.28- 3.33(m, 2H), 3.09-3.25 (m, 4H), 2.74-2.78 (m, 2H), 2.35-2.37 (m, 1H),1.85-2.07 (m, 6H), 1.70 (br, 4H). 570 238

δ 7.80 (s, 1H), 7.69-7.74 (m, 2H), 6.12-6.21 (m, 1H), 4.24-4.27 (m, 2H),4.16 (br, 2H), 4.05 (br, 2H), 3.09-3.23 (m, 4H), 2.69-2.78 (m, 4H),2.31- 2.37 (m, 1H), 1.89-2.12 (m, 8H), 1.75 (br, 2H), 1.60-1.64 (m, 2H).634 239

δ 7.81 (s, 1H), 7.75-7.79 (m, 2H), 6.10-6.19 (m, 1H), 4.20-4.22 (m, 4H),3.62-3.67 (m, 2H), 3.51- 3.57 (m, 2H), 3.24-3.27 (m, 2H), 3.08-3.17 (m,2H), 2.88-2.99 (m, 2H), 2.70-2.75 (m, 2H), 2.34- 2.39 (m, 1H), 1.98-2.07(m, 4H), 1.73 (br, 6H). 634 240

δ 7.67-7.70 (m, 1H), 7.47-7.52 (m, 2H), 6.11- 6.16 (m, 1H), 4.12-4.26(m, 2H), 3.84 (s, 2H), 3.10-3.29 (m, 4H), 2.75-2.84 (m, 4H), 2.32- 2.46(m, 1H), 1.60-2.04 (m, 12H). 678 241

δ 7.55-7.62 (m, 1H), 7.51-7.54 (m, 2H), 6.06- 6.17 (m, 1H), 3.93 (s,2H), 3.42-3.56 (m, 4H), 3.17-3.21 (m, 2H), 2.86-2.94 (m, 2H), 2.72- 2.80(m, 4H), 2.32-2.48 (m, 1H), 1.97-2.08 (m, 2H), 1.79-1.94 (m, 4H),1.59-1.64 (m, 4H). 678 242

δ 8.04 (s, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.40(t, J = 7.6 Hz, 1H), 6.12-6.20 (m, 1H), 4.21-4.24 (m, 2H), 3.98 (s, 2H),3.02- 3.21 (m, 4H), 2.05-2.13 (m, 2H), 1.91-2.00 (m, 4H), 1.73-1.77 (m,2H). 469 243

δ 7.78-7.81 (m, 2H), 7.36 (s, 1H), 6.13-6.21 (m, 1H), 4.22-4.26 (m, 2H),3.99 (s, 2H), 3.06-3.18 (m, 4H), 2.39 (s, 3H), 2.09-2.14 (m, 2H), 1.91-2.03 (m, 4H), 1.74-1.78 (m, 2H). 483 244

δ 7.63-7.65 (m, 3H), 6.09-6.18 (m, 1H), 4.19- 4.20 (m, 2H), 3.96 (br,2H), 3.75 (br, 2H), 3.01- 3.14 (m, 4H), 2.68-2.73 (m, 2H), 2.55-2.64 (m,2H), 2.30-2.35 (m, 1H), 1.72-2.01 (m, 10H), 1.56-1.60 (m, 2H). 634 245

δ 7.68 (s, 3H), 6.07-6.13 (m, 1H), 3.80-3.90 (m, 4H), 3.42-3.60 (m, 4H),3.05-3.09 (m, 2H), 2.75 (br, 2H), 2.46-2.59 (m, 4H), 2.28-2.32 (m, 1H),1.95-1.99 (m, 2H), 1.75-1.86 (m, 4H), 1.61- 1.63 (m, 4H). 634 246

δ 7.58 (s, 1H), 7.43 (d, J = 8.1 Hz, 1H), 7.33-7.36 (m, 1H), 6.07-6.13(m, 1H), 3.92 (br, 2H), 3.78 (br, 2H), 3.42-3.59 (m, 4H), 3.09-3.13 (m,2H), 2.82 (br, 2H), 2.49-2.64 (m, 4H), 2.26-2.31 (m, 1H), 1.94-1.98 (m,2H), 1.82-1.87 (m, 4H), 1.77- 1.79 (m, 4H). 600 247

δ 7.83 (d, J = 7.8 Hz, 1H), 7.72 (s, 1H), 7.64 (d, J = 8.1 Hz, 1H),6.07-6.16 (m, 1H), 3.86-3.89 (m, 2H), 3.73 (br, 2H), 3.41-3.60 (m, 4H),2.86-2.94 (m, 4H), 2.68-2.72 (m, 2H), 2.19-2.26 (m, 3H), 1.63-1.96 (m,10H). 634 248

δ 7.58-7.59 (m, 1H), 7.02-7.08 (m, 2H), 6.10- 6.23 (m, 1H), 4.22-4.26(m, 2H), 3.98 (s, 2H), 2.94-3.32 (m, 6H), 2.71-2.79 (m, 2H), 2.35- 2.44(m, 1H), 1.83-2.09 (m, 10H), 1.67-1.72 (m, 2H). 636 249

δ 7.70-7.80 (m, 1H), 7.43-7.50 (m, 2H), 6.12- 6.21 (m, 1H), 4.22-4.25(m, 2H), 3.93 (s, 2H), 3.04-3.35 (m, 4H), 2.74-2.90 (m, 4H), 2.42- 2.49(m, 1H), 2.02-2.08 (m, 4H), 1.76-2.00 (m, 6H), 1.62-1.66 (m, 2H). 577250

δ 8.08-8.10 (m, 2H), 7.61-7.63 (m, 2H), 6.16- 6.26 (m, 1H), 4.29-4.35(m, 4H), 3.12-3.39 (m, 4H), 2.24-2.26 (m, 2H), 2.04-2.20 (m, 4H), 1.96-2.01 (m, 2H). 469 251

δ 7.96-8.01 (m, 1H), 7.48-7.54 (m, 3H), 6.15- 6.24 (m, 1H), 3.98-4.32(m, 4H), 3.15-3.40 (m, 4H), 2.30 (br, 2H), 2.06-2.22 (m, 4H), 1.95-1.99(m, 2H). 469 252

δ 7.37 (br, 1H), 7.17-7.20 (m, 2H), 6.12-6.16 (m, 1H), 4.20 (br, 3H),4.02-4.18 (m, 1H), 3.81- 3.85 (m, 1H), 3.57-3.68 (m, 2H), 3.41-3.55 (m,3H), 3.25 (br, 2H), 3.09 (s, 2H), 2.87-2.99 (m, 1H), 2.71-2.79 (m, 1H),1.97 (t, J = 6.8 Hz, 2H), 1.70 (s, 4H), 1.41 (s, 3H). 636 253

δ 7.70-7.71 (m, 3H), 6.09-6.16 (m, 1H), 4.28- 4.33 (m, 2H), 4.16-4.21(m, 2H), 3.75-3.76 (m, 2H), 3.38-3.40 (m, 1H), 3.02-3.31 (m, 6H), 2.68-2.72 (m, 2H), 2.21-2.30 (m, 2H), 1.91-1.95 (m, 2H), 1.71-1.85 (m, 4H),1.55-1.58 (m, 2H). 620 254

(Chloroform-d) δ 7.56-7.59 (m, 1H), 7.36-7.39 (m, 1H), 7.00-7.03 (m,1H), 6.14-6.22 (m, 1H), 4.22-4.30 (m, 2H), 4.09 (s, 2H), 3.84 (s, 3H),3.07-3.25 (m, 4H), 2.20-2.21 (m, 2H), 2.02- 2.13 (m, 4H), 1.86-1.87 (m,2H). 499 255

δ 7.91 (s, 1H), 7.70-7.73 (m, 1H), 7.56-7.59 (m, 1H), 6.08-6.20 (m, 1H),4.45 (s, 2H), 3.56-3.57 (m, 4H), 3.43-3.47 (m, 2H), 3.30-3.34 (m, 2H),2.05-2.10 (m, 2H), 1.77 (br, 4H). 537 256

δ 7.73 (s, 1H), 7.67 (d, J = 8.1 Hz, 1H), 7.60 (d, J = 8.1 Hz, 1H),6.11-6.19 (m, 1H), 4.63-4.68 (m, 1H), 4.31-4.36 (m, 1H), 3.95-4.02 (m,1H), 3.81- 3.85 (m, 1H), 3.34-3.65 (m, 8H), 3.09-3.13 (m, 1H), 2.88-2.99(m, 2H), 2.77-2.81 (m, 1H), 2.11- 2.22 (m, 2H), 1.78-1.82 (m, 4H), 1.36(s, 3H). 636 257

δ 7.61-7.62 (m, 1H), 7.29-7.31 (m, 1H), 7.21- 7.23 (m, 1H), 6.14-6.20(m, 1H), 4.22-4.29 (m, 2H), 4.04 (s, 2H), 3.07-3.21 (m, 4H), 2.48 (s,3H), 2.13-2.17 (m, 2H), 1.94-2.09 (m, 4H), 1.77- 1.80 (m, 2H). 483 258

δ 7.76 (s, 1H), 7.64-7.66 (m, 1H), 7.56-7.58 (m, 1H), 6.08-6.16 (m, 1H),4.17 (br, 2H), 3.55-3.63 (m, 2H), 3.41-3.54 (m, 2H), 3.12-3.19 (m, 2H),2.96-3.03 (m, 2H), 1.94 (br, 2H), 1.66-1.68 (m, 4H). 537 259

δ 7.72 (s, 1H), 7.63-7.65 (m, 1H), 7.52-7.54 (m, 1H), 6.19-6.23 (m, 1H),4.83-4.87 (m, 1H), 4.32- 4.36 (m, 2H), 3.70-3.74 (m, 2H), 2.99-3.25 (m,5H), 2.50-2.55 (m, 3H), 2.06-2.13 (m, 6H), 1.88- 1.95 (m, 2H), 1.64-1.74(m, 4H). 620 260

δ 7.66-7.68 (m, 2H), 7.53-7.56 (m, 1H), 6.12- 6.20 (m, 1H), 4.60 (br,1H), 4.05-4.34 (m, 3H), 3.90-3.97 (m, 1H), 3.76-3.80 (m, 1H), 3.37- 3.40(m, 1H), 3.09-3.29 (m, 4H), 2.87-2.96 (m, 2H), 2.72-2.80 (m, 2H),2.26-2.55 (m, 3H), 2.10 (br, 3H), 1.86 (br, 2H), 1.45 (s, 3H). 636 261

δ 8.24 (s, 1H), 7.74-7.77 (m, 1H), 7.64-7.66 (m, 1H), 6.12-6.21 (m, 1H),4.10-4.40 (m, 4H), 3.12- 3.19 (m, 4H), 2.27 (br, 2H), 2.04-2.13 (m, 4H),1.93-1.96 (m, 2H). 537 262

δ 7.89 (s, 1H), 7.71-7.76 (m, 2H), 6.18-6.22 (m, 1H), 4.28-4.34 (m, 4H),4.10 (br, 2H), 3.34 (br. 1H), 3.04-3.22 (m, 6H), 2.81-2.83 (m, 2H),1.78- 2.30 (m, 9H), 1.64-1.69 (m, 1H). 620 263

δ 7.16-7.20 (m, 3H), 6.11-6.15 (m, 1H), 4.19 (br, 2H), 3.67-3.73 (m,4H), 3.01-3.19 (m, 2H), 2.77-2.89 (m, 4H), 2.38-2.47 (m, 1H), 1.91- 2.04(m, 4H), 1.78-1.85 (m, 6H), 1.56-1.60 (m, 2H). 678 264

δ 7.25 (s, 3H), 6.08-6.17 (m, 1H), 3.71-3.91 (m, 4H), 3.42-3.56 (m, 4H),2.70-2.92 (m, 6H), 2.34- 2.48 (m, 1H), 1.99-2.04 (m, 2H), 1.70-1.88 (m,4H), 1.62-1.65 (m, 4H). 678 265

δ 826 (s, 1H), 8.08 (d, J = 8.1 Hz, 1H), 7.93 (d, J = 8.1 Hz, 1H),6.09-6.17 (m, 1H), 4.16-4.20 (m, 2H), 3.90 (s, 2H), 3.00-3.16 (m, 2H),2.76-2.78 (m, 2H), 1.93-1.98 (m, 4H), 1.70-1.90 (m, 2H), 1.51-1.59 (m,2H). 537 266

δ 7.61 (s, 1H), 7.34-7.44 (m, 2H), 6.16-6.20 (m, 1H), 4.25-4.28 (m, 2H),4.17 (s, 2H), 3.12-3.32 (m, 4H), 2.02-2.25 (m, 6H), 1.85-1.89 (m, 2H).503 267

(Chloroform-d) δ 7.68-7.70 (m, 1H), 7.32-7.34 (m, 1H), 7.25 (s, 1H),5.72-5.80 (m, 1H), 4.18- 4.26 (m, 2H), 3.66 (br, 2H), 3.23-3.27 (m, 2H),2.92-3.06 (m, 6H), 2.69-2.79 (m, 2H), 2.61- 2.65 (m, 2H), 2.23-2.27 (m,2H), 1.98-2.11 (m, 2H), 1.70-1.82 (m, 5H), 1.50-1.68 (m, 3H). 654 268

(Chloroform-d) δ 7.61 (br, 1H), 7.15-7.17 (m, 1H), 6.74 (br, 1H),5.71-5.79 (m, 1H), 4.17-4.30 (m, 6H), 4.06-4.12 (m, 1H), 3.56 (br, 2H),2.92- 3.06 (m, 5H), 2.66 (br, 2H), 1.85 (br, 3H), 1.55- 1.64 (m, 5H).626 269

δ 7.43 (s, 1H), 7.29 (d, J = 12.4 Hz, 2H), 6.10- 6.20 (m, 1H), 4.17-4.22(m, 2H), 3.96 (br, 2H), 3.69-3.77 (m, 2H), 3.03-3.18 (m, 4H), 2.72- 2.76(m, 2H), 2.60-2.65 (m, 2H), 2.32-2.39 (m, 1H), 1.93-2.03 (m, 4H),1.71-1.90 (m, 6H), 1.56- 1.59 (m, 2H). 650 270

δ 7.51 (s, 1H), 7.35 (s, 2H), 6.13-6.16 (m, 1H), 4.28-4.32 (m, 2H),4.17-4.24 (m, 2H), 3.74 (br. 2H), 3.43-3.47 (m, 1H), 3.06-3.30 (m, 6H),2.72- 2.75 (m, 2H), 2.24-2.32 (m, 2H), 1.92-1.96 (m, 2H), 1.73-1.87 (m,4H), 1.56-1.59 (m, 2H). 636 271

δ 7.77 (s, 1H), 7.67 (s, 1H), 7.60 (s, 1H), 6.10- 6.20 (m, 1H),4.48-4.51 (m, 1H), 4.19-4.23 (m, 2H), 3.78-3.86 (m, 2H), 3.62-3.66 (m,1H), 3.04- 3.22 (m, 4H), 2.73-2.76 (m, 2H), 2.59-2.64 (m, 1H), 1.58-2.08(m, 12H). 648 272

δ 7.40-7.41 (m, 3H), 6.08-6.16 (m, 1H),4.16- 4.26 (m, 4H), 3.66 (br,2H), 3.40-3.43 (m, 1H), 3.00-3.30 (m, 6H), 2.68-2.72 (m, 2H), 2.21- 2.30(m, 2H), 1.69-1.97 (m, 6H), 1.55-1.59 (m, 2H). 586 273

(Chloroform-d) δ 7.65-7.66 (m, 1H), 7.27-7.31 (m, 2H), 5.70-5.83 (m,1H), 5.47-5.53 (m, 2H), 4.17-4.25 (m, 2H), 3.66 (s, 2H), 2.92-3.15 (m,4H), 2.62-2.69 (m, 4H), 2.26-2.27 (m, 1H), 1.67- 1.94 (m, 10H),1.48-1.52 (m, 2H). 619 274

δ 7.10 (br, 2H), 7.02 (s, 1H), 6.14-6.18 (m, 1H), 4.40 (br, 1H),4.21-4.28 (m, 2H), 3.96 (s, 2H), 3.52 (br, 1H), 3.29-3.38 (m, 1H),3.05-3.16 (m, 4H), 2.07-2.10 (m, 1H), 1.90-2.02 (m, 8H), 1.51- 1.74 (m,5H). 620 275

(Chloroform-d) δ 7.61 (s, 1H), 7.44-7.57 (m, 2H), 5.70-5.83 (m, 1H),5.49 (br, 2H), 4.17-4.26 (m, 2H), 3.71-3.82 (m, 2H), 3.57 (s, 2H),2.84-3.06 (m, 4H), 2.64-2.64 (m, 2H), 2.01-2.02 (m, 3H), 1.73-1.89 (m,10H), 1.42-1.52 (m, 2H). 633 276

(Chloroform-d) δ 7.51-7.53 (m, 2H), 7.37-7.43 (m, 1H), 5.71-5.80 (m,1H), 5.51 (br, 2H), 4.54- 4.78 (m, 1H), 4.20 (br, 2H), 3.93-4.00 (m,1H), 3.35-3.51 (m, 2H), 2.70-3.18 (m, 4H), 2.35- 2.62 (m, 3H), 2.01 (s,1H), 1.60-1.91 (m, 9H), 1.64 (br, 1H), 1.21-1.30 (m, 1H). 647 277

δ 7.32 (s, 1H), 7.20-7.23 (m, 2H), 6.09-6.18 (m, 1H), 4.07-4.13 (m, 4H),3.80-3.95 (m, 1H), 3.73- 3.76 (m, 1H), 3.59-3.64 (m, 2H), 3.51-3.55 (m,3H), 3.17 (br, 2H), 2.84-3.08 (m, 4H), 1.92-1.97 (m, 2H), 1.68-1.70 (m,4H). 622 278

δ 7.34 (br, 1H), 7.15 (s, 1H), 7.02 (s, 1H), 6.06- 6.17 (m, 1H),4.49-4.53 (m, 1H), 4.23-4.33 (m, 2H), 3.98-4.11 (m, 2H), 3.81-3.85 (m,1H), 3.66- 3.69 (m, 1H), 3.51 (br, 6H), 3.19-3.28 (m, 3H), 2.96-3.00 (m,1H), 1.90-1.94 (m, 2H), 1.65- 1.68 (m, 4H). 622 279

δ 7.32 (s, 1H), 7.12-7.14 (m, 2H), 6.08-6.17 (m, 1H), 4.00 (br, 2H),3.76-3.80 (m, 2H), 3.43-3.62 (m, 4H), 3.05-3.07 (m, 2H), 2.81-2.92 (m,4H), 2.34-2.41 (m, 1H), 1.93-2.06 (m, 2H), 1.74-1.91 (m, 4H), 1.61-1.72(m, 4H). 620 280

(Chloroform-d) δ 7.42-7.44 (m, 2H), 7.26-7.28 (m, 2H), 5.71-5.80 (m,1H), 4.17-4.25 (m, 2H), 3.58 (br, 2H), 2.91-3.05 (m, 3H), 2.64-2.66 (m,2H), 1.66-1.80 (m, 6H), 1.43-1.50 (m, 2H). 449 281

δ 7.60-7.68 (m, 2H), 7.52 (s, 1H), 6.08-6.16 (m, 1H), 4.34-4.60 (m, 1H),3.96-4.17 (m, 3H), 3.36- 3.39 (m, 2H), 2.82-3.20 (m, 4H), 2.59 (br, 3H),2.01-2.11 (m, 2H), 1.33-1.87 (m, 10H). 648

II. Biological Evaluation

Compounds are tested to assess their MAGL and serine hydrolase activityusing the following in vitro and in vivo assays.

In Vitro Competitive Activity-Based Protein Profiling.

Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0mg/mL total protein concentration) were preincubated with varyingconcentrations of inhibitors at 37° C. After 30 min, FP-Rh (1.0 μL, 50μM in DMSO) was added and the mixture was incubated for another 30 minat 37° C. Reactions were quenched with SDS loading buffer (50 μL-4X) andrun on SDS-PAGE. Following gel imaging, serine hydrolase activity wasdetermined by measuring fluorescent intensity of gel bands correspondingto MAGL, ABHD6 and FAAH using ImageJ 1.43 u software. Data from thisassay is shown in Table 2 (% inhibition at 1 μM).

In Vitro Competitive Activity-Based Protein Profiling (Human).

Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL,1.0-2.0 mg/mL total protein concentration) were preincubated withvarying concentrations of inhibitors at 37° C. After 30 min, FP-Rh orJW912 (1.0 μL, 50 μM in DMSO) was added and the mixture was incubatedfor another 30 min at room temperature. Reactions were quenched with SDSloading buffer (15 μL-4X) and run on SDS-PAGE. Following gel imaging,serine hydrolase activity was determined by measuring fluorescentintensity of gel bands corresponding to MAGL using ImageJ 1.49 ksoftware.

Preparation of Mouse Brain Proteomes from Inhibitor Treated Mice.

Inhibitors were administered to wild-type C57Bl/6J by oral gavage in avehicle, e.g. PEG400/Ethanol/PBS (7/2/1). Each animal was sacrificed 4 hfollowing administration and brain proteomes were prepared and analyzedaccording to previously established methods (See Niphakis, M. J., et al.(2011) ACS Chem. Neurosci. and Long, J. Z., et al. Nat. Chem. Biol.5:37-44). Data from this assay is shown in Table 2 (% inhibition at 5mg/kg).

Recombinant Expression of Human MAGL in HEK293T Cells.

hMAGL was expressed in HEK293T cells according to previously reportedmethods (see Niphakis, Long, and Blankman, J. L., et al. (2007) Chem.Biol. 14:1347-1356). Cell lysates were diluted with mock proteomes foruse in competitive ABPP experiments.

TABLE 2 MAGL FAAH ABHD6 MAGL FAAH ABHD6 MAGL FAAH ABHD6 MAGL % Inh % Inh% Inh % Inh % Inh % Inh IC₅₀ IC₅₀ IC₅₀ IC₅₀ 1 μM 1 μM 1 μM 5 mg/kg 5mg/kg 5 mg/kg Ex (mouse) (mouse) (mouse) (human) (mouse) (mouse) (mouse)(mouse) (mouse) (mouse) 1 ** * * ### # # 2 ** * * ### # # 3 ** * * ### ## 4 ** * * ### # # ### # # 5 *** * * ### # # ### # ## 6 ** * * 7 *** * *### ### # 8 *** * * ### ## ## 9 *** * * ### # # 10 *** * * ### ## # 11** * * ### # # 12 ** * * ### # # 13 ** * * ### # # 14 ** * * ### # # 15** * * ### # # 16 *** * * *** ### # # # # # 17 *** * * ### # ### ## # #18 *** * * ### # ## ## # # 19 *** * * ## # # 20 *** * * *** ## # # 21*** * ** ### # ### ### # ## 22 *** * ** ### # ### ### # # 23 *** * * #### # ## # # 24 *** * * ### # # ### # # 25 *** * ** ### # ### ## # # 26*** * ** ### # ### ## # # 27 ** * * ### # # 28 *** * * ### # # 29*** * * ### # ### ### ## ### 30 *** * * ### # # ### # # 31 *** * * ### ## ### # ## 32 *** * * ### # # ### # # 33 *** * * ### # # ### ## # 34*** * * ### # # ### # # 35 *** * * ### # # ### # # 36 *** * * ### # #### # # 37 *** * * ### # # ### # # 38 *** * * ### ## # 39 *** * * ### ## 40 *** * * ### # # 41 *** * * ### # # 42 *** * * ### # # ### # # 43*** * * ### # # ## # # 44 ** * * 45 *** * * ## # # 46 *** * * ### # # 47*** * * ### # # ### # # 48 *** * ** ### # ### ### # ## 49 ** * * ### # #50 *** * * ### # ## ## # # 51 *** * * ### # # ## # # 52 *** * * ### # ## # # 53 ** * * *** ### # # 54 *** * * ### # # ## # # 55 *** * * ### # #56 ** * * ## # # 57 ** * * ### # # 58 ** * ** ### # ### 59 ** * * ### ## 60 *** * * ### # # ### ## # 61 *** * * ### ## ## ### ### # 62 *** * *### # # ### ## ## 63 ** * * ### # # 64 *** * * ### # # ## # # 65 *** * *### # ## ## # ## 66 *** * * ### # # ## # # 67 *** * * ### # # ### # # 68*** * * *** ### # # ### # # 69 ** * ### # # 70 *** * ** ### # ### ### #### 71 *** * * ### # ## ### # ## 72 *** * * ### # # ## # # 73 *** * *### # # ## # # 74 *** * * ### # ## ## # # 75 *** * * ### # # ### # # 76*** * * ### # # ### # # 77 *** * * ### # # ### # # 78 *** * * ### # # ### # 79 *** * * ### # # ### # # 80 *** * * ### # # ### ## ## 81 *** * *### # # ### # # 82 *** * * ### # # ### # # 83 *** * * ### # # 84 ** * *### # # ### # # 85 *** * * ### # # ### # # 86 *** * * ### # # ### # # 87*** * * ### # # ## # # 88 *** * * ### # # ## # # 89 *** * * ### # # # ## 90 *** * * ### # # ## # # 91 *** * * ### # # ### # # 92 *** * ** ### #### 93 *** * * ### # # ### # # 94 *** * * ### # # # # # 95 ** * * ## # #96 *** * * ### # # ### # # 97 *** * * ### # # ### # # 98 ** * * ### # #99 *** * * ### # # ### # # 100 *** * * ### # # ### # # 101 *** * * ### ## ### # # 102 *** * * ### # # ### # # 103 ** * ** ### # ### 104 *** * *### ## # ## # # 105 *** * * ### # # # # # 106 ** * * ### # # 107 *** * *### # # ### ## # 108 *** * * ### # # ### # # 109 *** * * ### # # 110*** * * ### # # 111 *** * * ### # # 112 *** * * ### # # 113 *** * * #### # 114 *** * * ### # ## 115 ** * * ### # # 116 *** * * ### # # 117** * * ### # # 118 * * * ** ## # # 119 *** * ** *** ### # ### ### # ###120 *** * * *** ### # # ### # # 121 *** * * *** ### # # ### # # 122*** * * *** ### # # ### ## ## 123 *** * * *** ### # # ### # ## 124*** * * ### # # ### # # 125 *** * * ### # # ### # # 126 *** * * ### # ##127 ** * * ### # ## 128 *** * * ### # # ### # # 129 *** * * ### # ## #### # 130 *** * * ### # ## ### # # 131 *** * * ### # # 132 *** * * ### # #### # # 133 *** * * *** ### # # ### # # 134 *** * * *** ### # # ### # #135 *** * ** ### # ### 136 ** * ** ### # ### 137 ** * *** ### # ### 138** * *** ### # ### 139 ** * ** ### # ### 140 *** * ** ### # ### 141 ** *** ### # ### 142 ** * * ### # # 143 *** * * ### # # 144 ** * * ### # ##145 *** * * ### # # 146 *** * * ### # ## ### # ## 147 ** * * ### # # 148*** * * ### # # 149 ** * * ### # ## 150 *** * * ### # # ### # # 151*** * * ### # # ### ## ## 152 *** * ** ### # ### ### # ### 153 ** * ***### # ### 154 *** * ** ### # ### 155 *** * ** ### # ### 156 *** * ** #### ### 157 *** * ** ### # ### ### # ## 158 ** * * ### # # 159 *** * * #### ### 160 *** * *** ### # ### 161 *** * *** ### # ### 162 *** * ** ### #### 163 *** * ** ### # ## 164 *** * ** ### # ### 165 *** * * ### # ##166 *** * * ### # # # # # 167 *** * * ### # ## 168 *** * * ### # # ## ## 169 *** * * ### # ## 170 *** * * ### # # ## # # 171 ** * * ### # # 172*** * * ### # # # # # 173 *** * * ### # ## ## # # 174 *** * * ### # #### # # 175 *** * * ### # # 176 *** * * ### # # ## # # 177 ** * * ### ### ### # # 178 *** * * *** ### # ## 179 ** * * *** ### # # ### ## # 180*** * * ### # # ### ## ## 181 *** * ** ### # ## 182 *** * * ** ### # #183 *** * * ### # ## ### # # 184 *** * * ### # # ### # # 185 ** * ** #### ### 186 ** * ** ### # ## 187 *** * ** ### # ### 188 ** * ** ### # ##189 *** * ** ### # ## ## # # 190 *** * * ### # # 191 ** * * ### # ## 192*** * ** ### # ## 193 *** ### # # ## # # 194 *** ### # # ## # # 195*** * * *** ### # # # # # 196 *** ### # # ### # # 197 ** * * *** ### ### # # # 198 *** ### # # 199 *** * * *** ### # ## ## # # 200 *** ### # ### # # 201 *** ### # ### 202 *** ### # ### 203 *** ### # # 204 *** ### ## 205 *** ### # ## 206 *** ### # ## 207 ### # # 208 ### # ### 209 ***### # ## 210 *** ### # # ### # ## 211 *** ### # # ## # # 212 ### # # 213### # # 214 *** ### # # ### # # 215 *** ### # ### 216 *** ### # ## ## ## 217 *** ### # # ### # # 218 *** ### # # ## # # 219 *** ### # ### 220## # # 221 *** ### # # ### # # 222 *** ### # # 223 *** ### # # 224 ## ## 225 *** ### # # 226 *** ### # # ### # # 227 # # # 228 *** ### # ###229 *** ### # ### 230 *** ### # # ## # # 231 *** ### # # 232 *** ### ### 233 *** ### # ## 234 *** ### # ### 235 ** ### # # 236 *** ### # # #### # 237 ** ### # ## 238 ** * * *** ### # # ### # # 239 *** ### # # 240*** ### # # ### # # 241 *** ### # ### 242 ## # ## 243 ** ### # # 244 ***### # # ### # # 245 *** ### # ### 246 ** ### # ## 247 *** ### # ### 248*** ### # # ### # # 249 *** ### # # ## # # 250 ### # # 251 ## # # 252*** ### # ### 253 *** ### # # ## # # 254 ## # # 255 ** ### # ## 256 ***### # # # # # 257 # # # 258 * ### # ### 259 # # # 260 ** ### # # 261 ***## # # 262 *** ### # # ## # # 263 *** ### # ## 264 *** ### # ### 265 ***### # ### 266 ** ### # # 267 *** ### # ### # # # 268 *** ### # ## ## ### 269 *** ### # # ## # # 270 *** ### # # ## # # 271 *** ### # ## 272*** ### # # ### # # 273 ### # ## 274 *** ### # ## ### # # 275 *** ### ### ### # # 276 *** ### # ## 277 *** ### # ### 278 *** ### # ### 279 ***### # ### 280 *** ### # # 281 *** ### # ## # # # *** is less than 100nM; ** is between 1000 and 100 nM; * is greater than 1000 nM ### is ≥75%; ## is equal to or greater than 25% but less than 75%; # is < 25%

1.-46. (canceled)
 47. A method of treating acute pain, inflammatorypain, cancer pain, pain caused by peripheral neuropathy, central pain,fibromyalgia, migraine, vasoocclussive painful crises in sickle celldisease, spasticity or pain associated with multiple sclerosis,functional chest pain, rheumatoid arthritis, osteoarthritis, orfunctional dyspepsia, Persistent Motor Tic Disorder, Persistent VocalTic Disorder, attention deficit hyperactivity disorder (ADHD),obsessive-compulsive disorder (OCD), glaucoma, atopic dermatitis,pruritis, and Down's Syndrome in a patient, comprising administering tothe patient in need thereof a therapeutically effective amount of acompound of Formula (Ia):

wherein: R¹ is H or C₁₋₆alkyl; R² is H or C₁₋₆alkyl; each R³ isindependently selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,halogen, —CN, C₁₋₆haloalkyl, C₁₋₆aminoalkyl, heterocycloalkyl,—C₁₋₆alkyl(heterocycloalkyl), heteroaryl, —SF₅, —NR⁵R⁶, —OR⁷, —CO₂R⁸,—C(O)R⁸, and —C(O)NR⁸R⁹, wherein heterocycloalkyl and—C₁₋₆alkyl(heterocycloalkyl) are optionally substituted with one or twoR⁴; or two adjacent R³ form a heterocycloalkyl ring optionallysubstituted with one, two, or three R⁴; each R⁴ is independentlyselected from C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl, halogen, oxo,—CN, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸;each R⁵ and R⁶ is independently selected from H, C₁-6alkyl,C₁-6haloalkyl, C₁₋₆aminoalkyl, C3-8cycloalkyl,—C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),heterocycloalkyl, aryl, and heteroaryl; or R⁵ and R⁶, together with thenitrogen to which they are attached, form a heterocycloalkyl ringoptionally substituted with one, two, or three R¹⁰; each R⁷ isindependently selected from H, C₁₋₆alkyl, C₁₋₆haloalkyl, C₁₋₆aminoalkyl,C₃₋₈cycloalkyl, —C₁₋₆alkyl(heterocycloalkyl),—C₁₋₆alkyl-C(O)(heterocycloalkyl), heterocycloalkyl, aryl, andheteroaryl, wherein heterocycloalkyl, aryl, and heteroaryl areoptionally substituted with one or two groups selected from oxo,C₁₋₆alkyl, C₁₋₆haloalkyl, CO₂H, and C(O)NH₂; each R⁸ and R⁹ isindependently selected from H, C₁₋₆alkyl, C₁₋₆haloalkyl, C₃₋₈cycloalkyl,aryl, and heteroaryl; or R⁸ and R⁹, together with the nitrogen to whichthey are attached, form a heterocycloalkyl ring optionally substitutedwith one or two groups selected from C₁₋₆alkyl, C₁₋₆haloalkyl, CO₂H, andC(O)NH₂; each R¹⁰ is independently selected from C₁₋₆alkyl,C₃₋₈cycloalkyl, C₁₋₆haloalkyl, halogen, oxo, —CN, —CO₂R⁸, —C(O)R⁸,—C(O)NR⁸R⁹, —SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸; p is 0, 1, 2, 3, 4, or 5;n is 0 or 1; and m is 1 or 2; provided that when n is 0, then m is 2;and when n is 1, then m is 1; or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or pharmaceutically acceptable salt thereof.
 48. Themethod of claim 47, or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or pharmaceutically acceptable salt thereof, wherein eachR³ is independently selected from C₁₋₆alkyl, C₂₋₆alkynyl, halogen, —CN,C₁₋₆haloalkyl, heterocycloalkyl, —C₁₋₆alkyl(heterocycloalkyl),heteroaryl, —SF₅, —NR⁵R⁶, —OR⁷, —CO₂R⁸, and —C(O)NR⁸R⁹.
 49. The methodof claim 47, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, orpharmaceutically acceptable salt thereof, wherein R¹ and R² are both H.50. The method of claim 47, or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or pharmaceutically acceptable salt thereof, wherein R¹and R² are both —CH₃.
 51. The method of claim 47, or a solvate, hydrate,tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable saltthereof, wherein each R³ is independently selected from C₁₋₆alkyl,halogen, C₁₋₆haloalkyl, —C₁₋₆alkyl(heterocycloalkyl), —NR⁵R⁶, —OR⁷,—CO₂R⁸, and —C(O)NR⁸R⁹.
 52. The method of claim 51, or a solvate,hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptablesalt thereof, wherein each R³ is independently selected from halogen,C₁₋₆haloalkyl, —NR⁵R⁶, and —OR⁷.
 53. The method of claim 51, or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceuticallyacceptable salt thereof, wherein R⁵ and R⁶, together with the nitrogento which they are attached, form a heterocycloalkyl ring substitutedwith one or two R¹⁰ independently selected from C₁₋₆alkyl,C₃₋₈cycloalkyl, C₁₋₆haloalkyl, halogen, —CO₂R⁸, —C(O)R⁸, —C(O)NR⁸R⁹,—SO₂R⁸, —NR⁹C(O)R⁸, and —NR⁹SO₂R⁸.
 54. The method of claim 53, or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceuticallyacceptable salt thereof, wherein R⁵ and R⁶, together with the nitrogento which they are attached, form a heterocycloalkyl ring substitutedwith one or two R¹⁰ independently selected from C₁₋₆alkyl and —CO₂H. 55.The method of claim 51, or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or pharmaceutically acceptable salt thereof, wherein R⁵and R⁶, together with the nitrogen to which they are attached, form anunsubstituted heterocycloalkyl ring.
 56. The method of claim 51, or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceuticallyacceptable salt thereof, wherein R⁵ and R⁶, together with the nitrogento which they are attached, form a heterocycloalkyl ring, optionallysubstituted with one, two, or three R¹⁰, selected from:


57. The method of claim 51, or a solvate, hydrate, tautomer, N-oxide,stereoisomer, or pharmaceutically acceptable salt thereof, wherein R⁷ isindependently selected from C₁₋₆alkyl, C₁₋₆haloalkyl, C₁₋₆aminoalkyl,—C₁₋₆alkyl(heterocycloalkyl), —C₁₋₆alkyl-C(O)(heterocycloalkyl),heterocycloalkyl, and heteroaryl.
 58. The method of claim 47, or asolvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceuticallyacceptable salt thereof, wherein two adjacent R³ form a heterocycloalkylring optionally substituted with one, or two R⁴.
 59. The method of claim47, wherein p is
 2. 60. The method of claim 47, wherein p is
 1. 61. Themethod of claim 47, wherein n is 0 and m is
 2. 62. The method of claim47, wherein n is 1 and m is 1.